AU2007202950B2 - Antibodies that Immunospecifically Bind to Blys - Google Patents
Antibodies that Immunospecifically Bind to Blys Download PDFInfo
- Publication number
- AU2007202950B2 AU2007202950B2 AU2007202950A AU2007202950A AU2007202950B2 AU 2007202950 B2 AU2007202950 B2 AU 2007202950B2 AU 2007202950 A AU2007202950 A AU 2007202950A AU 2007202950 A AU2007202950 A AU 2007202950A AU 2007202950 B2 AU2007202950 B2 AU 2007202950B2
- Authority
- AU
- Australia
- Prior art keywords
- replaced
- amino acid
- blys
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Description
P/00/011 28/5/91 Regulation 3.2 AUSTRALIA Patents Act 1990 ORIGINAL COMPLETE SPECIFICATION STANDARD PATENT Name of Applicant: Human Genome Sciences, Inc. Actual Inventors Steven M Ruben Steven C Barash Gil H Choi Tristan Vaughan David Hilbert Address for service is: WRAY & ASSOCIATES Level 4, The Quadrant 1 William Street Perth, WA 6000 Attorney code: WR Invention Title: Antibodies that Immunospecifically Bind to Blys The following statement is a full description of this invention, including the best method of performing it known to me: 1/1 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS INTRODUCTION [0011 The present invention relates to antibodies and related molecules that immunospecifically bind to BLyS. The present invention also relates to methods and compositions for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to BLyS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS function or BLyS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to BLyS. BACKGROUND OF THE INVENTION [002] B lymphocyte stimulator (BLyS) is a member of the tumor necrosis factor ("TNF") superfamily that induces both in vivo and in vitro B cell proliferation and differentiation (Moore et a., Science 285: 260-263 (1999)). BLyS is distinguishable from other B cell growth and differentiation factors such as IL-2, IL-4, IL-5, [L-6, IL-7, IL-13, IL-15, CD40L, or CD27L (CD70) by its monocyte-specific gene and protein expression pattern and its specific receptor distribution and biological activity on B lymphocytes. BLyS expression is not detected on natural killer ("NK") cells, T cells or B cells, but is restricted to cells of myeloid origin. BLyS expression on resting monocytes is upregulated by interferon-gamma (IFN-gamma). The gene encoding BLyS has been mapped to chromosome 13q34. 1003] BLyS is expressed as a 285 amino acid type II membrane-bound polypeptide and a soluble 152 amino acid polypeptide (Moore et at., 1999 supra). The membrane-bound form of BLyS has a predicted transmembrane spanning domain between amino acid residues 47 and 73. The NH 2 -terminus of the soluble form of BLyS begins at Ala 1 3 of the membrane-bound form of BLyS. Soluble recombinant BLyS has 1/2 been shown to induce in vitro proliferation of murine splenic B cells and to bind to a cell surface receptor on these cells (Moore et al., 1999 supra). Soluble BLyS administration to mice has been shown to result in an increase in the proportion of CD 4 5 Rdull, Ly 6 D brigt (also known as ThB) B cells and an increase in serum IgM and IgA levels (Moore et al., 1999 supra). Thus, BLyS displays a B cell tropism in both its receptor distribution and biological activity. [0041 Based upon its expression pattern and biological activity, BLyS has been suggested to be involved in the exchange of signals between B cells and monocytes or their differentiated progeny. The restricted expression patterns of BLyS receptor and ligand suggest that BLyS may function as a regulator of T cell-independent responses in a manner analogous to that of CD40 and CD40L in T cell-dependent antigen activation. As such, antibodies and related molecules that immunospecifically bind to BLyS may find medical utility in, for example, the treatment of B cell disorders associated with autoimmunity, neoplasia, or immunodeficiency syndromes. SUMMARY OF THE INVENTION [005] The present invention encompasses antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeplide or polypeptide fragment of BLyS. In particular, the invention encompasses antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or polypeptide fragment of human BLyS (SEQ ID NOS:3228 and/or 3229) or BLyS expressed on human monocytes; murine BLyS (SEQ ID NOS:3230 and/or 3231) or BLyS expressed on murine monocytes; rat BLyS (either the soluble forms as given in SEQ ID NOS:3232, 3233, 3234 and/or 3235 or in a membrane associated form, e.g., on the surface of rat monocytes); or monkey BLyS (e.g., the monkey BLyS polypeptides of SEQ ID NOS:3236 and/or 3237, the soluble form of monkey BLyS, or BLyS expressed on monkey monocytes), preferably human BLyS. The present invention also encompasses methods and compositions for detecting, diagnosing, or prognosing diseases or disorders associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor in an animal, preferably a mammal, and most preferably a human, 2 comprising, or alternatively consisting of, use of antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to BLyS. Diseases and disorders which can be detected, diagnosed, or prognosed with the antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) of the invention include, but are not limited to, immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma). The present invention further encompasses methods and compositions for preventing, treating or ameliorating diseases or disorders associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor in an animal, preferably a mammal, and most preferably a human, comprising, or alternatively consisting of, administering to said animal an effective amount of one or more antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to BLyS. Diseases and disorders which can be prevented, treated or ameliorated by administering an effective amount of an antibody of the invention include, but are not limited to, immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma). [005A] In one aspect, the invention provides a method of treating a patient suffering from an autoimmune disease or condition comprising administering an isolated antibody which comprises a first amino acid sequence at least 85% identical to amino acid residues 1-123 of SEQ ID NO:327 or amino acid residues 1-123 of SEQ ID NO:2 and a second amino acid sequence at least 85% identical to amino acid residues 141-249 of SEQ ID NO:327 or amino acid residues 141-249 of SEQ ID NO:2, wherein said antibody immunospecifically binds a BLyS protein or a biologically active fragment thereof, and wherein said autoimmune disease or condition is selected from the group consisting of: 3/1 (a) idiopathic thrombocytopietic purpura (ITP); (b) rheumatoid arthritis; (c) Waldenstrom's macroglobulinaemia; (d) multiple sclerosis; (e) diabetes; (f) transplant rejection; (g) systemic lupus erythematosus (SLE); (h) Sjogren's syndrome; and (i) vasculitis. [005B] In another aspect, the invention provides a method of treating a patient suffering from an autoimmune disease or condition comprising administering an isolated antibody comprising amino acid residues 26-35, 50-66, 99-112, 163-173, 189-195, and 228-238 of SEQ ID NO: 327 or amino acid residues 26-35, 50-66, 99 112, 163-173, 189-195, and 228-238 of SEQ ID NO: 2, wherein said antibody immunospecifically binds a BLyS protein or a biologically active fragment thereof, and wherein said autoimmune disease or condition is selected from the group consisting of: (a) idiopathic thrombocytopietic purpura (ITP); (b) rheumatoid arthritis; (c) Waldenstrom's macroglobulinaemia; (d) multiple sclerosis; (e) diabetes; 3/2 (f) transplant rejection; (g) systemic lupus erythematosus (SLE); (h) Sjogren's syndrome; and (i) vasculitis. [006] Using phage display technology, the present inventors have identified single chain antibody molecules ("scFvs") that immunospecifically bind to BLyS, including scFvs that immunospecifically bind to soluble BLyS, scFvs that immunospecifically bind the membrane-bound form of BLyS, and scFvs that immunospecifically bind to both the soluble form and the membrane-bound form of BLyS. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs (e. g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of BLyS, the membrane-bound form of BLyS, and/or both the soluble form and membrane-bound form of BLyS, are also encompassed by the invention, 3/3 as are nucleic acid molecules that encode these scFvs, and/or molecules. [007] In particular, the invention relates to scFvs comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 - 2128, preferably SEQ ID NOS:834 - 872, 1570 - 1595, and 1886 - 1908, and most preferably SEQ ID NOS:1 - 46, 321 - 329, 1563 - 1569, and 1881 - 1885, as referred to in Table I below. In specific embodiments, the present invention relates to scFvs that immunospecifically bind the soluble form of BLyS, said scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1563 - 1569, preferably SEQ ID NOS:1570 - 1595, and most preferably SEQ ID NOS: 1563 - 1569, as referred to in Table 1, below. In other embodiments, the present invention also relates to scFvs that immunospecifically bind the membrane-bound form of BLyS, said scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1881 2128, preferably SEQ ID NOS:1886 - 1908, and most preferably SEQ ID NOS: 1881 1885, as referred to in Table 1 below. The present invention further relates to scFvs that immunospecifically bind both the membrane-bound form and soluble form of BLyS, said scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1 - 1562, preferably SEQ ID NOS: 834 - 872, and most prcfcrably SEQ ID NOS: I - 46, and 321 - 329, as referred to in Table I below. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of BLyS, the membrane-bound form of BLyS, and/or both the soluble form and membrane-bound form of BLyS, are also encompassed by the invention, as are nucleic acid molecules that encode these scFvs, and/or molecules. 10081 The present invention provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or polypeptide fragment of BLyS, said antibodies comprising, or alternatively consisting of, a polypeptide having the amino acid sequence of any one of the variable heavy ("VH") domains referred to in Table 1, below, or any one of the variable light ("VL") domains referred to in Table 1. In a preferred embodiment, antibodies of the present. invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VH domain contained in SEQ ID NOS: 1 4 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908, as referred to in Table 1 below. In another preferred embodiment, antibodies (including molecules comprising or alternatively consisting of, antibody fragments or variants thereof) of the present invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VL domain contained SEQ ID NOS:1 -46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 1908, as referred to in Table 1 below. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of BLyS, the membrane-bound form of BLyS, and/or both the soluble form and membrane-bound form of BLyS, are also encompassed by the invention, as are nucleic acid molecules that encode these antibodies, and/or molecules. [009] The present invention also provides antibodies (including molecules comprising or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or a polypeptide fragment of BLyS, said antibodies comprising, or alternatively consisting of, a polypeptide having the amino acid sequence of any one of the VH domains referred to in Table 1, below, and any one of the VL domains referred to in Table 1. In a preferred embodiment, the antibodies of the invention comprise or alternatively consist of, a polypeptide having the amino acid sequence of a VH and VL domain contained in the same scFv referred to in Table 1. In another preferred embodiment, antibodies of the present invention, comprise, or alternatively consist of, a VH domain from an scFv of SEQ ID NOS: 1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908, as disclosed in Table 1, and a VL domain from an scFv SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908, as disclosed in Table 1. In another preferred embodiment, antibodies of the present invention comprise, or alternatively consist of, the VH and VL domain from a single scFv of SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908, as disclosed in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of BLyS, the membrane-bound form of BLyS, and/or both the soluble form and membrane-bound form of BLyS, are also encompassed by the invention, 5 as are nucleic acid molecules that encode these antibodies, and/or molecules. [0101 The present invention also provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or a polypeptide fragment of BLyS, said antibodies comprising, or alternatively consisting of, a polypeptide having the amino acid sequence of any one, two, three or more of the VH complementarity determining regions ("CDRs") (i.e., VH CDR1, VHi CDR2, or VH4 CDR3) referred to in Table 1 and/or any one, two, three or more of the VL CDRs (i.e., VL CDR1, VL CDR2, or VL CDR3) referred to in Table 1. In one embodiment, antibodies of the present invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one of the VH CDRls referred to in Table I and/or any one of the VL CDRIs referred to in Table 1. In another embodiment, antibodies of the present invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one of the VH CDR2s referred to in Table 1 and/or any one of the VL CDR2s referred to in Table 1. In a preferred embodiment, antibodies of the present invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one of the VH CDR3s referred to in Table 1 and/or any one of the VL CDR3s referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies (e.g., including VH domains, VH CDRs, "VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that inmunospecifically bind the soluble form of BLyS, the membrane-bound form of BLyS, and/or both the soluble form and membrane-bound form of BLyS, are also encompassed by the invention, as are nucleic acid molecules that encode these antibodies, and/or molecules. [011] In another embodiment, antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) immunospecifically bind to a polypeptide or polypeptide fragment of BLyS, and comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one of the VH CDRls referred to in Table 1, any one of the VH CDR2s referred to in Table 1, and/or any one of the VH CDR3s referred to in Table 1. In another embodiment, antibodies of the present invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one of the VL CDR1s referred to in Table 1, any one of the VL CDR2s referred to in Table 1, and/or any one of the VL CDR3s referred to 6 in Table 1. In a preferred embodiment, antibodies of the present invention comprise, or alternatively consist of, at least one, two, three, four, five, six, or more CDRs that correspond to the same scFv referred to in Table 1, more preferably where CDRI, CDR2, and CDR3 of the VL domain correspond to the same scFv or where CDRI, CDR2, and CDR3 of the VH domain correspond to the same scFv, and most preferably where all six CDRs correspond to the same scFv referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of BLyS, the membrane-bound form of BLyS, and/or both the soluble form and membrane-bound form of BLyS, are also encompassed by the invention, as are nucleic acid molecules that encode these antibodies, and/or molecules. [0121 The present invention also provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that: immunospecifically bind to the soluble form of BLyS (e.g., a polypeptide consisting of amino acids 134 - 285 of SEQ ID NO:3228); that immunospecifically bind to the membrane-bound form of BLyS (e.g., a polypeptide consisting of amino acids 1 - 285 of SEQ I) NO:3228 or a BLyS polypeptide expressed on the surface of monocytes) and/or that immunospecifically bind to both the soluble form and membrane-bound form of BLyS. In a preferred embodiment, antibodies of the present invention inmunospecifically bind to the soluble form of BLyS and comprise, or alternatively consist of, a VH domain, VH CDR1, VH CDR2, VH CDR3, VL domain, VL CDRI, VL CDR2, and/or VL CDR3 corresponding to one or more scFvs, that immunospecifically bind to the soluble form of BLyS. In another preferred embodiment, antibodies of the present invention immunospecifically bind to the membrane-bound form of BLyS and comprise, or alternatively consist of, a VH domain, VH CDRl, VH CDR2, VH CDR3, VL domain, VL CDR1, VL CDR2, and/or VL CDR3 corresponding to one or more scFvs, that immunospecifically bind to the membrane-bound form of BLyS. In yet another preferred embodiment, antibodies of the present invention immunospecifically bind to the soluble form and membrane-bound form of BLyS and comprise, or alternatively consist of, a VH domain, VH CDR1, VH CDR2, VH CDR3, VL domain, VL CDR1, VL CDR2, and/or VL CDR3 corresponding to one or more scFvs, that immunospecifically binds to the soluble 7 form and membrane-bound form of BLyS. In another preferred embodiment, antibodies of the present invention comprise, or alternatively consist of, a VH domain and a VL domain corresponding to the same scFv disclosed in Table 1, which antibodies immunospecifically bind to the soluble form of BLyS, the membrane-bound form of BLyS, or both the soluble form and membrane-bound form of BLyS. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of BLyS, the membrane-bound form of BLyS, and/or both the soluble form and membrane-bound form of BLyS., are also encompassed by the invention, as are nucleic acid molecules that encode these antibodies, and/or molecules. [0131 A VH domain of an amino acid sequence disclosed herein may be combined with 10141 a VL domain of an amino acid sequence disclosed herein, or other VL domains, to provide a VH/VL pairing representing an antigen-binding site of an antibody. Similarly, a VL domain of an amino acid sequence disclosed herein may be combined with a VH domain of an amino acid sequence disclosed herein, or other VH domains. Further, one or more CDRs disclosed herein may be taken from a VH or VL domain and incorporated into a suitable framework as discussed infra. [015] The present invention provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof (including derivatives)) comprising, or alternatively consisting of, of VH domains, VL domains and/or CDRs described herein, which antibodies, immunospecifically bind to BLyS (e.g., soluble BLyS and membrane-bound BLyS) and can be routinely assayed for immunospecific binding to BLyS using methods known in the art, such as, for example, the immunoassays disclosed infra. Antibodies and antibody fragments or variants (including derivatives) of the invention may include, for example, one or more amino acid sequence alterations (addition, deletion, substitution and/or insertion of an amino acid residue). These alterations may be made in one or more framework regions and/or one or more CDR's. The antibodies of the invention (including antibody fragments, and variants and derivative thereof) can be routinely made by methods known in the art. Molecules 8 comprising, or alternatively consisting of, fragments or variants of any of the VH domains, VH CDRs, VL domains, and VL CDRs whose sequences are specifically disclosed herein may be employed in accordance with the present invention. Nucleic acid molecules encoding these antibodies and molecules (including fragments, variants, and derivatives) are also encompassed by the invention. [016] The present invention also provides panels of antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants) wherein the panel members correspond to one, two, three, four, five, ten, fifteen, twenty, or more different antibodies of the invention (e.g., whole antibodies, Fabs, F(ab') 2 fragments, Fd fragments, disulfide-linked Fvs (sdFvs), antiidiotypic (anti-Id) antibodies, and scFvs). The present invention further provides mixtures of antibodies, wherein the mixture corresponds to one, two, three, four, five, ten, fifteen, twenty, or more different antibodies of the invention (e.g., whole antibodies, Fabs, F(ab')2 fragments, Fd fragments, disulfide-linked Fvs (sdFvs), antiidiotypic (anti-Id) antibodies, and scFvs)). The present invention also provides for compositions comprising, or alternatively consisting of, one, two, three, four, five, ten, fifteen, twenty, or more antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof). A composition of the invention may comprise, or alternatively consist of, one, two, three, four, five, ten, fifteen, twenty, or more amino acid sequences of one or more antibodies or fragments or variants thereof. Alternatively, a composition of the invention may comprise, or alternatively consist of, nucleic acid molecules encoding one or more antibodies of the invention. 10171 The present invention also provides for fusion proteins comprising an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) of the invention, and a heterologous polypeptide (i.e., a polypeptide unrelated to an antibody or antibody domain). Nucleic acid molecules encoding these fusion proteins are also encompassed by the invention. A composition of the present invention may comprise, or alternatively consist of, one, two, three, four, five, ten, fifteen, twenty or more fusion proteins of the invention. Alternatively, a composition of the invention may comprise, or alternatively consist of, nucleic acid molecules encoding one, two, three, four, five, ten, fifteen, twenty or more fusion proteins of the invention. 9 - 10/1 [018] The present invention also provides for a nucleic acid molecule, generally isolated, encoding an antibody (including molecules such as scFvs, which comprise, or alternatively consist of, an antibody fragment or variant thereof) of the invention. The present invention also provides a host cell transformed with a nucleic acid molecule of the 5 invention and progeny thereof. The present invention also provides a method for the production of an antibody (including a molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof) of the invention. The present invention further provides a method of expressing an antibody (including a molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof) of the invention from 10 a nucleic acid molecule. These and other aspects of the invention are described in further detail below. [01 9a] The present invention also provides a method of treating a patient suffering from an autoimmune disease or condition comprising administering an isolated antibody which comprises a first amino acid sequence at least 85% identical to amino acid residues 1-123 15 of SEQ ID NO: 327 or amino acid residues 1-123 of SEQ ID NO: 2 and a second amino acid sequence at least 85% identical to amino acid residues 141-249 of SEQ ID NO: 327 or amino acid residues 141-249 of SEQ ID NO:2, wherein said antibody immunespecifically binds a BLyS protein or a biologically active fragment thereof, and wherein said autoimmune disease or condition is selected from the group consisting of: (a) 20 idiopathic thrombocytopietic purpura (ITP);(b) rheumatoid arthritis; (c) Waldenstrom's macroglobulinaemia; (d) multiple sclerosis; (e) diabetes; and (f) transplant rejection. [019b] The present invention also provides a method of treating a patient suffering from an autoimmune disease or condition comprising administering an isolated antibody which comprises a first amino acid sequence at least 95% identical to amino acid residues 1-123 25 of SEQ ID NO: 327 or amino acid residues 1-123 of SEQ ID NO: 2 and a second amino acid sequence at least 95% identical to amino acid residues 141-249 of SEQ ID NO: 327 or amino acid residues 141-249 of SEQ ID NO: 2, wherein said antibody immunospecifically binds a BLyS protein or a biologically active fragment thereof, and wherein said autoimmune disease or condition is selected from the group consisting of: (a) 30 idiopathic thrombocytopietic purpura (ITP); (b) rheumatoid arthritis; (c) Waldenstrom's macroglobulinaemia; (d) multiple sclerosis; (e) diabetes; and (f) transplant rejection.
- 10/2 [01 9c] The present invention also provides a method of treating a patient suffering from an autoimmune disease or condition comprising administering an isolated antibody which comprises a first amino acid sequence of amino acid residues 1-123 of SEQ ID NO: 327 or amino acid residues 1-123 of SEQ ID NO: 2 and a second amino acid sequence of amino 5 acid levels 141-249 of SEQ ID NO: 327 or amino acid residues 141-249 of SEQ ID NO: 2, wherein said antibody immunespecifically binds a BLyS protein or a biologically active fragment thereof, and wherein said autoimmune disease or condition is selected from the group consisting of: (a) idiopathic thrombocytopietic purpura (ITP); (b) rheumatoid arthritis; (c) Waldenstrom's macroglobulinaemia; (d) multiple sclerosis; (e) diabetes; and 10 (f) transplant rejection. [020] The present invention also encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS or BLyS receptor function in an animal, preferably a mammal, and most preferably a human, comprising using antibodies 15 (including molecules which comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically bind to BLyS. Diseases and disorders which can be detected, diagnosed or prognosed with the antibodies of the invention include, but are not limited to, immune disorders (e. g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory 20 disorders (e. g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e. g., AIDS), and proliferative disorders (e. g., leukemia, carcinoma, and lymphoma). [021] In specific embodiments, the present invention encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with hypergammaglobulinemia (e. g., AIDS, autoimmune diseases, and some 25 immunodeficiencies). In other specific embodiments, the present invention encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with hypogammaglobulinemia (e. g., an immunodeficiency). [022] The present invention further encompasses methods and compositions for preventing, treating or ameliorating diseases or disorders associated with aberrant BLyS or 30 BLyS receptor expression or inappropriate BLyS or BLyS receptor function in an animal, preferably a mammal, and most preferably a human, comprising administering to said animal an effective amount of one or more antibodies (including molecules which comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically bind to BLyS. Diseases and disorders which can be prevented, treated or inhibited by administering an effective amount of one or more antibodies or molecules of the invention include, but are not limited to, immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma). [023] In specific embodiments, the present invention encompasses methods and compositions (e.g., antagonistic anti-~BLyS antibodies) for preventing, treating or ameliorating diseases or disorders associated with hypergammaglobulinemia (e.g., AIDS, autoimmune diseases, and some immunodeficiency syndromes). In other specific embodiments, the present invention encompasses methods and compositions (e.g., agonistic anti-BLyS antibodies) for preventing, treating or ameliorating diseases or disorders associated with hypogammaglobulinemia (e.g., an immunodeficiency syndrome). 10241 Autoimmune disorders, diseases, or conditions that may be detected, diagnosed, prognosed, or monitored using the antibodies of the invention include, but are not limited to, autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmune neutropenia, autoirmmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, gluten-sensitive enteropathy, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g., IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia, Polyendocrinopathies, Purpura (e.g., Henloch-Scoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, myocarditis, IgA glomerulonephritis, dense deposit disease, rheumatic heart disease, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis, systemic lupus erhythematosus, discoid lupus, Goodpasture's syndrome, Pemphigus, Receptor autoimmunities such as, for example, (a) Graves' Disease , (b) Myasthenia Gravis, and (c) insulin resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura I1 , rheumatoid arthritis, schleroderma with anti-collagen antibodies, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison's disease, infertility, glomenilonephritis such as primary glomeruloncphritis and IgA nephropathy, bullous pemphigoid, Sjbgren's syndrome, diabetes mellitus, and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis), chronic active hepatitis, primary biliary cirrhosis, other endocrine gland failure, vitiligo, vasculitis, post MI, cardiotomy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, and other inflammatory, granulomatous, degenerative, and atrophic disorders). 10251 Immunodeficiencies that may be detected, diagnosed, prognosed, or monitored using the antibodies of the invention include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-linked infantile agammaglobulinemia, acquired agammaglobulinemia, adult onset agannnaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient hypogammaglobulinemia of infancy, unspecified hypogammaglobulinemia, agammaglobulinemia, common variable immunodeficiency (CVID) (acquired), Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic alymphoplasia-aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof syndrome combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency. DEFINITIONS 10261 The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that 12 contain an antigen binding site that immunospecifically binds an antigen. As such, the term antibody encompasses not only whole antibody molecules, but also antibody fragments as well as variants (including derivatives) of antibodies and antibody fragments. Examples of molecules which are described by the term "antibody" in this application include, but are not limited to: single chain Fvs (scFvs), Fab fragments, Fab' fragments, F(ab') 2 , disulfide linked Fvs (sdFvs), Fvs, and fragments comprising or alternatively consisting of, either a VL or a VH domain. The term "single chain Fv" or "scFv" as used herein refers to a polypeptide comprising a VL domain of antibody linked to a VH domain of an antibody. Antibodies that immunospecifically bind to BLyS may have cross reactivity with other antigens. Preferably, antibodies that immunospecifically bind to BLyS do not cross-react with other antigens. Antibodies that immunospecifically bind to BLyS can be identified, for example, by immunoassays or other techniques known to those of skill in the art, e.g., the immunoassays described in the Examples below. 10271 Antibodies of the invention include, but are not limited to, monoclonal, multispecific, human or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, antiidiotypic (anti-]d) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGi, IgG 2 , IgG3, IgG 4 , IgAI and IgA2) or subclass of immunoglobulin molecule. [0281 Preferably, an antibody of the invention comprises, or alternatively consists of, a VIi domain, VH CDR, VL domain, or VL CDR having an amino acid sequence of any one of those referred to in Table 1, or a fragment or variant thereof. (0291 An antibody of the invention "which binds the soluble form of BLyS" is one which binds the 152 amino acid soluble form of the BLyS protein (amino acids 134 285 of SEQ ID NO:3228). In specific embodiments of the invention, an antibody of the invention "which binds the soluble form of BLyS" does not also bind the membrane bound or membrane-associated form of BLyS. Assays which measure binding to the soluble form of BLyS include, but are not limited to, receptor binding inhibition assay or capture of soluble BLyS from solution as described in Examples 8 and 9. (030] An antibody of the invention "which binds the membrane-bound form of BLyS" is one which binds the membrane-associated (uncleaved) BLyS protein. In 13 specific embodiments of the invention, an antibody of the invention "which binds the membrane-bound form of BLyS" does not also bind the soluble form of BLyS. Binding to HIS-tagged BLyS (as described herein) in an ELISA is an indicator that an antibody binds the membrane-bound form of BLyS, but should not be relied upon as proof of specificity for the membrane-bound form of BLyS. Assays that may be relied upon as proof of an antibody's specificity for membrane-bound BLyS, include, but are not limited to, binding to plasma membranes expressing BLyS as described in Example 2. An antibody of the invention "which binds the both the soluble form and the membrane-bound form of BLyS" is one which binds both the membrane-bound form and the soluble form of BLyS. [0311 The term "variant" as used herein refers to a polypeptide that possesses a similar or identical function as a BLyS polypeptide, a fragment of BLyS, an anti-BLyS antibody or antibody fragment thereof, but does not necessarily comprise a similar or identical amino acid sequence of a BLyS polypeptide, a fragment of BLyS, an anti-BLyS antibody or antibody fragment thereof, or possess a similar or identical structure of a BLyS polypeptide, a fragment of BLyS, an anti-BLyS antibody or antibody fragment thereof. A variant having a similar amino acid refers to a polypeptide that satisfies at least one of the following: (a) a polypeptide comprising, or alternatively consisting of, an amino acid sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the amino acid sequence of a BLyS polypeptide, a fragment of BLyS, an anti-BLyS antibody or antibody fragment thereof (including a VH domain, VHCDR, VL domain, or VLCDR having an amino acid sequence of any one of those referred to in Table 1) described herein; (b) a polypeptide encoded by a nucleotide sequence, the complementary sequence of which hybridizes under stringent conditions to a nucleotide sequence encoding a BLyS polypeptide (e.g., SEQ ID NO:3228), a fragment of BLyS, an anti-BLyS antibody or antibody fragment thereof (including a VH domain, VHCDR, VL domain, or VLCDR having an amino acid sequence of any one of those referred to in Table 1), described herein, of at least 5 amino acid residues, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 30 amino acid residues, at least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid 14 residues, at least 100 amino acid residues, at least 125 amino acid residues, or at least 150 amino acid residues; and (c) a polypeptide encoded by a nucleotide sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99%, identical to the nucleotide sequence encoding a BLyS polypeptide, a fragment of BLyS, an anti-BLyS antibody or antibody fragment thereof (including a VH domain, VHCDR, VL domain, or VLCDR having an amino acid sequence of any one of those referred to in Table 1), described herein. A polypeptide with similar structure to a BLyS polypeptide, a fragment of BLyS, an anti-BLyS antibody or antibody fragment thereof, described herein refers to a polypeptide that has a similar secondary, tertiary or quarternary structure of a BLyS polypeptide, a fragment of BLyS, an anti-BLyS antibody, or antibody fragment thereof, described herein. The structure of a polypeptide can determined by methods known to those skilled in the art, including but not limited to, X-ray crystallography, nuclear magnetic resonance, and crystallographic electron microscopy. 10321 To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical overlapping positions/total number of positions x 100%). In one embodiment, the two sequences are the same length. 10331 The determination of percent identity between two sequences can be accomplished using a mathematical algorithm known to those of skill in the art. An example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul Proc. Natl. A cad. Sci. USA 87:2264-2268(1990), modified as in Karlin and Altschul Proc. Natl. Acad. Sci. USA 90:5873-5877(1993). The BLASTn and BLASTx programs of Altschul, et al. J. Mol. Biol. 215:403-410(1990) have incorporated 15 such an alogrithm. BLAST nucleotide searches can be performed with the BLASTn program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the BLASTx program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. Nucleic Acids Res. 25:3389-3402(1997). Alternatively, PSI-BLAST can be used to perform an iterated search which detects distant relationships between molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI-BLAST programs, the default parameters of the respective programs (e.g., BLASTx and BLASTn) can be used. (See http:/Avww.ncbi.nlm.nih.gov.) [034] Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). The ALIGN program (version 2.0) which is part of the GCG sequence alignment software package has incorporated such an alogrithm. Other algorithms for sequence analysis known in the art include ADVANCE and ADAM as described in Torellis and Robotti Comput. Apple. Biosci., 10 :3-5(1994); and FASTA described in Pearson and Lipman Proc. NatL. Acad. Sci. 85:2444-8(1988). Within FASTA, ktup is a control option that sets the sensitivity and speed of the search. [035] The term "derivative" as used herein, refers to a variant polypeptide of the invention that comprises, or alternatively consists of, an amino acid sequence of a BLyS polypeptide, a fragment of BLyS, or an antibody of the invention that immunospecifically binds to BLyS, which has been altered by the introduction of amino acid residue substitutions, deletions or additions. The term "derivative" as used herein also refers to a BLyS polypeptide, a fragment of BLyS, an antibody that immunospecifically binds to BLyS which has been modified, e.g., by the covalent attachment of any type of molecule to the polypeptide. For example, but not by way of limitation, a BLyS polypeptide, a fragment of BLyS, or an anti-BLyS antibody, may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylati on, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. A derivative of a BLyS polypeptide, a fragment of BLyS, or an anti-BLyS antibody, may be modified by chemical modifications using techniques known to those of 16 skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Further, a derivative of a BLyS polypeptide, a fragment of BLyS, or an anti-BLyS antibody, may contain one or more non-classical amino acids. A polypeptide derivative possesses a similar or identical function as a BLyS polypeptide, a fragment of BLyS, or an anti-BLyS antibody, described herein. [0361 The term "epitopes" as used herein refers to portions of BLyS having antigenic or immunogenic activity in an animal, preferably a mammal. An epitope having immunogenic activity is a portion of BLyS that elicits an antibody response in an animal. An eptiope having antigenic activity is a portion of BLyS to which an antibody immunospecifically binds as determined by any method known in the art, for example, by the immunoassays described herein. Antigenic epitopes need not necessarily be immunogenic. [037] The term "fragment" as used herein refers to a polypeptide comprising an amino acid sequence of at least 5 amino acid residues, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 30 amino acid residues, at least 35 amino acid residues, at least 40 amino acid residues, at least 45 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues, at least 125 amino acid residues, at least 150 amino acid residues, at least 175 amino acid residues, at least 200 amino acid residues, or at least 250 amino acid residues, of the amino acid sequence of BLyS, or an anti-BLyS antibody (including molecules such as scFv's, that comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically binds to BLyS. [0381 The term "fusion protein" as used herein refers to a polypeptide that comprises, or alternatively consists of, an amino acid sequence of an anti-BLyS antibody of the invention and an amino acid sequence of a heterologous polypeptide (i.e., a polypeptide unrelated to an antibody or antibody domain). [0391 The term "host cell" as used herein refers to the particular subject cell transfected with a nucleic acid molecule and the progeny or potential progeny of such a cell. Progeny may not be identical to the parent cell transfected with the nucleic acid molecule due to mutations or environmental influences that may occur in succeeding 17 generations or integration of the nucleic acid molecule into the host cell genome. DESCRIPTION OF THE FIGURES [0401 Figure 1. ELISA results for three scFvs, 1006E07, 1008D05 and I016F04, that immunospecifically bind to U937 membranes, but not to bind to or cross-react with TNF-alpha or BSA. [0411 Figure 2. The results for three scFvs, 1016H07, 1001C09 and 1018D07, in a receptor inhibition assay. [0421 Figure 3. ELISA results for two scFvs (1022D01 and 1031F02) demonstrating their ability to bind to human BLyS and to cross-react with mouse BLyS, but not to bind to or cross-react with other antigens of the TNF ligand family. [0431 Figure 4. ELISA results for three scFvs (1031F09, I050A12, and 105 1C04) binding to U937 plasma membranes when either BLyS or TNF-alpha is used as a competitor. 1044] Figure 5. Kinetic analysis of scFv antibody 1003C02. A dilution series of 1003C02 from 3nM to 825nM is shown. Association and dissociation curves were generated using a BlAcore 2000 and BlAevaluation 3.0 software. [0451 Figure 6. Typical titration curves for two scFv antibodies (1007F1 1 and 1050A07) are shown in Figure 6. Unlabelled BLyS competed for binding to its receptor with an IC 50 value of 0.8 nM. The ICso values for 1007F1 I and 1050A07 are 7.9 nM and 17.1 nM , respectively. The assay was performed in triplicate and standard error bars are shown. [001] Figure 7. ELISA results for three scFvs clones (1074B12, 1075F12 and 1075A02) that immunospecifically bind to immobilized BLyS, but not to U937 plasma membranes, TNF-alpha or BSA. As a control, a phage antibody that recognizes TNFa, is also shown in Figure 7. [0471 Figure 8. The results for two scFvs (1025B09 and 1026C04) in a receptor inhibition assay. [0481 Figure 9. ELISA results for two scFvs clones (1067F05 and 1078D02) demonstrating their ability to bind to immobilized human BLyS and to cross-react with 18 immobilized mouse BLyS, but not to bind to or cross-react with other antigens of the TNF ligand family. [049] As a control, a phage antibody that recognizes TNFa, is also shown in Figure 7. 1050] Figure 10. Kinetic analysis of scFV antibody 1002A01. A dilution series of I002A01from 3nM to 1650nM is shown. Association and dissociation curves were generated using a BlAcore 2000 and BlAevaluation 3.0 software. [051] Figure 11. Typical titration curves for two scFvs, 10068C06 and 1074B12, are shown in Figure 11. Unlabelled BILyS competed for binding to its receptor with an inhibitory constant 50 (ICso) value of 0.66 nM. The IC 50 values for 10068C06 and I074B12 are 61 nM and 13 nM , respectively. The assay was performed in triplicate and standard error bars are shown. [0521 Figure 12. ELISA results for three clones (1079C01, 1081C10 and I082A02) demonstrating their ability to bind histidine-tagged BLyS, U937 plasma membranes, but not to bind immobilized biotinylated BLyS. [0531 Figure 13. ELISA results for three scFvs (1079B04, 1079F08, and 1080B01) binding to U937 plasma membranes when either histidine-tagged BLyS or biotinylated BLyS is used as a competitor. (0541 Figure 14. An example of the dissociation section of a typical sensorgram for 8 scFvs is shown in Figure 14. An anti-TNFa antibody that does not recognize BLyS was included as a control. Of the 8 scFvs exemplified, 1079F06 was identified for further study due to the relatively high numbers of RU's bound to the surface. [0551 Figure 15. A typical example of the binding curves generated for the scFv antibody 1082C03 is shown in Figure 15. The off-rate for this clone was calculated as 2x10- 3 s-. The affinity of 1082C03 was calculated as 20 nM, assuming 100% activity of the scFv. [056] Figure 16. ELISA results for three scFvs (1079B04, 1079F08, and 1080B01) binding to P388 plasma membranes when either histidine-tagged BLyS or biotinylated BLyS is used as a competitor. DETAILED DESCRIPTION OF THE IVENTION 19 10571 The present invention encompasses antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to BLyS or a fragment or variant of BLyS. In particular, the invention provides antibodies such as, for example, single chain Fvs (scFvs) having an amino acid sequence of any one of SEQ ID NOS:l - 2128, as referred to in Table 1. In particular, the present invention encompasses antibodies that immunospecifically bind to a polypeptide, a polypeptide fragment or variant, or an epitope of human BLyS (SEQ ID NOS:3228 and/or 3229) or BLyS expressed on human monocytes; murine BLyS (SEQ ID NOS:3230 and/or 3231) or BLyS expressed on murine monocytes; rat BLyS (either the soluble forms as given in SEQ ID NOS:3232, 3233, 3234 and/or 3235 or in a membrane associated form, e.g., on the surface of rat monocytes); or monkey BLyS (e.g., the monkey BLyS polypeptides of SEQ ID NOS:3236 and/or 3237, the soluble form of monkey BLyS, or BLyS expressed on monkey monocytes) (as determined by immunoassays known in the art for assaying specific antibody-antigen binding). [0581 The polypeptide sequence shown in SEQ ID NO:3228 was obtained by sequencing and translating the cDNA of the HNEDU15 clone which was deposited on October 22, 1996 at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, and assigned ATCC Accession No. 97768. The deposited clone is contained in the pBluescript SK(-) plasmid (Stratagene, La Jolla, CA). The ATCC deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure. 10591 The polypeptide sequence shown in SEQ ID NO:3229 was obtained by sequencing and translating the cDNA of the HDPMC52 clone, which was deposited on December 10, 1998 at the American Type Culture Collection, and assigned ATCC Accession No. 203518. The deposited clone is contained in the pBluescript SK(-) plasmid (Stratagene, La Jolla, CA). The ATCC deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure. [0601 The BLyS polypeptides bound by the antibodies of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to antibodies that bind monomers and multimers 20 of the BLyS polypeptides of the invention, their preparation, and compositions (preferably, pharmaceutical compositions) containing them. In specific embodiments, the antibodies of the invention bind BLyS monomers, dimers, trimers or tetramers. In additional embodiments, the antibodies of the invention bind at least dimers, at least trimers, or at least tetramers of BLyS. [061] Multimeric BLyS bound by the antibodies of the invention may be homomers or heteromers. A BLyS homomer, refers to a mnultimer containing only BLyS polypeptides (including BLyS fragments, variants, and fusion proteins, as described herein). These homomers may contain BLyS polypeptides having identical or different amino acid sequences. In specific embodiments, the antibodies of the invention bind a BLyS homodimer (e.g., containing two BLyS polypeptides having identical or different amino acid sequences) or a BLyS homotrimer (e.g., containing three BLyS polypeptides having identical or different amino acid sequences). In a preferred embodiment, the antibodies of the invention bind homotrimers of BLyS. In additional embodiments, the antibodies of the invention bind a homomeric BLyS multimer which is at least a homodimer, at least a homotrimer, or at least a homotetramer. [0621 Heteromeric BLyS refers to a multimer containing heterologous polypeptides (i.e., polypeptides of a different protein) in addition to the BLyS polypeptides of the invention. In a specific embodiment, the antibodies of the invention bind a BLyS heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the antibodies of the invention bind a heteromeric BLyS multimer which is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer. In highly preferred embodiments, the antibodies of the invention bind a heterotrimer comprising both BLyS polypeptides and APRIL polypeptides (SEQ ID NO:3239; GenBank Accession No. AF046888; PCT International Publication Number W097/33902; J. Exp. Med. 188(6):1185-1190) or fragments or variants thereof. In other highly preferred embodiments, the antibodies of the invention bind a heterotrimer comprising one BLyS polypeptide (including fragments or variants) and two APRIL polypeptides (including fragments or variants). In still other highly preferred embodiments, the antibodies of the invention bind a heterotrimer comprising two BLyS polypeptides (including fragments or variants) and one APRIL polypeptide (including fragments or variants). In a further 21 nonexclusive embodiment, the beteromers bound by the antibodies of the invention contain CD40 ligand polypeptide sequence(s), or biologically active fragment(s) or variant(s) thereof. 1063] In particularly preferred embodiments, the antibodies of the invention bind homomeric, especially homotrimeric, BLyS polypeptides, wherein the individual protein components of the multimers consist of the mature form of BLyS (e.g., amino acids residues 134-285 of SEQ ID NO:3228, or amino acids residues 134-266 of SEQ ID NO:3229) or fragments or variants thereof. In other specific embodiments, antibodies of the invention bind heteromeric, especially heterotrimeric, BLyS polypeptides such as a heterotrimer containing two BLyS polypeptides and one APRIL polypeptide or a heterotrimer containing one BLyS polypeptide and two APRIL polypeptides, and wherein the individual protein components of the BLyS heteromer consist of the mature extracellular soluble portion of either BLyS (e.g., amino acids residues 134-285 of SEQ ID NO:3228, or amino acids residues 134-266 of SEQ ID NO:3229) or fragments or variants thereof, or the mature extracellular soluble portion APRIL (e.g., amino acid residues 105-250 of SEQ ID NO:3239) or fragments or variants thereof. [0641 In specific embodiments, the antibodies of the invention bind conformational epitopes of a BLyS monomeric protein. In specific embodiments, the antibodies of the invention bind conformational epitopes of a BLyS multimeric, especially trimeric, protein. In other embodiments, antibodies of the invention bind conformational epitopes that arise from the juxtaposition of BLyS with a heterologous polypeptide, such as might be present when BLyS forms heterotrimers (e.g., with APRIL polypeptides (e.g., SEQ ID SEQ ID NO:3239)), or in fusion proteins between BLyS and a heterologous polypeptide. [0651 BLyS multimers bound by the antibodies of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, BLyS multimers, such as, for example, homodimers or homotrimers, are formed when polypeptides of the 22 invention contact one another in solution. In another embodiment, BLyS heteromultimers, such as, for example, BLyS heterotrimers or BLyS heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, BLyS multimers are formed by covalent associations with and/or between the BLyS polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in SEQ ID NO:3228 or SEQ ID NO:3229). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a BLyS fusion protein. In one example, covalent associations are between the heterologous sequence contained in a fusion protein (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in a BLyS-Fc fusion protein. In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another TNF family ligand/receptor member that is capable of forming covalently associated multimers, such as for example, oseteoprotegerin (see, e.g., International Publication No. WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from CD40L, or a soluble fragment thereof. In another embodiment, two or BLyS polypeptides are joined through synthetic linkers (e.g., peptide, carbohydrate or soluble polymer linkers). Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple BLyS polypeptides separated by peptide linkers may be produced using conventional recombinant DNA technology. 10661 In one embodiment, antibodies of the invention immunospecifically bind a BLyS polypeptide having the amino acid sequence of SEQ ID NO:3228 or as encoded by the cDNA clone contained in ATCC No. 97768, or a polypeptide comprising a portion (i.e., a fragment) of the above polypeptides. In another embodiment, the invention 23 provides an antibody that binds an isolated BLyS polypeptide having the amino acid sequence of SEQ ID NO:3229 or the amino acid sequence encoded by the cDNA clone contained in ATCC No. 203518, or a an antibody that binds polypeptide comprising a portion (i.e, fragment) of the above polypeptides. [0671 Antibodies of the present invention immunospecifically bind to polypeptides comprising or alternatively, consisting of, the amino acid sequence of SEQ ID NO:3228, encoded by the cDNA contained in the plasmid having ATCC accession number 97768, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone. Antibodies of the present invention also bind to fragments of the amino acid sequence of SEQ ID NO:3228, encoded by the cDNA contained in the plasmid having ATCC accession number 97768, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone. 10681 Additionally, antibodies of the present invention bind polypeptides comprising or alternatively, consisting of, the amino acid sequence of SEQ ID NO:3229, encoded by the cDNA contained in the plasmid having ATCC accession number 203518, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone. Antibodies of the present invention also bind to fragments of the amino acid sequence of SEQ ID NO:3229, encoded by the cDNA contained in the plasmid having ATCC accession number 203518, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone. [0691 In addition, antibodies of the invention bind polypeptides or polypeptide fragments comprising or alternatively, consisting of, an amino acid sequence contained in SEQ ID NOS: 3230 through 3237. 10701 In specific embodiments, the antibodies of the present invention immunospecifically bind polypeptide fragments including polypeptides comprising or alternatively, consisting of, an amino acid sequence contained in SEQ ID NO:3228, encoded by the cDNA contained in the deposited clone, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone. Protein fragments may be "free-standing," or comprised 24 within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments that may be bound by the antibodies of the present invention, include, for example, fragments that comprise or alternatively, consist of from about amino acid residues: 1 to 50, 51 to 100, 101 to 150, 151 to 200, 201 to 250, and/or 251 to 285 of SEQ ID NO:3228. Moreover, polypeptide fragments can be at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 175 or 200 amino acids in length. [0711 In specific embodiments, antibodies of the present invention bind polypeptide fragments comprising, or alternatively consisting of, amino acid residues: 1-46, 31-44,47-72, 73-285, 73-83, 94-102, 148-152, 166-181, 185-209, 210-221, 226-237, 244-249,253-265, and/or 277-285 of SEQ IDNO:3228. [0721 It will be recognized by one of ordinary skill in the art that mutations targeted to regions of a BLyS polypeptide of SEQ ID NO:3228 which encompass the nineteen amino acid residue insertion which is not found in the BLyS polypeptide sequence of SEQ 1D NO:3229 (i.e., amino acid residues Val-142 through Lys-160 of the sequence of SEQ ID NO:3229) may affect the observed biological activities of the BLyS polypeptide. More specifically, a partial, non-limiting and non-exclusive list of such residues of the BLyS polypeptide sequence which may be targeted for mutation includes the following amino acid residues of the BLyS polypeptide sequence as shown in SEQ ID NO:3228: V-142; T-143; Q-144;D-145; C-146; L-147; Q-148; L-149; 1-150; A-151; D-152; S-153; E-154; T-155; P-156; T-157; 1-158; Q-159; and K-160. Thus, in specific embodiments, antibodies of the present invention that bind BLyS polypeptides which have one or more mutations in the region from V-142 through K-160 of SEQ ID NO:3228 are contemplated. [073] Polypeptide fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments that may be bound by antibodies of the present invention, include, for example, fragments that comprise or alternatively, consist of from about amino acid residues: 1 to 15, 16-30, 31-46, 47-55, 56 72, 73-104, 105-163, 163-188, 186-2.10 and 210-284 of the amino acid sequence disclosed in SEQ ID NO:3228. Additional representative examples of polypeptide fragments that may be bound by antibodies of the present invention, include, for example, fragments that 25 comprise or alternatively, consist of from about amino acid residues: 1 to 143, 1-150, 47 143, 47-150, 73-143, 73-150, 100-150, 140-145, 142-148, 140-150, 140-200, 140-225, and 140-266 of the amino acid sequence disclosed in SEQ ID NO:3229. Moreover, polypeptide fragments that may be bound by antibodies of the present invention, can be at least 10, 20, 30,40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 175 or 200 amino acids in length. In this context, "about" means the particularly recited ranges and ranges larger or smaller by several, a few, 5, 4, 3, 2 or 1 amino acid residues at either or both the amino- and carboxy-termini. [074] Additional preferred embodiments encompass antibodies that bind polypeptide fragments comprising, or alternatively consisting of, the predicted intracellular domain of BLyS (e.g., amino acid residues 1-46 of SEQ ID NO:3228), the predicted transmembrane domain of BLyS (e.g., amino acid residues 47-72 of SEQ ID NO:3228), the predicted extraccilular domain of BLyS (e.g., amino acid residues 73-285 of SEQ ID NO:3228), the mature soluble extracellular domain of BLyS (e.g., amino acids residues 134-285 of SEQ ID NO:3228), the predicted TNF conserved domain of BLyS (e.g., amino acids 191 to 284 of SEQ ID NO:3228), and a polypeptide comprising, or alternatively, consisting of the predicted intracellular domain fused to the predicted extracellular domain of BLyS (amino acid residues 1-46 fused to amino acid residues 73-285 of SEQ ID NO:3228). [0751 Further additional preferred embodiments encompass polypeptide fragments comprising, or alternatively consisting of, the predicted intracellular domain of BLyS (amino acid residues 1-46 of SEQ ID NO:3229), the predicted transmembrane domain of BLyS (amino acid residues 47-72 of SEQ ID NO:3229), the predicted extracellular domain of BLyS (amino acid residues 73-266 of SEQ ID NO:3229), the predicted TNF conserved domain of BLyS (amino acids 172 to 265 of SEQ ID NO:3229), and a polypeptide comprising, or alternatively, consisting of the predicted intracellular domain fused to the predicted extracellular domain of BLyS (amino acid residues 1-46 fused to amino acid residues 73-266 of SEQ ID NO:3229). [0761 Certain additional embodiments of the invention encompass antibodies that bind polypeptide fragments comprising, or alternatively consisting of, the predicted beta pleated sheet regions of the BLyS polypeptides of SEQ ID NO:3228 and SEQ I) NO:3229. These polypeptide fragments comprising the beta-pleated sheets of BLyS 26 comprise, or alternatively consist of, amino acid residues Gln-144 to Ala-151, Phe-172 to Lys-173, Ala-177 to Glu-179, Asn-183 to Ile-185, Gly-191 to Lys-204, His-210 to Val 219, Leu-226 to Pro-237, Asn-242 to Ala-251, Gly-256 to Ile-263 and/or Val-276 to Leu 284 of SEQ ID NO:3228. In another, nonexclusive embodiment, these polypeptide fragments comprising the beta-pleated sheets of BLyS comprise, or alternatively consist of, amino acid residues Phe-153 to Lys-154, Ala-158 to Glu-160, Asn-164 to Ile-166, Gly 172 to Lys-185, His-191 to Val-200, Leu-207 to Pro-218, Asn-223 to Ala-232, Gly-237 to Ile-244 and/or Val-257 to Leu-265 of SEQ ID NO:3229. [077] A partial, non-limiting, and exemplary list of polypeptides that may be bound by the antibodies of the invention includes polypeptides that comprise, or alternatively consist of, combinations of amino acid sequences of the invention includes, for example, [Met-I to Lys-1 13] fused to [Leu-1 14 to Thr-141] fused to [Val-142 to Lys 160] fused to [Gly-161 to Gln-198] fused to [Val-199 to Ala-248] fused to [Gly-249 to Leu-285] of SEQ ID NO:3228; or [Met-I to Lys-1 13] fused to [Val-142 to Lys-160) fused to [Gly-161 to Gln-198] fused to [Val-199 to Ala-248] fused to [Gly-249 to Leu-285] of SEQ ID NO:3228; or [Met-1 to Lys-1 13] fused to [Leu-1 14 to Thr-141] fused to [Val-142 to Lys-160] fused to [Gly-161 to Gln-198] fused to [Gly-249 to Leu-285] of SEQ ID NO:3228. Other combinations of amino acids sequences that may be bound by the antibodies of the invention may include the polypeptide fragments in an order other than that recited above (e.g., [Leu-l 14 to Thr-141] fused to [Val-199 to Ala-248] fused to [Gly 249 to Leu-285] fused to [Val- 142 to Lys-160] of (SEQ ID NO:3228). Other combinations of amino acids sequences that may be bound by the antibodies of the invention may also include heterologous polypeptide fragments as described herein and/or other polypeptides or polypeptide fragments of the present invention (e.g., [Met-i to Lys 113] fused to [Leu-l 14 to Thr-141] fused to [Val-142 to Lys-160] fused to [Gly-161 to Gin-198] fused to [Gly-249 to Leu-285] of SEQ ID NO:3228 fused to a FLAG tag ; or [Met-1 to Lys-I 13] of SEQ ID NO:3228 fused to [Leu-114 to Thr-141] of SEQ ID NO:3228 fused to [Glu-135 to Asn-165] of SEQ ID NO:39 fused to [Val-142 to Lys-160] of SEQ ID NO:3228 fused to [Gly-161 to Gln-198] of SEQ ID NO:3228 fused to [Val-199 to Ala-248] of SEQ ID NO:3228 fused to [Gly-249 to Leu-285] of SEQ ID NO:3228). [078] A partial, non-limiting, and exemplary list of polypeptides that may be bound by the antibodies of the invention includes polypeptides that comprise, or 27 alternatively consist of, combinations of amino acid sequences includes, for example, [Met-1 to Lys-113] fused to [Leu-114 to Thr-141] fused to [Gly-142 to Gln-179] fused to [Val-180 to Ala-229] fused to [Gly-2.30 to Leu-266] of SEQ ID NO:3229; [Met-I to Lys 113] fused to [Gly-142 to Gln-179] fused to [Val-180 to Ala-229] fused to [Gly-230 to Leu-266] of SEQ ID NO:3229; or [Met-I to Lys-1 13] fused to [Leu-1 14 to Thr-141] fused to [Gly-142 to Gln-179] fused to [Gly-230 to Leu-266] of SEQ ID NO:3229. Other of amino acids sequences that may be bound by the antibodies of the invention combinations may include the polypeptide fragments in an order other than that recited above (e.g., [Leu-1 14 to Thr-141] fused to [Val-180 to Ala-229] fused to [Gly-230 to Leu-266] fused to [Gly-142 to Gln-179] of SEQ ID NO:3229). Other combinations of amino acid sequences that may be bound by the antibodies of the invention may also include heterologous polypeptide fragments as described herein and/or other polypeptides or polypeptide fragments of the present invention (e.g., [Met-I to Lys- 113] fused to [Leu-114 to Thr-141] fused to [Gly-142 to Gln-179] fused to [Gly-230 to Leu-266] of SEQ ID NO:3229 fused to a FLAG tag (SEQ ID NO:3238) or, [Met-I to.Lys-113] of SEQ ID NO:3229 fused to [Leu-1 14 to Thr-141] of SEQ ID NO:3229 fused to [Glu-135 to Asn 165] of SEQ ID NO:39 fused to [Gly-142 to Gln-179] of SEQ ID NO:3229 fused to [Val 180 to Ala-229] of SEQ ID NO:3229 fused to [Gly-230 to Leu-266] of SEQ ID NO:3229. [079] Additional embodiments of the invention encompass antibodies that bind BLyS polypeptide fragments comprising, or alternatively consisting of, functional regions of polypeptides of the invention, such as the Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou.-Fasman alpha-regions, beta-regions, and coil-regions, Kyte-Doolittle hydrophilic regions and hydrophobic regions, Eisenberg alpha- and beta-amphipathic regions, Karplus-Schulz flexible regions, Emini surface-forming regions and Jameson-Wolf regions of high antigenic index set out in Tables 9 and 10 and as described herein. In a preferred embodiment, the polypeptide fragments bound by the antibodies of the invention are antigenic (i.e., containing four or more contiguous amino acids having an antigenic index of greater than or equal to 1.5, as identified using the default parameters of the Jameson-Wolf program) of a complete (i.e., full-length) BLyS polypeptide (e.g., SEQ ID NOS:3228 and 3229). [0801 The data representing the structural or functional attributes of the BLyS polypeptide of SEQ ID NO:3228 (Table 9) or the BLyS polypeptide of SEQ ID NO:3229 28 (Table 10), as described above, was generated using the various modules and algorithms of the DNA* STAR set on default parameters. Column I represents the results of a Gamier-Robson analysis of alpha helical regions; Column II represents the results of a Chou-Fasman analysis of alpha helical regions; Column III represents the results of a Gamier Robson analysis of beta sheet regions; Column IV represents the results of a Chou-Fasman analysis of beta sheet regions; Column V represents the results of a Garnier Robson analysis of turn regions; Column VI represents the results of a Chou-Fasman analysis of turn regions; Column VII represents the results of a Gamier Robson analysis of coil regions; Column VIII represents a Kyte-Doolittle hydrophilicity plot; Column IX represents a Hopp-Woods hydrophobicity plot; Column X represents the results of an Eisenberg analysis of alpha amphipathic regions; Column XI represents the results of an Eisenberg analysis of beta amphipathic regions; Column XII represents the results of a Karplus-Schultz analysis of flexible regions; Column XIII represents the Jameson-Wolf antigenic index score; and Column XIV represents the Emini surface probability plot. [0811 In a preferred embodiment, the data presented in columns VIII, IX, XIII, and XIV of Tables 9 and 10 can be used to determine regions of the BLyS polypeptide of SEQ ID NO:3228 (Table 9) or the BLyS polypeptide of SEQ ID NO:3229 (Table 10) which exhibit a high degree of potential for antigenicity. Regions of high antigenicity are determined from the data presented in columns VIII, IX, XIII, and/or XIV by choosing values which represent regions of the polypeptide which are likely to be exposed on the surface of the polypeptide in an environment in which antigen recognition may occur in the process of initiation of an immune response. [0821 . The above-mentioned preferred regions set out in Tables 9 and 10 include, but are not limited to, regions of the aforementioned types identified by analysis of the amino acid sequence set out in SEQ ID NO:2. As set out in Tables 9 and 10, such preferred regions include Gamier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle hydrophilic regions, Eisenberg alpha- and beta-amphipathic regions, Karplus-Schulz flexible regions, Jameson-Wolf regions of high antigenic index and Emini surface-forming regions. Preferably, antibodies of the present invention bind BLyS polypeptides or BLyS polypeptide fragments and variants comprising regions of BLyS that combine several 29 structural features, such as several (e.g., 1, 2, 3 , or 4) of the same or different region features set out above and in Tables 9 and 10. 30 Table 9 Res Position I II V i y VI VHI VIl IX x XI XII X II Xlv Met I A . . . . . . 0.73 -0.71 . . . 0.95 139 Asp 2 A . . . . T . 1.12 -0.66 * . 1.15 1.56 Asp 3 A . - - . T . 1.62 -1.09 . . 1.15 2.12 Ser 4 A . . . T . 2.01 -1.51 . . . 1.15 4.19 Thr 5 A . . . . T . 2.40 -2.13 . . F 1.30 4.35 GIu 6 A A - - - - - 2.70 -1.73 * F 0.90 4.51 Arg 7 A A . . . . . 2.81 -1.34 * * F 0.90 4.51 Glu 8 A A . . . . . 2.00 -1.73 * * F 0.90 6.12 Gin 9 A A . . . . . 1.99 -1.53 * F 0.90 2.91 Ser 10 A . . B . . 2.00 -1.04 * F 0.90 2.15 Arg 11 A . . B . . . 1.33 -0.66 * F 0.90 1.66 Leu 12 A . . B . . . 0.41 -0.09 * F 0.45 0.51 Thr 13 A . . B . . . 0.46 0.20 * * F -0.15 0.32 Ser 14 A A . . . . . 0.50 -0.19 *. 0.30 0.32 Cys 15 A A . . . . . 0.91 -0.19 * * . 0.30 0.78 Leu 16 A A . . . . 0.80 -0.87 * F 0.90 1.06 Lys 17 A A . . . . . 1.61 -1.36 . F 0.90 1.37 Lys 18 A A . - . . 1.32 -1.74 . F 0.90 4.44 Arg 19 A A . . . . . 1.67 -1.70 . F 0.90 5.33 GIu 20 A A . . . 1.52 -239 . * F 0.90 5.33 Glu 21 A A - - . . 2.38 -1.70 . * F 0.90- 2.20 Met 22 A A . . . 2.33 -1.70 . * F 0.90 2.24 Lys 23 A A . . . . . 1.62 -1.70 * F 0.90 2.24 Leu 24 A A . . . . 0.66 -1.13 * F 0.75 0.69 Lys 25 A A . . . . . 0.36 -0.49 . F 0.45 0.52 GIu 26 A A . B . . . -0.53 -0.71 * . 0.60 0.35 Cys 27 A A . B . . . -0.74 -0.03 . 0.30 030 Val 28 A A . B . . -1.00 -0.03 * . 0.30 0.12 Ser 29 A A - B - - . -0.08 0.40 * . -0.30 0.11 Ile 30 A . . B . . . -008 0.40 * * -0.30 0.40 Leu 31 A . . B - . -0.08 -0.17 * . . 0.45 1.08 Pro 32 . . . B . . C 0.29 -0.81 . F 1.10 1.39 Arg 33 . . . . T . . 0.93 -0.81 . * F 1.50 2.66 Lys 34 . . . . T . . 0.93 -1.07 . . F 1.84 4.98 GIu 35 . . . . . . C 0.97 -1.37 * * F 1.98 4.32 Ser 36 . . . . . T C 1.89 -1.16 * F 2.52 1.64 Pro 37 . . . . . T C 1.80 -1.16 * F 2.86 1.60 Ser 38 . . . . T T . 1.39 -0.77 * F 3.40 1.24 Val 39 A . . . . T . 1.39 -0.39 . * F 2.36 1.24 Arg 40 A . . . . . . 1.39 -0.77 * * F 2.46 1.60 Ser 41 A . . . . . . 1.34 -1.20 * F 2.46 2.00 Ser 42 . . . . T T . 1.60 -1.16 . * F 3.06 2.67 Lys 43 . . . . T T . 1.09 -1.80 . * F 3.06 2.72 Asp 44 . . . . T T . 1.13 -1.11 * F 3.40 1.67 Gly 45 A . . . . T . 0.43 -0.81 * F 2.66 1.03 Lys 46 A A . . . . . 0:14 -0.70 . . F 1.77 0.52 Leu 47 A A . . . . . 0.13 -0.20 * . 0.98 0.31 Leu 48 A A . . . . . -0.72 0.29 . . 0.04 0.46 Ala 49 A A . . . . . -1.53 0.54 . . -0.60 0.19 Ala 50 A A . . . . . -2.00 1.23 . . . -0.60 0.19 31 Table 9 (continued) Res Position 1 11 Il IV V VI Vil VIII IX X Xl X11 X1 XlV Thr 51 A A . . . . . -2.63 1.23 . . . -0.60 0.19 Leu 52 A A . . -2.63 1.04 . . . -0.60 0.19 Leu 53 A A . . . . . -2.63 1.23 . . . -0.60 0.15 Leu 54 A A . . . . -2.34 1.41 . . . -0.60 0.09 Ala 55 A A . . . -2.42 1.31 . . -0.60 0.14 Leu 56 A A . . . . . -2.78 1.20 . . . -0.60 0.09 Leu 57 A . . . T . -2.78 1.09 . . . -0.20 0.06 Ser 58 A . . . . T . -2.28 1.09 . . . -0.20 0.05 Cys 59 A . . . T . -2.32 1.07 . . . -0.20 0.09 Cys 60 A . . . . T . -2.59 1.03 . . . -0.20 0.08 Leu 61 . . B B . . . -2.08 0.99 . . . -0.60 0.04 Thr 62 . . B B . . . -1.97 0.99 . . . -0.60 0.11 Val 63 . . B B . . -1.91 1.20 . . . -0.60 0.17 Val 64 . . B B . . . -1.24 1.39 . . . -0.60 0.33 Ser 65 . . B B . . . -1.43 1.10 . . . -0.60 0.40 Phe 66 A . . D . . . -1.21 1.26 . . . -0.60 0.40 Tyr 67 A . . B . . . -1.49 1.11 . . . -0.60 0.54 Gin 68 A . . B . . . -1.44 0.97 . . . -0.60 0.41 Val 69 A . . B . . . -0.59 1.27 . . . -0.60 0.39 Ala 70 A . B . . . -0.63 0.89 . . . -0.60 0.43 Ala 71 A . B . . . 0.07 0.56 . * . -0.60 0.25 Leu 72 A . . . T . -0.50 0.16 . * . 0.10 0.55 Gin 73 A . . . . T . -1.09 0.20 . . F 0.25 0.45 Gly 74 A . . . . T . -0.53 0.20 . . F 0.25 0.45 Asp 75 A . . . . T . -0.76 0.09 . F 0.25 0.73 Leu 76 A A . . . . . -0.06 0.09 . . F -0.15 0.35 Ala 77 A A . . . . . 0.17 -0.31 . . 0.30 0.69 Set 78 A A . . . . 0.17 -0.24 . . 0.30 0.42 Lou 79 A A . . . . . -0.30 -0.24 . . 0.30 0.88 Arg 80 A A . . . . . -0.30 -0.24 . * . 0.30 0.72 Ala 81 A A . . . . . 0.17 -0.34 . * . 0.30 0.93 Glu 82 A A . . . . . 0.72 -0.30 . * . 0.45 1.11 LCu 83 A A . . . . . 0.99 -0.49 . . 0.30 0.77 Gin 84 A A - . . . . 1.21 0.01 . . -0.15 1.04 Gly 85 A A . . . . . 1.10 0.01 * * -0.30 0.61 His 86 A A . . . . . 1.73 0.01 * . -0.15 1.27 His 87 A A . . . . . 0.92 -0.67 . * . 0.75 1.47 Ala 88 A A . . . . . 1.52 -039 . . 0.45 1.22 Glu 89 A A . . . . . 0.93 -039 . . . 0.45 1.39 Lys 90 A A . . . . . 0.93 -039 * . F 0.60 1.03 Leu 91 A . . . . T . 0.38 -0.46 . . 0.85 1.01 Pro 92 A . . . . T . 0.07 -0.46 . . . 0.70 0.59 Ala 93 A . . . . T . 0.07 -0.03 . . . 0.70 0.29 Gly 94 A . . . . T . -0.14 0.47 . . . -0.20 0.36 Ala 95 A . . . . . . -0.14 0.21 . . -0.10 0.36 Gly 96 A . . . . . . 0.08 -0.21 . . F 0.65 0.71 Ala 97 A . . . . . . -0.06 -0.21 . . F 0.65 0.72 Pro 98 A . . . . . . -0.28 -0.21 . * F 0.65 0.71 Lys 99 A A . . . . . 0.07 -0.03 . . F 0.45 0.59 Ala 100 A A . . . . . 0.66 -0.46 . . F 0.60 1.01 32 Table 9 (continued) Res Position I 11 III IV V VI VII VIll IX X XI XI XIII xiv Gly 101 A A . . . . . 0.41 -0.96 . . F 0.90 1.13 Leu 102 A A . . . . . 0.79 -0.89 . . F 0.75 0.57 Glu 103 A A . . . . . 0.41 -0.46 * . F 0.45 0.88 Glu 104 A A . . . . . -0.49 -0.46 * . F 0.45 0.89 Ala 105 A A . . . . . -0.21 -0.24 . . . 0.30 0.81 Pro 106 A A . . . . . -0.46 -0.44 . . . 0.30 0.67 Ala 107 A A . . . . . 0.01 0.06 . . . -0.30 0.39 Val 108 A A . . . . . -0.80 0.49 . * -0.60 0.38 Thr 109 A A . . . . . -0.76 0.67 . * . -0.60 0.20 Ala 110 A A . . . . -1.06 0.24 * * . -0.30 0.40 Gly 111 A A . . . . -1.54 0.43 * . -0.60 0.38 Leu 112 A A . . . . . -0.96 0.57 * * . -0.60 0.23 Lys 113 . A B . . . . -0.31 0.09 * * . -0.30 0.39 lIe 114 . A B . . . -0.21 0.01 . . -0.30 0.61 Phe 115 . A B . . . . -0.21 0.01 * . . 0.15 1.15 Glu 116 . A . . . . C -0.08 -0.17 * F 1.25 0.58 Pro 117 . A . . . . C 0.39 0.26 * * F 1.10 1.28 Pro 118 . . . . . C 0.34 -0.00 . . F 2.20 1.47 Ala 119 . . . . . T C 0.89 -0.79 * F 3.00 1.47 Pro 120 . . . . . 7 C 1.59 -0.36 F 2.25 0.94 Gly 121 . . . . T T . 1.29 -0.39 . F 2.1.5 0.98 Glu 122 . . . . T T . 1.20 -0.43 . . F 2.00 1.30 Gly 123 . . . . . . C 1.41 -0.54 . . F 1.60 1.12 Asn 124 . . . . T C 2.00 -0.57 . . F 1.50 1.97 Ser 125 . . . . . T C 1.91 -0.60 . * F 1.50 1.82 Ser 126 . . . . . T C 2.37 -0.21 . F 1.54 2.47 Gin 127 . . . . . T C 2.37 -0.64 . * F 2.18 3.01 Asn 128 . . . . . . C 2.76 -0.64 . . F 2.32 3.61 Ser 129 . . . . . T C 2.87 -1.03 . . F 2.86 5.39 Arg 130 . . . . T T . 2.58 -1.41 . F 3.40 6.09 Asn 131 . . . . T T . 2.02 -1.31 . F 3.06 3.83 LyS 132 . . . . T T . 2.02 -1.07 . F 2.72 2.12 Arg 133 . . . . T . . 1.68 -1.06 * . F 2.18 1.88 Ala 134 . . . . . . C 1.77 -0.63 * . F 1.64 1.15 Val 135 . . . . . . C 1.66 -0.60 * . F 1.49 0.89 Gin 136 . . . . . . C 1.66 -0.60 * . F 1.83 0.79 Gly 137 . . . . . T C 1.30 -0.60 * . F 2.52 1.35 Pro 138 . . . . . T C 0.33 -0.61 * . F 2.86 2.63 Glu 139 . . . . T T . 0.61 -0.61 * . F 3.40 1.13 Glu 140 A . . . . T . 1.47 -0.53 * . F 2.66 1.64 Thr 141 A . . . . . . 1.47 -0.56 . . F 2.12 1.84 Val 142 A . . . . . . 1.14 -0.99 . . F 1.78 1.77 Thr 143 A . . . . T . 0.54 -0.41 . . F 1.19 0.55 Gin 144 A . . . . T . 0.54 0.27 . F 0.25 0.31 Asp 145 A . . . . T . -0.27 0.19 * . F 0.25 0.73 Cys 146 A . . . . T . -0.84 0.23 * . . 0.10 0.42 L.Cu 147 A A . . . . . -0.58 0.43 . . -0.60 0.17 Gin 148 A A . . . . . -0.27 0.53 . . -0.60 0.10 Leu 149 A A . . . . . -0.57 0.53 * . -0.30 0.32 Ile 150 A A . . . . . -0.57 0.34 * . 0.30 0.52 33 Table 9 (continued) Res Position 1 11 111 IV V VI VII Vill IX X XI X1XIO XIV Ala 151 . A . . . . C -0.21 -0.34 . * . 1.40 0.52 Asp 152 . . . . T T . 0.39 -0.26 . * F 2.45 0.91 Ser 153 . . . . . T C 0.08 -0.51 . . F 3.00 2.00 Glu 154 . . . . T C -0.00 -0.71 . . F 2.70 2.86 Thr 155 . . . . T C 0.89 -0.53 * . F 2.40 1.20 Pro 156 . . B . . C 1.52 -0.13 * . F 1.56 1.55 Thr 157 . B T . . 1.18 -0.51 * . F 1.92 1.79 lie 158 A . . B . 1.18 -0.09 . . F 1.08 1.23 GIn 159 . . . . T T . 0.93 -0.19 . . F 2.04 1.07 Lys 160 . . . . T T . 0.93 0.14 * . F 1.60 1.16 Gly 161 . . . . T T . 0.44 0.14 . F 1.44 2.38 Ser 162 . . . . T T . -0.10 0.24 . F 1.28 1.19 Tyr 163 . . . B T . . 0.58 0.49 * . . 0.12 0.44 Thr 164 . . B B . . . 0.29 0.91 * . -0.44 0.69 Phe 165 - . . B D . . . -0.57 1.40 * . . -0.60 0.54 Val 166 . . B B . . . -1.03 1.70 . . . -0.60 0.29 Pro 167 . . B B . . . -1.03 1.63 . . . -0.60 0.16 Trp 168 A . . B . . . -1.49 1.53 . * . -0.60 0.25 Leu 169 A B . . . -1.13 1.53 . . -0.60 0.29 Lu 170 A B . . . -0.32 0.89 * . . -0.30 0.38 Ter 171 A . . . 0.19 0.46 * . . 0.20 0.71 Phe 172 . T . . 0.10 -0.03 * . . 1.80 0.85 Lys 173 . . . . T T . -0.20 -0.33 * . F 2.60 1.38 Arg 174 . . . . . T C -0.20 -0.51 . . F 3.00 1.04 Gly 175 . . . . . . T C 0.61 -0.21 . . F 2.25 0.99 Ser 176 A . . . . T . 0.91 -1.00 . F 2.05 0.86 Ala 177 A A . . . . . 1.66 -1.00 * . F 1.35 0.76 Leu 178 A A . . . . . 1.61 -1.00 . . F 1.20 1.54 Glu 179 A A . . . . . 1.50 -3.43 . . F 0.90 1.98 Glu 180 A A . . . . . 1.89 -1.41 * . F 0.90 3.16 Lys 181. A A . . . . . 1.30 -1.91 . F 0.90 7.66 Glu 182 A A . . . . . 1.08 -1.91 . . F 0.90 3.10 Asn 183. A A . . . . . 1.03 -1.23 F 0.90- 1.48 Lys 184 A A . . . . . 1.08 -0.59 * F 0.75 0.55 lie 185 A A . . . . . 1.08 -0.59 * * . 0.60 0.63 Leu 186 A A . . . . . 0.72 -0.59 * * 0.60 0.68 Val 187 A A . . . . . 0.38 -0.50 . * . 0.30 0.49 Lys 188 A A . . . . . 0.13 -0.07 * * F 0.45 0.69 GIu 189 A . . . . T . -0.61 0.00 * F 0.40 1.32 Thr 190 . . . T T .- 0.42 0.10 . * F 0.80 1.54 Gly 191 . . . . T T . -0.50 0.24 * . F 0.65 0.67 Tyr 192 . . . . T T . 0.11 0.93 * * . 0.20 0.27 Phe 193 . . B B . . . -0.28 1.69 . . . -0.60 0.29 Phe 194 . . . B B . . . -0.28 1.63 . * . -0.60 0.29 lie 195 . . B B . . . -0.82 1.60 . . . -0-60 0.32 Tyr 196 . . B B . . . -1.29 1.49 . . . -0.60 0.28 Gly 197 . . . B T . . -1.29 1.39 . . . -0.20 0.26 GIn 198 . . . B T . . -0.90 1.36 . . . -0.20 0.59 Val 199 . . B . . C -0.20 1.16 . . -0.40 0.54 LCu 200 . . B . . C 0.73 0.40 . . . -0.10 0.92 34 Table 9 (continued) Res Position I U 1ll IV V VI VII VIII IX X XT XI XII XIV Tyr 201 . . . . T T . 0.67 -0.03 . . . 1.25 1.06 Thr 202 . . . . T T . 0.77 0.06 . . F 0.80 2.06 Asp 203 . . . . T T . 0.18 0.17 . . F 0.80 3.91 Lys 204 A . . . . T . 0.43 -0.01 . . F 1.00 2.52 Thr 205 A A . . . . . 0.90 -0.16 . . F 0.60 1.73 Tyr 206 A A . . . . . 1.11 -0.21 . . . 0.45 1.03 Ala 207 A A . . . . . 0.61 0.29 . . -0.30 0.70 Met 208 A A . . . . . -0.28 0.97 . . . -0.60 0.40 Gly 209 A A - B . . . -0.32 1.17 . . -0.60 0.18 His 210 A A . B . . . 0.10 0.81 . . -0.60 0.31 LCu 211 A A . B . . . 0.39 0.31 . . . -0.30 0.61 lie 212 A A . B . . . 1.02 -0.30 . . 0.45 1.22 Gin 213 A A . B . . . 0.77 -0.73 . . 0.75 1.80 Arg 214 A A . B . . . 1.08 -0.59 . * F 0.90 1.62 Lys 215 A A . B . . . 0.26 -0.77 F 0.90 3.14 Lys 216 A A . B . . . 0.37 -0.81 . * F 0.90 1.35 Val 217 . A B B . . . 0.91 -0.43 . 0.30 0.60 His 218 . A B B . . . 0.91 -0.00 . * .- 0.30 0.29 Val 219 . A B B . . . 0.80 -0.00 . 0.30 0.25 Pbe 220 . . B B . . -0.06 -0.00 . . 0.30 0.57 Gly 221 A . . B . . . -0.40 0.04 . * . -0.30 0.35 Asp 222 A . . . . . . -0.36 -0.07 . . 0.50 0.63 GIu 223 A . . . . . . -1.18 -0.03 * . . 0.50 0.60 Leu 224 A . . B . . . -0.63 -0.17 . . . 0.30. 0.45 Ser 225 A . . B . . . -0.74 -0.11 . . . 0.30 0.39 Leu 226 A . . B . . . -1.10 0.57. . -0.60 0.18 Val 227 A . . B . . . -0.99 1.36 . * -0.60 0.19 Thr 228 A . . B . . . -1.66 0.67 * -0.60 0.28 Leu 229 A . . B . . . -1.73 0.86 . . -0.60 0.18 Phe 230 A . . B . . . -1.43 0.86. * . . -0.60 0.17 Arg 231 A . . B . . . -0.62 0.61 * . -0.60 0.21 Cys 232 . . . B T . . -0.37 0.53 . . -0.20 0.41 Ile 233 . . . B T . . -0.27 0.46 * . . -0.20 0.46 Gin 234 . . . B T . . 0.54 0.10 * . . 0.10 0.37 Asn 235 . . . B . . C 0.93 0.10 . . 0.05 1.19 Met 236 . . . B . . C 0.01 0.01 . F 0.20 2.44 Pro 237 . . . B . . C 0.47 0.01 . F 0.44 1.16 Glu 238 . . . . T . . 1.36 0.04 * F 1.08 1.12 Thr 239 . . . . . . C 1.36 0.04 * . F 1.12 1.82 Leu 240 . . . . . . C 1.06 -0.17 . F 1.96 1.89 Pro 241 . . . . T . . 0.99 -0.21 . . F 2.40 1.46 Asn 242 . . . . T . . 0.96 0.36 . . F 1.41 0.54 Asn 243 . . . . . T T . 0.66 0.63 . . F 1.22 1.03 Scr 244 . . . . T T . 0.38 0.33 . . F 1.13 0.89 Cys 245 . . . . T T . 0.84 0.40 . . . 0.74 0.56 Tyr 246 . . . . T T . 0.17 0.43 . . . 0.20 0.35 Ser 247 A . . . . . . -0.42 0.71 . . . -0.40 0.18 Ala 248 A A . . . . . -0.38 0.83 . . . -0.60 0.34 Gly 249 A A . . . . . -0.89 0.26 . . . -0.30 0.43 lie 250 A A . . . . . -0.22 0.19 * . . -0.30 0.27 35 Table 9 (continued) Res Position I 11 mI IV V vi Vil ViII IX X Xi XIIXIII XIV Ala 251 A A . . . . . 0.02 -0.20 * . 0.30 0.46 Lys 252 A A . . . . . -0.02 -0.70 . . . 0.60 0.80 Leu 253 A A . . . . . 0.57 -0.70 . . F 0.90 1.13 Giu 254 A A . . . . . 0.91 -1.39 . . F 0.90 1.87 Glu 255 A A - . . - - 0.99 -1.89 - . F 0.90 1.62 Gly 256 A A . . . . . 1.58 -1.20 . * F 0.90 1.62 Asp 257 A A . . . . . 0.72 -1.49 . * F 0.90 1.62 Glu 258 A A . . . . . 0.94 -0.80 * F 0.75 0.77 Leu 259 A A . - - - . 0.06 -0.30 * * . 0.30 0.79 Gin 260 A A . . . . -0.16 -0.04 . . 0.30 0.33 Leu 261 A A . . . . 0.30 0.39 * . . -0.30 0.30 Ala 262 A A . . . . 0.30 0.39 * . -0.30 0.70 Ile 263 A A . . . . 0.30 -0.30 . * . 0.30 0.70 Pro 264 A . . . T . 0.52 -0.30 . F 1.00 1.37 Arg 265 A . . . T . 0.52 -0.49 . * F 1.00 1.37 Glu 266 A . . . T . 0.44 -0.59 * * F 1.30 3.38 Asn 267 A . . . . T . 0.73 -0.59 * * F 1.30 1.53 Ala 268 A . . . . . 0.81 -063 * * . 0.95 1.05 Gin 269 A . . . . . . 1.02 0.06 * * . -0.10 0.50 Ile 270 A . . . . . . 0.57 0.06 . . 0.15 0.52 Ser 271 . . . . - C 0.57 0.09 . . 0.60 0.51 Leu 272 . . . . . . C -0.29 -0.41 . * F 1.60 0.49 Asp 273 . . . . T T . -0.01 -0.17 . * F 2.25 0.52 Gly 274 . . . . T T . -0.71 -0.37 . * F 2.50 0.56 Asp 275 . . . . T T . -0.52 0.03 . * F 1.65 0.59 Val 276 A . . . T . -0.57 0.13 . F 1.00' 0.30 Thr 277 A . . B . . . -0.34 0.56 . . -0.10 0.30 Phe 278 A . . B . . . -1.16 0.63 . . -0.35 0.18 Phe 279 A . . B . . . -0.77 1.31 . . -0.60 0.20 Gly 280 A A . . . . -1.58 0.67 . . -0.60 0.28 Ala 281 A A . . . . . -1.53 0.87 . * . -0.60 0.27 Leu 282 A A . . . . . -1.61 0.77 . . -0.60 0.26 Lys 283 A A . . . . . -1.30 0.41 * . -0.60 0.33 Leu 284 A A . . . . . -0.99 0.41 . . . -0.60 0.42 Leu 285 A A . . . . . -1.03 0.34 . . -0.30 0.65 36 Table 10 Res Position I 11 Ill IV V VI VII VIII IX X XI XIIXIII XIV Met I A . . . . . . 0.73 -0.71 . . 0.95 1.39 Asp 2 A . . . . T . 1.12 -0.66 * . . 1.15 1.56 Asp 3 A . . . . T . 1.62 -1.09* . . 1.15 2.12 Ser 4 A . . . . T . 2.01 -1.51 . . . 1.15 4.19 Thr 5 A . . . . T . 2.40 -2.13 . . F 1.30 4.35 Glu 6 A A . . . . . 2.70 -1.73 * * F 0.90 4.51 Arg 7 A A . . . . . 2.81 -1.34 * F 0.90 4.51 Glu 8 A A . . . . . . 2.00 -1.73 * F 0.90 6.12 Gln 9 A A . . . . . 1.99 -1.53 * * F 0.90 2.91 Ser 10 A . . B . . . 2.00 -1.04* F 0.90 2.15 Arg 11 A . . B . . . 1.33 -0.66 * * F D.90 1.66 Leu 12 A . . B . . . 0.41 -0.09 * F 0.45 0.51 Thr 13 A . B . . . 0.46 0.20 * F -0.15 0.32 Ser 14 A A . . . . . 0.50 -0.19 *. 0.30 0.32 Cys 15 A A . . . . . 0.91 -0.19 * * 0.30 0.78 Leu 16 A A . . . . . 0.80 -0.87 * F 0.90 1.06 Lys 17 A A . . . . . 1.61 -1.36 . * F 0.90 1.37 Lys 18 A A . . . 1.32 -1.74 . F 0.90 4.44 Arg 19 A A . . . . . 1.67 -1.70. * F 0.90 5.33 GIu 20 A A . . 1.52 -2.39 . * F 0.90 5.33 Glu 21 A A - - - 2.38 -1.70 . F 0.90 2.20 Met 22 A A . . . . 2.33 -1.70. * F 0.90 2.24 Lys 23 A A . . . . 1.62 -1.70 F 0.90 2.24 Leu 24 A A . . . . 0.66 -1.13 * F 0.75 0.69 Lys 25 A A . . . . 0.36 -0.49 . F 0.45 0.52 Glu 26 A A . B . . -0.53 -0.71 . 0.60 0.35 Cys 27 A A . B . . . -0.74 -0.03 . 0.30 0.30 Val 28 A A . B . . . -1.00 -. 03* . 0.30 012 Ser 29 A A . B . . . -0.08 0.40 * . -0.30 0.11 lie 30 A . . B . . . -0.08 0.40 . -0.30 0.40 Lcu 31 A . . B . . . -0.08 -0.17 . . 0.45 1.08 Pro 32 . . . B . . C 0.29 -0.81 . F 1.10 1.39 Arg 33 . . . . T . . 0.93 -0.81 . * F 1.50 2.66 Lys 34 . . . . T . . 0.93 -1.07 . . F 1.84 4.98 Glu 35 . . . . . . C 0.97 -1.37 * * F 1.98 4.32 Ser 36 . . . . . T C 1.89 -1.16 * F 2.52 1.64 Pro 37 . . . . . T C 1.80 -1.16 F 2.86 1.60 Ser 38 . . . . T T . 1.39 -0.77 * . F 3.40 1.24 Val 39 A . . . . T . 1.39 -0.39 . F 2.36 1.24 Arg 40 A . . . . . - 1.39 -0.77 F 2.46 1.60 Ser 41 A . . . . . . 1.34 -1.20 * * F 2.46 2.00 Ser 42 . . . . T T . 1.60 -1.16. F 3.06 2.67 Lys 43 . . . . T T . 1.09 -1.80 F 3.06 2.72 Asp 44 - . . . T T . 1.13 -1.11 * F 3.40 1.67 Gly 45 A . . . . T . 0.43 -0.81* F 2.66 1.03 Lys 46 A A . . . . . 0.14 -0.70 . . F 1.77 0.52 Leu 47 A A . . . . . 0.13 -0.20 * . . 0.98 0.31 Lu 48 A A . . . . . -0.72 0.29 . . 0.04 0.46 Ala 49 A A . . . . . -1.53 0.54 . . -0.60 0.19 Ala 50 A A . . . . . -2.00 1.23 . . . -0.60 0.19 37 Table 10 (continued) Res Position I 11 III IV V VI VlI VIII IX X XI XI XIII XIV Thr 51 A A . . -2.63 1.23 . . -0.60 0.19 Leu 52 A A -2.63 1.04 . . . -0.60 0.19 Leu 53 A A . . . . . -2.63 1.23 . . . -0.60 0.15 Leu 54 A A . . . . -2.34 1.41 . . . -0.60 0.09 Ala 55 A A . . . . -2.42 1.31 . . . -0.60 0.14 Leu 56 A A . . . . -2.78 1.20 . . . -0.60 0.09 Leu 57 A . . . T . -2.78 1.09 . . . -0.20 0.06 Ser 58 A . . . T . -2.28 1.09 . . . -0.20 0.05 Cys 59 A . . . T . -2.32 1.07 . . . -0.20 0.09 Cys 60 A . . . T . -2.59 1.03 . . . -0.20 0.08 Len 61 . . B B . . -208 0.99 . . . -0.60 0.04 Thr 62 . . B B -1.97 0.99 . . . -0.60 0.11 Val 63 . . B B . -1.91 1.20 . . . -0.60 0.17 Val 64 . . . B B . . -1.24 1.39 . . . -0.60 033 Ser 65 . . B B . . -1.43 1.10 . . . -0.60 0.40 Phe 66 A . . B . . -1.21 1.26 . . . -0.60 0.40 Tyr 67 A . . B . . -1.49 1.11 . . . -0.60 0.54 Gin 68 A . . B . . -1.44 0.97 . . . -0.60 0.41 Val 69 A . . B . . . -0.59 1.27 . . . -0.60 0.39 Ala 70 A . . B . . . -0.63 0.89 . . . -0.60 0.43 Ala I1 A . . B . . . 0.07 0.56 . * . -0.60 0.25 Leu 72 - A . . . . T . -0.50 0.16 . . . 0.10 0.55 Gin 73 A . . . . T . -1.09 0.20 . . F 0.25 0.45 Gly 74 A . . . . T . -0.53 0.20 . . F 0.25 0.45 Asp 75 A . . . . T . -0.76 0.09 . F 0.25 0.73 Leu 76 A A . . . . . -0.06 0.09 . F -0.15 0.35 Ala 77 A A . . . . . 0.17 -0.31 . . 0.30 0.69 Ser 78 A A . . . . . 0.17 -0.24 . . 0.30 0.42 Leu 79 A A . . . . . -0.30 -0.24 . . 0.30 0.88 Arg 80 A A . . . . . -0.30 -0.24. . 0.30 0.72 Ala 81 A A . . . . . 0.17 -0.34 . * . 0.30 0.93 Glu 82 A A . . . . . 0.72 -0.30 . . 0.45 1.11 Leu 83 A A . . . . . 0.99 -0.49 . . 0.30 0.77 Gin 84 A A . . . . . 1.21 0.01 . . -0.15 1.04 Gly 85 A A . . . . . 1.10 0.01 * * -0.30 0.61 His 86 A A . . . . . 1.73 0.01 . -0.15 1.27 His 87 A A . . . . . 0.92 -0.67 . . 0.75 1.47 Ala 88 A A . . . . . 1.52 -0.39. . 0.45 1.22 Glu 89 A A . . . . . 0.93 -0.39 . . . 0.45 1.39 Lys 90 A A . . . . . 0.93 -0.39 * . F 0.60 1.03 Leu 91 A . . . . T . 0.38 -0.46 * . . 0.85 1.01 Pro 92 A . . . . T . 0.07 -0.46 . . . 0.70 0.59 Ala 93 A . . . . T . 0.07 -0.03 . . . 0.70 0.29 Gly 94 A . . . . T . -0.14 0.47 . . . -0.20 0.36 Ala 95 A . . . . . . -0.14 0.21 . . -0.10 0.36 Gly 96 A . . . . . . 0.08 -0.21 . . F 0.65 0.71 Ala 97 A . . . . . . -0.06 -0.21 . . F 0.65 0.72 Pro 98 A . . . . . . -0.28 -0.21 . F 0.65 0.71 Lys 99 A A . . . . . 0.07 -0.03 . . F 0.45 0.59 Ala 100 A A . . . . . 0.66 -0.46 . . F 0.60 1.01 38 Table 10 (continued) Res Position I 11 III IV V VI VII VUII IX X XI XII XIII XIV Gly 101 A A . . . . . 0.41 -0.96 . . F 0.90 1.13 Leu 102 A A . . . . . 0.79 -0.89 . . F 0.75 0.57 Glu 103 A A . . . . . 0.41 -0.46 . F 0.45 0.88 Glu 104 A A . . . . . -0.49 -0.46 * F 0.45 0.89 Ala 105 A A . . . . . -0.21 -0.24 . . . 0.30 0.81 Pro 106 A A . . . . -0.46 -0.44 . . 0.30 0.67 Ala 107 A A . . . . . 0.01 0.06 . . . -0.30 0.39 Val 108 A A . . . . . -0.80 0.49 . -0.60 0.38 Tbr 109 A A . . . . . -0.76 0.67 . . -0.60 0.20 Ala 110 A A . . . . . -1.06 0.24 * * -0.30 0.40 Gly 1II A A . . . . . -1.54 0.43 * * . -0.60 0.38 Leu 112 A A . . . . . -0.96 0.57 * -0.60 0.23 Lys 113 . A B . . . . -0.31 0.09 * * . -0.30 0.39 lie 114 . A B . . . . -0.21 0.01 * . -0.30 0.61 Phe 115 . A B . . . . -0.21 0.01 * . . 0.15 1.15 Glu 116 . A . . . . C -0.08 -0.17 . F 1.25 0.58 Pro 117 . A . . . . C 0.39 0.26 * * F 1.10 1.28 Pro 118 . . . . . . C 0.34 0.00 * . . F 2.20 1.47 Ala 119 . . . . . T C 0.89 -0.79. F 3.00 1.47 Pro 120 . . . . . T C 1.59 -0.36 . * F 2.25 0.94 Gly 121 . . . . T T . 1.29 -0.39 . F 2.15 0.98 Glu 122 . . . . T T . 1.20 -0.43 . . F 2.00 1.30 Gly 123 . . . . . . C 1.41 -0.54 . . F 1.60 1.12 Asn 124 . . . . . T C 2.00 -0.57 . . F 1.50 1.97 Ser 125 . . . . . T C 1.91 -0.60 . * F 1.50 1.82 Ser 126 . . . . . T C 237 -0.21. F 1.54 2.47 GIn 127 . . . . . T C 2.37 -0.64. * F 2.18 3.01 Asn 128 . . . . . . C 2.76 -0.64 . . F 2.32 3.61 Ser 129 . . . . . T C 2.87 -1.03 . . F 2.86 5.39 Arg 130 . . . . T T . 2.58 -1.41* . F 3.40 6.09 Asn 131 . . . . T T . 2.02 -1.31* . F 3.06 3.83 Lys 132 . . . . T T . 2.02 -1.07* . F 2.72 2.12 Arg 133 . . . . T . . 1.68 -1.06 * . F 2.18 1.88 Ala 134 . . . . . . C 1.77 -0.63 . F 1.64 1.15 Val 135 . . . . . . C 1.66 -0.60 * . F 1.15 0.89 GIn 136 . . . . . . C 1.66 -0.60 * . F 1.49 0.79 Gly 137 . . . . . T C 1.30 -0.60 * . F 2.18 1.35 Pro 138 . . . . . T C 0.84 -0.61 * . F 2.52 2.63 Glu 139 . . . . . T C 1.13 -0.83 . F 2.86 1.50 Glu 140 . . . . T T . 1.74 -0.84 . . F 3.40 2.03 Thr 141 . . . . T . . 1.43 -0.51 . . F 2.86 2.06 Gly 142 . . . . T T . 1.08 -0.46 . . F 2.42 1.72 Ser 143 . . . . T T . 0.43 0.33 . . F 1.33 0.86 Tyr 144 . . . . T T . 0.22 0.97 . . . 0.54 0.44 Thr 145 . . . . T T -0.07 0.91 . . . 0.20 0.69 Phe 146 . . B B . . . -0.57 1.40 . . . -0.60 0.54 Val 147 . . B B . . . -1.03 1.70 . . . -0.60 0.29 Pro 148 . . B B . . . -1.03 1.63 . . . -0.60 0.16 Trp 149 A . . B . . . -1.49 1.53. * -0.60 0.25 Leu 150 A . . B . . . -1.13 1.53 * . . -0.60 0.29 39 Table 10 (continued) Res Position I H1 III IV V VI VII VIII IX X X " XII XIII XIV Leu 151 A . . B . . . -0.32 0.89 * . -030 0.38 Ser 152 A . . . . . . 0.19 0.46 * . . 0.20 0.71 Phe 153 . . T . . 0.10 -0.03 * . . 1.80 0.85 Lys 154 . . . . T T . -0.20 -0.33 * . F 2.60 1.38 Arg 155 . . . . . T C -0.20 -0.51 . . F 3.00 1.04 Gly 156 . . . . . T C 0.61 -0.21 . . F 2.25 0.99 Ser 157 A . . . . T . 0.91 -1.00 * . F 2.05 0.86 Ala 158 A A . . . . . 1.66 -1.00 . F 1.35 0.76 Leu 159 A A . . . . . 1.61 -1.00 . . F 1.20 1.54 Glu 160 A A . . . . . 1.50 -1.43 . . F 0.90 1.98 Glu 161 A A . . . . . 1.89 -1.41 * . F 0.90 3.16 Lys 162 A A . . . . . 1.30 -1.91* . F 0.90 7.66 GIu 163 A A . . . . . 1.08 -1.91 . . F 0.90 3.10 Asn 164 A A . . . . . 1.03 -1.23 * F 0.90 1.48 Lys 165 A A . . . . . 1.08 -0.59 * . F 0.75 0.55 lIe 166 A A . . . . 1.08 -0.59 * . 0.60 0.63 Leu 167 A A . . . . . 0.72 -0.59 * * . 0.76 0.68 Val 168 A A . . . . . 0.38 -0.50 . . 0.92 0.49 Lys 169 A A . . . . . 0.13 -0.07 * * F 0.93 0.69 Glu 170 A . . . . T . -0.61 0.00'* * F 1.64 1.32 Thr 171 . . . . T T . -0.42 0.10 . * F 1.60 1.54 Gly 172 . . . . T T . -0.50 0.24 * . F 1.29 0.67 Tyr 173 . . . . T T . 0.11 0.93 * . 0.68 0.27 Phe 174 . . B B . . . -0.28 1.69 . . . -0.28 0.29 Phe 175 . . B B . . . -0.28 1.63 . * . -0.44 0.29 Ile 176 . . . B B . . . -0.82 1.60 . . . -0.60 0.32 Tyr 177 . . B B . . . -1.29 1.49 . . . -0.60 0.28 Gly 178 . . . B T . . -1.29 1.39 . . . -0.20 0.26 Gin 179 . . . B T . . -0.90 1.36 . . . -0.20 0.59 Val 180 . . . B . . C -0.20 1.16 . . . -0.40 0.54 Lu 181 . . . B . . C 0.73 0.40 . . . -0.10 0.92 Tyr 182 . . . . T T . 0.67 -0.03 . . . 1.25 1.06 Thr 183 . . . . T T . 0.77 0.06. . . F 0.80 2.06 Asp 184 . . . . T T . 0.18 0.17 . . F 0.80 3.91 Lys 185 A . . . . T . 0.43 -0.01 . . F 1.00 2.52 Thr 186 A A . . . . . 0.90 -0.16 . . F 0.60 1.73 Tyr 187 A A . . . . . 1.11 -0.21 . . . 0.45 1.03 Ala 188 A A . . . . . 0.61 0.29 . . . -0.30 0.70 Met 189 A A . . . . . -0.28 0.97 . . . -0.60 0.40 Gly 190 A A . B . . . -0.32 1.17 . . -0.60 0.18 His 191 A A . B . . . 0.10 0.81 * . . -0.60 0.31 Leu 192 A A . B . . . 0.39 0.31 . . . -0.30 0.61 lie 193 A A . B . . . 1.02 -0.30 . . . 0.45 1.22 Gin 194 A A . B . . ,. 0.77 -0.73. * 0.75 1.80 Arg 195 A A . B . . . 1.08 -0.59* * F 0.90 1.62 Lys 196 A A . B . . . 0.26 -0.77* * F 0.90 3.14 Lys 197 A A . B . . . 0.37 -0.81. * F 0.90 1.35 Val 198 . A B B . . . 0.91 -0.43* * 0.30 0.60 His 199 . A B B . . . 0.91 0.00 * . 0.30 0.29 Val 200 . A B B . . . 0.80 0.00 * * . 0.30 0.25 40 Table 10 (continued) Res Position I 11 lII IV V VI VII VilI IX X Xi XIIXIII XIV Phe 201 . . B B . . . -0.06 0.00 * . 0.30 0.57 Gly 202 A . . B . . . -0.40 0.04. * . -030 0.35 Asp 203 A . . . . . . -0.36 -0.07 * . . 0.50 0.63 Glu 204 A . . . . . . -1.18 -0.03 * . 0.50 0.60 Leu 205 A . . B . . . -0.63 -0.17 . . . 0.30 0.45 Ser 206 A . . B . . . -0.74 -0.11 . . . 0.30 0.39 Leu 207 A . . B . . . -1.10 0.57 . * . -0.60 0.18 Val 208 A . . B . . . -0.99 1.36 . * . -0.60 0.19 Thr 209 A . . B . . . -1.66 0.67 * . -0.60 0.28 Leu 210 A . . B . . . -1.73 0.86 * . . -0.60 0.18 Phe 211 A . . B . . . -1.43 0.86 * . . -0.60 0.17 Arg 212 A . . B . . . -0.62 0.61 * . . -0.60 0.21 Cys 213 . . . B T . . -0.37 0.53 * . -0.20 0.41 Ile 214 . . . B T . . -0.27 0.46 . . -0.20 0.46 Gin 215 . . . B T . . 0.54 0.10 * . . 0.10 0.37 Aso 216 . . . B . . C 0.93 0.10 . . 0.05 1.19 Met 217 . . . B . . C 0.01 0.01 * . F 0.20 2.44 Pro 218 . . . B . . C 0.47 0.01 * . F 0.44 1.16 Glu 219 . . . . T . . 1.36 0.04 * F 1.08 1.12 Thr 220 . . . . . . C 1.36 0.04 * . F 1.12 1.82 Leu 221 . . . . . . C .1.06 -0.17 * F 1.96 1.89 Pro 222 . . . . T . . 0.99 -0.21 . . F 2.40 1.46 Asn 223 . . . . T . . 0.96 0.36 . . F 1.41 0.54 Asn 224 . . . . T T . 0.66 0.63 . . F 1.22 1.03 Ser 225 . . . . T T . 0.38 0.33 . . F 1.13 0.89 Cys 226 . . . . T T . 0.84 0.40 . . . 0.74 0.56 Tyr 227 . . . . T T . 0.17 0.43 . . . 0.20 0.35 Ser 228 A . . . . . . -0.42 0.71 . . . -0.40 0.18 Ala 229 A A . . . . . -0.38 0.83 . . . -0.60 0.34 Gly 230 A A . . . - -0.89 0.26 . . . -0.30 0.43 Ile 231 A A . . . . . -0.22 0.19 . . -0.30 0.27 Ala 232 A A . . - - - 0.02 -0.20 . . 0.30 0.46 Lys 233 A A . . . . . -0.02 -0.70 . . . 0.60 0.80 Leu 234 A A . . . . . 0.57 -0.70 . . F 0.90 1.13 Glu 235 A A . . . . . 0.91 -1.39 . . F 0.90 1.87 Glu 236 A A . . . . . 0.99 -1.89 . . F 0.90 1.62 Gly 237 A A . . . . . 1.58 -1.20 . * F 0.90 1.62 Asp 238 A A . . . . . 0.72 -1.49 . F 0.90 1.62 Glu 239 A A . . . - . 0.94 -0.80 F 0.75 0.77 Leu 240 A A . . . . . 0.06 -0.30 . -0.30 0.79 Gin 241 A A . . . . . -0.16 -0.04 . . 0.30 0.33 Leu 242 A A . . . . . 0.30 0.39 * . . -0.30 0.30 Ala 243 A A . . . . . 0.30 0.39 * . . -0.30 0.70 lIe 244 A A . . . . . 0.30 -0.30 . . 0.30 0.70 Pro 245 A . . . T . 0.52 -0.30. * F 1.00 1.37 Arg 246 A . . . - T . 0.52 -0.49. * F 1.00 1.37 Glu 247 A . . . . T . 0.44 -0.59* * F 1.30 3.38 Asn 248 A . . . . T . 0.73 -0.59 * F 1.30 1.53 Ala 249 A . . . . . . 0.81 -0.63 * . 0.95 1.05 Gin 250 A . . . . . . 1.02 0.06 . -0.10 0.50 41 Table 10 (continued) Res Position I H1 U IV V VI VII VIII IX X X1 XII xn1 XIV Ile 251 A . . . . . . 0.57 0.06 * . 0.15 0.52 Ser 252 . . . . . . C 0.57 0.09 . . 0.60 0.51 Leu 253 . . . . . C -0.29 -0.41 . * F 1.60 0.49 Asp 254 . . . . T T . -0.01 -0.17. * F 2.25 0.52 Gly 255 . . . . T T . -0.71 -0.37 . * F 2.50 0.56 Asp 256 . . . . T T . -0.52 0.03. * F 1.65 0.59 Val 257 A . . . T . -0.57 0.13 . F 1.00 0.30 Thr 258 A . . B . . . -0.34 0.56. . -0.10 0.30 Phe 259 A . . B . . . -1.16 0.63 . . -0.35 0.18 Phe 260 A . B . . . -0.77 1.31 . * . -0.60 0.20 Gly 261 A A . . . . . -1.58 0.67 . * . -0.60 0.28 Ala 262 A A . . . . . -1.53 0.87 . . -0.60 0.27 LIu 263 A A . . . . . -1.61 0.77 . . -0.60 0.26 Lys 264 A A . . . . . -1.30 0.41 . . -0.60 0.33 Icu 265 A A . . . . . -0.99 0.41 . . . -0.60 0.42 Leu 266 A A . . . . . -1.03 0.34 * . . -0.30 0.65 42 10831 In another embodiment, the invention provides antibodies that bind a polypeptide comprising, or alternatively consisting of, an epitope-bearing portion of a polypeptide of the invention. The epilope of this polypeptide portion may be an immunogenic or antigenic epitope of a polypeptide of the invention. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen et al., Proc. Nat. Acad. Sci. USA 81:3998- 4002 (1983). 10841 As to the selection of polypeptides bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G., Shinnick, T. M., Green, N. and Learner, R. A. (1983) "Antibodies that react with predetermined sites on proteins", Science, 219:660-666. Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. See, for instance, Wilson et al., Cell 37:767-778 (1984) at 777. [0851 In specific embodiments, antibodies of the present invention bind antigenic epitope-bearing peptides and polypeptides of BLyS and preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids contained within the amino acid sequence of a BLyS polypeptide. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. 43 10861 Non-limiting examples of antigenic polypeptides or peptides that can be used to generate BLyS-specific antibodies and which may be bound by the antibodies of the invention include: a polypeptide comprising, or alternatively consisting of, amino acid residues from about Phe-l 15 to about Leu-147 in SEQ ID NO:3228; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ile-I50 to about Tyr-163 in SEQ ID NO:3228; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ser-171 to about Phe-194 in SEQ ID NO:3228; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Glu-223 to about Tyr-246 in SEQ ID NO:3228; and a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ser-271 to about Phe-278 in Figures IA and lB (SEQ ID NO:3223). In this context, "about" means the particularly recited ranges and ranges larger or smaller by several, a few, 5, 4, 3, 2 or 1 amino acid residues at either or both the amino- and carboxy-termini. These polypeptide fragments have been determined to bear antigenic epitopes of the BLyS polypeptide by the analysis of the Jameson-Wolf antigenic index, as disclosed Table 9, above. [0871 Non-limiting examples of antigenic polypeptides or peptides that can be used to generate BLyS-specific antibodies and which may be bound by the antibodies of the invention include: a polypeptide comprising, or alternatively consisting of, amino acid residues from about Pro-32 to about Leu-47 in SEQ ID NO:3229; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Glu-l 16 to about Ser-143 in SEQ ID NO:3229; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Phe-153 to about Tyr-173 in SEQ ID NO:3229; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Pro-218 to about Tyr-227 in SEQ ID NO:3229; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ala-232 to about Gln-241 in SEQ ID NO:3229; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ile-244 to about Ala-249 in SEQ I) NO:3229; and a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ser-252 to about Val-257 in SEQ ID NO:3229. In this context, "about" means the particularly recited ranges and ranges larger or smaller by several, a few, 5, 4, 3, 2 or 1 amino acid residues at either or both the amino- and carboxy-termini. These polypeptide fragments have been determined to bear antigenic epitopes of the BLyS polypeptide by the analysis of the Jameson-Wolf 44 antigenic index, as disclosed in Table 10 generated by the Protean component of the DNA*STAR computer program (as set forth above). [088] BLyS epitope-bearing peptides and polypeptides may be produced by any conventional means. See, e.g., Houghten, R. A. (1985) General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Nad. Acad. Sci. USA 82:5131-5135; this "Simultaneous Multiple.Peptide Synthesis (SMPS)" process is further described in U. S. Patent No. 4,631,211 to Houghten et al. (1986). [089] The present invention encompasses antibodies that bind polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:3228, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. 97768, or encoded by a polynucleotide that hybridizes to cDNA sequence contained in ATCC deposit No. 97768 (e.g., under hybridization conditions described herein). 1090] The present invention also encompasses antibodies that bind polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:3229, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. 203518, or encoded by a polynucleotide that hybridizes to the cDNA sequence contained in ATCC deposit No. 203518 (e.g., under hybridization conditions described herein). [0911 The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses antibodies that bind a polypeptide comprising an epitope. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not 45 necessarily be immunogenic. [092] BLyS polypeptide fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131 5135 (1985), further described in U.S. Patent No. 4,631,211). [093] In the present invention, antibodies of the present invention bind antigenic epitopes preferably containing a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes that may be bound by antibodies of the present invention are at least 10, 15, 20, 25, 30, 35, 40,45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in irmmunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)). [0941 Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Nati. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes of BLyS may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting). 46 [095] Epitope-bearing BLyS polypeptides may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization,, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemocyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier-coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 micrograms of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a-useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a-solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art. [0961 As one of skill in the art will appreciate, and as discussed above, the antibodies of the present invention may bind polypeptides comprising an immunogenic or antigenic epitope fused to other polypeptide sequences. For example, the BLyS polypeptides may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CHI, CH2, CH3, or any combination thereof and portions thereof), or albumin (including but not limited to recombinant human albumin or fragments or variants thereof (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)), resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4 polypeptide and various domains of the constant regions of the heavy or light chains of 47 mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84 86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by.Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Nat]. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix-binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni 24 nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers. [0971 In another embodiment, the antibodies of the present invention bind BLyS polypeptides and/or the epitope-bearing fragments thereof that are fused with a heterologous antigen (e.g., polypeptide, carbohydrate, phospholipid, or nucleic acid). In specific embodiments, the heterologous antigen is an immunogen. 10981 In a more specific embodiment, the heterologous antigen is the gpl20 protein of HIV, or a fragment thereof. 10991 In another embodiment, antibodies of the present invention bind BLyS polypeptides and/or the epitope-bearing fragments thereof that are fused with polypeptide sequences of another TNF ligand family member (or biologically active fragments or variants thereof). In a specific embodiment, the antibodies of the present invention bind BLyS polypeptides of the present invention are fused with a CD40L polypeptide sequence. In a preferred embodiment, the CD40L polypeptide sequence is soluble. 101001 In another embodiment, antibodies of the present invention bind mutant 48 BLyS polypeptides that have been generated by random mutagenesis of a polynucleotide encoding the BLyS polypeptide, by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, antibodies of the present invention bind one or more components, motifs, sections, parts, domains, fragments, etc., of BLyS recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are, for example, TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), AIM-il (International Publication No. WO 97/34911), APRIL (J. Exp. Med. 188(6):1185 1190), endokine-alpha (International Publication No. WO 98/07880), OPG, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202),312C2 (International Publication No. WO 98/06842), TR12, CAD, and v-FLIP. In further embodiments, the heterologous molecules are any member of the TNF family. [01011 In another preferred embodiment, antibodies of the present invention bind BLyS polypeptides of the invention (including biologically active fragments or variants thereof), that are fused with soluble APRIL polypeptides (e.g., amino acid residues 105 through 250 of SEQ ID NO:3239), or biologically active fragments or variants thereof. [0102] To improve or alter the characteristics of BLyS polypeptides, protein engineering may be employed. Recombinant DNA technology known to those skilled in the art can be used to create novel mutant proteins or "muteins including single or multiple amino acid substitutions, deletions, additions or fusion proteins. Such modified polypeptides can show, e.g., enhanced activity or increased stability. In addition, they may be purified in higher yields and show better solubility than the corresponding natural polypeptide, at least under certain purification and storage conditions. For instance, for many proteins, including the extracellular domain or the mature form(s) of a secreted 49 protein, it is known in the art that one or more amino acids may be deleted from the N-terminus or C-terminus without substantial loss of biological function. For instance, Ron et al., J. Biol. Chem., 268:2984-2988 (1993) reported modified KGF proteins that had heparin binding activity even if 3, 8, or 27 amino-terminal amino acid residues were missing. Accordingly, antibodies of the present invention may bind BLyS polypeptide mutants or variants generated by protein engineering. [01031 In the present case, since the protein of the invention is a member of the TNF polypeptide family, deletions of N-terminal amino acids up to the Gly (G) residue at position 191 in SEQ ID NO:3228 may retain some biological activity such as, for example, the ability to stimulate lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, and cytotoxicity to appropriate target cells. Polypeptides having further N-terminal deletions including the Gly (G) residue would not be expected to retain biological activities because it is known that this residue in TNF-related polypeptides is in the beginning of the conserved domain required for biological activities. -owever, even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities may still be retained. Thus, the ability of the shortened protein to induce and/or bind to antibodies which recognize the complete or extracellular domain of the protein generally will be retained when less than the majority of the residues of the complete or extracellular domain of the protein are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete protein retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. 101041 Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of the BLyS of SEQ ID NO:3228, up to the glycine residue at position 191 (Gly-191 residue from the amino terminus). In particular, the present invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of residues n 1 -285 of SEQ ID NO:3228, where n' is an integer in the range of the amino acid position of amino acid residues 2-190 of the amino acid sequence in SEQ ID NO:3228. More in particular, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group 50 consisting of residues 2-285, 3-285, 4-285, 5-285, 6-285, 7-285, 8-285, 9-285, 10-285, 11-285, 12-285, 13-285, 14-285, 15-285, 16-285, 17-285, 18-285, 19-285, 20-285, 21-285, 22-285, 23-285, 24-285, 25-285, 26-285, 27-285, 28-285, 29-285, 30-285, 31-285, 32-285, 33-285, 34-285, 35-285, 36-285, 37-285, 38-285, 39-285, 40-285, 41-285, 42-285, 43-285, 44-285, 45-285, 46-285, 47-285, 48-285, 49-285, 50-285, 51-285, 52-285, 53-285, 54-285, 55-285, 56-285, 57-285, 58-285, 59-285, 60-285, 61-285, 62-285, 63-285, 64-285, 65-285, 66-285, 67-285, 68-285, 69-285, 70-285, 71-285, 72-285, 73-285, 74-285, 75-285, 76-285, 77-285, 78-285, 79-285, 80-285, 81-285, 82-285, 83-285, 84-285, 85-285, 86-285, 87-285, 88-285, 89-285, 90-285, 91-285, 92-285, 93-285, 94-285, 95-285, 96-285, 97-285, 98-285, 99-285, 100-285, 101-285, 102-285, 103-285, 104-285, 105-285, 106-285, 107-285, 108-285, 109-285, 110-285, 111-285, 112-285, 113-285, 114-285, 115-285, 116-285, 117-285, 118-285, 119-285, 120-285, 121-285, 122-285, 123-285, 124-285, 125-285, 126-285, 127-285, 128-285, 129-285, 130-285, 131-285, 132-285, 133-285, 134-285, 135-285, 136-285, 137-285, 138-285, 139-285, 140-285, 141-285, 142-285, 143-285, 144-285, 145-285, 146-285, 147-285, 148-285, 149-285, 150-285, 151-285, 152-285, 153-285, 154-285, 155-285, 156-285, 157-285, 158-285, 159-285, 160-285, 161-285, 162-285, 163-285, 164-285, 165-285, 166-285, 167-285, 168-285, 169-285, 170-285, 171-285, 172-285, 173-285, 174-285, 175-285, 176-285, 177-285, 178-285, 179-285, 180-285, 181-285, 182-285, 183-285, 184-285, 185-285, 186-285, 187-285, 188-285, 189-285, and 190-285 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. [0105] Furthermore, since the predicted extracellular domain of the BLyS polypeptides of the invention may itself elicit biological activity, deletions of N- and C-terminal amino acid residues from the predicted extracellular region of the polypeptide (spanning positions Gln-73 to Leu-285 of SEQ ID NO:3228) may retain some biological activity such as, for example, ligand binding, stimulation of lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, and modulation of cell replication or modulation of target cell activities. However, even if deletion of one or more amino acids from the N-terminus of the predicted extracellular domain of a BLyS polypeptide results 51 in modification or loss of one or more biological functions of the polypeptide, other functional activities may still be retained. Thus, the ability of the shortened polypeptides to induce and/or bind to antibodies which recognize the complete or mature or extracellular domains of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature or extracellular domains of the polypeptides are removed from the N -terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. [0106] . Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of BLyS shown in SEQ ID NO:3228, up to the glycine residue at position number 280. In particular, the present invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of residues n 2 -285 of SEQ ID NO:3228, where n2 is an integer in the range of the amino acid . position of amino acid residues 73-230 in SEQ ID NO:3228, and 73 is the position of the first residue from the N-terminus of the predicted extracellular domain of the BLyS polypeptide (disclosed in SEQ ID NO:3228). More in particular, in certain embodiments, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues of Q-73 to L-285; G-74 to L-285; D-75 to L-285; L-76 to L-285; A-77 to L-285; S-78 to L-285; L-79 to L-285; R-80 to L-285; A-81 to L-285; E-82 to L-285; L-83 to L-285; Q-84 to L-285; G-85 to L-285; H-86 to L-285; H-87 to L-285; A-88 to L-285; E-89 to L-285; K-90 to L-285; L-91 to L-285; P-92 to L-285; A-93 to L-285; G-94 to L-285; A-95 to L-285; G-96 to L-285; A-97 to L-285; P-98 to L-285; K-99 to L-285; A-100 to L-285; G-101 to L-285; L-102 to L-285; E-103 to L-285; E-104 to L-285; A-105 to L-285; P-106 to L-285; A-107 to L-285; V-108 to L-285; T-109 to L-285; A-I 10 to L-285; G-111 to L-285; L-112 to L-285; K-113 to L-285; 1-114 to L-285; F-115 to L-285; E-116 to L-285; P-117 to L-285; P-l l8 to L-285; A-119 to L-285; P-120 to L-285; G-121 to L-285; E-122 to L-285; G-123 to L-285; N-124 to L-285; S-125 to L-285; S-126 to L-285; Q-127 to L-285; N-128 to L-285; S-129 to [-285; R-130 to L-285; N-131 to L-285; K-132 to L-285; R-133 to L-285; A-134 to L-285; V-135 to L-285; Q-136 to L-285; G-137 to L-285; P-138 to L-285; E-139 to L-285; E-140 to L-285; T-141 to L-285; V-142 to L-285; 52 T-143 to L-285; Q-144 to L-285; D-145 to L-285; C-146 to L-285; L-147 to L-285; Q-148 to L-285; L-149 to L-285; 1-150 to L-285; A-151 to L-285; D-152 to L-285; S-153 to L-285; E-154 to L-285; T-155 to L-285; P-156 to L-285; T-157 to L-285; 1-158 to L-285; Q-159 to L-285; K-160 to L-285; G-161 to L-285; S-162 to L-285; Y-163 to L-285; T-164 to L-285; F-165 to L-285; V-166 to L-285; P-167 to L-285; W-168 to L-285; L-169 to L-285; L-170 to L-285; S-171 to L-285; F-172 to L-285; K-173 to L-285; R-174 to L-285; G-175 to L-285; S-176 to L-285; A-177 to L-285; L-178 to L-285; E-179 to L-285; E-180 to L-285; K-181 to L-285; E-182 to L-285; N-183 to L-285; K-184 to L-285; 1-185 to L-285; L-186 to L-285; V-187 to L-285; K-188 to L-285; E-189 to L-285; T-190 to L-285; G-191 to L-285; Y-192 to L-285; F-193 to L-285; F-194 to L-285; 1-195 to L-285; Y-196 to L-285; G-197 to L-285; Q-198 to L-285; V-199 to L-285; L-200 to L-285; Y-201 to L-285; T-202 to L-285;;D-203 to L-285; K-204 to L-285; T-205 to L-285; Y-206 to L-285; A-207 to L-285; M-208 to L-285; G-209 to L-285; H-210 to L-285; L-211 to L-285; 1-212 to L-285; Q-213 to L-285; R-214 to L-285; K-215 to L-285; K-216 to L-285; V-217 to L-285; 11-218 to L-285; V-219 to L-285; F-220 to L-285; G-221 to L-285; D;-222 to L-285; E-223 to L-285; L-224 to L-285; S-225 to L-285; L-226 to L-285; V-227 to L-285; T-228 to L-285; [-229 to L-285; F-230 to L-285; R-231 to L-285; C-232 to L-285; 1-233 to L-285; Q-234 to L-285; N-235 to L-285; M-236 to L-285; P-237 to L-285; E-238 to L-285; T-239 to L-285; L-240 to L-285; P-241 to L-285; N-242 to L-285; N-243 to L-285; S-244 to L-285; C-245 to [-285; Y-246 to L-285; S-247 to L-285; A-248 to L-285; G-249 to L-285; 1-250 to L-235; A-251 to L-285; K-252 to L-285; L-253 to L-285; E-254 to L-285; E-255 to L-285; G-256 to L-285; D-257 to L-285; E-258 to L-285; L-259 to L-285; Q-260 to L-285; L-261 to L-285; A-262 to L-285; 1-263 to L-285; P-264 to L-285; R-265 to L-285; E-266 to L-285; N-267 to L-285; A-268 to L-285; Q-269 to L-285; 1-270 to L-285; S-271 to L-285; L-272 to L-285; D-273 to L-285; G-274 to L-285; D-275 to L-285; V-276 to L-285; T-277 to L-285; F-278 to L-285; F-279 to L-285; and G-280 to L-285 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. [01071 Highly preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an 53 amino acid sequence least 80%, 85%, 90% identical and more preferably at least 95%, 96%, 97%, 98%, 99% or 100% identical to BLyS polypeptide having the amino acid sequence at positions 134-285 of SEQ ID NO:3228. 101081 Preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 90% identical to a BLyS polypeptide having the amino acid sequence at positions 134-285 of SEQ ID NO:3228. More preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 95% identical to a BLyS polypeptide having the amino acid sequence at positions 134-285 of SEQ ID NO:3228. More preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 96% identical to a BLyS polypeptide having the amino acid sequence at positions 134-285 of SEQ ID NO:3228. 101091 Additionally, more preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 97% to a BLyS polypeptide having the amino acid sequence at positions 134-285 of SEQ ID NO:3228. Additionally, more preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 98% to a BLyS polypeptide having the amino acid sequence at positions 134-285 of SEQ ID NO:3228. Additionally, more preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 99% identical to BLyS polypeptide having the amino acid sequence at positions 134-285 of SEQ ID NO:3228. [01101 In specific embodiments, antibodies of the present invention bind polypeptides comprising, or alternatively consisting of, one of the following N-terminally deleted polypeptide fragments of BLyS: amino acid residues Ala-71 through Leu-285, amino acid residues Ala-81 through Leu-285, amino acid residues Leu-1 12 through Leu-285, amino acid residues Ala-134 through Leu-285, amino acid residues Leu-147 through Leu-285, and amino acid residues Gly-161 through Leu-285 of SEQ ID NO:3228. [0111] Similarly, many examples of biologically functional C-terminal deletion 54 polypeptides are known. For instance, Interferon gamma shows up to ten times higher activities by deleting 8-10 amino acid residues from the carboxy terminus of the protein (D6beli et al., J. Biotechnology 7:199-216 (1988). Since the present protein is a member of the TNF polypeptide family, deletions of C-terminal amino acids up to the leucine residue at position 284 are expected to retain most if not all biological activity such as, for example, ligand binding, the ability to stimulate lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, and modulation of cell replication. Polypeptides having deletions of up to about 10 additional C-terminal residues (i.e., up to the glycine residue at position 274) also may retain some activity such as receptor binding, although such polypeptides would lack a portion of the conserved TNF domain which extends to about Leu-284 of SEQ ID NO:3228. However, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities may still be retained. Thus, the ability of the shortened protein to induce and/or bind to antibodies which recognize the complete or mature protein generally will be retained when less than the majority of the residues of the complete or mature protein are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of-a complete protein retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. [0112] Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the BLyS polypeptide of SEQ ID NO:3228, up to the glycine residue at position 274 (Gly-274). In particular, the present invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of residues 1-m' of the amino acid sequence in SEQ ID NO:3228, where ml is any integer in the range of the amino acid position of amino acid residues 274-284 in SEQ ID NO:3228. More in particular, the invention provides antibodies that bind BLyS polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues 1-274, 1-275, 1-276, 1-277, 1-278, 1-279, 1-280, 1-281, 1-282, 1-283 and 1-284 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 55 99% identical to the amino acid sequence of BLyS polypeptides described above. [0113] Also provided are antibodies that bind BLyS polypeptides comprising, or alternatively consisting of, BLyS polypeptides with one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues ni-m 1 of SEQ ID NO:3228, where ni and mi are integers as defined above. Also included are antibodies that bind a polypeptide comprising, or alternatively consisting of, a portion of the complete BLyS amino acid sequence encoded by the deposited cDNA clone contained in ATCC Accession No. 97768 where this portion excludes from I to 190 amino acids from the amino terminus or from 1 to 11 amino acids from the C-terminus of the complete amino acid sequence (or any combination of these N-terminal and C-terminal deletions) encoded by the cDNA clone in the deposited plasmid. [01141 Similarly, deletions of C-terminal amino acid residues of the predicted extracellular domain of BLyS up to the leucine residue at position 79 of SEQ ID NO:3228 may retain some biological activity, such as, for example, ligand binding, stimulation of lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, and modulation of cell replication or modulation of target cell activities. Polypeptides having further C-terminal deletions including Leu-79 of SEQ ID NO:3228 would not be expected to retain biological activities. 101151 However, even if deletion of one or more amino acids from the C-terminus of a polypeptide results in modification or loss of one or more biological functions of the polypeptide, other functional activities may still be retained. Thus, the ability of the shortened polypeptide to induce and/or bind to antibodies which recognize the complete, mature or extracellular forms of the polypeptide generally will be retained when less than the majority of the residues of the complete, mature or extracellular forms of the polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of the predicted extracellular domain retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. (01161 Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the predicted extracellular domain of BLyS polypeptide shown in SEQ ID NO:3228, up to the leucine residue at position 79 of SEQ ID NO:3228. In particular, 56 the present invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of residues 73-m 2 of the amino acid sequence in SEQ ID NO:3228, where m 2 is any integer in the range of the amino acid position of amino acid residues 79 to 285 in the amino acid sequence in SEQ IID NO:3228, and residue 78 is the position of the first residue at the C- terminus of the predicted extracellular domain of the BLyS polypeptide (disclosed in SEQ ID NO:3228). More in particular, in certain embodiments, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues Q-73 to Leu-285; Q-73 to L-284; Q-73 to K-283; Q-73 to L-282; Q-73 to A-281; Q-73 to G-280; Q-73 to F-279; Q-73 to F-278; Q-73 to T-277; Q-73 to V-276; Q-73 to D-275; Q-73 to G-274; Q-73 to D-273; Q-73 to L-272; Q-73 to S-271; Q-73 to 1-270; Q-73 to Q-269; Q-73 to A-268; Q-73 to N-267; Q-73 to E-266; Q-73 to R-265; Q-73 to P-264; Q-73 to 1-263; Q-73 to A-262; Q-73 to L-261; Q-73 to Q-260; Q-73 to L-259; Q-73 to E-258; Q-73 to D-257; Q-73 to G-256; Q-73 to E-255; Q-73 to E-254; Q-73 to L-253; Q-73 to K-252; Q-73 to A-251; Q-73 to 1-250; Q-73 to G-249; Q-73 to A-248; Q-73 to S-247; Q-73 to Y-246; Q-73 to C-245; Q-73 to S-244; Q-73 to N-243; Q-73 to N-242; Q-73 to P-241; Q-73 to L-240; Q-73 to T-239; Q-73 to E-238; Q-73 to P-237; Q-73 to M-236; Q-73 to N-235; Q-73 to Q-234; Q-73 to 1-233; Q-73 to C-232; Q-73 to R-231; Q-73 to F-230; Q-73 to L-229; Q-73 to T-228; Q-73 to V-227; Q-73 to L-226; Q-73 to S-225; Q-73 to L-224; Q-73 to E-223; Q-73 to D-222; Q-73 to G-221; Q-73 to F-220; Q-73 to V-219; Q-73 to H-218; Q-73 to V-217; Q-73 to K-216; Q-73 to K-215; Q-73 to R-214; Q-73 to Q-213; Q-73 to 1-212; Q-73 to L-21 1; . Q-73 to H-210; Q-73 to G-209; Q-73 to M-208; Q-73 to A-207; Q-73 to Y-206; Q-73 to T-205; Q-73 to K-204; Q-73 to D-203; Q-73 to T-202; Q-73 to Y-201; Q-73 to L-200; Q-73 to V-199; Q-73 to Q-198; Q-73 to 0-197; Q-73 to Y-196; Q-73 to 1-195; Q-73 to F-194; Q-73 to F-193; Q-73 to Y-192; Q-73 to G-191; Q-73 to T-190; Q-73 to E-189; Q-73 to K-188; Q-73 to V-187; Q-73 to L-186; Q-73 to 1-185; Q-73 to K-184; Q-73 to N-183; Q-73 to E-182; Q-73 to K-181; Q-73 to E-180; Q-73 to E-179; Q-73 to L-178; Q-73 to A-177; Q-73 to S-176; Q-73 to G-175; Q-73 to R-174; Q-73 to K-173; Q-73 to F-172; Q-73 to S-171; Q-73 to L-170; Q-73 to L-169; Q-73 to W-168; Q-73 to P-167; Q-73 to V-166; Q-73 to F-165; Q-73 to T-164; Q-73 to Y-163; Q-73 to S-162; Q-73 to G-161; Q-73 to K-160; Q-73 to Q-159; Q-73 to 1-158; Q-73 to T-157; Q-73 to P-156; 57 Q-73 to T-155; Q-73 to E-154; Q-73 to S-153; Q-73 to D-152; Q-73 to A-151; Q-73 to 1-150; Q-73 to L-149; Q-73 to Q-148; Q-73 to L-147; Q-73 to C-146; Q-73 to D-145; Q-73 to Q-144; Q-73 to T-143; Q-73 to V-142; Q-73 to T-141; Q-73 to E-140; Q-73 to E-139; Q-73 to P-138; Q-73 to G-137; Q-73 to Q-136; Q-73 to V-135; Q-73 to A-134; Q-73 to R-133; Q-73 to K-132; Q-73 to N-131; Q-73 to R-130; Q-73 to S-129; Q-73 to N-128; Q-73 to Q-127; Q-73 to S-126; Q-73 to S-125; Q-73 to N-124; Q-73 to G-123; Q-73 to E-122; Q-73 to G-121; Q-73 10 P-120; Q-73 to A-119; Q-73 to P-118; Q-73 to P-1 17; Q-73 to E-1 16; Q-73 to F-I 15; Q-73 to 1-114; Q-73 to K-i 13; Q-73 to L-1 12; Q-73 to G-1 11; Q-73 to A-1 10; Q-73 to T-109; Q-73 to V-108; Q-73 to A-107; Q-73 to P-106; Q-73 to A-105; Q-73 to E-104; Q-73 to E-103; Q-73 to L-102; Q-73 to G-101; Q-73 to A-100; Q-73 to K-99; Q-73 to P-98; Q-73 to A-97; Q-73 to G-96; Q-73 to A-95; Q-73 to G-94; Q-73 to A-93; Q-73 to P-92; Q-73 to L-91; Q-73 to K-90; Q-73 to E-89; Q-73 to A-88; Q-73 to H-87; Q-73 to H-86; Q-73 to G-85; Q-73 to Q-84; Q-73 to L-83; Q-73 to E-82; Q-73 to A-81; Q-73 to R-80; and Q-73 to L-79 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. 101171 The invention also provides antibodies that bind polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini of the predicted extracellular domain of BLyS, which may be described generally as having residues n 2 -m 2 of SEQ ID NO:3228 where n 2 and m 2 are integers as defined above. [01181 In another embodiment, antibodies of the present invention bind polypeptides consisting of a portion of the extracellular domain of the BLyS amino acid sequence encoded by the cDNA plasraid contained in the deposit having ATCC accession no. 97768, where this portion excludes from 1 to about 206 amino acids from the amino terminus of the extracellular domain of the amino acid sequence encoded by the cDNA plasmid contained in the deposit having ATCC accession no. 97768, or from I to about 206 amino acids from the carboxy terminus of the extracellular domain of the amino acid sequence encoded by the cDNA plasmid contained in the deposit having ATCC accession no. 97768, or any combination of the above amino terminal and carboxy terminal deletions, of the entire extracellular domain of the amino acid sequence encoded by the 58 cDNA plasmid contained in the deposit having ATCC accession no. 97768. 10119) As mentioned above, even if deletion of one or more amino acids from the N-terminus of a polypeptide results in modification or loss of one or more functional activities (e.g., biological activity) of the polypeptide, other functions or biological activities may still be retained. Thus, the ability of a shortened BLyS mutein to induce and/or bind to antibodies which recognize the full-length or mature forms or the extracellular domain of the polypeptide generally will be retained when less than the majority of the residues of the full-length or mature or extracellular domain of the polypeptide are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a BLyS mutein with a large number of deleted N-terminal amino acid residues may retain some functional (e.g., biological or immunogenic) activities. In fact, peptides composed of as few as six BLyS amino acid residues may often evoke an immune response. 10120] Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the amino terminus of the predicted full-length amino acid sequence of the BLyS shown in SEQ ID NO:3228, up to the glycine residue at position number 280 of the sequence shown SEQ ID NO:3228 and polynucleotides encoding such polypeptides. In particular, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues n 3 -285 of the sequence shown in SEQ ID NO:3228, where n 3 is an integer in the range of the amino acid position of amino acid residues 1 to 280 of the amino acid sequence in SEQ ID NO:3228. [0121] More in particular, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues of D-2 to L-285; D-3 to L-285; S-4 to L-285; T-5 to L-285; E-6 to L-285; R-7 to L-285; E-8 to L-285; Q-9 to L-285; S-10 to L-285; R-1 I to L-285; L-12 to L-285; T-13 to L-285; S-14 to L-285; C-15 to L-285; L-16 to L-285; K-17 to L-285; K-18 to L-285; R-19 to L-285; E-20 to L-285; F-21 to L-285; M-22 to L-285; K-23 to L-285; L-24 to L-285; K-25 to L-285; E-26 to L-285; C-27 to L-285; V-28 to L-285; S-29 to L-285; 1-30 to L-285; L-31 to L-285; P-32 to L-285; R-33 to L-285; K-34 to L-285; E-35 59 to L-285; S-36 to L-285; P-37 to L-285; S-38 to L-285; V-39 to L-285; R-40 to L-285; S-41 to L-285; S-42 to L-285; K-43 to L-285; D-44 to L-285; G-45 to L-285; K-46 to L-285; L-47 to L-285; L-48 to L-285; A-49 to L-285; A-50 to L-285; T-51 to L-285; L-52 to L-285; L-53 to L-285; L-54 to L-285; A-55 to L-285; L-56 to [-285; L-57 to L-285; S-58 to L-285; C-59 to L-285; C-60 to L-285; L-61 to L-285; T-62 to L-285; V-63 to L-285; V-64 to L-285; S-65 to L-285; F-66 to L-285; Y-67 to L-285; Q-68 to L-285; V-69 to L-285; A-70 to L-285; A-71 to L-285; L-72 to L-285; Q-73 to L-285; G-74 to L-285; D-75 to L-285; L-76 to L-285; A-77 to L-285; S-78 to L-285; [,79 to L-285; R-80 to L-285; A-81 to L-285; E-82 to L-285. L-83 to L-285; Q-84 to L-285; G-85 to L-285; H-86 to L-285; H-87 to L-285; A-88 to L-285; E-89 to L-285; K-90 to L-285; L-91 to L-285; P-92 to L-285; A-93 to L-285; G-94 to L-285; A-95 to L-285; G-96 to L-285; A-97 to L-285; P-98 to L-285; K-99 to L-285; A-100 to L-285; G-101 to L-285; L-102 to L-285; E-103 to L-285; E-104 to L-285; A-105 to L-285; P-106 to L-285; A-107 to L-285; V-108 to L-285; T-109 to L-285; A-110 to L-285; G-111 to L-285; [-112 to L-285; K-113 to L-285; 1-114 to L-285, F-115 to L-285; &116 to L-285; P-1 17 to L-285; P-118 to L-285; A-119 to L-285; P-120 to L-285; G-121 to L-285; &122 to L-285; G-123 to L-285; N-124 to L-285; S-125 to L-285; S-126 to L-285; Q-127 to L-285; N-128 to L-285; S-129 to L-285; R-130 to L-285; N-131 to L-285; K-132 to L-285; R-133 to L-285; A-134 to L-285; V-135 to L-285; Q-136 to L-285; G-137 to L-285; P-138 to L-285; E-139 to L-285; E-140 to L-285; T-141 to L-285; V-142 to L-285; T-143 to L-285; Q-144 to L-285; D-145 to L-285; C-146 to L-285; L-147 to [-285; Q-148 to L-285; L-149 to L-285; I-150 to L-285; A-151 to L-285; D-152 to L-285; S-153 to L-285; E-154 to L-285; T-155 to L-285; P-156 to L-285; T-157 to L-285; 1-158 to L-285; Q-159 to L-285; K-160 to L-285; G-161 to L-285; S-162 to L-285; Y-163 to L-285; T-164 to L-285; F-165 to L-285; V-166 to L-285; P-167 to L-285; W-168 to [-285; L-169 to [-285; L-170 to L-285; S-171 to L-285; F-172 to L-285; K-173 to L-285; R-174 to L-285; G-175 to L-285; S-176 to L-285; A-177 to L-285; L-178 to L-285; E-179 to L-285; E180 to L-285; K-181 to L-285; E-182 to L-285; N-183 to L-285; K-184 to L-285; 1-185 to L-285; [-186 to L-285; V-187 to L-285; K-188 to L-285; E-189 to L-285; T-190 to L-285; G-191 to L-285; Y-192 to L-285; F-193 to L-235; F-194 to L-285; 1-195 to L-285; Y-196 to L-285; G-197 to L-285; Q-198 to L-285; V-199 to L-285; L-200 to L-285; Y-201 to L-285; T-202 to L-285; D-203 to L-285; K-204 to L-285; T-205 to [-285; Y-206 to L-285; A-207 to 60 L-285; M-208 to L-285; G-209 to L-285; H-210 to L-285; [-211 to L-285; 1-212 to L-285; Q-213 to L-285; R-214 to L-285; K-215 to L-285; K-216 to L-285; V-217 to L-285; H-218 to L-285; V-219 to L-285; F-220 to L-285; G-221 to L-285; D-222 to L-285; E-223 to L-285; L-224 to L-285; S-225 to L-285; L-226 to L-285; V-227 to L-285; T-228 to L-285; L-229 to L-285; F-230 to L-285; R-231 to L-285; C-232 to L-285; 1-233 to L-285; Q-234 to L-285; N-235 to L-285; M-236 to L-285; P-237 to L-285; F-238 to L-285; T-239 to L-285; L-240 to L-285; P-241 to L-285; N-242 to L-285; N-243 to L-285; S-244 to L-285; C-245 to L-285; Y-246 to L-285; S-247 to I-285; A-248 to L-285; G-249 to L-285; 1-250 to L-285; A-251 to L-285; K-252 to L-285; L-253 to L-285; E-254 to L-285; E-255 to L-285; G-256 to L-285; D-257 to L-285; Fr258 to L-285; I-259 to L-285; Q-260 to L-285; [-261 to L-285; A-262 to L-285; 1-263 to L-285; P-264 to L-285; R-265 to L-285; E-266 to L-285; N-267 to L-285; A-268 to L-285; Q-269 to L-285; 1-270 to L-285; S-271 to L-285; L-272 to L-285; D-273 to L-285; G-274 to L-285; D-275 to L-285; V-276 to L-285; T-277 to L-285; F-278 to L-285; F-279 to L-285; and G-280 to L-285 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. [01221 Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more functional activities (e.g., biological activity) of the protein, other functional activities may still be retained. Thus, the ability of a shortened BLyS mutein to induce and/or bind to antibodies which recognize the complete or mature form or the extracellular domain of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature form or the extracellular domain of the polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a BLyS mutein with a large number of deleted C-terminal amino acid residues may retain some functional (e.g., biological or immunogenic) activities. In fact, peptides composed of as few as six BLyS amino acid residues may often evoke an immune response. [01231 Accordingly, the present invention further provides in another embodiment, 61 antibodies that bind polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the BLyS shown in SEQ ID NO:3228, up to the glutamic acid residue at position number 6, and polynucleotides encoding such polypeptides. In particular, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues 1-m 3 of SEQ ID NO:3228, where m 3 is an integer in the range of the amino acid position of amino acid residues 6-284 of the amino acid sequence in SEQ ID NO:3228. 101241 More in particular, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues M-1 to L-284; M-1 to K-283; M-1 to L-282; M-1 to A-281; M-1 to G-280; M-1 to F-279; M-1 to F-278; M-1 to T-277; M-1 to V-276; M-1 to D-275; M-I to G-274; M-1. to D-273; M-1 to L-272; M-1 to S-271; M-1 to 1-270; M-1 to Q-269; M-1 to A-268; M-1 to N-267; M-1 to E-266; M-1 to R-265; M-1 to P-264; M-1 to 1-263; M-1 to A-262; M-1 to L-261; M-1 to Q-260; M-1 to L-259; M-1 to E-258; M-1 to D-257; M-1 to G-256; M-1 to E-255; M-1 to E-254; M-1 to L-253; M-1 to K-252; M-1 to A-251; M-1 to 1-250; M-1 to G-249; M-1 to A-248; M-1 to S-247; M-1 to Y-246; M-1 to C-245; M-1 to S-244; M-1 to N-243; M-1 to N-242; M-1 to P-241; M-1 to L-240; M-1 to T-239; M-1 to E-238; M-1 to P-237; M-1 to M-236:, M-1 to N-235; M-1 to Q-234; M-1 to 1-233; M-1 to C-232; M-1 to R-231; M-1 to F-230; M-1 to L-229; M-1 to T-228; M-1 to V-227; M-1 to L-226; M-1 to S-225; M-1 to L-224; M-1 to E-223; M-1 to D-222; M-1 to G-221; M-1 to F-220; M-1 to V-219; M-1 to H-218; M-1 to V-217; M-1 to K-216; M-1 to K-215; M-1 to R-214; M-1 to Q-213; M-1 to 1-212; M-1 to L-21 1; M-1 to H-210; M-1 to G-209; M-1 to M-208; M-1 to A-207; M-1 to Y-206; M-1 to T-205; M-1 to K-204; M-1 to D-203; M-1 to T-202; M-1 to Y-201; M-1 to L-200; M-1 to V-199; M-1 to Q-198; M-1 to G-197; M-1 to Y-196; M-1 to 1-195; M-1 to F-194; M-1 to F-193; M-1 to Y-192; M-1 to G-191; M-1 to T-190; M-1 to E-189; M-1 to K-188: M-1 to V-187; M-1 to L-186; M-1 to 1-185; M-1 to K-184; M-1 to N-183; M-1 to E-182; M-1 to K-181; M-1 to E-180; M-1 to E-179; M-1 to L-178; M-1 to A-177; M-1 to S-176; M-1 to G-175; M-1 to R-174; M-1 to K-173; M-1 to F-172; M-1 to S-171; M-1 to L-170; M-1 to L-169; M-1 to W-168; M-1 to P-167; M-1 to V-166; M-1 to F-165; M-1 to T-164; M-1 to Y-163; M-1 to S-162; M-1 to G-161; M-l to K-160; M-1 to Q-159; M-1 to 1-158; M-1 to T-157; M-1 to P-156; M-1 to T-155; M-1 to E-154; M-1 to S-153; M-1 to D-152;. M-1 to A-151; M-1 to 1-150; M-1 to L-149; M-1 to 62 Q-148; M-1 to L-147; M-1 to C-146; M-1 to D-145; M-1 to Q-144; M-1 to T-143; M-1 to V-142; M-1 to T-141; M-1 to E-140; M-1 to E-139; M-1 to P-138; M-1 to G-137; M-1 to Q-136; M-1 to V-135; M-1 to A-134; M-1 to R-133; M-1 to K-132; M-1 to N-131; M-1 to R-130; M-1 to S-129; M-1 to N-128; M-1 to Q-127; M-1 to S-126; M-1 to S-125; M-1 to N-124; M-1 to G-123; M-1 to E-122; M-1 to G-121; M-1 to P-120; M-1 to A-119; M-1 to P-118; M-1 to P-117; M-1 to E-116; M-1 to F-115; M-1 to I-114; M-1 to K-113; M-1 to L-1 12; M-1 to G-111; M-1 to A-1.10; M-1 to T-109; M-1 to V-108; M-1 to A-107; M-1 to P-106; M-1 to A-105; M-1 to E-104; M-1 to E-103; M-1 to L-102; M-1 to G-101; M-I to A-100; M-1 to K-99; M-1 to P-98; M-1 to A-97; M-1 to G-96; M-1 to A-95; M-1 to G-94; M-1 to A-93; M-1 to P-92; M-1 to L-91; M-1 to K-90; M-1 to E-89; M-1 to A-88; M-1 to H-87; M-1 to H-86; M-1 to G-85; M-1 to Q-84; M-1 to L-83; M-1 to E-82; M-1 to A-81; M-1 to R-80; M-1 to L-79; M-1 to S-78; M-1 to A-77; M-1 to L-76; M-1 to D-75; M-1 to G-74; M-1 to Q-73; M-1 to L-72; M-1 to A-71; M-1 to A-70; M-l to V-69; M-1 to Q-68; M-1 to Y-67; M-l to F-66; M-1 to S-65; M-1 to V-64; M-l to V-63; M-1 to T-62; M-1 to L-61; M-1 to C-60; M-- to C-59; M- Ito S-58; M-1 to L-57; M-1 to L-56; M-1 to A-55; M-1 to L-54; M-1 to L-53; M-1 to L-52; M-1 to T-51; M-1 to A-50; M-1 to A-49; M-1 to L-48; M-1 to L-47; M-1 to K-46; M-1 to G-45; M-1 to D-44; M-1 to K-43; M-1 to S-42; M-1 to S-41; M-1 to R-40; M-1 to V--39; M-1 to S-38; M-1 to P-37; M-1 to S-36; M-1 to E-35; M-1 to K-34; M-1 to R-33; M-1 to P-32; M-1 to L-31; M-1 to 1-30; M-1 to S-29; M-1 to V-28; M-1 to C-27; M-1 to E-26; M-1 to K-25; M-1 to L-24; M-1 to K-23; M-1 to M-22; M-1 to E-21; M-1 to E-20; M-.l to R-19; M-1 to K-18; M-1 to K-17; M-1 to L-16; M-1 to C-15; M-1 to S-14; M-1 to T-13; M-1 to L-12; M-1 to R-11; M-1 to S-10; M-1 to Q-9; M-1 to E-8; M-1 to R-7; and M-1 to E-6 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. [01251 The invention also provides antibodies that bind polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini of a BLyS polypeptide, which may be described generally as having residues n -m of SEQ ID NO:3228, where n 3 and m 3 are integers as defined above. [01261 Furthermore, since the predicted extracellular domain of the BLyS 63 polypeptide of SEQ ID NO:3229 may itself elicit functional activity (e.g., biological activity), deletions of N- and C-terminal amino acid residues from the predicted extracellular region of the polypeptide at positions Gln-73 to Leu-266 of SEQ ID NO:3229 may retain some functional activity, such as, for example, ligand binding, to stimulation of lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, modulation of cell replication, modulation of target cell activities and/or immunogenicity. However, even if deletion of one or more amino acids from the N-terminus of the predicted extracellular domain of a BLyS polypeptide results in modification or loss of one or more functional activities of the polypeptide, other functional activities may still be retained. Thus, the ability of the shortened polypeptides to induce and/or bind to antibodies which recognize the complete or mature or extracellular domains of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature or extracellular domains of the polypeptides are removed from the N-terninus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. [0127] Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of BLyS shown in SEQ ID NO:3229, up to the glycine residue at position number 261. In particular, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues n 4 -- 266 of SEQ ID NO:3229, where n 4 is an integer in the range of the amino acid position of amino acid residues 73-261 of the amino acid sequence in SEQ ID NO:3229, and 261 is the position of the first residue from the N-terminus of the predicted extracellular domain BLyS polypeptide (shown in SEQ ID NO:3229). [01281 More in particular, in certain embodiments, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues of Q-73 to L-266; G-74 to L-266; D-75 to L-266; L-76 to L-266; A-77 to L-266; S-78 to L-266; L-79 to L-266; R-80 to L-266; A-81 to L-266; E-82 to L-266; L-83 to L-266; Q-84 to L-266; G-85 to L-266; H-86 to L-266; H-87 to L-266; A-88 to L-266; E-89 to L-266; K-90 to L-266; L-91 to L-266; P-92 to L-266; A-93 to L-266; G-94 to L-266; A-95 to L-266; G-96 to L-266; A-97 to 64 L-266; P-98 to L-266; K-99 to L-266; A-100 to L-266; G-101 to L-266; L-102 to L-266; E-103 to L-266; E-104 to L-266; A-105 to L-266; P-106 to L-266; A-107 to L-266; V-108 to L-266; T-109 to L-266; A-110 to L-266; G-1 11 to L-266; L-112 to L-266; K-1 13 to L-266; 1-114 to L-266; F-115 to L-266; E,116 to L-266; P-117 to L-266; P-118 to L-266; A- 119 to L-266; P-120 to L-266; G-121 to L-266; E-122 to L-266; G-123 to L-266; N-124 to L-266; S-125 to L-266; S-126 to L--266; Q-127 to L-266; N-128 to L-266; S-129 to L-266; R-130 to L-266; N-131 to L-266; K-132 to L-266; R-133 to [-266; A-134 to L-266; V-135 to L-266; Q-136 to L-266; G-137 to L-266; P-138 to L-266; E-139 to L-266; E-140 to L-266; T-141 to L-266; G-142 to L-266; S-143 to L-266; Y-144 to L-266; T-145 to L-266; F-146 to L-266; V-147 to L-266; P-148 to L-266; W-149 to L-266; L-150 to L-266; L-151 to L-266; S-152 to L-266; F-153 to L-266; K-154 to L-266; R-155 to L-266; G-156 to L-266; S-157 to L-266; A-158 to L-266; L-159 to L-266; E-160 to L-266; E-161 to L-266; K-162 to L-266; E-163 to L-266; N-164 to L-266; K-165 to L-266; 1-166 to L-266; L-167 to L-266; V-168 to L-266; K-169 to L-266; E-170 to L-266; T-171 to L-266; G-172 to L-266; Y-173 to L-266; F-174 to L-266; F-175 to L-266; 1-176 to L-266; Y-177 to L-266; G-178 to L-266; Q-179 to L-266; V-180 to L-266; L-181 to L-266; Y-182 to L-266; T-183 to L-266; D-184 to-L-266; K-185 to L-266; T-186 to L-266; Y-187 to L-266; A-188 to L-266; M-189 to L-266; G-190 to L-266; H-191 to L-266; -192 to L-266; 1-193 to L-266; Q-194 to L-266; R-195 to L-266; K-196 to L-266; K-197 to L-266; V-198 to L-266; H-199 to L-266; V-200 to L-266; F-201 to L-266; G-202 to L-266; D-203 to L-266; E-204 to L-266; L-205 to L-266; S-206 to L-266; L-207 to L-266; V-208 to L-266; T-209 to L-266; L-210 to I-266; F-211 to L-266; R-212 to L-266; C-213 to L-266; 1-214 to L-266; Q-215 to L-266; N-216 to L-266; M-217 to L-266; P-218 to L-266; E-219 to L-266; T-220 to L-266; L-221 to L-266; P-222 to L-266; N-223 to L-266; N-224 to L-266; S-225 to L-266; C-226 to L-266; Y-227 to L-266; S-228 to L-266; A-229 to L-266; G-230 to L-266; 1-231 to L-266; A-232 to L-266; K-233 to L-266; L-234 to L-266; E-235 to L-266; E-236 to L-266; G-237 to L-266; D-238 to L-266; E-239 to L-266; L-240 to L-266; Q-241 to L-266; L-242 to L-266; A-243 to L-266; 1-244 to L-266; P-245 to L-266; R-246 to L-266; E-247 to L-266; N-248 to L-266; A-249 to L-266; Q-250 to L-266; 1-251 to L-266; S-252 to L-266; L-253 to L-266; D-254 to L-266; G-255 to L-266; D-256 to L-266; V-257 to L-266; T-258 to L-266; F-259 to L-266; F-260 to L-266; and G-261 to L-266 of SEQ ID NO:3229. The present invention is also directed to antibodies 65 that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. [01291 Similarly, deletions of C-terminal amino acid residues of the predicted extracellular domain of BLyS up to the leucine residue at position 79 of SEQ ID NO:3229 may retain some functional activity, such as, for example, ligand binding, the ability to stimulate lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, modulation of cell replication, modulation of target cell activities and/or immunogenicity. Polypeptides having further C-termirnal deletions including Leu-79 of SEQ ID NO:3229 would not be expected to retain biological activities. 10130] However, even if deletion of one or more amino acids from the C-terminus of a polypeptide results in modification or loss of one or more functional activities (e.g., biological activity) of the polypeptide, other functional activities may still be retained. Thus, the ability of the shortened polypeptide to induce and/or bind to antibodies which recognize the complete, mature or extracellular forms of the polypeptide generally will be retained when less than the majority of the residues of the complete, mature or extracellular forms of the polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of the predicted extracellular domain retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art [01311 Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues from the carboxy terminus of the amino acid sequence of the predicted extracellular domain of BLyS shown in SEQ ID NO:3229, up to the leucine residue at position 79 of SEQ ID NO:3229. In particular, the present invention provides antibodies that bind polypeptides having the amino acid sequence of residues 73-M 4 of the amino acid sequence in SEQ ID NO:3229, where M 4 is any integer in the range of the amino acid position of amino acid residues 79-265 of the amino acid sequence in SEQ ID NO:3229. [0132] More in particular, in certain embodiments, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues Q-73 to L-265; Q-73 to K-264; Q-73 to L-263; Q-73 to A-262; Q-73 to G-261; Q-73 to F-260; Q-73 to F-259; Q-73 to 66 T-258; Q-73 to V-257; Q-73 to D-256; Q-73 to G-255; Q-73 to D-254; Q-73 to L-253; Q-73 to S-252; Q-73 to 1-251; Q-73 to Q-250; Q-73 to A-249; Q-73 to N-248; Q-73 to E-247; Q-73 to R-246; Q-73 to P-245; Q-73 to 1-244; Q-73 to A-243; Q-73 to L-242; Q-73 to Q-241; Q-73 to L-240; Q-73 to E-239; Q-73 to D-238; Q-73 to G-237; Q-73 to E-236; Q-73 to E-235; Q-73 to L-234; Q-73 to K-233; Q-73 to A-232; Q-73 to 1-231; Q-73 to G-230; Q-73 to A-229; Q-73 to S-228; Q-73 to Y-227; Q-73 to C-226; Q-73 to S-225; Q-73 to N-224; Q-73 to N-223; Q-73 to P-222; Q-73 to L-221; Q-73 to T-220; Q-73 to E-219; Q-73 to P-218; Q-73 to M-217; Q-73 to N-216; Q-73 to Q-215; Q-73 to 1-214; Q-73 to C-213; Q-73 to R-212; Q-73 to F-211; Q-73 to L-210; Q-73 to T-209; Q-73 to V-208; Q-73 to L-207; Q-73 to S-206; Q-73 to L-205; Q-73 to E-204; Q-73 to D-203; Q-73 to G-202; Q-73 to F-201; Q-73 1o V-200; Q-73 to H-199; Q-73 to V-198; Q-73 to K-197; Q-73 to K-196; Q-73 to R-195; Q-73 to Q-194; Q-73 to 1-193; Q-73 to L-192; Q-73 to H-191; Q-73 to G-190; Q-73 to Q-7389; Q-73 to A-188; Q-73 to Y-187; Q-73 to T-186; Q-73 to K-185; Q-73 to D-184; Q-73 to T-183; Q-73 to Y-182; Q-73 to L-181; Q-73 to V-180; Q-73 to Q-179; Q-73 to G-178; Q-73 to Y-177; Q-73 to 1-176; Q-73 to F-175; Q-73 to F-174; Q-73 to Y-173; Q-73 to G-172; Q-73 to T-171; Q-73 to E-170; Q-73 to K-169; Q-73 to V-168; Q-73 to L-167; Q-73 to 1-166; Q-73 to K-165; Q-73 to N-164; Q-73 to E-163; Q-73 to K-162; Q-73 to E-161; Q-73 to E-160; Q-73 to L-159; Q-73 to A-158; Q-73 to S-157; Q-73 to G-156; Q-73 to R-155; Q-73 to K-154; Q-73 to F-153; Q-73 to S-152; Q-73 to L-151; Q-73 to L-150; Q-73 to W-149; Q-73 to P-148; Q-73 to V-147; Q-73 to F-146; Q-73 to T-145; Q-73 to Y-144; Q-73 to S-143; Q-73 to G-142; Q-73 to T-141; Q-73 to E-140; Q-73 to E-139; Q-73 to P-1 38; Q-73 to G-137; Q-73 to Q-136; Q-73 to V-135; Q-73 to A-134; Q-73 to R-133; Q-73 to K-132; Q-73 to N-131; Q-73 to R-130; Q-73 to S-129; Q-73 to N-128; Q-73 to Q-127; Q-73 to S-126; Q-73 to S-125; Q-73 to N-124; Q-73 to G-123; Q-73 to E-122; Q-73 to G-121; Q-73 to P-120; Q-73 to A-119; Q-73 to P-118; Q-73 to P-117; Q-73 to E-116; Q-73 to F-115; Q-73 to 1-114; Q-73 to K-1 13; Q-73 to L-112; Q-73 to G-1 11; Q-73 to A-1 10; Q-73 to T-109; Q-73 to V-108; Q-73 to A-107; Q-73 to P-106; Q-73 to A-105; Q-73 to E-104; Q-73 to E-103; Q-73 to L-102; Q-73 to G-101; Q-73 to A-100; Q-73 to K-99; Q-73 to P-98; Q-73 to A-97; Q-73 to G-96; Q-73 to A-95; Q-73 to G-94; Q-73 to A-93; Q-73 to P-92; Q-73 to L-91; Q-73 to K-90; Q-73 to E-89; Q-73 to A-88; Q-73 to H-87; Q-73 to H-86; Q-73 to G-85; Q-73 to Q-84; Q-73 to L-83; Q-73 to E-82; Q-73 to A-81; Q-73 to 67 R-80; Q-73 to L-79; and Q-73 to S-78 of SEQ ID NO:3229. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. [0133] The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini of the predicted extracellular domain of BLyS, which may be described generally as having residues n 4 -m 4 of SEQ ID NO:3229 where n 4 and m 4 are integers as defined above. [01341 In another embodiment, antibodies of the present invention bind polypeptides consisting of a portion of the extracellular domain of the BLyS amino acid sequence encoded by the cDNA clone contained in the deposit having ATCC Accession No. 203518, where this portion excludes from I to about 260 amino acids from the amino terminus of the extracellular domain of the amino acid sequence encoded by cDNA clone contained in the deposit having ATCC Accession No. 203518, or from 1 to about 187 amino acids. from the carboxy terminus of the extracellular domain of the amino acid sequence encoded by cDNA clone contained in the deposit having ATCC Accession No. 203518, or any combination of the above amino terminal and carboxy terminal deletions, of the entire extracellular domain of the amino acid sequence encoded by the cDNA clone contained in the deposit having ATCC Accession No. 203518. [0135] As mentioned above, even if deletion of one or more amino acids from the N-terminus of a polypeptide results in modification or loss of one or more functional activities (e.g., biological activity) of the polypeptide, other functional activities may still be retained. Thus, the ability of a shortened BLyS polypeptide to induce and/or bind to antibodies which recognize the full-length or mature forms or the extracellular domain of the polypeptide generally will be retained when less than the majority of the residues of the full-length or mature or extracellular domain of the polypeptide are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a BLyS mutein with a large number of deleted N-terminal amino acid residues may retain functional (e.g., immunogenic) activities. In fact, peptides composed of as few as six 68 BLyS amino acid residues may often evoke an immune response. 101361 Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the amino terminus of the predicted full-length amino acid sequence of the BLyS polypeptide shown in SEQ ID NO:3229, up to the glycine residue at position number 261 of the sequence shown SEQ ID NO:3229 and polynucleotides encoding such polypeptides. In particular, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues n 5 -266 of the sequence shown in SEQ ID NO:3229, where n 5 is an integer in the range of the amino acid position of amino acid residues I to 261 of the amino acid sequence in SEQ ID NO:3229. 101371 More in particular, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues of D-2 to L-266; D-3 to L-266; S-4 to L-266; T-5 to L-266; E-6 to L-266; R-7 to L-266; E-8 to L-266; Q-9 to L-266; S-10 to L-266; R- 11 to L-266; L-12 to L-266; T-13 to L-266; S-14 to L-266; C-15 to L-266; L-16 to L-266; K-17 to L-266; K-18 to L-266; R-19 to L-266; E-20 to L-266; E-21 to L-266; M-22 to L-266; K-23 to L-266; L-24 to L-266; K-25 to L-266; E-26 10 L-266; C-27 to L-266; V-28 to L-266; S-29 to L-266; 1-30 to L-266; L-31 to L-266; P-32 to L-266; R-33 to L-266; K-34 to L-266; E-35 to L-266; S-36 to L-266; P-37 to L-266; S-38 to L-266; V-39 to L-266; R-40 to L-266; S-41 to L-266; S-42 to L-266; K-43 to L-266; D-44 to L-266; G-45 to L-266; K-46 to L-266; L-47 to L-266; L-48 to L-266; A-49 to L-266; A-50 to L-266; T-51 to L-266; L-52 to L-266; L-53 to L-266; L-54 to L-266; A-55 to L-266; L-56 to L-266; L-57 to L-266; S-58 to L-266; C-59 to L-266; C-60 to L-266; L-61 to L-266; T-62 to L-266; V-63 to L-266; V-64 to L-266; S-65 to L-266; F-66 to L-266; Y-67 to L-266; Q-68 to L-266; V-69 to L-266; A-70 to L-266; A-71 to L-266; L-72 to L-266; Q-73 to L-266; G-74 to L-266; D-75 to L-266; L-76 to L-266; A-77 to L-266; S-78 to L-266; L-79 to L-266; R-80 to L-266; A-81 to L-266; E-82 to L-266; L-83 to L-266; Q-84 to L-266; G-85 to L-266; H-86 to L-266; H-87 to L-266; A-88 to L-266; E-89 to L-266; K-90 to L-266; L-91 to L-266; P-92 to L-266; A-93 to L-266; G-94 to L-266; A-95 to L-266; G-96 to L-266; A-97 to L-266; P-98 to L-266; K-99 to L-266; A-100 to L-266; G-I01 to L-266; L-102 to L-266; E-103 to L-266; E-104 to L-266; A-105 to L-266; P-106 to L-266; A-107 to L-266; V-108 to L-266; T-109 to L-266; A-1 10 to L-266; G- 111 to L-266; L- 112 to L-266; K- 113 to 69 L-266; 1-114 to L-266; F-115 to L-266; E116 to L-266; P-117 to L-266; P-118 to L-266; A-119 to L-266; P-120 to L-266; G-121 to L-266; E-122 to L-266; G-123 to L-266; N-124 to L-266; S-125 to L-266; S-126 to I,266; Q-127 to L-266; N-128 to L-266; S-129 to L-266; R-130 to L-266; N-131 to L-266; K-132 to L-266; R-133 to L-266; A-134 to L-266; V-135 to L-266; Q-136 to L-266; G-137 to L-266; P-138 to L-266; E-139 to L-266; E-140 to L-266; T-141 to L-266; G-142 to L-266; S-143 to L-266; Y-144 to L-266; T-145 to L-266; F-146 to L-266; V-147 to L-266; P-148 to L-266; W-149 to L-266; I150 to L-266; L-151 to L-266; S-152 to L-266; F-153 to L-266; K-154 to L-266; R-155 to L-266; G-156 to L-266; S-157 to L-266; A-158 to L-266; L-159 to L-266; E-160 to L-266; E-161 to L-266; K-162 to L-266; E-163 to L-266; N-164 to L-266; K-165 to L-266; 1-166 to L-266; L-167 to L-266; V-168 to L-266; K-169 to L-266; E-170 to L-266; T-171 to L-266; G-172 to L-266; Y-173 to L-266; F-174 to L-266; F-175 to L-266; 1-176 to L-266; Y-177 to L-266; G-178 to L-266; Q-179 to L-266; V-180 to L-266; L-181 to L-266; Y-182 to L-266; T-183 to L-266; D-184 to L-266; K-185 to L-266; T-186 to L-266; Y-187 to L-266; A-188 to L-266; M-189 to L-266; G-190 to L-266; H-191 to L-266; I.192 to L-266; 1-193 to L-266; Q-194 to L-266; R-195 to L-266; K-196 to L-266; K-197 to L-266; V-198 to L-266; H-199 to L-266; V-200 to L-266; F-201 to L-266; G-202 to L-266; D-203 to L-266; E-204 to L-266; L-205 to L-266; S-206 to L-266; L-207 to L-266; V-208 to L-266; T-209 to L-266; L-210 to L-266; F-211 to L-266; R-212 to L-266; C-213 to L-266; 1-214 to L-266; Q-215 to L-266; N-216 to L-266; M-217 to L-266; P-218 to L-266; E-219 to L-266; T-220 to L-266; L-221 to L-266; P-222 to L-266; N-223 to L-266; N-224 to L-266; S-225 to L-266; C-226 to L-266; Y-227 to L-266; S-228 to L-266; A-229 to L-266; G-230 to L-266; 1-231 to L-266; A-232 to L-266; K-233 to L-266; L-234 to L-266; E-235 to L-266; E-236 to L266; G-2.37 to L-266; D-238 to L-266; E-239 to L-266; L-240 to L-266; Q-241 to L-266; L-242 to L-266; A-243 to L-266; 1-244 to L-266; P-245 to L-266; R-246 to L-266; E-247 to L-2.66; N-248 to L-266; A-249 to L-266; Q-250 to L-266; 1-251 to L-266; S-252 to L-266; L-253 to L-266; D-254 to L-266; G-255 to L-266; D-256 to L-266; V-257 to L-266; T-258 to L-266; F-259 to L-266; F-260 to L-266; and G-261 to L-266 of SEQ ID NO:3229. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. 70 101381 Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more functional activities (e.g., biological activities) of the protein, other functional activities may still be retained. Thus, the ability of a shortened BLyS mutein to induce and/or bind to antibodies which recognize the complete or mature form or the extracellular domain of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature form or the extracellular domain of the polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a BLyS mutein with a large number of deleted C-terminal amino acid residues may retain some functional (e.g., immunogenic) activities. In fact, peptides composed of as few as six BLyS amino acid residues may often evoke an immune response. [01391 Accordingly, the present invention further provides in another embodiment, antibodies that bind polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the BLyS shown in SEQ ID NO:3229, up to the glutamic acid residue at position number 6, and polynucleotides encoding such polypeptides. In particular, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues 1-m 5 of SEQ ID NO:3229, where m' is an integer in the range of the amino acid position of amino acid residues 6 to 265 in the amino acid sequence of SEQ ID NO:3229. [01401 More in particular, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues M-1 to L-265; M-1 to K-264; M-1 to L-263; M-1 to A-262; M-1 to G-261; M-1 to F-260; M-1 to F-259; M-1 to T-258; M-1 to V-257; M-1 to D-256; M-1 to G-255; M-1 to D-254; M-1 to L-253; M-1 to S-252; M-1 to 1-251; M-1 to Q-250; M-1 to A-249; M-1 to N-248; M-1 to E-247; M-1 to R-246; M-1 to P-245; M-1 to 1-244; M-1 to A-243; M-1 to L-242; M-1 to Q-241; M-1 to L-240; M-1 to E-239; M-1 to D-238; M-1 to G-237; M-1 to E-236; M-1 to E-235; M-1 to L-234; M-1 to K-233; M-1 to A-232; M-1 to 1-231; M-1 to G-230; M-1 to A-229; M-1 to S-228; M-1 to Y-227; M-1 to C-226; M-1 to S-225; M-1 to N-224; M-1 to N-223; M-1 to P-222; M-1 to L-221; M-1 to T-220; M-1 to E-219; M-1 to P-218; M-1 to M-217; M'1 to N-216; M-I to Q-215; M-1 to 1-214; M-I to 71 C-213; M-1 to R-212; M-1 to F-211; IM-1 to L-210; M-1 to T-209; M-1 to V-208; M-1 to L-207; M-1 to S-206; M-1 to L-205; M-1 to E-204; M-1 to D-203; M-1 to G-202; M-1 to F-201; M-1 to V-200; M-1 to H-199; M-1 to V-198; M-1 to K-197; M-1 to K-196; M-1 to R-195; M-1 to Q-194; M-1 to 1-193; M-1 to L-192; M-1 to H-191; M-1 to G-190; M-1 to M-189; M-1 to A-188; M-1 to Y-187; M-1 to T-186; M-1 to K-185; M-1 to D-184; M-1 to T-183; M-1 to Y-182; M-1 to L-181; M-1 to V-180; M-1 to Q-179; M-1 to G-178; M-1 to Y-177; M-1 to 1-176; M-1 to F-175; M-1 to F-174; M-1 to Y-173; M-1 to G-172; M-1 to T-171; M-1 to E-170; M-1 to K-169; -1 to V-168; M-1 to L-167; M-1 to 1-166; M-1 to K-165; M-1 to N-164; M-1 to E-163; M-1 to K-162; M-1 to E-161; M-1 to E-160; M-1 to L-159; M-1 to A-158; M-I to S-157; M-l to G-156; M-1 to R-155; M-1 to K-154; M-1 to F-153; M-1 to S-152; M- Ito L-151; M-1 to L-150; M-1 to W-149; M-1 to P-148; M-1 to V-147; M-1 to F-146; M-1 to T-145; M-1 to Y-144; M-1 to S-143; M-1 to G-142; M-1 to T-141; M-1 to E-140; M-1 to E-139; M-1 to P-138; M-1 to G-137; M-1 to Q-136; M-1 to V-135; M-1 to A-134; M-1 to R-133; M-1 to K-132; M-1 to N-131; M-1 to R-130; M-1 to S-129; M-1 to N-128; M-1 to Q-127; M-1 to S-126; M-1 to S-125; M-1 to N-124; M-1 to G-123; M-1 to E-122; M-1 to G-121; M-1 to P-120; M-1 to A-119; M-1 to P-1 18; M-1 to P-117; M-1 to E-116; M-1 to F-115; M-1 to I-114; M-1 to K-113; M-1 to L-1 12; M-1 to G-111; M-1 to A-110; M-1 to T-109; M-1 to V-108; M-1 to A-107; M-1 to P-106; M-1 to A-105; M-1 to E-104; M-1 to E-103; M-1 to L-102; M-1 to G-101; M-1 to A-100; M-1 to K-99; M-I to P-98; M-1 to A-97; M-1 to G-96; M-1 to A-95; M-1 to G-94; M-I to A-93; M-1 to P-92; M-1 to L-91; M-1 to K-90; M-1 to E-89; M-1 to A-88; M-1 to H-87; M-1 to H-86; M-1 to G-85; M-1 to Q-84; M-1 to L-83; M-1 to E-82; M-1 to A-81; M-1 to R-80; M-1 to L-79; M-1 to S-78; M-1 to A-77; M-1 to L-76; M-1 to D-75; M-1 to G-74; M-1 to Q-73; M-1 to L-72; M-1 to A-71; M-1 to A-70; M-1 to V-69; M-1 to Q-68; M-1 to Y-67; M-1 to F-66; M-1 to S-65; M-1 to V-64; M-1 to V-63; M-1 to T-62; M-1 to L-61; M-1 to C-60; M-1 to C-59; M-1 to S-58; M-1 to L-57; M-1 to L-56; M-1 to A-55; M-1 to L-54; M-1 to L-53; M-1 to L-52; M-1 to T-51; M-1 to A-50; M-1 to A-49; M-1 to L-48; M-1 to L-47; M-1 to K-46; M-1 to G-45; M-1. to D-44; M-1 to K-43; M-1 to S-42; M-1 to S-41; M-1 to R-40; M-1 to V-39; M-1 to S-38; M-1 to P-37; M-1 to S-36; M-1 to E-35; M-1 to K-34; M-1 to R-33; M-1 to P-32; M-1 to L-31; M-1 to 1-30; M-1 to S-29; M-1 to V-28; M-1 to C-27; M-1 to E-26; M-1 to K-25; M-1 to L-24; M-1 to K-23; M-1 to M-22; M-1 to E-21; M-1 to E-20; M-1 to R-19; M-1 to K-18; M-1 to K-17; M-1 to L-16; M-1 to C-15; 72 M-1 to S-14; M-1 to T-13; M-1 to L-12; M-1 to R-1 1; M-1 to S-10; M-1 to Q-9; M-1 to E-8; M-I to R-7; and M-1 to E-6 of SEQ ID NO:3229. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. 101411 The invention also provides antibodies that bind polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini of a BLyS polypeptide, which may be described generally as having residues n 5 -m 5 of SEQ ID NO:3229, where n 5 and m 5 are integers as defined above. (01421 In additional embodiments, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues 134-m 6 of SEQ ID NO:3228, where m 6 is an integer from 140 to 285, corresponding to the position of the amino acid residue in SEQ ID NO:3228. For example, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues A-134 to Leu-285; A-134 to L-284; A-134 to K-283; A-134 to L-282; A-134 to A-281;-A-134 to G-280; A-134 to F-279; A-134 to F-278; A-134 to T-277; A-134 to V-276; A-134 to D-275; A-134 to G-274; A-134 to D-273; A-134 to L-272; A-134 to S-271; A-134 to 1-270; A-134 to Q-269; A-134 to A-268; A-134 to N-267; A-134 to E-266; A-134 to R-265; A-134 to P-264; A-134 to 1-263; A-134 to A-262; A-134 to L-261; A-134 to Q-260; A-134 to L-259; A-134 to E-258; A-134 to D-257; A-134 to G-256; A-134 to E-255; A-134 to E-254; A-134 to L-253; A-134 to K-252; A-134 to A-251; A-134 to 1-250; A-134 to G-249; A-134 to A-248; A-134 to S-247; A-134 to Y-246; A-134 to C-245; A-134.to S-244; A-134 to N-243; A-134 to N-242; A-134 to P-241; A-134 to L-240; A-134 to T-239; A-134 to E-238; A-134 to P-237; A-134 to M-236; A-134 to N-235; A-134 to Q-234; A-134 to 1-233; A-134 to C-232; A-134 to R-231; A-134 to F-230; A-134 to L-229; A-134 to T-228; A-134 to V-227; A-134 to L-226; A-134 to S-225; A-134 to L-224; A-134 to E-223; A-134 to D-222; A-134 to G-221; A-134 to F-220; A-134 to V-219; A-134 to H-218; A-134 to V-217; A-134 to K-216; A-134 to K-215; A-134 to R-214; A-134 to Q-21 3 ; A-134 to 1-212; A-134 to L-21 1; A-134 to H-210; A-134 to G-209; A-134 to M-208; A-134 to A-207; A-134 to Y-206; A-134 to T-205; A-134 to K-204; A-134 to 73 D-203; A-134 to T-202; A-134 to Y-201; A-134 to L-200; A-134 to V-199; A-134 to Q-198; A-134 to G-197; A-134 to Y-196; A-134 to 1-195; A-134 to F-194; A-134 to F-193; A-134 to Y-192; A-134 to G-191; A-134 to T-190; A-134 to E-189; A-134 to K-188; A-134 to V-187; A-134 to L-186; A-134 to 1-185; A-134 to K-184; A-134 to N-183; A-134 to E-182; A-134 to K-181; A-134 to E-180; A-134 to E-179; A-134 to L-178; A-134 to A-177; A-134 to S-176; A-134 to G-175; A-134 to R-174; A-134 to K-173; A-134 to F-172; A-134 to S-171; A-134 to L-170; A-134 to L-169; A-134 to W-168; A-134 to P-167; A-134 to V-166; A-134 to F-165; A-134 to T-164; A-134 to Y-163; A-134 to S-162; A-134 to G-1 61; A-134 to K-160; A-134 to Q-159; A-134 to 1-158; A-134 to T-157;-A-134 to P-156; A-134 to T-155; A-134 to E-154; A-134 to S-153; A-.134 to D-152; A-134 to A-151; A-134 to 1-150; A-134 to L-149; A-134 to Q-148; A 134 to L-147; A-134 to C-146; A-134 to D-145; A-134 to Q-144; A-134 to T-143; A-134 to.V-142; A-134 to T-141; and A-134 to E-140 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. [0143] In additional embodiments, antibodies of the present invention may bind polypeptide fragments comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues: M-1 to C-15; D-2 to L-16; D-3 to K-17; S 4 to K-18; T-5 to R-19; E-6 to E-20; R-7 to E-21; E-8 to M-22; Q-9 to K-23; S-10 to L-24; R-1 Ito K-25; L-12 to E-26; T-13 to C-27; S-14 to V-28; C-15 to S-29; L-16 to 1-30; K-17 to L-31; K-18 to P-32; R-19 to R-33; E-20 to K-34; E-21 to E-35; M-22 to S-36; K-23 to P-37; L-24 to S-38; K-25 to V-39; E-26 to R-40; C-27 to S-41; V-28 to S-42; S-29 to K 43; 1-30 to D-44; L-31 to G-45; P-32 to K-46; R-33 to L-47; K-34 to L-48; E-35 to A-49; S-36 to A-50; P-37 to T-51; S-38 to L-52; V-39 to L-53; R-40 to L-54; S-41 to A-55; S-42 to L-56; K-43 to L-57; D-44 to S-58; G-45 to C-59; K-46 to C-60; L-47 to L-61; L-48 to T-62; A-49 to V-63; A-50 to V-64; T-51 to S-65; L-52 to F-66; L-53 to Y-67; L-54 to Q 68; A-55 to V-69; L-56 to A-70; L-57 to A-71; S-58 to L-72; C-59 to Q-73; C-60 to G-74; L-61 to D-75; T-62 to L-76; V-63 to A-77; V-64 to S-78; S-65 to L-79; F-66 to R-80; Y 67 to A-81; Q-68 to E-82; V-69 to L-83; A-70 to Q-84; A-71 to G-85; L-72 to H-86; Q-73 to H-87; G-74 to A-88; D-75 to E-89; L-76 to K-90; A-77 to L-91; S-78 to P-92; L-79 to 74 A-93; R-80 to G-94; A-81 to A-95; E--82 to G-96; L-83 to A-97; Q-84 to P-98; G-85 to K 99; H-86 to A-100; H-87 to G-101; A-88 to L-102; E-89 to E-103; K-90 to E-104; L-91 to A-105; P-92 to P-106; A-93 to A-107; G-94 to V-108; A-95 to T-109; G-96 to A-110; A 97 to G-111; P-98 to L-112; K-99 to K-113; A-100 to I-114; G-101 to F-115; L-102 to E 116; E-103 to P-117; E-104 to P-118; A-105 to A-119; P-106 to P-120; A-107 to G-121; V-108 to E-122; T-109 to G-123; A-110 to N-124; G-111 to S-125; L-112 to S-126; K 113 to Q-127; I-114 to N-128; F-115 to S-129; E-116 to R-130; P-l17 to N-131; P-118 to K-132; A-119 to R-133; P-120 to A-134; G-121 to V-135; E-122 to Q-136; G-123 to G 137; N-124 to P-138; S-125 to E-139; S-126 to E-140; Q-127 to T-141; N-128 to V-142; S-129 to T-143; R-130 to Q-144; N-131 to D-145; K-132 to C-146; R-133 to L-147; A 134 to Q-148; V-135 to L-149; Q-136 to 1-150; G-137 to A-15 1; P-138 to D-152; E-139 to S-153; E-140 to E-154; T-141 to T-1:55; V-142 to P-156; T-143 to T-157; Q-144 to I-158; D-145 to Q-159; C-146 to K-160; L-147 to G-161; Q-148 to S-162; 1-149 to Y-163; 1-150 to T-164; A-151 to F-165; D-152 to V-166; S-153 to P-167; E-154 to W-168; T-155 to L 169; P-156 to L-170; T-157 to S-171; 1-158 to F-172; Q-159 to K-173; K-160 to R-174; G-161 to G-175; S-162 to S-176; Y-163 to A-177; T-164 to L-178; F-165 to E-179; V-166 to E-180; P-167 to K-181; W-168 to E-182; L-169 to N-183; L-170 to K-184; S-171 to I 185; F-172 to L-186; K-173 to V-187; R-174 to K-188; G-175 to E-189; S-176 to T-190; A-177 to G-191; L-178 to Y-192; E-179 to F-193; E-180 to F-194; K-181 to I-195; E-182 to Y-196; N-183 to G-197; K-184 to Q-198; 1-185 to V-199; L-186 to L-200; V-187 to Y 201; K-188 to T-202; E-189 to D-203; T-190 to K-204; G-191 to T-205; Y-192 to Y-206; F-193 to A-207; F-194 to M-208; 1-195 to G-209; Y-196 to H-210; G-197 to L-21 1; Q 198 to 1-212; V-199 to Q-213; L-200 to R-214; Y-201 to K-215; T-202 to K-216; D-203 to V-217; K-204 to H-218; T-205 to V-219; Y-206 to F-220; A-207 to G-221; M-208 to D-222; G-209 to E-223; H-210 to L-224; L-211 to S-225; 1-212 to L-226; Q-213 to V 227; R-214 to T-228; K-215 to L-229; K-216 to F-230; V-217 to R-231; H-218 to C-232; V-219 to 1-233; F-220 to Q-234; G-221 to N-235; D-222 to M-236; E-223 to P-237; L-224 to E-238; S-225 to T-239; L-226 to L-240; V-227 to P-241; T-228 to N-242; L-229 to N 243; F-230 to S-244; R-231 to C-245; C-232 to Y-246; 1-233 to S-247; Q-234 to A-248; N-235 to G-249; M-236 to 1-250; P-237 to A-251; E-238 to K-252; T-239 to L-253; L-240 to E-254; P-241 to E-255; N-242 to G-256; N-243 to D-257; S-244 to E-258; C-245 to L 259; Y-246 to Q-260; S-247 to L-261; A-248 to A-262; G-249 to 1-263; 1-250 to P-264; 75 A-251 to R-265; K-252 to E-266; L-253 to N-267; E-254 to A-268; E-255 to Q-269; G 256 to 1-270; D-257 to S-271; E-258 to L-272; L-259 to D-273; Q-260 to G-274; L-261 to D-275; A-262 to V-276; 1-263 to T-277; P-264 to F-278; R-265 to F-279; E-266 to G-280; N-267 to A-281; A-268 to L-282; Q-269 to K-283; 1-270 to L-284; and S-271 to L-285 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. [0144] In additional embodiments, antibodies of the present invention may bind polypeptide fragments comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues: M-I to C-15; D-2 to L-16; D-3 to K-17; S 4 to K-18; T-5 to R-19; E-6 to E-20; R-7 to E-21; E-8 to M-22; Q-9 to K-23; S-10 to L-24; R-11 to K-25; L-12 to E-26; T-13 to C-27; S-14 to V-28; C-I5 to S-29; L-16 to 1-30; K-17 to L-31; K-18 to P-32; R-19 to R-33; E-20 to K-34; E-21 to E-35; M-22 to S-36; K-23 to P-37; L-24 to S-38; K-25 to V-39; E-26 to R-40; C-27 to S-41; V-28 to S-42; S-29 to K 43; 1-30 to D-44; L-31 to GA5; P-32 to K-46; R-33 to L-47; K-34 to L-48; E-35 to A-49; S-36 to A-50; P-37 to T-51; S-38 to L-52; V-39 to L-53; R-40 to L-54; S-41 to A-55; S-42 to L-56; K-43 to L-57; D-44 to S-58; G45 to C-59; K-46 to C-60; L-47 to L-61; L-48 to T-62; A-49 to V-63; A-50 to V-64; T-51 to S-65; L-52 to F-66; L-53 to Y-67; L-54 to Q 68; A-55 to V-69; L-56 to A-70; L-57 to A-71; S-58 to L-72; C-59 to Q-73; C-60 to G-74; L-61 to D-75; T-62 to L-76; V-63 to A-77; V-64 to S-78; S-65 to L-79; F-66 to R-80; Y 67 to A-81; Q-68 to E-82; V-69 to L-83; A-70 to Q-84; A-71 to G-85; L-72 to H-86; Q-73 to H-87; G-74 to A-88; D-75 to E-89; L-76 to K-90; A-77 to L-91; S-78 to P-92; L-79 to A-93; R-80 to G-94; A-81 to A-95; E-82 to 0-96; L-83 to A-97; Q-84 to P-98; G-85 to K 99; H-86 to A-100; H-87 to G-101; A-88 to L-102; E-89 to E-103; K-90 to E-104; L-91 to A-105; P-92 to P-106; A-93 to A-107; 0-94 to V-108; A-95 to T-109; G-96 to A-i 10; A 97 to G-111; P-98 to L-112; K-99 to K-113; A-100 to I-114; G-101 to F-115; L-102 to E 116; E-103 to P-1 17; E-104 to P-1 18; A-105 to A-119; P-106 to P-120; A-107 to G-121; V-108 to E-122; T-109 to G-123; A-110 to N-124; G-11 to S-125; L-112 to S-126; K 113 to Q-127; I-114 to N-128; F-115 to S-129; E-116 to R-130; P-117 to N-131; P-118 to K-132; A-I 19 to R-133; P-120 to A-134; G-121 to V-135; E-122 to Q-136; G-123 to G 137; N-124 to P-138; S-125 to E-139; S-126 to E-140; Q-127 to T-141; N-128 to G-142; 76 S-129 to S-143; R-130 to Y-144;N-131 to T-145;K-132 to F-146;R-133 to V-147; A 134 to P-148; V-135 to W-149; Q-136 to L-150; G-137 to L-151; P-138 to S-152; E-139 to F-153;E-140 to K-154;T-141 to R-155; G-142 to G-156; S-143 to S-157;Y-144 to A 158; T-145 to L-159; F-146 to E-160; V-147 to E-161; P-148 to K-162; W-149 to E-163; L-150 to N-164; L-151 to K-165; S-152 to 1-166; F-153 to L-167; K-154 to V-168; R-155 to K-169; G-156 to E-170; S-157 to T-171; A-158 to G-172; L-159 to Y-173; E-160 to F 174; E-161 to F-175; K-162 to 1-176; E-163 to Y-177; N-164 to G-178; K-165 to Q-179; 1-166 to V-180; L-167 to L-181; V-168 to Y-182; K-169 to T-183; E-170 to D-184; T-171 to K-185; G-172 to T-186; Y-173 to Y-187; F-174 to A-188; F-175 to M-189; 1-176 to G 190; Y-177 to H-191; G-178 to L-192; Q-179 to 1-193; V-180 to Q-194; L-181 to R-195; Y-182 to K-196; T-183 to K-197; D-184 to V-198; K-185 to H-199; T-186 to V-200; Y 187 to F-201; A-188 to G-202; M-189 to D-203; G-190 to E-204; H-191 to L-205; L-192 to S-206; 1-193 to L-207; Q-194 to V-208; R-195 to T-209; K-196 to L210; K-197 to F 211; V-198 to R-212; H-199 to C-213; V-200 to 1-214; F-201 to Q-215; G-202 to N-216; D-203 to M-217; E-204 to P-218; L-205 to E-219; S-206 to T-220; L-207 to L-221; V-208 to P-222; T-209 to N-223; L-210 to N-224; F-21 Ito S-225; R-212 to C-226; C-213 to Y 227; 1-214 to S-228; Q-215 to A-229; N-216 to G-230; M-217 to 1-231; P-218 to A-232; E-219 to K-233; T-220 to L-234; L-221 to E-235; P-222 to E-236; N-223 to G-237; N-224 to D-238; S-225 to E-239; C-226 to L-240; Y-227 to Q-241; S-228 to L-242; A-229 to A 243; G-230 to 1-244; 1-231 to P-245; A-232 to R-246; K-233 to E-247; L-234 to N-248; E 235 to A-249; E-236 to Q-250; G-237 to 1-251; D-238 to S-252; E-239 to L-253; L-240 to D-254; Q-241 to 0-255; L-242 to D-256; A-243 to V-257; 1-244 to T-258; P-245 to F 259; R-246 to F-260; E-247 to G-261; N-248 to A-262; A-249 to L-263; Q-250 to K-264; 1-251 to L-265; and S-252 to L-266 of SEQ ID NO:3229. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. [01451 In additional embodiments, antibodies of the present invention may bind polypeptide fragments comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues: M-1 to F-15; D-2 to C-16; E-3 to S-17; S-4 to E-18; A-5 to K-19; K-6 to G-20; T-7 to E-21; L-8 to D-22; P-9 to M-23; P-10 to K-24; 77 P-11 to V-25; C-12 to G-26; L-13 to Y-27; C-14 to D-28; F-15 to P-29; C-16 to 1-30; S-17 to T-31; E-18 to P-32; K-19 to Q-33; G-20 to K-34; E-21 to E-35; D-22 to E-36; M-23 to G-37; K-24 to A-38; V-25 to W-39; G-26 to F-40; Y-27 to G-41; D-28 to 1-42; P-29 to C 43; 1-30 to R-44; T-31 to D-45; P-32 to G-46; Q-33 to R-47; K-34 to L-48; E-35 to L-49; E-36 to A-50; G-37 to A-51; A-38 to T-52; W-39 to L-53; F-40 to L-54; G-41 to L-55; I 42 to A-56; C-43 to L-57; R-44 to L-58; D-45 to S-59; G-46 to S-60; R-47 to S-61; L-48 to F-62; L-49 to T-63; A-50 to A-64; A-51 to M-65; T-52 to S-66; L-53 to L-67; L-54 to Y-68; L-55 to Q-69; A-56 to L-70; L-57 to A-71; L-58 to A-72; S-59 to L-73; S-60 to Q 74; S-61 to A-75; F-62 to D-76; T-63 to L-77; A-64 to M-78; M-65 to N-79; S-66 to L-80; L-67 to R-81; Y-68 to M-82; Q-69 to E-83; L-70 to L,84; A-71 to Q-85; A-72 to S-86; L 73 to Y-87; Q-74 to R-88; A-75 to G-89; D-76 to S-90; L-77 to A-91; M-78 to T-92; N-79 to P-93; L-80 to A-94; R-81 to A-95; M-82 to A-96; E-83 to G-97; L-84 to A-98; Q-85 to P-99; S-86 to E-100; Y-87 to L-101; R-88 to T-102; G-89 to A-103; S-90 to G-104; A-91 to V-105; T-92 to K-106; P-93 to L-1.07; A-94 to L-108; A-95 to T-109; A-96 to P-110; G-97 to A-1 11; A-98 to A-112; P-99 to P-113; E-100 to R-114; L-101 to P-115; T-102 to H-116; A-103 toN-117; G-104 to S-118; V-105 to S-119; K-106 to R-120; L-107 to G 121; L-108 to H-122; T-109 to R-123; P-110 to N-124; A-111 to R-125; A-112 to R-126; P-113 to A-127; R-114 to F-128; P-115 to Q-129; H-116 to G-130; N-117 to P-131; S-118 to E-132; S-119 to E-133; R-120 to T-134; G-121 to E-135; H-122 to Q-136; R-123 to D 137; N-124 to V-138; R-125 to D-139; R-126 to L-140; A-127 to S-141; F-128 to A-142; Q-129 to P-143; G-130 to P-144; P-131 to A-145; E-132 to P-146; E-133 to C-147; T-134 to L-148; E-135 to P-149; Q-136 to G-150; D-137 to C-151; V-138 to R-152; D-139 to H 153; L-140 to S-154; S-141 to Q-155; A-142 to H-156; P-143 to D-157; P-144 to D-158; A-145 to N-159; P-146 to G-160; C-147 to M-161; L-148 toN-162; P-149 to L-163; G 150 to R-164; C-151 to N-165; R-152 to 1-166; H-153 to I-167; S-154 to Q-168; Q-155 to D-169; H-156 to C-170; D-157 to L- 171; D-158 to Q-17 2 ; N-159 to L-173; G-160 to I 174; M-161 to A-175; N-162 to D-176; L-163 to S-177; R-164 to D-178; N-165 to T-179; 1-166 to P-180; 1-167 to A-181; Q-168 to L-182; D-169 to E-183; C-170 to E-184; L-171 to K-185; Q-172 to E-186; L-173 to N-187; 1-174 to K-188; A-175 to 1-189; D-176 to V 190; S-177 to V-191; D-178 to R-192; T-179 to Q-193; P-180 to T-194; A-181 to G-195; L-182 to Y-196; E-183 to F-197; E-184 to-F-198; K-185 to 1-199; E-186 to Y-200; N-187 to S-201; K-188 to Q-202; 1-189 to 1-203; V-190 to L-204; V-191 to Y-205; R-192 to T 78 206; Q-193 to D-207; T-194 to P-208; G-195 to 1-209; Y-196 to F-210; F-197 to A-21 1; F-198 to M-212; 1-199 to G-213; Y-200 to H-214; S-201 to V-215; Q-202 to 1-216; V-203 to Q-217; L-204 to R-218; Y-205 to K-219; T-206 to K-220; D-207 to V-221; P-208 to H 222; 1-209 to V-223; F-210 to F-224; A-21 Ito G-225; M-212 to D-226; G-213 to E-227; H-214 to L-228; V-215 to S-229; 1-216 to L-230; Q-217 to V-231; R-218 to T-232; K-219 to L-233; K-220 to F-234; V-221 to R-235; H-222 to C-236; V-223 to 1-237; F-224 to Q 238; G-225 to N-239; D-226 to M-240; E-227 to P-241; L-228 to K-242; S-229 to T-243; L-230 to L-244; V-231 to P-245; T-232 to N-246; L-233 to N-247; F-234 to S-248; R-235 to C-249; C-236 to Y-250; 1-237 to S--251; Q-238 to A-252; N-239 to G-253; M-240 to I 254; P-241 to A-255; K-242 to R-256; T-243 to L-257; L-244 to E-258; P-245 to E-259; N-246 to G-260; N-247 to D-261; S-248 to E-262; C-249 to 1-263;.Y-250 to Q-264; S-251 to L-265; A-252 to A-266; G-253 to 1-267; 1-254 to P-268; A-255 to R-269; R-256 to E 270; L-257 to N-271; E-258 to A-272; E-259 to Q-273; G-260 to 1-274; D-261 to S-275; E-262 to R-276; 1-263 to N-277; Q-264 to G-278; L-265 to D-279; A-266 to D-280; 1-267 to T-281; P-268 to F-282; R-269 to F-283; E-270 to G-284; N-271 to A-285; A-272 to L 286; Q-273 to K-287; 1-274 to L-288; and S-275 to L-289 of SEQ ID NO:38. The present invention is also directed to antibodies that bind BLyS polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of BLyS polypeptides described above. [0146] It will be recognized by one of ordinary skill in the art that some amino acid sequences of the BLyS polypeptides can be varied without significant effect of the structure or function of the polypeptide. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the polypeptide which determine activity. [01471 Thus, the invention further includes antibodies that bind variations of BLyS polypeptides which show BLyS polypeptide functional activity (e.g., biological activity) or which include regions of BLyS polypeptide such as the polypeptide fragments described herein. Such mutants include deletions, insertions, inversions, repeats, and type substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., "Deciphering the Message in Protein 79 Sequences: Tolerance to Amino Acid Substitutions," Science 247:1306-1310 (1990), wherein the authors indicate that there are two main approaches for studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selections or screens to identify sequences that maintain functionality. [01481 As the authors state, these studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions. are described in Bowie, J. U. et al., supra, and the references cited therein. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues. Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gin, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe, Tyr. [01491 Thus, antibodies of the present invention may bind fragments, derivatives or analogs of the polypeptide of SEQ ID NO:3228, or that encoded by the deposited cDNA plasmid, such as (i) polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) polypeptides in which one or more of the amino acid residues includes a substituent group, or (iii) polypeptides in which the extracellular domain of the polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) polypeptides in which the additional amino acids are fused to the extracellular domain of the polypeptide, such as an IgG Fe fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the extracellular domain of the polypeptide or a proprotein sequence. 101501 Antibodies of the present invention may bind fragments, derivatives or analogs of the polypeptide of SEQ I) NO:3229, or that encoded by the deposited cDNA 80 plasmid, such as (i) polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) polypeptides in which one or more of the amino acid residues includes a substituent group, or (iii) polypeptides in which the extracellular domain of the polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) polypeptides in which the additional amino acids are fused to the extracellular domain of the polypeptide, such as, a soluble biologically active fragment of another TNF ligand family member (e.g., CD40 Ligand), an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the extracellular domain of the polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein. [01511 Thus, the antibodies of the invention may bind BLyS polypeptides that include one or more amino acid substitutions, deletions or additions, either from natural mutations or human manipulation. As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 13). [0152 TABLE 13. Conservative Amino Acid Substitutions. 101531 Aromatic [01591 Phenylalanine [01601 Tryptophan [01611 Tyrosine [01541 Hydrophobic 101621 Leucine [01631 Isoleucine 101641 Valine 10155] Polar 101651 Glutamine 101661 Asparagine [0156] Basic (01671 Arginine [01681 Lysine [01691 Histidine [01571 Acidic 101701 Aspartic Acid [0171] Glutamic Acid 81 [01581 Small 101721 Alanine [01731 Serine [01741 Threonine 101751 Methionine 101761 Glycine [0177] In one embodiment of the invention, antibodies of the present invention bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of a BLyS polypeptide having an amino acid sequence which contains at least one conservative amino acid substitution, but not more than 50 conservative amino acid substitutions, even more preferably, not more than 40 conservative amino acid substitutions, still more preferably, not more than 30 conservative amino acid substitutions, and still even more preferably, not more than 20 conservative amino acid substitutions. In one embodiment of the invention, antibodies of the present invention bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of a BLyS polypeptide having an amino acid sequence which contains at least one conservative amino acid substitution; but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or I conservative amino acid substitutions. 101781 For example, site directed changes at the amino acid level of BLyS can be made by replacing a particular amino acid with a conservative substitution. Antibodies of the present invention may bind BLyS amino acid sequences containing conservative substitution mutations of the polypeptide of SEQ ID NO:3228 including: M1 replaced with A, G, 1, L, S, T, or V; D2 replaced with E; D3 replaced with E; S4 replaced with A, G, I, L, T, M, or V; T5 replaced with A, G, I, L, S, M, or V; E6 replaced with D; R7 replaced with H, or K; E8 replaced with D; Q9 replaced with N; SIO replaced with A, G, I, L, T, M, or V; R1 I replaced with H, or K; L12 replaced with A, G, I, S, T, M, or V; T13 replaced with A, G, I, L, S, M, or V; S14 replaced with A, G, 1, L, T, M, or V; L16 replaced with A, G, 1, S, T, M, or V; K17 replaced with H, or R; K18 replaced with H, or R; R19 replaced with H, or K; E20 replaced with D; E21 replaced with D; M22 replaced with A, G, I, L, S, T, or V; K23 replaced with H, or R; L24 replaced with A, G, I, S, T, M, or V; K25 replaced with H, or R; E26 replaced with D; V28 replaced with A, G, I, L, S, T, or M; S29 replaced with A, G, I, L, T, M, or V; 130 replaced with A, G, L, S, T, M, or V; L31 replaced with A, G, 1, S, T, M, or V; R33 replaced with H, or K; K34 replaced with H, or R; E35 replaced with D; S36 replaced with A, G, I, L, T, M, or V; S38 replaced with 82 A, G, I, L, T, M, or V; V39 replaced with A, G, I, L, S, T, or M; R40 replaced with H, or K; S41 replaced with A, G, I, L, T, M, or V; S42 replaced with A, G, I, L, T, M, or V; K43 replaced with H, or R; D44 replaced with E; G45 replaced with A, I, L, S, T, M, or V; K46 replaced with H, or R; L47 replaced with A, G, 1, S, T, M, or V; L48 replaced with A, G, I, S, T, M, or V; A49 replaced with G, 1, L, S, T, M, or V; A50 replaced with G, 1, L, S, T, M, or V; T51 replaced with A, G, 1, L, S, M, or V; L52 replaced with A, G, 1, S, T, M, or V; L53 replaced with A, G, I, S, T, M, or V; L54 replaced with A, G, 1, S, T, M, or V; A55 replaced with G, I, L, S, T, M, or V; L56 replaced with A, G, 1, S, T, M, or V; L57 replaced with A, G, 1, S, T, M, or V; S58 replaced with A, G, 1, L, T, M, or V; L61 replaced with A, G, 1, S, T, M, or V; T62 replaced with A, G, I, L, S, M, or V; V63 replaced with A, G, I, L, S, T, or M; V64 replaced with A, G, 1, L, S, T, or M; S65 replaced with A, G, 1, L, T, M, or V; F66 replaced with W, or Y; Y67 replaced with F, or W; Q68 replaced with N; V69 replaced with A, G, 1, L, S, T, or M; A70 replaced with G, I, L, S, T, M, or V; A71 replaced with G, I, L, S, T, M, or V; L72 replaced with A, G, 1, S, T, M, or V; Q73 replaced with N; G74 replaced with A, I, L, S, T, M, or V; D75 replaced with E; L76 replaced with A, G, 1, S, T, M, or V; A77 replaced with G, I, L, S, T, M, or V; S78 replaced With A, G, 1, L, T, M, or V; L79 replaced with A, G, I, S, T, M, or V; R80 replaced with H, or K; A81 replaced with G, I, L, S, T, M, or V; E82 replaced with D; L83 replaced with A, G, I, S, T, M, or V; Q84 replaced with N; G85 replaced with A, I, L, S, T, M, or V; H86 replaced with K, oi R; H87 replaced with K, or R; A88 replaced with G, I, L, S, T, M, or V; E89 replaced with D; K90 replaced with H, or R; L91 replaced with A, G, I, S, T, M, or V; A93 replaced with G, 1, L, S, T, M, or V; G94 replaced with A, I, L, S, T, M, or V; A95 replaced with G, I, L, S, T, M, or V; G96 replaced with A, I, L, S, T, M, or V; A97 replaced with G, I, L, S, ', M, or V; K99 replaced with H, or R; A100 replaced with G, I, L, S, T, M, or V; G101 replaced with A, I, L, S, T, M, or V; L102 replaced with A, G, 1, S, T, M, or V; E103 replaced with D; E104 replaced with D; A]05 replaced with G, I, L, S, T, M, or V; A107 replaced with G, 1, L, S, T, M, or V; V108 replaced with A, G, 1, L, S, T, or M; T109 replaced with A, G, I, L, S, M, or V; Al 10 replaced with G, 1, L, S, T, M, or V; G l replaced with A, I, L, S, T, M, or V; LI 12 replaced with A, G, 1, S, T, M, or V; K 113 replaced with H, or R; 1114 replaced with A, G, L, S, T, M, or V; F115 replaced with W, or Y; El 16 replaced with D; Al 19 replaced with G, 1, L, S, T, M, or V; G121 replaced with A, I, L, S, T, M, or V; E122 replaced with D; G123 replaced with A, 83 1, L, S, T, M, or V; N124 replaced with Q; S125 replaced with A, G, 1, L, T, M, or V; S126 replaced with A, G, I, L, T, M, or V; Q127 replaced with N; N128 replaced with Q; S129 replaced with A, G, 1, L, T, M, or V; R130 replaced with H, or K; N 131 replaced with Q; K132 replaced with H, or R; R133 replaced with H, or K; A134 replaced with G, I, L, S, T, M, or V; V135 replaced with A, G, I, L, S, T, or M; Q136 replaced with N; G137 replaced with A, I, L, S, T, M, or V; E139 replaced with D; E140 replaced with D; T141 replaced with A, G, 1, L, S, M, or V; V142 replaced with A, G, I, L, S, T, or M; T143 replaced with A, G, 1, L, S, M, or V; Q144 replaced with N; D145 replaced with E; L147 replaced with A, G, I, S, T, M, or V; Q148 replaced with N; L149 replaced with A, G, I, S, T, M, or V; 1150 replaced with A, G, L, S, T, M, or V; A151 replaced with G, 1, L, S, T, M, or V; D152 replaced with E; S153 replaced with A, G, 1, L, T, M, or V; E154 replaced with D; T155 replaced with A, G, I, L, S, M, or V; TI 57 replaced with A, G, I, L, S, M, or V; 1158 replaced with A, G, L, S, T, M, or V; Q159 replaced with N; K160 replaced with H, or R; G161 replaced with A, I, L, S, T, M, or V; S162 replaced with A, G, 1, L, T, M, or V; Y163 replaced with F, or W; T164 replaced with A, G, , L, S, M, or V; F165 replaced with W, or Y; V166 replaced with A, G, I, L, S, T, or M; W168 replaced with F, or Y; L169 replaced with A, G, I, S, T, M, or V; L170 replaced with A, G, 1, S, T, M, or V; S171 replaced with A, G, I. L, T, M, or V; F172 replaced with W, or Y; K173 replaced with H, or R; R174 replaced with H, or K; G175 replaced with A, 1, L, S, T, M, or V; S176 replaced with A, G, 1, L, T, M, or V; A177 replaced with G, I, L, S, T, M, or V; L178 replaced with A, G, 1, S, T, M, or V; E179 replaced with D; E180 replaced with D; K181 replaced with H, or R; E182 replaced with D; N183 replaced with Q; K184 replaced with H, or R; 1185 replaced with A, G, L, S, T, M, or V; L186 replaced with A, G, I, S, T, M, or V; VI 87 replaced with A, G, 1, L, S, T, or M; K1 88 replaced with H, or R; E189 replaced with D; T190 replaced with A, G, 1, L, S, M, or V; G191 replaced with A, 1, L, S, T, M, or V; Y192 replaced with F, or W; F193 replaced with W, or Y; F194 replaced with W, or Y; It95 replaced with A, G, L, S, T, M, or V; Y196 replaced with F, or W; G197 replaced with A, I, L, S, T, M, or V; Q198 replaced with N; V199 replaced with A, G, I, L, S, T, or M; L200 replaced with A, G, I, S, T, M, or V; Y201 replaced with F, or W; T202 replaced with A, G, 1, L, S, M, or V; D203 replaced with E; K204 replaced with H, or R; T205 replaced with A, G, 1, L, S, M, or V; Y206 replaced with F, or W; A207 replaced with G, 1, L, S, T, M, or V; M208 replaced with A, G, I, L, S, T, or V; 84 G209 replaced with A, I, L, S, T, M, or V; H210 replaced with K, or R; L211 replaced with A, G, 1, S, T, M, or V; 1212 replaced with A, G, L, S, T, M, or V; Q213 replaced with N; R214 replaced with H, or K; K215 replaced with H, or R; K216 replaced with H, or R; V217 replaced with A, G, 1, L, S, T, (or M; H218 replaced with K, or R; V219 replaced with A, G, 1, L, S, T, or M; F220 replaced with W, or Y; G221 replaced with A, I, L, S, T, M, or V; D222 replaced with E; E223 replaced with D; L224 replaced with A, G, I, S, T, M, or V; S225 replaced with A, G, I, L, T, M, or V; L226 replaced with A, G, 1, S, T, M, or V; V227 replaced with A, G, 1, L, S, T, or M; T228 replaced with A, G, 1, L, S, M, or V;-L229 replaced with A, 0, 1, S, T, M, or V; F230 replaced with W, or Y; R231 replaced with H, or K; 1233 replaced with A, G, L, S,.T, M, or V; Q234 replaced with N; N235 replaced with Q; M236 replaced with A, G, I, L, S, T, or V; E238 replaced with D; T239 replaced with A, G, I, L, S, M, or V; L240 replaced with A, G, 1, S, T, M, or V; N242 replaced with Q; N243 replaced with Q; S244 replaced with A, G, I, L, T, M, or V; Y246 replaced with F, or W; S247 replaced with A, G, 1, L, T, M, or V; A248 replaced with G, I, L, S, T, M, or V; G249 replaced with A, I, L, S, T, M, or V; 1250 replaced with A, G, L, S, T, M, or V; A251 replaced with G, I, L, S, T, M, or V; K252 replaced with H, or R; L253 replaced with A, G, I, S, T, M, or V; E254 replaced with D; E255 replaced with D; G256 replaced with A, I, L, S, T, M, or V; D257 replaced with E; E258 replaced with D; L259 replaced with A, G, I, S, T, M, or V; Q260 replaced with N; L261 replaced with A, G, I, S, T, M, or V; A262 replaced with G, I, L, S, T, M, or V; 1263 replaced with A, G, L, S, T, M, or V; R265 replaced with H, or K; E266 replaced with D; N267 replaced with Q; A268 replaced with G, I, L, S, T, M, or V; Q269 replaced with N; 1270 replaced with A, G, L, S, T, M, or V; S271 replaced with A, G, 1, L, T, M, or V; L272 replaced with A, G, I, S, T, M, or V; D273 replaced with E; G274 replaced with A, I, L, S, T, M, or V; D275 replaced with E; V276 replaced with A, G, I, L, S, T, or M; T277 replaced with A, G, 1, L, S, M, or V; F278 replaced with W, or Y; F279 replaced with W, or Y; G280 replaced with A, 1, L, S, T, M, or V; A281 replaced with G, 1, L, S, T, M, or V; L282 replaced with A, G, 1, S, T, M, or V; K283 replaced with H, or R; L284 replaced with A, G, I, S, T, M, or V; and/or L285 replaced with A, G, I, S, T, M, or V. [0179] In another embodiment, site directed changes at the amino acid level of BLyS can be made by replacing a particular amino acid with a conservative substitution. Antibodies of the present invention may bind BLyS amino acid sequences containing 85 conservative substitution mutations of the polypeptide of SEQ ID NO:3229 including: MI replaced with A, G, I, L, S, T, or V; D2 replaced with E; D3 replaced with E; S4 replaced with A, G, 1, L, T, M, or V; T5 replaced with A, G, I, L, S, M, or V; E6 replaced with D; R7 replaced with H, or K; E8 replaced with D; Q9 replaced with N; Si 0 replaced with A, G, 1, L, T, M, or V; Rll replaced with H, or K; L12 replaced with A, G, 1, S, T, M, or V; T13 replaced with A, G, I, L, S, M, or V; S14 replaced with A, G, 1, L, T, M, or V; L16 replaced with A, G, 1, S, T, M, or V; K17 replaced with H, or R; K 18 replaced with H, or R; R19 replaced with H, or K; E20 replaced with D; E21 replaced with D; M22 replaced with A, G, 1, L, S, T, or V; K23 replaced with H, or R; L24 replaced with A, G, I, S, T, M, or V; K25 replaced with H, or R; E26 replaced with D; V28 replaced with A, G, I, L, S, T, or M; S29 replaced with A, G, I, L, T, M, or V; 130 replaced with A, G, L, S, T, M, or V; L31 replaced with A, G, I, S, T, M, or V; R33 replaced with H, or K; K34 replaced with H, or R; E35 replaced with D; S36 replaced with A, G, 1, L, T, M, or V; S38 replaced with A, G, I, L, T, M, or V; V39 replaced with A, G, 1, L, S, T, or M; R40 replaced with H, or K; S41 replaced with A, G, 1, L, T, M, or V; S42 replaced with A, G, I, L, T, M, or V; K43 replaced with H, or R; D44 replaced with E; G45 replaced with A, I, L, S, T, M, or V; K46 replaced with H, or R; L47 replaced with A, G, 1, S, T, M, or V; L48 replaced with A, G, 1, S, T, M, or V; A49 replaced with G, I, L, S, T, M, or V; A50 replaced with G, 1, L, S, T, M; or V; T51 replaced with A, G, I, L, S, M, or V; L52 replaced with A, G, I, S, T, M, or V; L53 replaced with A, G, 1, S, T, M, or V; L54 replaced with A, G, I, S, T, M, or V; A55 replaced with G, I, L, S, T, M, or V; L56 replaced with A, G, I, S, T, M, or V; L57 replaced with A, G, 1, S, T, M, or V; S58 replaced with A, G, 1, L, T, M, or V; L61 replaced with A, G, I, S, T, M, or V; T62 replaced with A, G, I, L, S, M, or V; V63 replaced with A, G, 1, L, S, T, or M; V64 replaced with A, G, I, L, S, T, or M; S65 replaced with A, G, 1, L, T, M, or V; F66 replaced with W, or Y; Y67 replaced with F, or W; Q68 replaced with N; V69 replaced with A, G, 1, L, S, T, or M; A70 replaced with G, I, L, S, T, M, or V; A71 replaced with G, I, L, S, T, M, or V; L72 replaced with A, G, I, S, T, M, or V; Q73 replaced with N; G74 replaced with A, 1, L, S, T, M, or V; D75 replaced with E; L76 replaced with A, G, I, S, T, M, or V; A77 replaced with G, I, L, S, T, M, or V; S78 replaced with A, G, 1, L, T, M, or V; L79 replaced with A, G, I, S, T, M, or V; R80 replaced with H, or K; A81 replaced with G, I, L, S, T, M, or V; E82 replaced with D; L83 replaced with A, G, 1, S, T, M, or V; Q84 replaced with N; G85 replaced with A, I, L, S, 86 T, M, or V; H86 replaced with K, or R; 1-187 replaced with K, or R; A88 replaced with G, I, L, S, T, M, or V; E89 replaced with D; K90 replaced with H, or R; L91 replaced with A, G, I, S, T, M, or V; A93 replaced with G, I, L, S, T, M, or V; G94 replaced with A, I, L, S, T, M, or V; A95 replaced with G, 1, L, S, T, M, or V; G96 replaced with A, I, L, S, T, M, or V; A97 replaced with G, I, L, S, T, M, or V; K99 replaced with H, or R; A100 replaced with G, I, L, S, T, M, or V; G101 replaced with A, 1, L, S, T, M, or V; L102 replaced with A, G, 1, S, T, M, or V; E103 replaced with D; E104 replaced with D; A105 replaced with G, I, L, S, T, M, or V; A107 replaced with G, 1, L, S, T, M, or V; V108 replaced with A, G, I, L, S, T, or M; T109 replaced with A, G, 1, L, S, M, or V; Al 10 replaced with G, 1, L, S, T, M, or V; GIll replaced with A, I, L, S, T, M, or V; L 112 replaced with A, G, I, S, T, M, or V; KI 13 replaced with H, or R; 1114 replaced with A, G, L, S, T, M, or V; F115 replaced with W, or Y; El 16 replaced with D; A 119 replaced with G, I, L, S, T, M, or V; G121 replaced with A, I, L, S, T, M, or V; E122 replaced with D; G123 replaced with A, 1, L, S, T, M, or V; N124 replaced with Q; S125 replaced with A, G, I, L, T, M, or V; S126 replaced with A, G, I, L, T, M, or V; Q127 replaced with N; N 128 replaced with Q; SI 29 replaced with A, G, I, L, T, M, or V; R130 replaced with H, or K; N 131 replaced with Q; K132 replaced with H, or R; R133 replaced with H, or K; A134 replaced with G, 1, L, S, T, M, or V; V135 replaced with A, G, 1, L, S, T, or M; Q136 replaced with N; G137 replaced with A, I, L, S, T, M, or V; E139 replaced with D; E140 replaced with D; T141 replaced with A, G, I, L, S, M, or V; G142 replaced with A, I, L, S, T, M, or V; S143 replaced with A, G, I, L, T, M, or V; Y144 replaced with F, or W; T145 replaced with A, G, I, L, S, M, or V; F146 replaced with W, or Y; V147 replaced with A, G, I, L, S, T, or M; W149 replaced with F, or Y; LI 50 replaced with A, G, I, S, T, M, or V; L15.1 replaced with A, G, 1, S, T, M, or V; S152 replaced with A, G, 1, L, T, M, or V; F153 replaced with W, or Y; K154 replaced with H, or R; R155 replaced with H, or K; G156 replaced with A, I, L, S, T, M, or V; S157 replaced with A, G, I, L, T, M, or V; A158 replaced with G, I, L, S, T, M, or V; L159 replaced with A, G, I, S, T, M, or V; E160. replaced with D; E161 replaced with D; K162 replaced with H, or R; E163 replaced with D; N164 replaced with Q; K165 replaced with H, or R; 1166 replaced with A, G, L, S, T, M, or V; L167 replaced with A, G, 1, S, T, M, or V; V168 replaced with A, G, I, L, S, T, or M; K169 replaced with H, or R; E170 replaced with D; T171 replaced with A, G, I, L, S, M, or V; G172 replaced with A, I, L, S, T, M, or V; Y173 replaced with F, or W; F174 87 replaced with W, or Y; F175 replaced with W, or Y; 1176 replaced with A, G, L, S, T, M, or V; Y177 replaced with F, or W; G178 replaced with A, I, L, S, T, M, or V; Q179 replaced with N; V180 replaced with A, G, I, L, S, T, or M; L181 replaced with A, GI, S, T, M, or V; Y182 replaced with F, or W; T183 replaced with A, G,1, L, S, M, or V; D184 replaced with E; K185 replaced with H, or R; T186 replaced with A, G, I, L, S, M, or V; Y187 replaced with F, or W; A188 replaced with G, 1, L, S, T, M, or V; M189 replaced with A, G, I, L, S, T, or V; G 190 replaced with A, I, L, S, T, M, or V; H 191 replaced with K, or R; L192 replaced with A, G, I, S, T, M, or V; 1193 replaced with A, G, L, S, T, M, or V; Q194 replaced with N; R195 replIced with H, or K; K196 replaced with H, or R; K197 replaced with H, or R; V198 replaced with A, G, 1, L, S, T, or M; H 199 replaced with K, or R; V200 replaced with A, G, I, L, S, T, or M; F201 replaced with W, or Y; G202 replaced with A, I, L, S, T, M, or V; D203 replaced with E; E204 replaced with D; L205 * replaced with A, G3, 1, S, T, M, or V; S206 replaced with A, G, I, L, T, M, or V; L207 replaced with A, G, I, S, T, M, or V; V208 replaced with A, G, 1, L, S, T, or M; T209 replaced with A, G, 1, L, S, M, or V; L210 replaced with A, G, 1, S, T, M, or V; F211 replaced with W, or Y; R212 replaced with H, or K; 1214 replaced with A, G, L, S, T, M, or V; Q215 replaced with N; N216 replaced with Q; M217 replaced with A, G, I, L, S, T, or V; E219 replaced with D; T220 replaced with A, G, I, L, S, M, or V; L221 replaced with A, G3,I, S, T, M, or V; N223 replaced with Q; N224 replaced with Q; S225 replaced with A, G, 1, L, T, M, or V; Y227 replaced with F, or W; S228 replaced with A, G, I, L, T, M, or V; A229 replaced with G, I, L, S, T, M, or V; G230 replaced with A, I, L, S, T, M, or V; 1231 replaced with A, G, L, S, T, M, or V; A232 replaced with G, 1, L, S, T, M, or V; K233 replaced with H, or R; L234 replaced with A, G, I, S, T, M, or V; E235 replaced with D; E236 replaced with D; G237 replaced with A, I, L, S, T, M, or V; D238 replaced with E; E239 replaced with D; L240 replaced with A, G, 1, S, T, M, or V; Q241 replaced with N; L242 replaced with A, G,I, S, T, M, or V; A243 replaced with G, I, L, S, T, M, or V; 1244 replaced with A, G, L, S, T, M, or V; R246 replaced with H, or K; E247 replaced with D; N248 replaced with Q; A249 replaced with G, I, L, S, T, M, or V; Q250 replaced with N; 1251 replaced with A, G, L, S, T, M, or V; S252 replaced with A, G, I, L, T, M, or V; L253 replaced with A, G, I, S, T, M, or V; D254 replaced with E; (255 replaced with A, I, L, S, T, M, or V; D256 replaced with E; V257 replaced with A, G, I, L, S, T, or M; T258 replaced with A, G, I, L, , M, or V; F259 replaced with W, or Y; F260 replaced 88 with W, or Y; G261 replaced with A, 1, L, S, T, M, or V; A262 replaced with G, I, L, S, T, M, or V; L263 replaced with A, G, I, S, T, M, or V; K264 replaced with H, or R; L265 replaced with A, G, I, S, T, M, or V; and/or L266 replaced with A, G, 1, S, T, M, or V. 101801 In another embodiment, site directed changes at the amino acid level of BLyS can be made by replacing a particular amino acid with a conservative substitution. Antibodies of the present invention may bind BLyS amino acid sequences containing conservative substitution mutations of the polypeptide of any one of SEQ ID NOS:3230 3237. 101811 Amino acids in the BLyS polypeptides that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for functional activity, such ligand binding and the ability to stimulate lymphocyte (e.g., B cell) as, for example, proliferation, differentiation, and/or activation. Accordingly, antibodies of the present invention may bind amino acids in the BLyS polypeptides that are essential for function. In preferred embodiments, antibodies of the present invention bind amino acids in the BLyS polypeptides that are essential for function and inhibit BLyS polypeptide function. In other preferred embodiments, antibodies of the present invention bind amino acids in the BLyS polypeptides that are essential for function and enhance BLyS polypeptide function. 101821 Of special interest are substitutions of charged amino acids with other charged or neutral amino acids which may produce proteins with highly desirable improved characteristics, such as less aggregation. Aggregation may not only reduce activity but also be problematic when preparing pharmaceutical formulations, because aggregates can be immunogenic (Pinckard el al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993). [0183] In another embodiment, the invention provides for antibodies that bind polypeptides having amino acid sequences containing non-conservative substitutions of the amino acid sequence provided in SEQ ID NO:3228. For example, non-conservative substitutions of the BLyS protein sequence provided in SEQ ID NO:3228 include: M1 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D2 replaced with H, K, R, A, G, I, L, 89 S, T, M, V, N, Q, F, W, Y, P, or C; D3 replacedwith H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S4 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T5 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E6 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R7 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E8 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q9 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, F, W, Y, P, or C; S10 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; RI I replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L12 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T13 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S14 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C15 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L16 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K17 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K18 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, -P, or C; R19 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E20 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E21 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; M22 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K23 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; L24 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K25 replaced with D, E, A, G,1, L, S, T, M, V, N, Q, F, W, Y, P, or C; E26 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; C27 replaced with D, E, H, K, R, A, 0, 1, L, S, T, M, V, N, Q, F, W, Y, or P; V28 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S29 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 130 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L31 replaced with D,'E, H, K, R, N, Q, F:, W, Y, P, or C; P32 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; R33 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K34 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E35 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; S36 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P37 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; S38 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V39 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R40 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S41 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S42 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K43 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D44 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; (45 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or 90 C; K46 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; L47 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L48 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A49 replaced with D, E, E, K, R, N, Q, F, W, Y, P, or C; A50 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T'51 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L52 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L53 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L54 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A55 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L56 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L57 replaced wilh D, E, H, K, R, N, Q, F, W, Y, P, or C; S58 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C59 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or P; C60 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L61 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T62 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V63 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V64 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S65 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F66 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Y67 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Q68 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; V69 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A70 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A71 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L72 replaced with D, E, H, K, R, N, Q, F. W, Y, P, or C; Q73 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G74 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D75 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; L76 replaced with D, E, H, K, R, N, Q, F., W, Y, P, or C; A77 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S78 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L79 replaced with D, E, H, K, R, N, Q, F:, W, Y, P, or C; R80 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A81 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E82 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L83 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q84 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G85 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H86 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H87 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A88 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E89 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K90 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; L91 replaced with 91 D, E, H, K, R, N, Q, F, W, Y, P, or C; P92 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A93 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G94 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A95 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G96 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A97 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P98 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; K99 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Al00 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G101 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L102 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E103 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E104 replaced with H, K, R, A, G, I, L, S, T, L, V, N, Q, F, W, Y, P, or C; A105 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P106 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; Al 07 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V108 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T109 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Al 10 replaced with D, E, H, K, R, N, Q, F, W,- Y, P, or C; G111 replaced with D, F, H, K, R, N, Q, F, W, Y, P, or C; LI 12 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; KI 13 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Il14 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Fl 15 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; E116 replaced with H, K, R, A, G, I, L; S, T, M, V, N, Q, F, W, Y, P, or C, P117 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; P118 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; A 119 replaced with D., E, H, K, R, N, Q, F, W, Y, P, or C; P120 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G121 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E122 replaced with H, K, R, A, G, 1, L, S, T, M, V, N,Q F, W, Y, P, or C; G123 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N124 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S125 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S126 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q127 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N128 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S129 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R130 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N131 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; K132 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R133 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A 134 replaced with D, 92 E, H, K, R, N, Q, F, W, Y, P, or C; V 135 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q136 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G137 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P138 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E139 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; E140 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; T141 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V142 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T143 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q144 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; D145 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; C146 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L147 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Ql48 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L149 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 1150 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A151 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D152 replaced with H, K, R, A, 0, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; S153 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; El 54 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T155 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P156 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; T157 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 1158 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q159 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, F, W, Y; P, or C; K160 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G161 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S162 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y163 replaced with D,.E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T164 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F165 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; V166 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P167 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; W168 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L169 replaced with D, E, H, K, R, N, Q, F, W, Y, P., or C; L170 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S171 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F172 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; K173 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; R174 replaced with D, E, A, G,1, L, S, T, M, V, N, Q, F, W, Y, P, or C; G175 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S176 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A177 replaced with D, E, H, K, R, N, Q, F, W, 93 Y, P, or C; L178 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E179 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q F, W, Y, P, or C; E180 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; K181 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E182 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; N183 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, F, W, Y, P, or C; K1(84 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; 1185 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L186 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; VI 87 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; KI 88 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P,. or C; E189 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; T190 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G191 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y192 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F 193 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F194 replaced with D, E, H, K, R, N, Q, A, G, I, L,.S, T, M, V, P, or C; 1195 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y196 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V; P, or C;.G197 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q198 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; V199 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L200 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y201 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; T202 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D203 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K204 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; 1205 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y206 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; A207 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M208 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G209 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H210 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L211 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 1212 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q213 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R214 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F. W, Y, P, or C; K215 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K216 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V217 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H218 replaced with D, E, A, G, I, L, S, T, -M, V, N, Q, F, W, Y, P, or C; V219 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F220 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, 94 T, M, V, P, or C; G221 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D222 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E223 replaced with H, K, R, A, G, , L, S, T, M, V, N, Q, F, W, Y, P, or C; L224 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S225 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L226 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V227 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 1228 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L229 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F230 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; R231 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C232 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; 1233 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q234 replaced with D, E, H; K, R, A, G, 1, L, S, T, M, V, F, W, Y, P, or C; N235 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, F, W, Y, P, or C; M236 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P237 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E238 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T239 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L240 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P241 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; N242 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N243 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V F, W, Y, P, or C; S244 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C245 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or P; Y246 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S247 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A248 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G249 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 1250 replaced with D, E, H, K, R, N, Q, F. W, Y, P, or C; A251 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K252 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L253 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E254 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E255 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; G256 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D257 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; E258 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L259 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q260 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L261 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A262 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 1263 replaced with D, E, H, K, R, N, 95 Q, F, W, Y, P, or C; P264 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; R265 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E266 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; N267 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A268 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q269 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, F, W, Y, P, or C; 1270 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S271 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L272 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D273 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G274 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D275 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V276 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T277 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F278 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F279 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G280 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or-C; A281 replaced with D, E, H, K, R; N, Q, F, W, Y, P, or C; L282 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K283 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L284 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; and/or L285 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C. [01841 In an additional embodiment, antibodies of the present invention bind BLyS polypeptides comprising, or alternatively consisting of, a BLyS amino acid sequence in which more than one amino acid (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 and 50) is replaced with the substituted amino acids as described above (either conservative or nonconservative). [01851 In another embodiment of the invention, antibodies of the present invention bind BLyS polypeptides with non-conservative substitutions of the sequence provided in SEQ ID NO:3229 including: Ml replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D2 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D3 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S4 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T5 replaced with ), E, H, K, R, N, Q, F, W, Y, P, or C; E6 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R7 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E8 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q9 replaced with D, E, H, K, R, A, 0, I, L, S, T, M, V, F, W, Y, P, or C; S10 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; RIl replaced with D, E, A, G, 1, 96 L, S, T, M, V, N, Q, F, W, Y, P, or C; L12 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T13 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S14 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C15 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L16 replaced with ), E, H, K, R, N, Q, F, W, Y, P, or C; K17 replaced with D, E, A, G, I, L, S, T, M, V, N, Q F, W, Y, P, or C; K18 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R19 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E20 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E21 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; M22 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K23 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L24 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K25 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; E26 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C27 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or P; V28 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S29 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 130 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 1.31 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P32 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; R33 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K34 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E35 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S36 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P37 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; S38 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V39 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R40 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S41 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S42 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K43 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; D44 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G45 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K46 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; LA7 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L48 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A49 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A50 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T51 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L52 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L53 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L54 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A55 replaced with D, E, H, K, R, N, 97 Q, F, W, Y, P, or C; L56 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L57 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S58 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C59 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or P; C60 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L61 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T62 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V63 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V64 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S65 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F66 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Y67 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; Q68 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; V69 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A70 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A71 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L72 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q73 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G74 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D75 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L76 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A77 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S78 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L79-replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R80 replaced with D, E, A, G, [, L, S, T, M, V, N, Q, F, W, Y, P, or C; A81 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E82 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L83 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q84 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G85 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H86 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H87 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A88 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E89 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; K90 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; L91 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P92 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A93 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G94 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A95 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G96 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A97 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P98 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K99 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A100 replaced with D, 98 E, H, K, R, N, Q, F, W, Y, P, or C; GIO replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L102 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E103 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E104 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A105 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P106 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; A107 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V108 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T109 replaced with D, E, H, K, R,N, Q, F, W, Y, P, or C; A11O replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; GIll replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Li 12 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K113 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; 1114 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F115 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; E 116 replaced with U, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P117 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; P118 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A 119 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P120 replaced with D, E, 1-1, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G121 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E122 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G123 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N124 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Sl25 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S 126 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q127 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N128 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, F, W, Y, P, or C; S129 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R130 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N131 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; K132 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; RI 33 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A134 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V135 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q136 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G137 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P138 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; El 39 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E140 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T141 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G142 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 99 S143 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y144 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T145 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F146 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V147 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P148 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; W149 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; L150 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L151 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S152 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F153 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; K154 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; R155 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; G156 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S157 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A158 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L159 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E160 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E161 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K162 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; El 63 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N164 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, F, W, Y, P, or C; K165 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; 1166 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L167 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V168 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K169 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; E170 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T171 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G172 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y173 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F174 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F175 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; 1176 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y177 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; G178 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q179 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; V180 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L181 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y182 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; T183 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D184 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; K185 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T186 100 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y187 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; A188 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M189 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G190 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H191 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; L192 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 1193 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q194 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R195 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K196 replaced with D, E, A, G. I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K197 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V198 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H 199 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; V200 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F201 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; G202 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D203 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E204 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; L205 replaced with D, E, H, K, R, N. Q, F, W, Y, P, or C; S206 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L207 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V208 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T209 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L210 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F211 replaced with D, E, H, K, R, N, Q, A; G, I, L, S, T, M, V, P, or C; R212 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C213 replaced with D, E, fH, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; 1214 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q215 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N216 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; M217 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P218 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; E219 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T220 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L221 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P222 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; N223 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, F, W, Y, P, or C; N224 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, F, W, Y, P, or C; S225 replaced with D, E, H, K, R:, N, Q, F, W, Y, P, or C; C226 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; Y227 replaced with D, E, H, K, R, N, Q, A, G, 1, L, S, T, M, V, P, or C; S228 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 101 A229 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G230 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 1231 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A232 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K233 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L234 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E235 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E236 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G237 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D238 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; E239 replaced with H, K, R, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; L240 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q241 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L242 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A243 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 1244 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P245 replaced with D, E, H, K, R,. A, G, 1, L, S, T, M, V, N, Q, F, W, Y, or C; R246 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; E247 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N248 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A249 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q250 replaced with D, E, H, K, R, A, G, 1, L, S, T, M, V, F, W, Y, P, or C; 1251 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S252 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L253 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D254 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G255 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D256 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, ori C; V257 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T258 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F259 replaced with D, E, H, K, R, N, Q, A, G,.I, L, S, T, M, V, P, or C; F260 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G261 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A262 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L263 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K264 replaced with D, E, A, G, 1, L, S, T, M, V, N, Q, F, W, Y, P, or C; L265 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; and/or L266 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C. [01861 In another embodiment, site directed changes at the amino acid level of BLyS can be made by replacing a particular amino acid with a non-conservative substitution. Antibodies of the present invention may bind BLyS amino acid sequences containing non-conservative substitution mutations of the polypeptide of any one of SEQ 102 ID NOS:3230-3237. [01871 In an additional embodiment, antibodies of the present invention bind BLyS polypeptides comprising, or alternatively consisting of, a BLyS amino acid sequence in which more than one amino acid (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 and 50) is replaced with the substituted amino acids as described above (either conservative or nonconservative). [01881 Replacement of amino acids can also change the selectivity of the binding of a ligand to cell surface receptors. For example, Ostade et al., Nature 361:266-268 (1993) describes certain mutations resulting in selective binding of TNF-alpha to only one of the two known types of TNF receptors. Since BLyS is a member of the TNF polypeptide family, mutations similar to those in TNF-alpha are likely to have similar effects in BLyS polypeptides. [0189 Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol. Biol. 224:899-904 (1992) and de Vos et al. Science 255:306-312 (1992)). (0190] Since BLyS is a member of the TNF-related protein family, mutations may be made in sequences encoding amino acids in the TNF conserved domain, e.g., in positions Gly-191 through Leu-284 of SEQ ID NO:3228 or in positions Gly-172 through Leu-265 of SEQ ID NO:3229, may modulate rather than completely eliminate functional activities (e.g., biological activities) of BLyS polypeptides or fragments or variants thereof. Accordingly, antibodies of the present invention may bind BLyS polypeptides that have mutations in the TNF conse rved domain. In preferred embodiments, antibodies of the present invention may bind BLyS polypeptides that have mutations in the TNF conserved domain and act as antagonists of BLyS. In other preferred embodiments, antibodies of the present invention may bind BLyS polypeptides that have mutations in the TNF conserved domain and act as agonists of BLyS. 101911 Recombinant DNA technology known to those skilled in the art (see, for instance, DNA shuffling supra) can be used to create novel mutant proteins or muteins including single or multiple amino acid substitutions, deletions, additions or fusion proteins. Such modified polypeptides can show, e.g., enhanced activity or increased stability. In addition, they may be purified in higher yields and show better solubility than 103 the corresponding natural polypeptide, at least under certain purification and storage conditions. [01921 Thus, the invention also encompasses antibodies that bind BLyS derivatives and analogs that have one or more amino acid residues deleted, added, or substituted to generate BLyS polypertides, e.g., that are better suited for expression, scale up, etc., in the host cells. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges; N-linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and purified from yeast hosts which are known to hyperglycosylate N-linked sites. To this end, a variety of amino acid substitutions at one or both of the first or third amino acid positions on any one or more of the glycosylation recognition sequences in the BLyS polypeptides of the invention, and/or an amino acid deletion at the second position of any one or more such recognition sequences will prevent glycosylation of the BLyS at the modified tripeptide sequence (see, e.g., Miyajimo et al., EMBO J 5(6):1193-1197). By way of non-limiting example, mutation of the serine at position 244 to alanine either singly or in combination with mutation of the asparagine at position 242 to glutamine abolishes glycosylation of the mature soluble form of BLyS (e.g., amino acids 134-285 of SEQ ID NO:3228) when expressed in the yeast Picheapastoris. A mutant BLyS polypeptide in which only the asparagine at position 242 is mutated to glutamine, is still gycosylated when expressed in Pichea pastoris. In this mutant, the glycosylation event may be due to the activation or unmasking of an 0-linked glyscosylation site at serine 244. Similar mutations affecting glycosylation could also be made in the BLyS polypeptide of SEQ ID NO:3229, i.e., aspargine-223 to glutamine and/or serine-224 to alanine of SEQ ID NO:3229. Additionally, one or more of the amino acid residues of the polypeptides of the invention (e.g., arginine and lysine residues) may be deleted or substituted with another residue to eliminate undesired processing by proteases such as, for example, furins or kexins. One possible result of such a mutation is that BLyS polypeptide of the invention is not cleaved and released from the cell surface. Accordingly, antibodies of the invention may bind BLyS derivatives and analogs that have one or more amino acid residues deleted, added, or substituted. In other embodiments, antibodies of the invention may bind BLyS derivatives, variants or analogs that are unable to be cleaved from the cell surface. 104 101931 In a specific embodiment, antibodies of the invention bind BLyS polypeptides in which Lys-132 and/or Arg-133 of the BLyS sequence shown in SEQ ID NO:3228 is mutated to another amino acid residue, or deleted altogether, to prevent or diminish release of the soluble form of BLyS from cells expressing BLyS. In a more specific embodiment, antibodies of the invention bind BLyS polypeptides in which Lys-132 of the BLyS sequence shown in SEQ ID NO:3228 is mutated to Ala-132. In another, nonexclusive specific embodiment, antibodies of the invention bind BLyS polypeptides in which Arg-133 of the BLyS sequence shown in SEQ ID NO:3228 is mutated to Ala- 133. These mutated proteins, and/or have uses such as, for example, in ex vivo therapy or gene therapy, to engineer cells expressing a BLyS polypeptide that is retained on the surface of the engineered cells. [0194] In a specific embodiment, antibodies of the invention bind BLyS polypeptides in which Cys-146 of the BLyS sequence shown in SEQ ID NO:3228 is mutated to another amino acid residue, or deleted altogether, for example, to aid preventing or diminishing oligomerization ofthe mutant BLyS polypeptide when expressed in an expression system. In a specific embodiment, antibodies of the invention bind BLyS polypeptides in which Cy:s-146 is replaced with a shrine amino acid residue. [0195] In another specific embodiment, antibodies of the invention bind BLyS polypeptides in which Cys-232 of the BLyS sequence shown in SEQ ID NO:3228 is mutated to another amino acid residue, or deleted altogether, for example, to aid preventing or diminishing oligomerization of the mutant BLyS polypeptide when expressed in an expression system. In a specific embodiment, antibodies of the invention bind BLyS polypeptides in which Cy:s-232 is replaced with a serine amino acid residue. Polypeptides encoding these polypeptides are also encompassed by the invention. [01961 In yet another specific embodiment, antibodies of the invention bind BLyS polypeptides in which Cys-245 of the BLyS sequence shown in SEQ ID NO:3228 is mutated to another amino acid residue, or deleted altogether, for example, to aid preventing or diminishing oligomerization of the mutant BLyS polypeptide when expressed in an expression system. In a specific embodiment, antibodies of the invention bind BLyS polypeptides in which Cys-245 is replaced with a serine amino acid residue. Polypeptides encoding these polypeptides are also encompassed by the invention. [01971 The polypeptides of the present invention are preferably provided in an 105 isolated form, and preferably are substantially purified. A recombinantly produced version of the BLyS polypeptides can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). 101981 The antibodies of the present invention bind BLyS polypeptides including the complete polypeptide encoded by the deposited cDNA (ATCC Deposit No. 97768) including the intracellular, transmembrane and extracellular domains of the polypeptide encoded by the deposited cDNA, the mature soluble polypeptide encoded by the deposited cDNA, the extracellular domain minus the intracellular and transmembrane domains of the protein, the complete polypeptide of SEQ ID NO:3228, the mature soluble polypeptide of SEQ ID NO:3228, e.g., amino acids 134-285 of SEQ ID NO:3228, the extracellular domain of SEQ ID NO:3228, amino acid residues 73-285 of SEQ ID NO:3228 minus the intracellular and transmembrane domains, as well as polypeptides which have at least 80%, 85%, 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98% or 99% similarity to those described above. Polynucleotides encoding these polypeptides are also encompassed by the invention. [01991 The antibodies of the present invention bind BLyS polypeptides including the complete polypeptide encoded by the deposited cDNA including the intracellular, transmembrane and extracellular domains of the polypeptide encoded by the deposited cDNA (ATCC Deposit No. 203518), the mature soluble polypeptide encoded by the deposited cDNA, the extracellular domain minus the intracellular and transmembrane domains of the protein, the complete polypeptide of SEQ ID NO:3229, the mature soluble of SEQ ID NO:3229, e.g., amino acid residues 134-266 of SEQ ID NO:3229, the extracellular domain of SEQ ID NO:3229, e.g., amino acid residues 73-266 of SEQ ID NO:3229 minus the intracellular and transmembrane domains, as well as polypeptides which have at least 80%, 85%, 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98% or 99% similarity to those described above. Polynucleotides encoding these polypeptides are also encompassed by the invention. [02001 Further antibodies of the present invention bind polypeptides including polypeptides at least 80%, or at least 85% identical, more preferably at least 90% or 95% identical, still more preferably at least 96%, 97%, 98% or 99% identical to the polypeptide encoded by the deposited cDNA (ATCC Deposit No. 97768) or to the polypeptide of SEQ 106 ID NO:3228, and also include antibodies that bind portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids. [0201] Further antibodies of the present invention bind polypeptides including polypeptides at least 80%, or at least 85% identical, more preferably at least 90% or 95% identical, still more preferably at least 96%, 97%, 98% or 99% identical to the polypeptide encoded by the deposited cDNA (ATCC Deposit No. 203518) or to the polypeptide of SEQ ID NO:3229, and also include antibodies that bind portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids. Polynucleotides encoding these polypeptides are also encompassed by the invention. [02021 By "% similarity" for two polypeptides is intended a similarity score produced by comparing the amino acid sequences of the two polypeptides using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711) and the default settings for determining similarity. Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2:482-489, 1981) to find the best segment of similarity between two sequences. 102031 By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a reference amino acid sequence of a BLyS polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the BLyS polypeptide. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. 102041 As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence of SEQ ID NO:3228, the amino acid sequence encoded by the deposited cDNA 107 clone HNEDUI 5 (ATCC Accession No. 97768), or fragments thereof, or, for instance, to the amino acid sequence of SEQ ID NO:3229, the amino acid sequence encoded by the deposited cDNA clone HDPMC52 (ATCC Accession No. 203518), or fragments thereof, can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed. [0205] In a specific embodiment, the identity between a reference (query) sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, is deternmed using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990)). Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty= 1, Joining Penalty=20, Randomization Group Length=O, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter. According to this embodiment, if the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction is made to the results to take into consideration the fact that the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C--terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. A determination of whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is 108 what is used for the purposes of this embodiment. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence. For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for the purposes of this embodiment. [02061 Antibodies that Immunospecifically bind BLyS Polypeptides 102071 The present invention also encompasses antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to BLyS polypeptides, which antibodies comprise, or alternatively consist of, all or a portion of a heavy and/or light chain variable domain of the scFvs referred to in Table 1. [02081 The present invention also encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS or BLyS receptor function in an animal, preferably a mammal, and most preferably a human, comprising using antibodies (including molecules which comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically bind to BLyS. Diseases and disorders which can 109 be detected, diagnosed or prognosed with the antibodies of the invention include, but are not limited to, immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma). 102091 The present invention further encompasses methods and compositions for preventing, treating or ameliorating diseases or disorders associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS or BLyS receptor function in an animal, preferably a mammal, and most preferably a human, comprising administering to said animal an effective amount of one or more antibodies (including molecules which comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically bind to BLyS. Diseases and disorders which can be prevented, treated or inhibited by administering an effective amount of one or more antibodies or molecules of the invention include, but are not limited to, immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma). [02101 Anti-BLyS Antibodies [02111 The antibodies of the present invention were discovered, in part, using phage display technology. Single chain antibody molecules ("scFvs") displayed on the surface of phage particles were screened to identify those scFvs that immunospecifically bind to BLyS, including the membrane-bound form and soluble form of BLyS. The present invention encompasses the scFvs and portions thereof that were identified to immunospecifically bind to BLyS, including scFvs that immunospecifically bind to the soluble form of BLyS, scFvs that immunospecifically bind to the membrane-bound form of BLyS, and scFvs that immunospecifically bind to both the soluble form and membrane bound form of BLyS. In particular, the present invention encompasses scFvs comprising, or alternatively consisting of, the amino acid sequence of SEQ ID NOS: I - 2128, as referred to in Table 1. Preferably, the scFvs of the present invention comprise, or alternatively consist of, the amino acid sequence of SEQ ID NOS:1 - 46, 321 - 329, 834 110 872, 1563 - 1595, or 1881 - 1908. The scFvs include scFvs that bind to soluble BLyS (e.g., scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1563 - 1880), scFvs that bind to the membrane-bound form of BLyS (e.g., scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1881 2128), and scFvs that bind to both the soluble form and the membrane-bound form of BLyS (e.g., scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1 - 1562). Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs, that immunospecifically bind to BLyS are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants. [02121 In one embodiment of the present invention, scFvs that immunospecifically bind to BLyS comprise a polypeptide having the amino acid sequence of any one of the VH domains referred to in Table I and/or any one of the VL domains referred to in Table 1. In preferred embodiments, scFvs of the present invention comprise the amino acid sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention comprise the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In another embodiment, scFvs that immunospecifically bind to BLyS, comprise a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs referred to in Table 1 and/or any one, two, three, or more of the VL CDRs referred to in Table 1. In preferred embodiments, scFvs of the present invention comprise the amino acid sequence of a VH CDR and VL CDR from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention comprise the amino acid sequence of a VH CDR and VL CDR from different scFvs referred to in Table 1. Molecules comprising, or alternatively consisting of, antibody fragments or variants of the scFvs referred to in Table I that immunospecifically bind to BLyS are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants. 102131 (Table 1 can be found at the end of the specification just prior to the claims.) I11 102141 In another embodiment of the present invention, an scFv that immunospecifically binds to a soluble form of BLyS, comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:1563 - 1880 as referred to in Table 1. In a preferred embodiment, an scFv that immunospecifically binds to a soluble form of BLyS comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS: 1570 1595. In an even more preferred embodiment, an scFv that immunospecifically binds to a soluble form of BLyS comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:1563 - 1569. [0215] In another embodiment of the present invention, an scFv that immunospecifically binds to a membrane-bound form of BLyS comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS: 1881 - 2128 as referred to in Table 1. In a preferred embodiment, an scFv that immunospecifically binds to a membrane bound form of BLyS comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:1886 - 1908. In an even more preferred embodiment, an scFv that immunospecifically binds to a membrane-bound form of BLyS comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS: 1881 - 1885. [02161 In another embodiment of the present invention, an scFv that immunospecifically binds to both the soluble form and membrane-bound form of BLyS comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS: 1 - 1562. as referred to in Table 1. In a preferred embodiment, an scFv that immunospecifically binds to'both the soluble form and membrane-bound form of BLyS comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:834 - 872. In another preferred embodiment, an scFv that immunospecifically binds to both the soluble form and membrane-bound form of BLyS comprises, or alternatively consists of, any one of the amino acids sequences of SEQ ID NOS: 1 - 46 or 321 - 329. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs, that immunospecifically bind to the soluble form of BLyS and/or the membrane-bound form of BLyS are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants. 02171 In another embodiment of the present invention, scFvs that immunospecifically bind to the soluble form of BLyS, comprise a polypeptide having the amino acid sequence of any one of the VH domains contained in SEQ ID NOS:1563 112 1880 as disclosed in Table 1 and/or any one of the VL domains contained in SEQ ID NOS: 1563 - 1880 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of BLyS, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of BLyS, comprise a polypeptide having amino acid sequence of a VH CDR and VL CDR from different scFvs referred to in Table 1. In another embodiment, scFvs that immunospecifically bind to the soluble form of BLyS, comprise a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs SEQ ID NOS:1563 - 1880 as disclosed in Table 1 and/or any one, two, three, or more of the VL CDRs contained in contained SEQ ID NOS:1563 - 1880, as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of BLyS, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of BLyS, comprise a polypeptide having the of the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In a preferred embodiment, scFvs that immunospecifically bind to the soluble form of BLyS, comprise a polypeptide having the amino acid sequence of any one of the VH CDR3s contained in SEQ ID NOS:1563 - 1880 as disclosed in Table I and/or any one of the VL CDR3s contained in SEQ ID NOS: 1563 - 1880-as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of BLyS, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of BLyS, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from different scFvs referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs, that immunospecifically bind to BLyS, preferably the soluble form of BLyS, are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants. [0218] In another embodiment of the present invention, scFvs that 113 immunospecifically bind to the membrane-bound form of BLyS comprise a polypeptide having the amino acid sequence of any one of the VH domains contained in SEQ ID NOS:1881 - 2128 as disclosed in Table I and/or any one of the VL domains contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of BLyS, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the membrane-bound form of BLyS, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In another embodiment, scFvs that immunospecifically bind to the membrane-bound form of BLyS, comprise a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table I and/or any one, two, three, or more of the VL CDRs contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the membrane-bound form of BLyS, comprise a polypeptide having the amino acid sequence of a VE domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the membrane-bound form of BLyS, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In a preferred embodiment, seFvs that immunospecifically bind to the membrane-bound form of BLyS, comprise a polypeptide having the amino acid sequence of any one of the VH CDR3s contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1 and/or any one of the VL CDR3s contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1. In preferred embodiments, scFvs of the: present invention that immunospecifically bind to the membrane-bound form of BLyS, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the membrane-bound form of BLyS, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from different scFvs referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs, that immunospecifically bind to BLyS, preferably the membrane-bound form of BLyS, are 114 also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants. [0219] In another embodiment of the present invention, scFvs that immunospecifically bind to the soluble form and membrane-bound form of BLyS, comprise a polypeptide having the amino acid sequence of any one of the VH domains contained in SEQ D NOS:1 - 1562 as disclosed in Table 1 and/or any one of the VL domains contained in SEQ ID NOS:1 - 1562 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble and membrane-bound forms of BLyS, comprise a polypeptide having the amino acid. sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble form and membrane-bound form of BLyS, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from different scFvs referred to in. Table 1. In another embodiment, scFvs that immunospecifically bind to the soluble form and membrane-bound form of BLyS comprise a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs contained in SEQ ID NOS:1 1562 as disclosed in Table 1 and/or any one, two, three, or more of the VL CDRs contained in SEQ ID NOS:I - 1562 as disclosed in Table 1. In preferred embodiments, scFvs of ths present invention that inmunospecifically bind to the soluble form and membrane-bound form of BLyS, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble and membrane-bound forms of BLyS, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In a preferred embodiment, scFvs that immunospecifically bind to the soluble and membrane-bound forms of BLyS, comprise a polypeptide having the amino acid sequence of any one of the VH CDR3s contained in SEQ ID NOS:1 - 1562 as disclosed in Table I and/or any one of the VL CDR3s contained in SEQ ID NOS:1 - 1562, as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble and membrane-bound forms of BLyS, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention 115 that immunospecifically bind to the soluble and membrane-bound forms of BLyS, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from different scFvs referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs or molecules, that immunospecifically bind to BLyS, preferably the soluble and membrane-bound forms of BLyS, are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants. [0220] The present invention provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or a polypeptide fragment of BLyS. In particular, the invention provides antibodies corresponding to the scFvs referred to in Table 1, such scFvs may routinely be "converted" to immunoglobulin molecules by inserting, for example, the nucleotide sequences encoding the VH and/or VL domains of the scFv into an expression vector containing the constant domain sequences and engineered to direct the expression of the immunoglobulin molecule, as described in more detail in Example 20, inf-a. [0221] In one embodiment, the invention provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) wherein said antibodies comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one of the VH domains contained in the sequences referred to in Table 1. The present invention also provides antibodies that immunospecifically bind to a polypeptide, or polypeptide fragment of BLyS, wherein said antibodies comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one, two, three, or more of the VH CDRs contained in the sequences referred to in Table 1. Molecules comprising, or alternatively consisting of, these antibodies, or antibody fragments or variants thereof, that irtmunospecifically bind to BLyS or a BLyS fragment are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments and/or variants. [02221 In one embodiment of the present invention, antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind BLyS, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VH CDR referred to in Table 1. In 116 particular, the invention provides antibodies that immunospecifically bind BLyS, comprising, or alternatively consisting of, a polypeptide having the amino acid sequence of a VH CDR] contained in SEQ ID NOS:1 - 46,321 - 329,1563 - 1569, or 1881 - 1885 as disclosed in Table 1. In another embodiment, antibodies that immunospecifically bind BLyS, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VII CDR2 contained in SEQ ID NOS:1 - 46, 321 - 329, 1563 - 1569, or 1881 - 1885 as disclosed in Table 1. In a preferred embodiment, antibodies that immunospecifically bind BLyS, comprise, or alternatively consist of a polypeptide having the amino acid sequence of a VII CDR3 contained in SEQ ID NOS:1 - 46, 321 - 329, 1563 - 1569, or 1881 - 1885 as disclosed in Table 1. In yet another embodiment, antibodies that immunospecifically bind BLyS, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VH CDRl contained in SEQ ID NOS:834 - 872, 1570 1595, or 1886 - 1908 as disclosed in Table 1; a VH CDR2 contained in SEQ ID NOS: SEQ ID NOS: SEQ ID NOS:834 - 872, 1570 - 1595, or 1886 - 1908; and/or a VH CDR3 contained in SEQ ID NOS: SEQ ID NOS:834 - 872, 1570 - 1595, or 1886 - 1908 as disclosed in Table 1. Preferably, antibodies of the invention comprise, or alternatively consist of, VH CDRs that are derived from the same scFv as disclosed in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies that immunospecifically bind to BLyS are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants. [02231 The present invention provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants) that immunospecifically bind to a polypeptide, or polypeptide fragment of BLyS. In particular, the invention provides antibodies wherein said antibodies comprise, or alternatively consist of, a VL domain having an amino acid sequence of any one of the VL domains referred to in Table 1. The present invention also provides antibodies that immunospecifically bind to a polypeptide or polypeptide fragment of BLyS, wherein said antibodies comprise, or alternatively consist of, a VL CDR having an amino acid sequence of any one, two, three, or more of the VL CDRs contained in the sequences referred to in Table 1. Molccules comprising, or alternatively consisting of, fragments or variants of these antibodies that immunospecifically bind to BLyS are also encompassed by the 117 invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants. 10224] In one embodiment of the present invention, antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind BLyS, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VL CDR referred to in Table 1. In particular, the invention provides antibodies that immunospecifically bind BLyS, comprising, or alternatively consisting of, a polypeptide having the amino acid sequence of a VL CDR1 contained in SEQ ID NOS:1 - 46, 321 - 329, 1563 - 1569, or 1881 - 1885 as disclosed in Table 1. In another embodiment, antibodies that immunospecifically bind BLyS comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VL CDR2 contained in SEQ ID NOS:1 - 46, 321 - 329, 1563 - 1569, or 1881 - 1885 as disclosed in Table 1. In a preferred embodiment, antibodies comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VL CDR3 contained in SEQ ID NOS: in SEQ ID NOS:l - 46, 321. - 329, 1563 - 1569, or 1881 - 1885 disclosed in Table 1. In yet another embodiment, antibodies that immnospecifically bind BLyS comprise, or alternatively consist of: a polypeptide having the amino acid sequence of a VL CDRI contained in SEQ ID NOS:834- 872, 1570 - 1595, or 1886 - 1908 as disclosed in Table 1; a VL CDR2 SEQ ID NOS :834 - 872, 1570 - 1595, or 1886 - 1908 as disclosed in Table 1; and a VL CDR3 contained SEQ ID NOS:834 - 872, 1570 - 1595, or 1886 - 1908 as disclosed in Table 1. Preferably, antibodies of the invention comprise, or alternatively consist of, VL CDRs that are derived from the same scFv as disclosed in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies, that immunospecifically bind to BLyS are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants. 10225] The present invention also provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or a polypeptide fragment of BLyS, wherein said antibodies comprise, or alternatively consist of, a VH domain of one of the scFvs referred to in Table I combined with a VL domain of one of the scFvs referred to in Table 1, or other VL domain. The present invention further provides antibodies (including 118 molecules comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or a polypeptide fragment of BLyS, wherein said antibodies comprise, or alternatively consist of, a VL domain of one of the scFvs referred to in Table I combined with a VH domain of one of the scFvs referred to in Table 1, or other VH domain. In a preferred embodiment, antibodies that immunospecifically bind to a polypeptide or a polypeptide fragment of BLyS, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VH domain contained SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1 and a VL domain contained in contained SEQ ID NOS:1 - 46, 321 329, 834 - 872, 1563 - 1595, or 1881- 1908 as disclosed in Table 1. In a further preferred embodiment, the antibodies of the invention comprise, or alternatively consist of, a VH and a VL domain from the same scFv as disclosed in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies, that immunospecifically bind to BLyS are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants. 102261 The present invention also provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants) that immunospecifically bind to a polypeptide or polypeptide fragment of BLyS, wherein said antibodies comprise, or alternatively consist of, one, two, three, or more VH CDRs and one, two, three or more VL CDRs, as referred to in Table 1. In particular, the invention provides for antibodies that inmunospecifically bind to a polypeptide or polypeptide fragment of BLyS, wherein said antibodies comprise, or alternatively consist of, a VH CDR1 and a VL CDR1, a VH CDRI and a VL CDR2, a VH CDR1 and a VL CDR3, a VH CDR2 and a VL CDRI, VH CDR2 and VL CDR2, a VH CDR2 and a VL CDR3, a VH CDR3 and a VH CDRI, a VH CDR3 and a VL CDR2, a VH CDR3 and a VL CDR3, or any combination thereof, of the VH CDRs and VL CDRs referred to in Table 1. In a preferred embodiment, one or more of these combinations are from the same scFv as disclosed in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies, that immunospecifically bind to BLyS are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants. 119 10227] In a preferred embodiment the invention provides antibodies wherein the VH CDRX (where X=1, 2, or 3) and VL CDRY (where Y= 1, 2, or 3) are from scFvs with the same specificity (i.e., from scFvs that bind soluble BLyS, from scFvs that bind membrane-bound BLyS, or from scFvs that bind both soluble and membrane-bound BLyS. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies, that immunospecificafly bind to BLyS are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants. 102281 The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that inimunospecifically binds an antigen. As such, the term "antibody" encompasses not only whole antibody molecules, but also antibody fragments, as well as variants (including derivatives) of antibodies and antibody fragments. Antibodies of the invention include, but are not limited to, monoclonal, multispecific, human or chimeric antibodies, single chain antibodies, single chain Fvs (scFvs), Fab fragments, F(ab') 2 fragments, Fd fragments, disulfide-linked Fvs (sdFvs), antiidiotypic (anti-id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGi, IgG 2 , IgG 3 , IgG 4 , IgA -and IgA 2 ) or subclass of immunoglobulin molecule. The antibodies of the present invention also include molecules comprising, or alternatively consisting of, a polypeptide having an amino acid sequence of a portion of an amino acid sequence contained SEQ ID NOS:I - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908. Preferably, an antibody of the invention comprises, or alternatively consists of, a polypeptide having an amino acid sequence of a VH domain, VH CDR, VL domain, or VL CDR of any one those contained in the sequences referred to in Table 1. Antibodies of the invention also include molecules comprising, or alternatively consisting of, fragments or variants of the above antibodies that immunospecifically bind BLyS. 102291 Most preferably the antibodies of the present invention are whole antibodies or antibody fragments that immunospecifically bind human BLyS. Antibody fragments of the invention that immunospecifically bind human BLyS include, but are not limited to, Fab, Fab' and F(ab') 2 , Fd fragments, single-chain Fvs (scFv), single-chain 120 antibodies, disulfide-linked Fvs (sdFvs), fragments comprising, or alternatively consisting of, either a VL or VH domain, and epitope binding fragments of any of the above. 102301 BLyS-binding antibody fragments, including single-chain antibodies, may comprise, or alternatively consist of, the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CHI, CH2, and CH3 domains. In a preferred embodiment, the antibodies of the invention comprise, or alternatively consist of, a polypeptide that immunospecifically binds to BLyS, said polypeptides comprise, or alternatively consist of, one, two, three, four, five, six or more CDRs referred to in Table 1, preferably a polypeptide having an amino acid sequence of a VH CDR3 and/or a VL CDR3 of contained SEQ ID NOS:I - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 1908 as disclosed in Table 1. Most preferably, antibodies of the invention comprise, or alternatively consist of, one, two, three, four, five, six or more CDRs from the same scFv, as referred to in Table 1. The antibodies of the invention may be from any animal origin, including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken. Most preferably, the antibodies are human antibodies. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries and xenomice or other organisms that have been genetically engineered to produce human antibodies. For a detailed discussion of a few of the technologies for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598; and Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995), which are incorporated by reference herein in their entirety. Human antibodies or "humanized" chimeric monoclonal antibodies can be produced using techniques described herein or otherwise known in the art. For example, methods for producing chimeric antibodies are known in the art. See, for review the following references which are hereby incorporated in their entirety: Morrison, Science 229:1202 (1985); Oi et al., Bio Techniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); 121 Neuberger et al., Nature 314:268 (1985). In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharn (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above. 102311 The antibodies of the present invention may be monovalent, bivalent, trivalent or multivalent. For example, monovalent scFvs can be multimerized either chemically or by association with another protein or substance. An scFv that is fused to a hexahistidine tag or a Flag tag can be multimerized using Ni-NTA agarose (Qiagen) or using anti-Flag antibodies (Stratagene, Inc.). [02321 The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a BLyS polypeptide, or fragment thereof, or may be specific for both a BLyS polypeptide, or fragment thereof, and a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et aL., J. Immunol. 147:60 69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et.aL., J. Immunol. 148:1547-1553 (1992). [0233] The antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may bind immunospecifically to murine BLyS (e.g., a polypeptide having the amino acid sequence of human BLyS (SEQ ID NOS:3228 and/or 3229) or BLyS expressed on human monocytes; murine BLyS (SEQ ID NOS:3230 and/or 3231) or BLyS expressed on murine monocytes; rat BLyS (either the soluble forms as given in SEQ ID NOS:3232, 3233, 3234 and/or 3235 or in a membrane associated form, e.g., on the surface of rat monocytes); or monkey BLyS (e.g., the monkey BLyS polypeptides of SEQ ID NOS:3236 and/or 3237, the soluble form of monkey BLyS, or BLyS expressed on monkey monocytes), preferably the antibodies of the invention bind immunospecifically to human BLyS. Preferably, the antibodies of the invention bind immunospecifically to human and monkey BLyS. Also preferably, the antibodies of the invention bind immunospecifically to human BLyS and murine BLyS. More preferably, antibodies of the invention, bind immunospecifically and with higher affinity to human BLyS than to murine BLyS. 122 [0234] Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, antibodies of the present invention cross react with APRIL (SEQ ID NO:3239; GenBank Accession No. AF046888; J. Exp. Med. 188(6):1185-1190; PCT International Publication W097/33902). In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art-and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under hybridization conditions (as described herein). [0235] In preferred embodiments, the antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), immunospecifically bind to BLyS and do not cross-react with any other antigens. In more preferred embodiments, the antibodies of the invention immunopecifically bind to BLyS and do not cross-react with TRAIL, APRIL, Endokine alpha, TNF-alpha, TNF-beta, Fas-L or LIGHT. [0236] The present invention also provides for a nucleic acid molecule, generally 123 [0237] isolated, encoding an antibody of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof). In one embodiment, a nucleic acid molecule of the invention encodes an antibody comprising, or alternatively consisting of, a VH domain having an amino acid sequence of any one of the VH domains referred to in Table 1. In another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VH CDR1 having an amino acid sequence of any one of the VH CDRIs referred to in Table 1. In another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VH CDR2 having an amino acid sequence of any one of the VH CDR 2 s referred to in Table 1. In yet another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VH CDR3 having an amino acid sequence of any one of the VH CDR3s referred to in Table 1. Nucleic acid molecules encoding antibodies that immunospecifically bind BLyS and comprise, or alternatively consist of, fragments or variants of the VH domains and/or VH CDRs are also encompassed by the invention. [0238] In another embodiment, a nucleic acid molecule of the invention encodes an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), comprising, or alternatively consisting of, a VL domain having an amino acid sequence of any one of the VL.domains referred to in Table 1. In another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VL CDR1 having amino acid sequence of any one of the VL CDRls referred to in "Table 1. In another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VL CDR2 having an amino acid sequence of any one of the VL CDR2s referred to in Table I. In yet another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VL CDR3 having an amino acid sequence of any one of the VL CDR3s referred to in Table 1. Nucleic acid encoding antibodies that immunospecifically bind BLyS and comprise, or alternatively consist of, fragments or variants of the VL domains and/or VLCDR(s) are also encompassed by the invention. 102391 In another embodiment, a nucleic acid molecule of the invention encodes an antibody (including molecules comprising, or alternatively consisting of, antibody 124 fragments or variants thereof), comprising, or alternatively consisting of, a VH domain having an amino acid sequence of any one of the VH domains referred to in Table I and a VL domain having an amino acid sequence of any one of the VL domains referred to in Table 1. In another embodiment, a nucleic acid molecule of the invention encodes an antibody comprising, or alternatively consisting of, a VH CDRI, a VL CDRI, a VH CDR2, a VL CDR2, a VH CDR3, a VL CDR3, or any combination thereof having an amino acid sequence referred to in Table 1. Nucleic acid encoding antibodies that immunospecifically bind BLyS and comprise, or alternatively consist of, fragments or variants of the VL and/or domains and/or VHCDR(s) and/or VLCDR(s) are also encompassed by the invention. 102401 The present invention also provides antibodies that comprise, or alternatively consist of, variants (including derivatives) of the VH domains, VH CDRs, VL domains, and VL CDRs described herein, which antibodies immunospecifically bind to BLyS. Standard techniques known to those of skill in the art can be used to introduce mutations in the nucleotide sequence encoding a molecule of the invention, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis which result in amino acid substitutions. Preferably, the variants (including derivatives) encode less than 50 amino acid substitutions, less than 41) amino acid subsitutions, less than 30 amino acid substitutions, less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the reference VH domain, VHCDRI, VHCDR2, VHCDR3, VL domain, VLCDR1, VLCDR2, or VLCDR3. In specific embodiments, the variants encode substitutions of VHCDR3. In a preferred embodiment, the variants have conservative amino acid substitutions at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a side chain with a similar charge. Families of amino acid residues having side chains with similar charges have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, 125 isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains ( e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity (e.g., the ability to bind BLyS). Following mutagenesis, the encoded protein may routinely be expressed and the functional and/or biological activity of the encoded protein, (e.g., ability to immunospecifically bind BLyS) can be determined using techniques described herein or by routinely modifying techniques known in the art. 102411 The antibodies of the invention include derivatives (i.e., variants) that are modified, e.g., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not affect the ability of the antibody to immunospecifically bind to BLyS. For example, but not by way of limitation, derivatives of the invention include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivati2ation by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids. 102421 In a specific embodiment, an antibody of the invention (including a molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof), that immunospecifically binds BLyS, comprises, or alternatively consists of, an amino acid sequence encoded by a nucleotide sequence that hybridizes to a nucleotide sequence that is complementary to that encoding one of the VH or VL domains referred to in Table 1 under stringent conditions, e.g., hybridization to filter-bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45* C followed by one or more washes in 0.2xSSC/0. I% SDS at about 50-65* C, under highly stringent conditions, e.g., hybridization to filter-bound nucleic acid in 6xSSC at about 450 C followed by one or more washes in 0.1 xSSC/0.2% SDS at about 68" C, or under other stringent hybridization conditions which are known to those of skill in the art (see, for example, Ausubel, F.M. et al., eds. , 1989, Current Protocols in Molecular Biology, Vol. 1, Green Publishing 126 Associates, Inc. and John Wiley & Sons, Inc., New York at pages 6.3.1-6.3.6 and 2.10.3). In another embodiment, an antibody of the invention that immunospecifically binds to BLyS, comprises, or alternatively consists of, an amino acid sequence encoded by a nucleotide sequence that hybridizes to a nucleotide sequence that is complementary to that encoding one of the VH CDRs or VL CDRs referred to in Table 1 under stringent conditions, e.g., hybridization under conditions as described above, or under other stringent hybridization conditions which are known to those of skill in the art. In another embodiment, an antibody of the invention that immunospecifically binds to BLyS, comprises, or alternatively consists of, an amino acid sequence encoded by a nucleotide sequence that hybridizes to a nucleotide sequence that is complementary to that encoding one of the VH CDR3s referred to in Table 1 under stringent conditions e.g., hybridization under conditions as described above, or under other stringent hybridization conditions which are known to those of skill in the art. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. [0243] In another embodiment, an antibody (including a molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof), that immunospecifically binds to BLyS comprises, or alternatively consists of, a polypeptide - having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least.70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical, to any one of the VH domains referred to in Table 1. In another embodiment, an antibody of the invention that immunospecifically binds to BLyS comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical, to any one of the VH CDRs referred to in Table 1. In another embodiment, an antibody of the invention that immunospecifically binds to BLyS comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%., or at least 99% identical to any one of the VH CDR3s referred to in Table 1. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. 127 [0244] In another embodiment, an antibody of the invention (including a molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof), that immunospecifically binds to BLyS comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80/o, at least 85%, at least 90%, at least 95%, or at least 99% identical, to any one of the VL domains referred to in Table 1. In another embodiment, an antibody of the invention that immunospecifically binds to BLyS comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical, to any one of the VL CDRs referred to in Table 1. In another embodiment, an antibody of the invention that immunospecifically binds to BLyS comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%,.at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical, to any one of the VL CDR3s referred to in Table 1. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. [02451 . Antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may also be described or specified in terms of their binding affinity for to BLyS polypeptides or fragments or variants of BLyS polypeptides (e.g., to the soluble form of BLyS and/or membrane-bound form of BLyS). In specific embodiments, antibodies of the invention bind BLyS polypeptides, or fragments or variants thereof, with a dissociation constant or K 0 of less than or equal to 5 X 10-2 M, 10.2 M, 5 X 10 M, 10- 3 M, 5 X 104 M, 10-4 M, 5 X 10- M, or 10 5M. More preferably, antibodies of the invention bind BLyS polypeptides or fragments or variants thereof with a dissociation constant or KD less than or equal to 5 X 10~-' M, 10~-' M, 5 X 10 7 M, 10-'M, 5 X 10-'M, or 10a M. Even more preferably, antibodies of the invention bind BLyS polypeptides or fragments or variants thereof with a dissociation constant or KD less than or equal to 5 X 10- M, 10- M, 5 X 1014 M, I 10 M, 5 X 10~" M, 10~11 M, 5 X 10-12 M, 10-12 M, 5 X - M, 10-1 M, 5 X 10-'4 M, 10-4 M, 5 X 10-15 M, or 10~" M. The invention encompasses antibodies that bind BLyS polypeptides 128 with a dissociation constant or KD that is within any one of the ranges that are between each of the individual recited values. 102461 In specific embodiments, antibodies of the invention bind BLyS polypeptides or fragments or variants thereof with an off rate (kog) of less than or equal to 5 X 10-2 sec-', 10-2 sec-, 5 X 10- sec" or I03 sec 1 . More preferably, antibodies of the invention bind BLyS polypeptides or fragments or variants thereof with an off rate (kog) less than or equal to 5 X 104 sec', 1104 sec- 1 , 5 X 10- sec", or 10- sec 1 5 X 106 sec-, 10 6 sec1, 5 X 10~7 sec' or 10~7 sec". The invention encompasses antibodies that bind BLyS polypeptides with an off rate (kff) that is within any one of the ranges that are between each of the individual recited values. [02471 In other embodiments, antibodies of the invention bind BLyS polypeptides or fragments or variants thereof with an on rate (kon) of greater than or equal to 103 M sec-', 5 X 10' M' sec 1 , 10' M- sec-1 or 5 X 104 M-' sec- 1 . More preferably, antibodies of the invention bind BLyS polypeptide3 or fragments or variants thereof with an on rate (kon)greater than or equal to 105 M- sec", 5 X 10' M- sec-, 106 M- sec-1, or 5 X 106 M-1 sec- 1 or 107 M 1 sec-. The invention encompasses antibodies that bind BLyS polypeptides with on rate (k,,) that is within any one of the ranges that are between each of the individual recited values. 102481 The invention also encompasses antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that have one or more of the same biological characteristics as one or more of the antibodies described herein. By "biological. characteristics" is meant, the in vitro or in vivo activities or properties of the antibodies, such as, for example, the ability to bind to BLyS (e.g., the soluble form of BLyS, the membrane-bound form of BLyS, the soluble form and membrane-bound form of BLyS), and/or an antigenic and/or epitope region of BLyS), the ability to substantially block BLyS/BLyS receptor (e.g., TACI - GenBank accession number AAC51790 and/or BCMA -GenBank accession number NP_001183) binding, or the ability to block BLyS mediated biological activity (e.g., stimulation of B cell proliferation and immunoglobulin production). Optionally, the antibodies of the invention will bind to the same epitope as at least one of the antibodies specifically referred to herein. Such epitope binding can be routinely determined using assays known in the art. 129 [02491 The present invention also provides for antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that neutralize BLyS or a fragment thereof, said antibodies comprising, or alternatively consisting of, a portion (i.e., a VH domain, VL domain, VH CDR1, VH CDR2, VH CDR3, VL CDRI, VL CDR2, or VL CDR3) of an scFv referred to in Table 1, more preferably having an amino acid sequence contained in SEQ ID NOS:834 - 872, 1570 1595, or 1886 - 1908, and even more preferably having an amino acid sequence contained in SEQ ID NOS:1 - 46, 321 - 329, 1563 - 1569, or 1881 - 1885 as disclosed in Table 1, or a fragment or variant thereof. By an antibody that "neutralizes BLyS or a fragment thereof" is meant an antibody that diminishes or abolishes the ability of BLyS to bind to its receptor (e.g., TACI and BCMA) to stimulate B cell proliferation, to stimulate immunoglobulin secretion by B cells, and/or to stimulate the BLyS receptor signalling cascade. In one embodiment, an antibody that neutralizes BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH domain contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that neutralizes BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL domain contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that neutralizes BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR domain in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In a preferred embodiment, an antibody that neutralizes BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR3 contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that neutralizes BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR domain contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 1908 as disclosed in Table 1, or a fragment or variant thereof. In another preferred embodiment, an antibody that neutralizes BLyS or a fragment thereof, comprises, or 130 alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR3 contained in SEQ ID NOS:l - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. [02501 The present invention also provides for antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that inhibit (i.e., diminish or abolish) BLyS mediated B cell proliferation as determined by any method known in the art such as, for example, the assays described in Examples 21 and 22, infra, said antibodies comprising, or alternatively consisting of, a portion (e.g., a VH domain, VL domain, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, or VL CDR3) of an scFv having an amino acid sequence SEQ ID NOS:834 - 872, 1570 - 1595, 1886 - 1908, and even more preferably having an amino acid sequence SEQ ID NOS:1 46, 321 - 329, 1563 - 1569, 1881 - 1885 as disclosed in Table I or a fragment or variant thereof. In one embodiment, an antibody that inhibits BLyS mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH domain contained in SEQ ID NOS:I - 46, 321 - 329, 834 - 872, 1563 1595, or 1881 - 1908, as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that inhibits BLyS mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL domain contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In a preferred embodiment, an antibody that inhibits BLyS mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR3 contained in SEQ ID NOS:I - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In another preferred embodiment, an antibody that inhibits BLyS mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR3 contained SEQ ID NOS: I 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. 102511 The present invention also provides for antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that 131 enhance the activity of BLyS or a fragment thereof, said antibodies comprising, or alternatively consisting of, a portion (i.e., a VH domain, VL domain, VH CDRl, VH CDR2, VH CDR3, VL CDRI, VL CDR2, or VL CDR3) of an scFv having an amino acid sequence SEQ ID NOS:834 - 872, 1570 - 1595, or 1886 - 1908, and preferably having an amino acid sequence of SEQ ID NOS:1 - 46, 321 - 329, 1563 - 1569, or 1881 - 1885, as disclosed in Table 1, or a fragment or variant thereof. By an antibody that "enhances the activity of BLyS or a fragment thereof" is meant an antibody increases the ability of BLyS to bind to its receptor (e.g., TACI or BCMA), to stimulate B cell proliferation, to stimulate immunoglobulin secretion by B cells, and/or to stimulate the BLyS receptor signalling cascade. In one embodiment, an antibody that enhances the activity of BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH domain contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that enhances the activity of BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of aVL domain contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that enhances the activity of BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR domain contained in SEQ ID NOS:l - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In a preferred embodiment, an antibody that enhances the activity of BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR3 contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that enhances BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR domain contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In another preferred embodiment, an antibody that enhances the activity of BLyS or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR3 contained in SEQ ID NOS: 1 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a 132 fragment or variant thereof. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. 102521 The present invention also provides for antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that stimulate BLyS mediated B cell proliferation as determined by any method known in the art, such as, for example, the assays described in Examples 21 and 22, infra, said antibodies comprising, or alternatively consisting of, a portion (e.g., a VH domain, VL domain, VH CDRI, VII CDR2, VH CDR3, VL CDRI, VL CDR2, or VL CDR3) of an scFv having an amino acid sequence-of SEQ ID NOS:834 - 872, 1570 - 1595, or 1886 1908, and even more preferably having an amino acid sequence of SEQ ID NOS:1 - 46, 321 - 329, 1563 - 1569, or 1881 - 1885 as disclosed in Table I or a fragment or variant thereof. In one embodiment, an antibody that stimulates BLyS mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH domain contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that stimulates BLyS mediated B cell proliferation, comprises,. or alternatively consists of, a polypeptide having the amino acid sequence of a VL domain contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In a preferred embodiment, an antibody that stimulates BLyS mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR3 contained in SEQ ID NOS:1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. In another preferred embodiment, an antibody that stimulates BLyS mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR3 contained in SEQ ID NOS: 1 - 46, 321 - 329, 834 - 872, 1563 - 1595, or 1881 - 1908 as disclosed in Table 1, or a fragment or variant thereof. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. [02531 The present invention also provides for fusion proteins comprising, or alternatively consisting of, an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that immunospecifically binds to BLyS, and a heterologous polypeptide. Preferably, the heterologous polypeptide to which 133 the antibody is fused to is useful for B-cell function or is useful to target the antibody to B cells. In an alternative preferred embodiment, the heterologous polypeptide to which the antibody is fused to is useful for monocyte cell function or is useful to target the antibody to a monocyte. In another embodiment, the heterologous polypeptide to which the antibody is fused is albumin (including but not limited to recombinant human serum albumin or fragments or variants thereof (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)). In a preferred embodiment, antibodies of the present invention (including fragments or variants thereof) are fused with the mature form of human serum albumin (i.e., amino acids 1 - 585 of human serum albumin as shown in Figures 1 and 2 of EP Patent 0 322 094) which is herein incorporated by reference in its entirety. In another preferred embodiment, antibodies of the present invention (including fragments or variants thereof) are fused with polypeptide fragments comprising, or alternatively consisting of, amino acid residues l-x of human serum albumin, where x is an integer from 1 to 585 and the albumin fragment has human serum albumin activity. In another preferred embodiment, antibodies of the present invention (including fragments or variants thereof) are fused with polypeptide fragments comprising, or alternatively consisting of, amino acid residues l-z of human serum albumin, where z is an integer from 369 to 419, as described in U.S. Patent 5,766,883 herein incorporated by reference in its entirety. Antibodies of the present invention (including fragments or variants thereof) may be fused to either the N- or C-terminal end of the heterologous protein (e.g., immunoglobulin Fc polypeptide or human serum albumin polypeptide). [02541 In one embodiment, a fusion protein of the invention comprises, or alternatively consists of, a polypeptide having the amino acid sequence of any one or more of the VH domains referred to in Table I or the amino acid sequence of any one or more of the VL domains referred to in Table 1 or fragments or variants thereof, and a heterologous polypeptide sequence. In another embodiment, a fusion protein of the present invention comprises, or alternatively consists of, a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs referred to in Table 1, or the amino acid sequence of any one, two, three, or more of the VL CDRs referred to in Table 1, or fragments or variants thereof, and a heterologous polypeptide sequence. In a 134 preferred embodiment, the fusion protein comprises, or alternatively consists of, a polypeptide having the amino acid sequence of, a VH CDR3 referred to in Table 1, or fragment or variant thereof, and a beterologous polypeptide sequence, which fusion protein immunospecifically binds to BLyS. In another embodiment, a fusion protein comprises, or alternatively consists of a polypeptide having the amino acid sequence of at least one VH domain referred to in Table 1 and the amino acid sequence of at least one VL domain referred to in Table I or fragments or variants thereof, and a heterologous polypeptide sequence. Preferably, the VH and VL domains of the fusion protein correspond to the same scFv referred to in Table 1. In yet another embodiment, a fusion protein of the invention comprises, or alternatively consists of a polypeptide having the amino acid sequence of any one, two, three or more of the VH CDRs referred to in Table I and the amino acid sequence of any one, two, three or more of the VL CDRs referred to in Table 1, or fragments or variants thereof, and a heterologous polypeptide sequence. Preferably, two, three, four, five, six, or more of the VHCDR(s) or VLCDR(s) correspond to the same scFv referred to in Table 1. Nucleic acid molecules encoding these fusion proteins are also encompassed by the invention. [02551 The present invention also provides: antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that immunospecifically bind to the soluble form of BLyS; antibodies that immunospecifically bind to the membrane-bound form of BLyS; and antibodies that immunospecifically bind to both the soluble form and membrane-bound form of BLyS. [02561 In one embodiment of the present invention, antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to the soluble form of BLyS, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS:1563 - 1880 as disclosed in Table 1 and/or the amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS: 1563 - 1880 as disclosed in Table 1, or fragment(s) or variant(s) (including derivative) thereof. Preferably, the VH and VL domains of the antibody correspond to the same scFv as disclosed in Table 1. In another embodiment, antibodies that immunospecifically bind to the soluble form of BLyS are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one, two, 135 three, or more of the VH CDRs contained SEQ ID NOS: 1563 - 1880 as disclosed in Table 1 and/or the amino acid sequence of any one, two, three, or more of the VL CDRs contained in SEQ ID NOS: 1563 - 1880 as disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, two, three, four, five, six or more of the VH and VL CDRs of the antibody correspond to the same scFv as disclosed in Table 1. In a preferred embodiment, antibodies that immunospecifically bind to the soluble form of BLyS are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH CDR3s contained in SEQ ID NOS: 1563 - 1880 as disclosed in Table 1 and/or the amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS: 1563 - 1880 as disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, the VHCDR3 and VLCDR3 of the antibody correspond to the same scFv, as disclosed in Table 1. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. [0257] In another embodiment of the present invention, antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to the membrane-bound form of BLyS are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1 and/or the amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1, or a fragment or variant thereof. Preferably, the VH and VL domains of the antibody correspond to the same scFv as disclosed in Table 1. In another embodiment, antibodies that immunospecifically bind to the membrane-bound form of BLyS are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1 and/or the amino acid sequence of any one, two, three, or more of the VL CDRs contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, two, three, four, five, six or more of the VH and VL CDRs of the antibody correspond to the same scFv as disclosed in Table 1. In a preferred embodiment, antibodies that immunospecifically bind to the membrane-bound form of BLyS are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH CDR3s contained in SEQ ID NOS: 1881 - 2128 as disclosed in 136 Table 1 and/or the amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, the VHCDR3 and VLCDR3 of the antibody correspond to the same scFv, as disclosed in Table 1. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. [02581 In another embodiment of the present invention, antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to the soluble form and membrane-bound form of BLyS, are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS: 1 - 1562 as disclosed in Table I and/or the amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS: 1 - 1562 as disclosed in Table 1, or a fragment or variant thereof. Preferably, the VH and VL domains of the antibody correspond to the same scFv as disclosed in Table 1. In another embodiment, antibodies that immunospecifically bind to the soluble form and membrane-bound form of BLyS arc provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs contained in SEQ ID NOS:.1 1562 as disclosed in Table 1 and/or the amino acid sequence of any one, two, three, or more of the VL CDRs contained in SEQ ID NOS: I - 1562 as disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, two, three, four, five, six or more of the VHI and VL CDRs of the antibody correspond to the same scFv as disclosed in Table 1. In a preferred embodiment, antibodies that immunospecifically bind to the soluble form and membrane-bound form of BLyS are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH CDR3s contained in SEQ ID NOS: 1 - 1562, disclosed in Table 1 and/or the amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS: 1 - 1562, disclosed in Table 1, or fragment(s) or variant(s) thereof Preferably, the VHCDR3 and VLCDR3 of the antibody correspond to the same scFv, as disclosed in Table 1. [0259] The present invention also provides for mixtures of antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to BLyS, wherein the mixture has at least one, two, three, four, five or more different antibodies of the invention. In particular, 137 the invention provides for mixtures of different antibodies that immunospecifically bind to the soluble form of BLyS, the membrane-bound form of BLyS, and/or both the membrane-bound form and soluble form of BLyS. In specific embodiments, the invention provides mixtures of at least 2, preferably at least 4, at least 6, at least 8, at least 10, at least 12, at least 15, at least 20, or at least 25 different antibodies that immunospecifically bind to BLyS, wherein at least 1, at least 2, at least 4, at least 6, or at least 10, antibodies of the mixture is an antibody of the invention. In a specific embodiment, each antibody of the mixture is an antibody of the invention. [02601 The present invention also provides for panels of antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to BLyS, wherein the panel has at least one, two, three, four, five or more different antibodies of the invention. In particular, the invention provides for panels of different antibodies that immunospecifically bind to the soluble form of BLyS, the membrane-bound form of BLyS, and/or both the membrane bound form and soluble form of BLyS. In specific embodiments, the invention provides for panels of antibodies that have different affinities for BLyS, different specificities for BLyS, or different dissociation rates. The invention provides panels of at least 10, preferably at least 25, at least 50, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 550, at least 600, at least 650, at least 700, at least 750, at least 800, at least 850, at least 900, at least 950, or at least 1000, antibodies. Panels of antibodies can be used, for example, in 96 well plates for assays such as ELISAs. 10261] The present invention further provides for compositions comprising, one or more antibodies (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the invention). In one embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS:1563 - 1880 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDRls contained in SEQ ID NOS:1563 - 1880 as disclosed in Table 1, or 138 a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR2s contained in SEQ ID NOS:1563 - 1880 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of anyone or more of the VH CDR3s contained in SEQ ID NOS:1563 - 1880, as disclosed in Table I or a variant thereof. [02621 The present invention further provides-for compositions comprising, one or more antibodies (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the invention). In one embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDRls contained in SEQ ID NOS:1881 - 2128 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR2s contained in SEQ ID NOS:181 - 2128 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR3s contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1 or a variant thereof. [02631 The present invention further provides for compositions comprising, one or more antibodies (including scFvs, or molecules comprising, or alternatively consisting of antibody fragments or variants of the invention). In one embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS:1 - 1562 as disclosed in Table 1, or a 139 variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDRIs contained in SEQ ID NOS:1 - 1562 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR2s contained in SEQ ID NOS:1 - 1562 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR3s contained in SEQ ID NOS:1 - 1562 as disclosed in Table I or a variant thereof. 102641 Other embodiments of the present invention providing for compositions comprising, one or more antibodies (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the invention) are listed below. In another embodiment, a composition of the present invention comprises, one, two, three; four, five, or more antibodies that comprise, or alternative consist of, a polypeptide having an amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS: 1563 - 1380 as disclosed in Table 1, or a variant thereof In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR1s contained in SEQ ID NOS: 1563 - 1880 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR2s contained SEQ ID NOS:1563 - 1880 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS: 1563 - 1880 as disclosed in Table 1, or a variant thereof. 140 [02651 Other embodiments of the present invention providing for compositions comprising, one or more antibodies (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the invention) are listed below. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS:1881 - 2128 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide : having an amino acid sequence of any one or more of the VL CDRIs contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR2s SEQ ID NOS:1881 - 2128 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS: 1881 - 2128 as disclosed in Table 1, or a variant thereof. [0266] Other embodiments of the present invention providing for compositions comprising, one or more antibodies (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the invention) are listed below. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS: I - 1562 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDRIs contained in SEQ ID NOS:I - 1562 as disclosed in Table: 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid 141 sequence of any one or more of the VL CDR2s SEQ ID NOS: I - 1562 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS:1 - 1562 as disclosed in Table 1, or a variant thereof. {0267] In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH domains in disclosed in Table 1, or a variant thereof, and an amino acid sequence of any one or more of the VL domains disclosed in Table 1, or a variant thereof wherein the VH and VL domains are from scFvs with the same specificity (i.e., from scFvs that bind soluble BLyS (SEQ ID NOS:1563 - 1880), from scFvs that bind membrane-bound BLyS (SEQ ID 1881 - 2128), or from scFvs that bind both soluble and membrane-bound BLyS (SEQ ID NOS: I - 1562). In a preferred embodiment the invention provides antibodies wherein the VII CDRX (where X= 1,2, or 3) and VL CDRY (where Y= 1,2, or 3) are from scFvs with the same specificity (i.e., from scFvs that bind soluble BLyS (SEQ ID NOS:1563 - 1880), from scFvs that bind membrane-bound BLyS (SEQ ID NOS:1881 2128), or from scFvs that bind both soluble and membrane-bound BLyS (SEQ ID NOS:I - 1562). In yet another embodiment, a composition of the present invention comprises one or more fusion proteins. [0268] As discussed in more detail below, a composition of the invention may be used either alone or in combination with other compositions. The antibodies (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the present invention) may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387. 142 (02691 Antibodies of the present invention (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the present invention) may be used, for example, but not limited to, to purify and detect BLyS, and to target the polypeptides of the present invention to cells expressing membrane-bound BLyS or BLyS receptor, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of BLyS in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety). Methods Producing Antibodies 102701 The antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the invention) can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques. 102711 The single chain Fvs disclosed in Table I were generated using phage display methods known in the art. Furthermore, other scFvs that immunospecifically bind BLyS may be generated using phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In particular, DNA sequences encoding VH and VL domains are amplified from animal cDNA libraries (e.g., human or murine cDNA libraries of lymphoid tissues) or synthetic cDNA libraries. The DNA encoding the VH and VL domains are joined together by an scFv linker by PCR and cloned into a phagemid vector (eg., p CANTAB 6 or pComb 3 HSS). The vector is electroporated in E. coli and the E. coli is infected with helper phage. Phage used in these methods are typically filamentous phage including fd and M13 and the VH and VL domains are usually recombinantly fused to either the phage gene III or gene VIII. Phage expressing an antigen binding domain that binds to an antigen of interest (i.e., BLyS or a fragment thereof) can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Examples of phage display methods that can be used to make the antibodies of the present invention include, but are not limited to, those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); 143 Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et aL., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280(1994); PCT application No. PCT/GB91/01 134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/1 1236; WO 95/15982; WO 95/20401; WO97/13844; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety. [02721 As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described below. Techniques to recombinantly produce Fab, Fab' and F(ab')2 fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864 869 (1992); Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties). [02731 To generate whole antibodies, PCR primers including VH or VL nucleotide sequences, a restriction site, and a flanking sequence to protect the restriction site can be used to amplify the VH or VL sequences in scFv clones. Utilizing cloning techniques known to those of skill in the art, the PCR amplified VH domains can be cloned into vectors expressing a VH constant region, e.g., the human gamma 4 constant region, and the PCR amplified VL domains carn be cloned into vectors expressing a VL constant region, e.g., human kappa or lambda constant regions. Preferably, the vectors for expressing the VH or VL domains comprise a promoter suitable to direct expression of the heavy and light chains in the chosen expression system, a secretion signal, a cloning site for the immunoglobulin variable domain, immunoglobulin constant domains, and a selection marker such as neomycin. The VH and VL domains may also be cloned into one vector expressing the necessary constant regions. The heavy chain conversion vectors and light chain conversion vectors are then co-transfected into cell lines to generate stable or transient cell lines that express full-length antibodies, e.g., IgG, using techniques known to those of skill in the art. 144 10274] Cell lines that express antibodies that comprise the VH and VL domains of scFvs of the invention have been deposited with the American Type Culture Collection ("ATCC") on the dates listed in Table 2 and given the ATCC Deposit Numbers identified in Table 2. The ATCC is located at 10801 University Boulevard, Manassas, VA 20110 2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure. Cell Line Corresponding SEQ ID ATCC ATCC Deposit scFv NO: Deposit Date Number NSO-B11-15 I050B11-15 24 PTA-3238 March 27, 2001 NSO-anti-BLyS-6D08-18 1006D08 2 PTA-3239 March 27, 2001 NSO- anti-BLyS-116A01-60 1116A01 327 PTA-3240 March 27,2001 1026C04K 1026C04-K 1563 PTA-3241 March 27,2001 1050A12 1050A12 12 PTA-3242 March 27, 2001 1050-B11 1050BIl 9 PTA-3243 March 27,2001 [02751 Accordingly, in one embodiment, the invention provides antibodies that comprise the VH and VL domains of scFvs of the invention. [0276] In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line NSO-B1 1-15. [02771 In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line NSO-anti-BLyS-6D08-18. [0278] In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line NSO- anti-BLyS-1 16A01-60. [02791 In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line 1026C04K. [02801 In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line 1050A12. [02811 In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line NSO-B 11. 145 [02821 In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a BLyS polypeptide. In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDRI, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a BLyS polypeptide by between 1% and 10% in a competitive inhibition assay. In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDRI, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table I to a BLyS polypeptide by between 1% and 10% in a competitive inhibition assay. [02831 In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a BLyS potypeptide by at least 10% and up to 20% in a competitive inhibition assay. (0284] In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDRI, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table I to a BLyS polypeptide by at least 20% and up to 30% in a competitive inhibition assay. [0285] In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDRI, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table I to a BLyS polypeptide by at least 30% and up to 40% in a competitive inhibition assay. (0286] In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table I to a BLyS polypeptide by at least 40% and up to 50% in a competitive inhibition assay. 146 [02871 In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR 1, VHCDR2, VHCDR3, VL CDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a BLyS polypeptide by at least 50% and up to 60% in a competitive inhibition assay. 102881 In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a BLyS polypeptide by at least 60% and up to 70% in a competitive inhibition assay. [02891 In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDRI, VHCDR2, VHCDR3, VLCDRI, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table I to a BLyS polypeptide by at least 70% and up to 80% in a competitive inhibition assay. 102901 In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a BLyS polypeptide by at least 80% and up to 90% in a competitive inhibition assay. 102911 In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table I to a BLyS polypeptide by at least 90% and up to 100% in a competitive inhibition assay. (02921 In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC deposit number PTA-3238 to a BLyS polypeptide. [02931 In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC deposit number PTA-3239 to a BLyS polypeptide. 147 102941 In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC deposit number PTA-3240 to a BLyS polypeptide. 102951 In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC deposit number PTA-3241 to a BLyS polypeptide. [02961 In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC deposit number PTA-3242 to a BLyS polypeptide. [02971 In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC deposit number PTA-3243 to a BLyS polypeptide. 102981 For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use human or chimeric antibodies. Completely human antibodies are particularly desirable for therapeutic treatment of human patients. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, W098/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety. In a specific embodiment, antibodies of the present invention comprise one or more VH and VL domains corresponding to the human scFvs of the invention and framework regions from another immunoglobulin molecule, preferably a human immunoglobulin molecule. In a specific embodiment, antibodies of the present invention comprise one or more CDRs corresponding to the human scFvs of the invention and framework regions from another immunoglobulin molecule, preferably a human immunoglobulin molecule. In other embodiments, an antibody of the present invention comprises one, two, three, four, five, six or more VL CDRs or VHI CDR. corresponding to one or more of the human scFvs referred to in Table 1, or fragments or variants thereof, and framework regions (and, optionally CDRs not derived from the scFvs in Table 1) from a human immunoglobulin 148 molecule. In a preferred embodiment, an antibody of the present invention comprises a VH CDR3, VL CDR3, or both, corresponding to the same scFv, or different scFvs referred to in Table 1, or fragments or variants thereof, and framework regions from a human immunoglobulin. [0299] A chimeric antibody is a molecule in which different portions of the antibody are derived from different immunoglobulin molecules such as antibodies having a variable region derived from a human antibody and a non-human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., . Immunol. Methods 125:191-202 (1989); U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Chimeric antibodies comprising one or more CDRs from human species and framework regions from a non-human immunoglobulin molecule (e.g., framework regions from a canine or feline immunoglobulin molecule) can be produced using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332). In a preferred embodiment, chimeric antibodies comprise a human CDR3 having an amino acid sequence of any one of the VH CDR3s or VL CDR3s referred to in Table 1, or a variant thereof, and non-human framework regions or human framework regions different from those of the frameworks in the corresponding scFv disclosed in Table 1. Often, framework residues in the framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) 149 [0300] Further, the antibodies of the invention can, in tum, be utilized to generate anti-idiotype antibodies that "mimic" BLyS polypeptides using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444 (1993); and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies of the invention which bind to BLyS and competitively inhibit the binding of BLyS to its receptor (as determined by assays well known in the art such as, for example, that disclosed, infra) can be used to generate antiidiotypes that "mimic" a BLyS ligand/receptor-binding domain and, as a consequence, bind to and neutralize BLyS receptors (e.g., TACl, BCMA, and TR20). Such neutralizing anti-idiotypes (including molecules comprising, or alternatively consisting of, antibody fragments or variants, such as Fab fragments of such anti-idiotypes) can be used in therapeutic regimens to neutralize BLyS. For example, such anti-idiotypic antibodies can be used to bind BLyS ligands/receptors, and thereby block BLyS mediated biological activity. Alternatively, anti-idiotypes that "mimic" a BLyS binding domain may bind to BLyS receptor(s) and induce BLyS receptor mediated signalling (e.g., activation of nuclear factor of activated T cells (NF-AT), nuclear factor-kappa B (NF-kappa B), and/or AP- 1). Such agonistic anti idiotypes (including agonistic Fab fragments of these anti-idiotypes) can be used in therapeutic regimens to induce or enhance BLyS receptor mediated signalling. For example, such anti-idiotypic antibodies can be used to bind BLyS ligands/receptors, and thereby stimulate BLyS mediated biological activity (e.g., B cell proliferation and/or immunoglobulin production). [03011 Once an antibody molecule of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) has been chemically synthesized or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, or more generally, a protein molecule, such as, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. Further, the antibodies of the present invention may be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification. 150 Polynucleotides Encoding an Antibody [03021 The invention provides polynucleotides comprising, or alternatively consisting of, a nucleotide sequence encoding an antibody of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof). The invention also encompasses polynucleotides that hybridize under high stringency, or alternatively, under intermediate or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides complementary to nucleic acids having a polynucleotide sequence that encodes an antibody of the invention or a fragment or variant thereof. 103031 The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. Since the amino acid sequences of the scFv antibodies and VH domains, VL domains and CDRs thereof, are known (as described in Table 1), nucleotide sequences encoding these antibodies can be determined using methods well known in the art, i.e., the nucleotide codons known to encode the particular amino acids are assembled in such a way to generate a nucleic acid that encodes the antibody, of the invention. Such a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR. [0304] Alternatively, a polynucleotide encoding an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes 151 the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art. [03051 Once the nucleotide sequence of the antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions. 103061 In a specific embodiment, one or more of the VH and VL domains referred to in Table 1, or fragments or variants thereof, is inserted within framework regions using recombinant DNA techniques known in the art. In a specific embodiment, one, two, three, four, five, six, or more of the CDRs referred to in Table 1, or fragments or variants thereof, is inserted within framework regions using recombinant DNA techniques known in the art. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions, the contents of which are hereby incorporated by reference in its entirety). Preferably, the polynucleotides generated by the combination of the framework regions and CDRs encode an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that specifically binds to BLyS. Preferably, as discussed supra, polynucleotides encoding variants of antibodies or antibody fragments having one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules, or antibody fragments or variants, lacking one or more intrachain 152 disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and fall within the ordinary skill of the art. Recombinant Expression of an Antibdy [03071 Recombinant expression of an antibody of the invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof (e.g., a heavy or light chain of an antibody of the invention or a portion thereof or a single chain antibody of the invention)), requires construction of an expression vector(s) containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule (e.g., a whole antibody, a heavy or light chain of an antibody, or portion thereof (preferably, but not necessarily, containing the heavy or light chain variable domain)), of the invention has been obtained, the vector(s) for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention (e.g., a whole antibody, a heavy or light chain of an antibody, a heavy or light chain variable domain of an antibody, or a portion thereof, or a heavy or light chain CDR, a single chain Fv, or fragments or variants thereof), operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89'01036; and U.S. Patent No. 5,122,464, the contents of each of which are hereby incorporated by reference in its entirety) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy chain, the entire light chain, or both the entire heavy and light chains. [03081 The expression vector(s) is(are) transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing 153 polynucleotide(s) encoding an antibody of the invention (e.g., whole antibody, a heavy or light chain thereof, or portion thereof, or a single chain antibody of the invention, or a fragment or variant thereof), operable linked to a heterologous promoter. In preferred embodiments, for the expression of entire antibody molecules, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below. [0309] A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected.with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include, but are not limited to, microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as Escherichia coli, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., Gene 45:101 (1986); Cockett et al., Bio/Technology 8:2 (1990)). 103101 In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being 154 expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the E. coli expression vector pUR278 (Ruther et al., EMBO 1. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101 3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione 5-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety. [03111 In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) may be used as a vector to express foreign genes. The virus grows in Spodopterafrugiperda cells. Antibody coding sequences may be cloned individually into non-essential regions (for example, the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example, the polyhedrin promoter). [03121 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region El or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 8 1:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both 155 natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see, e.g., Bittner et al., Methods in Enzymol. 153:51-544 (1987)). [03131 In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERY, BHK, Hela, COS, NSO, MDCK, 293, 3T3, W138, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and HsS78Bst. [03141 For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant ' plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into thcir chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compositions that interact directly or indirectly with the antibody molecule. [0315] A number of selection systems may be used, including but not limited to, the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), 156 hypoxanthineguanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:8 17 (1980)) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et aL., Nati. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. NatI. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 (Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62: 191-217 (1993); TIB TECH 11(5):155-2 15 (May, 1993)); and hygro, which confers resistance to hygromycin (Santerre et aL., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et aL. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli ei al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et aL., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties. [03161 . The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the coding sequence of the antibody, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)). [03171 The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, 157 both heavy and light chain polypeptides. In such situations, the light chain is preferably placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2 197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA. 103181 Once an antibody molecule of the invention has been produced by recombinant expression, it may be-purified by any method known in the art for purification of an immunoglobulin molecule, or more generally, for purification of a protein, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. Further, the antibodies of the present invention may be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification. Antibody Characterization 10319] Antibodies of the present invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be characterized in a variety of ways. In particular, antibodies and related molecules of the invention may be assayed for the ability to immunospecifically bind to BLyS or a fragment of BLyS (e.g., to the soluble form or the membrane-bound form of BLyS) using techniques described herein or routinely modifying techniques known in the art. BLyS or BLyS fragments that may be immunospecifically bound by the compositions of the invention include, but are not limited to, buman'BLyS (SEQ ID NOS:3228 and/or 3229) or BLyS expressed on human monocytes; murine BLyS (SEQ ID NOS:3230 and/or 3231) or BLyS expressed on murine monocytes; rat BLyS (either the soluble forms as given in . SEQ ID NOS:3232, 3233, 3234 and/or 3235 or in a membrane associated form, e.g., on the surface of rat monocytes); or monkey BLyS (e.g., the monkey BLyS polypeptides of SEQ ID NOS:3236 and/or 3237, the soluble form of monkey BLyS, or BLyS expressed on monkey monocytes) or fragments thereof. Preferably compositions of the invention bind human BLyS (SEQ ID NOS:3228 and/or 3229) or fragments thereof. Assays for the ability of the antibodies of the invention to immunospecifically bind BLyS or a fragment of BLyS may be performed in solution (e.g., Houghten, BiofTechniques 158 13:412-421(1992)), on beads (e.g., Lam, Nature 354:82-84 (1991)), on chips (e.g., Fodor, Nature 364:555-556 (1993)), on bacteria (e.g., U.S. Patent No. 5,223,409), on spores (e.g., Patent Nos. 5,571,698; 5,403,484; and 5,223,409), on plasmids (e.g., Cull et al., Proc. NatI. Acad. Sci. USA 89:1865-1869 (1992)) or on phage (e.g., Scott and Smith, Science 249:386-390 (1990); Devlin, Science 249:404-406 (1990); Cwirla et al., Proc. Natl. Acad. Sci. USA 87:6378-6382 (1990); and Felici, J. Mol. Biol. 222:301-310 (1991)) (each of these references is incorporated herein in its entirety by reference). Antibodies that have been identified to immunospecifically bind to BLyS or a fragment of BLyS can then be assayed for their specificity and affinity for BLyS or a fragment of BLyS using or routinely modifying techniques described herein or otherwise known in the art. [03201 The antibodies of the invention may be assayed for immunospecific binding to BLyS and cross-reactivity with other antigens by any method known in the art. In particular, the ability of an antibody to immunospecifically bind to the soluble form or membrane-bound form of BLyS and the specificity of the antibody, fragment, or variant for BLyS polypeptide from a particular species (e.g., murine, monkey or human, preferably human) may be determined using or routinely modifying techniques described herein or otherwise known in art. [03211 Immunoassays which can be used to analyze immunospecific binding and cross-reactivity include, but are not limited to, competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation). [0322] Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, 159 aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1 to 4 hours) at 40 degrees C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 40 degrees C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analys is. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel ct al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1. [0323] Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 32 P or 1251) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Cnrrent Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1. (03241 ELISAs comprise preparing antigen, coating the well of a 96-well microtiter plate with the antigen, washing away antigen that did not bind the wells, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the wells and incubating for a period of time, washing away unbound antibodies or non-specifically bound 160 antibodies, and detecting the presence of the antibodies specifically bound to the antigen coating the well. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, the detectable molecule could be the antigen conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase). One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1. [03251 The binding affinity of an antibody (including an scFv or other molecule comprising, or alternatively consisting of, antibody fragments or variants thereof) to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3 H or '1I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen.. The affinity of the antibody of the present invention for BLyS and the binding off-rates can be determined from the data by Scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, BLyS is incubated with an antibody of the present invention conjugated to a labeled compound (e.g., 3H or 1251) in the presence of increasing amounts of an unlabeled second anti-BLyS antibody. [03261 In a preferred embodiment, BlAcore kinetic analysis is used to determine the binding on and off rates of antibodies (including an scFv or other molecule comprising, or alternatively consisting of, antibody fragments or variants thereof) to BLyS, or fragments of BLyS. BlAcore kinetic analysis comprises analyzing the binding and dissociation of BLyS from chips with immobilized antibodies on their surface as described in detail in Examples 6, 12, 17 and 18, infra. [0327] The antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) can also be assayed for their ability to inhibit, increase, or not significantly alter, the binding of 161 BLyS to a BLyS receptor (e.g., TACI and BCMA) using techniques known to those of skill in the art. For example, cells expressing a receptor for BLyS (e.g., IM9, REH, ARH 77cells, Namalwa, and RPMI-8226 B cell tumor lines as wells as peripheral CD20+ B cells) can be contacted with BLyS in the presence or absence of an antibody, and the ability of the antibody to inhibit, increase, or not significantly alter, BLyS binding to the cells can be measured. BLyS binding to cells can be measured by, for example, flow cytometry or a scintillation assay. BLyS or the antibody can be labeled with a detectable compound such as a radioactive label (e.g., 3 2 p, 3 5 S, and 1251) or a fluorescent label (e.g., fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, _Q-phthaldehyde and fluorescamine) to enable detection of an interaction between BLyS and a BLyS receptor and/or BLyS and an antibody of the invention. Alternatively, the ability of antibodies of the invention to inhibit, increase, or not significantly alter, BLyS binding to a BLyS receptor can be determined in cell-free assays. For example, native or recombinant BLyS (e.g., that having the amino acid sequence of amino acids 134 - 285 of SEQ ID NO:3228) or a fragment thereof can be contacted with an antibody and the ability of the antibody to inhibit, increase, or not significantly alter, BLyS from binding to a BLyS receptor can be determined. Preferably, the antibody is immobilized on a solid support and BLyS or a BLyS fragment is labeled with a detectable compound. Alternatively, BLyS or a BLyS fragment is immobilized on a solid support and the antibody is labeled with a detectable compound. BLyS may be partially or completely purified (e.g., partially or completely free of other polypeptides) or part of a cell lysate. Further, the BLyS polypeptide may be a fusion protein comprising BLyS or a biologically active portion thereof and a domain such as an Immunoglobulin Fc or glutathionine-S-transferase. For example, amino acid residues 1-154 of TACI (GenBank accession number AAC51790), or 1-48 of BCMA (GenBank accession number NP_001183) may be fused to the F; region of an IgG molecule and used in a cell free assay to determine the ability of antibodies of the invention to inhibit, increase, or not significantly alter, BLyS binding to a BLyS receptor. Alternatively, BLyS can be biotinylated using techniques well known to those of skill in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, IL). [0328] The antibodies of the invention (including scFvs or other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), can also 162 be assayed for their ability to inhibit, stimulate, or not significantly alter, BLyS-induced B cell proliferation using techniques known to those of skill in the art. For example, B-cell proliferation can be assayed by 3 H-thymidine incorporation assays and trypan blue cell counts (see, e.g., Moore et al., Science 285: 260-263 (1999)). Further, the antibodies of the invention, or fragments or variants thereof, can be assayed for their ability to block, stimulate, or not significantly alter, BLyS-induced activation of cellular signaling molecules and transcription factors such as calcium-modulator and cyclophilin ligand ("CAML"), calcineurin, nuclear factor of activated T cells transcription factor ("NF-AT"), nuclear factor-kappa B ("NF-kappa B"), and AP-I using techniques known to those of skill in the art (see, e.g., von Bulow and Bram, Science 278:138-141(1997)). For example, NF-AT activity can be determined by electromobility gel shift assays, by detecting the expression of a protein known to be regulated by NF-AT (e.g., IL-2 expression), by detecting the induction of a reporter gene ( e.g., an NF-AT regulatory element operably linked to a nucleic acid encoding a detectable marker such as luciferase, beta-galactosidase or chloramphenicol acetyltransferase (CAT)), or by detecting a cellular response (e..g., cellular differentiation, or cell proliferation). [0329] The antibodies of the invention, or fragments or variants thereof can also be assayed for their ability to neutralize, enhance, or not significantly alter, BLyS activity. For example, antibodies or fragments or variants thereof, may be routinely tested for their ability to inhibit BLyS from binding, to cells expressing the receptor for BLyS (see Example 3, infra). Selection and Screening for Antibodies that Immunospecifically Bind to Soluble BLyS [03301 Antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be screened in a variety of assays to identify those antibodies that immunospecifically bind to the soluble form of BLyS. In one particular assay, antibodies that bind to the biotinylated soluble form of BLyS in solution are captured on streptavidin coated magnetic beads. This assay may be relatively applied to identify antibodies of the invention that neutralize and/or bind to BLyS. Additionally, antibodies may be assayed in neutralization assays described herein or otherwise known in the art (see Example 3, infra). For example, 163 antibodies may be tested for their ability to inhibit soluble BLyS (e.g., biotinylated BLyS) from binding to IM9 cells. In this assay, labeled soluble BLyS (e.g., biotinylated BLyS) is incubated with candidate anti-BLyS antibodies to allow for the formation of BLyS -anti BLyS antibody complexes. Following incubation, an aliquot of the BLyS-anti-BLyS antibody sample is added to IM9 cells. The binding of soluble BLyS may be determined using techniques known in the art. For example, the binding of biotinylated BLyS to IM9 cells may be detected using a fluorimeter following the addition of streptavidin-delfia. Biotinylated BLyS, if it is not bound by antibodies that neutralize BLyS, binds to the cells is detected. Thus, an antibody that decreases the amount of bio-BLyS that binds to IM-9 cells (relative to a control sample in which the BLyS had been preincubated with an irrelevant antibody or no antibody at all) is identified as one that binds to and neutralizes the soluble form of BLyS. In another assay, antibodies are screened using ELISAs for those antibodies that bind to biotinylated soluble BLyS, but do not bind membrane-bound BLyS, such as, for example, BLyS on membranes from U937 cells (see Examples 2 and 9, infra). In these assays, soluble BLyS (e.g., biotinylated BLyS) and membrane-bound BLyS (e.g., on U937 membranes) are incubated in separate samples with the same antibodies and those antibodies that bind to the soluble BLyS (biotinylated BLyS), but not membrane-bound BLyS (e.g., on U937 membranes) are captured and identified. 103311 Antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be tested to identify those antibodies that do not cross-react with APRIL, endokine-alpha, VEGI, TRAIL, TNF-alpha, TNF-beta, Fas-L, LIGHT, and PBS (see Example 4, infra). Antibodies may also be tested for their affinity for BLyS using, for example, BIAcore analysis (see Examples 6, 12, 17 and 18 infra). Antibodies may also be tested for their ability to stimulate, inhibit, or not alter, BLyS-induced immunoglobulin production and/or B-cell proliferation using techniques known to those of skill in the art. For example, human B-cells, BLyS and antibodies may be incubated together in 96 well plates and sH thymidine incorporation may be measured using a scintillation counter. Selection and Screening for Antibodies that Immunospecifically Bind to Membrane bound BLyS 164 [03321 Antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be screened in a variety of assays to identify those antibodies that immunospecifically bind to the membrane-bound form of BLyS In one particular assay, antibodies that bind to BLyS on U937 membranes or immobilized histidine-tagged BLyS are captured. Other cell lines that express BLyS that might be useful for testing antibody binding to membrane-bound form of BLyS include, K-562, HL-60 and THP-1 cells. In another assay, antibodies are screened using ELISAs for those antibodies (or antibody fragments or variants) that bind to BLyS on U937 membranes or to histidine-tagged BLyS. In this assay, antibodies are added to 96 well plates coated with U937 membranes or histidine-tagged BLyS and those antibodies or antibody fragments or variants that bind to the U937 membranes or histidine-tagged BLyS are captured. In another assay, antibodies are screened using ELISAs for those antibodies (or antibody fragments or variants thereof) that do not bind to biotinylated BLyS (soluble BLyS) but bind to membrane-bound BLyS, such as, for example, that on membranes from J937 cells (see Example 2, infra). In these assays, soluble BLyS (e.g., biotinylated BLyS) and membrane-bound BLyS (e.g., on U937 membranes) are incubated in separate samples with the same antibodies (or antibody fragments or variants) and those antibodies (or antibody fragments or variants) that do not bind to the soluble BLyS (biotinylated BLyS), but bind the membrane-bound BLyS (e.g., on U937 membranes) are captured and identified. In other assays, antibodies are screened using ELISAs to determine which of the antibodies (or antibody fragments or variants) that bind to histidine-tagged BLyS or membranes from U937 cells do not cross-react with APRIL, endokine-alpha, VEGI, TRAIL, TNF-alpha, TNF-beta, Fas-L, LIGHT, and PBS (See Example 4, infra). ELISAs can also be used to determine which of the antibodies (or antibody fragments or variants) that bind to histidine-tagged BLyS or membranes from U937 cells bind to BLyS in the presence of TNF-alpha (see Example 4, infra). Antibodies or fragments or variants thereof that immunospecifically bind to the membrane-bound form of BLyS may also be tested for their affinity for histidine-tagged BLyS using high throughput BlAcore analysis (see Example 14, infra). [0333] Additionally, antibodies of the invention may be screened against cells engineered to express an "uncleavable" form of BLyS in order to determine their specificity for the membrane-bound form of BLyS. Mutations in BLyS which may 165 achieve this result include, but are not limited to, the mutation or deletion of amino acid residues Lys-132 and/or Arg-133 of the BLyS sequence shown in SEQ ID NO:3228. A typical mutagenesis might include mutation of one or both of residues Lys- 132 or Arg- 133 to alanine residues. Cells expressing such an "uncleavable" form of BLyS provide a profound reagent to use in assaying the ability of antibodies to bind the membrane-bound form of BLyS. Selection and Screening for Antibodies that 1mmunospecifically Bind to Soluble and Membrane-bound BLyS [0334] Antibodies of the invention (including scFvs and other molecules comprising, or alternately consisting of, antibody fragments or variants) may be screened in a variety of assays to identify those antibodies or antibody fragments or variants that immunospecifically bind to the soluble form and membrane-bound form of BLyS. In one particular assay, antibodies that bind to immobilized BLyS are captured. In another assay, antibodies are screened using ELISAs for those antibodies (or antibody fragments or variants) that inhibit the binding of soluble BLyS (e.g. soluble bio-BLyS) to IM-9 cells as described supra. In other assays, antibodies are screened using ELISAs for those antibodies that bind to membranes from U937 cells. Additionally, further ELISA assays may be performed using techniques known in the art to determine which antibodies do not cross-react with APRIL, endokine-alpha, VEGI, TRAIL, TNF-alpha, TNF-beta, Fas-L, LIGHT, and PBS, or those antibodies that bind to BLyS in the presence of TNF-alpha (see Example 4 infra). Antibodies may be assayed in neutralization assays using techniques described herein or otherwise known in the art. Antibodies that immunospecifically bind to the soluble and membrane-bound forms of BLyS may also be tested for their affinity for BLyS using high-throughput BlAcore analysis. Antibody Coniugates [03351 The present invention encompasses antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), recombinantly fused or chemically conjugated (including both covalent and non covalent conjugations) to a heterologous polypeptide (or portion thereof, preferably at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at 166 least 90 or at least 100 amino acids of the polypeptide) to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. For example, antibodies of the invention may be used to target heterologous polypeptides to particular cell types (e.g., cells of monocytic lineage and B-cells), either in vitro or in vivo, by fusing or conjugating the heterologous polypeptides to antibodies of the invention that are specific for particular cell surface antigens (e.g., membrane-bound BLyS on cells of monocytic lineage) or which bind antigens that bind particular cell surface receptors (e.g., TACI and/or BCMA located on B cells). Antibodies fused or conjugated to heterologous polypeptides may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/2 1232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446 2452 (1991), which are incorporated by reference in their entireties. [0336] In one embodiment, a fusion protein comprises a polypeptide having an amino acid sequence of any one of the VHI domains referred to in Table 1, and a heterologous polypeptide. In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VH CDRI s referred to in Table 1, and a heterologous polypeptide. In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VH CDR2s referred to in Table 1, and a heterologous polypeptide. In a preferred embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VH CDR3s referred to in Table 1 (i.e., SEQ ID NOS:2129 - 3227), and a heterologous polypeptide. [0337] In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VL domains referred to in Table 1, and a heterologous polypeptide. In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VL CDRls referred to in Table 1, and a heterologous polypeptide. In yet another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VL CDR2s referred to in Table 1, and a heterologous polypeptide. In a preferred embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VL CDR3s referred to in Table 1, and a heterologous polypeptide. 167 [03381 In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VH domains referred to in Table 1, and one or more VL domains referred to in Table 1, and a heterologous polypeptide. In another embodiment, a fusion protein of the present invention comprises a polypeptide having the amino acid sequence of any one of the VH CDRs referred to in Table 1, and any one of the VL CDRs referred to in Table 1, and a heterologous polypeptide. [0339] The present invention further includes compositions comprising, or alternatively consisting of, heterologous polypeptides fused or conjugated to antibody fragments. For example, the heterologous polypeptides may be fused or conjugated to a Fab fragment, Fd fragment, Fv fragment, F(ab) 2 fragment, or a portion thereof. Methods for fusing or conjugating polypeptides to antibody portions are known in the art. See, e.g., U.S. Patent-Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 9 1/06570; Ashkenazi et aL., Proc. Nati. Acad. Sci. USA 88: 10535-10539 (1991); Zheng et al., J. Immunol. 154:5590 5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341 (1992) (said references incorporated by reference in their entireties). 103401 - Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of antibodies (including scFvs and other molecules comprising , or alternatively consisting of, antibody fragments or variants thereof), such methods can be used to generate antibodies with altered activity (e.g., antibodies with higher affinities and lower dissociation rates). See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724 33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, polyaucleotides encoding antibodies of the invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more portions of a polynucleotide encoding an antibody which portions 168 immunospecifically bind to BLyS may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. [03411 Moreover, the antibodies of the present invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), can be fused to marker sequences, such as a polypeptides to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa histidine polypeptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein . (Wilson et al., Cell 37:767 (1984)) and the "flag" tag (DYKDDDDK, (SEQ ID No: 3238) Stratagene, La Jolla, CA). 103421 The present invention further encompasses antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants -thereof), conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor or prognose the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include, but are not limited to, various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include, but are not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include, but are not limited to, streptavidinlbiotin and avidin/biotin; examples of suitable fluorescent materials include, but are not limited to, 169 umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes, but is not limited to, luminol; examples of bioluminescent materials include, but are not limited to, luciferase, luciferin, and aequorin; and examples of suitable radioactive material include, but are not limited to, iodine (m3y1, 1, '23, mIi), carbon (1 4 C), sulfur ( 5 S), tritium (H), indium (""'In, " 3 "In, 'zIn, '"In), and technetium ( 9 fc, ""Tc), thallium (2"Ti), gallium (mGa, 'Ga), palladium ('"Pd), molybdenum ("Mo), xenon (mXe), fluorine (' 8 F), '-Sm, '"Lu, *Gd, 1 49 pM, '40L, '75Yb, '"Ho, "Y, 41 Sc, '"Re, "gRe, 42Pr, '05Rh, "Ru, "Ge, - 5 Co,."Zn, "Sr, 2 P, '5Gd, '"Yb, - 1 Cr, 54Mn, "Se, "3Sn, and "Tin. 103431 Further, an antibody of the invention (including an scFv or other molecule comprising, or alternatively consisting of, antibody fragments or variants thereof), may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, 213 Bi. In specific embodiments, antibodies of the invention are attached to macrocyclic chelators useful for conjugating radiometal ions, including but not limited to, "'In, ""Lu, 9Y, '"Ho, and l"Sm, to polypeptides. In preferred embodiments, the radiometal ion associated with the macrocyclic chelators attached to antibodies of the invention is .'In. In preferred embodiments, the radiometal ion associated with the macrocyclic chelators attached to antibodies of the invention is "Y. In specific embodiments, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-NN',N",N"'-tetraacetic acid (DOTA). In other specific embodiments, the DOTA is attached to the antibody of the invention via a linker molecule. Examples of linker molecules useful for conjugating DOTA to a polypeptide are commonly known in the art - see, for example, DeNardo et al., Clin Cancer Res. 4(10):2483-90, 1998; Peterson et al., Bioconjug. Chem. 10(4):553-7, 1999; and Zimmerman et al, Nucl. Med. Biol. 26(8):943-50, 1999 which are hereby incorporated by reference in their entirety. [0344] A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells and includes such molecules as small molecule toxins and enzymatically active 170 toxins of bacterial, fungal, plant, or animal origin, or fragments thereof. Examples include, but are not limited to, paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide (VP-16), tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, thymidine kinase, endonuclease, RNAse, and puromycin and frragments, variants or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5 fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cisdichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine), improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretanine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide trinethylolomelamine, chlornaphazine, cholophosphamide, estramustine, ifosfamide, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, chlorcizotocin, fotemustine, nimustine, ranimustine, aclacinomysins, azaserine, cactinonycin, calichearnicin, carabicin, carminomycin, carzinophilin, chromomycins, detoiubicin, 6-diazo-5-oxo-Lenorleucine, epirubicin, esorubicin, idarubicin, marcellomycin, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, quelamycin, rodorubicin, streptonigrin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pteropterin, trimetrexate, fludarabine, thiamiprine, ancitabine, azacitidine, 6-azauridine, carmofur, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone, 171 aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, dernecolcine, diaziquone, elfornithine, elliptiniurn acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, mitoguazone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllinic acid, 2-ethylhydrazide, procarbazine, PSKO, razoxane, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2, 2',2"-tri chlorotriethylamine, urethan, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside ("Ara-C"), taxoids, e.g. paclitaxel (TAXOL", Bristol-Myers Squibb Oncology, Princeton, NJ) doxetaxel (TAXOTERE", Rh6ne-Poulenc Rorer, Antony, France), gemcitabine, ifosfamide, vinorelbine, navelbine, novantrone, teniposide, aminopterin, xeloda, ibandronate, CPT-I 1, topoisomerase inhibitor RFS 2000, difluoromethylornithine (DMFO), retinoic acid, esperamicins, capecitabine, and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4 hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, toremifene (Fareston), and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin, and pharmaceutically acceptable salts, acids or derivatives of any of the above. [03451 Techniques known in the art may be applied to label antibodies of the invention. Such techniques include, but are not limited to, the use of bifunctional conjugating agents (see e.g., U.S. Patent Nos. 5,756,065; 5,714,631; 5,696,239; 5,652,361; 5,505,931; 5,489,425; 5,435,990; 5,428,139; 5,342,604; 5,274,119; 4,994,560; and 5,808,003; the contents of each of which are hereby incorporated by reference in its entirety) and direct coupling reactions (e.g., Bolton-Hunter and Chloramine-T reaction). 103461 The antibodies of the invention which are conjugates can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such 172 proteins may include, but are not limited to, for example, a toxin such as abrin, ricin A, alpha toxin, pseudomonas exotoxin, or diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin; a protein such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF-alpha, TNF beta, AIM I (see, International Publication No. WO 97/33899), AIM II (see, International Publication No. WO 97/34911), Fas Ligand (Takahashi et al., Int. Immunol., 6:1567-1574 (1994)), VEGI (see, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-I (IL- 1), interleukin-2 (IL-2), interleukin 6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), or other growth factors. [03471 Antibodies of the invention.(including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. 103481 Techniques for conjugating a therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal AntibodiesAnd Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A . Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev. 62:119-58 (1982). [03491 Alternatively, an antibody of the invention can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety. 173 103501 An antibody of the invention (including an scFv or and other molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof), with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic. Use of Antibodies for Epitone Mapping [03511 The present invention provides antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that can be used to identify epitopes of BLyS. In particular, the antibodies of the present invention can be used to identify epitopes of human BLyS (SEQ ID NOS:3228 and/or 3229) or BLyS expressed on human monocytes; murine BLyS (SEQ ID NOS:3230 and/or 3231) or BLyS expressed on marine monocytes; rat BLyS (either the soluble forms as given in SEQ ID NOS:3232, 3233, 3234 and/or 3235 or in a membrane associated form, e.g., on the surface of rat monocytes); or monkey BLyS (e.g., the monkey BLyS polypeptides of SEQ ID NOS:3236 and/or 3237, the soluble form of monkey BLyS, or BLyS expressed on monkey monocytes)using techniques described herein or otherwise known in the art. Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211.) Diagnostic Uses of Antibodies [03521 Labeled antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor diseases and/or disorders associated with the aberrant expression and/or activity of BLyS or BLyS receptor. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample from an individual using one or more antibodies of the invention that inimunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase or decrease in the assayed level of BLyS compared to the standard level of BLyS is indicative of aberrant expression. 174 [03531 By "biological sample" is intended any fluids and/or cells obtained from an individual, body fluid, body tissue, body cell, cell line, tissue culture, or other source which may contain BLyS protein or mRNA. Body fluids include, but are not limited to, sera, plasma, urine, synovial fluid, spinal fluid, saliva, and mucous. Tissues samples may be taken from virtually any tissue in the body. Tissue samples may also be obtained from autopsy material. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source. 103541 The invention also provides for the detection of aberrant expression of . BLyS receptor comprising (a) assaying the expression of BLyS receptor in a biological sample from an individual using one or more antibodies or fragments or variants thereof that immunospecifically binds only to soluble BLyS, but does not inhibit BLyS /BLyS receptor binding. Such an antibody, by way of an example that is not to be construed as limiting, would be one that is able to capture a biotinylated BLyS from solution (see Example 8), but that would not prevent BLyS from binding to IM-9 cells (see Example 3). and (b) comparing the level of BLyS receptor with a standard level of BLyS receptor, e.g., in normal tissue or cell samples, whereby an increase or decrease in the assayed level of BLyS receptor compared to the standard level of BLyS receptor is indicative of aberrant expression. [03551 Antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor autoimmune disorders and/or immunodeficiencies, and/or diseases or conditions associated therewith. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample from an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase or decrease in the assayed level of BLyS compared to the standard level of BLyS is indicative of an autoimmune disorder or disease and/or an immunodeficiency. In specific embodiments, an increase in the assayed level of BLyS is indicative of an autoimmune disorder or disease. In other specific embodiments, a decrease in the assayed level of BLyS is indicative of an immunodeficiency. 175 [0356] Antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) which specifically bind to BLyS but, do not inhibit BLyS/BLyS receptor binding can be used for diagnostic purposes to detect, diagnose, progncise, or monitor autoimmune disorders and/or immunodeficiencies, and/or diseases or conditions associated therewith. The invention provides for the detection of aberrant expression of BLyS receptor comprising: (a) assaying the expression of BLyS receptor in a biological sample from an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS receptor with a standard level of BLyS receptor, e.g., in normal biological samples, whereby an increase or decrease in the assayed level of BLyS receptor compared to the standard level of BLyS receptor is indicative of an autoimmune disorder or disease and/or an immunodeficiency. In specific embodiments, an increase in the assayed level of BLyS receptor is indicative of an autoimmune disorder or disease. In other specific embodiments, a decrease in the assayed level of BLyS receptor is indicative of an immunodeficiency. [03571 Autoimmune disorders, diseases, or conditions that may be detected, diagnosed, prognosed, or monitored using the antibodies of the invention include, but are not limited to, autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmune neutropenia, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, gluten-sensitive enteropathy, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g., IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia, Polyendocrinopathies, Purpura (e.g., Henloch-Scoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, myocarditis, IgA glomerulonephritis, dense deposit disease, rheumatic heart disease, Guillain-Barre Syndrome, diabetes mellitus (e.g. Type I diabetes mellitus or insulin dependent diabetes mellitis), juvenile onset diabetes, and autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis, systemic lupus erhythematosus, discoid lupus, Goodpasture's syndrome, Pemphigus, Receptor autoimmunities such as, for example, (a) Graves' Disease , (b) Myasthenia Gravis, and (c) insulin resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, schleroderma with anti-collagen antibodies, mixed connective tissue disease, 176 polymyositis/dermatomyositis, pernicious anemia (Addison's disease), idiopathic Addison's disease, infertility, glomerulonephritis such as primary glomerulonephritis and IgA nephropathy, bullous pemphigoid, Sj6gren's syndrome, diabetes millitus, and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis), chronic active hepatitis, primary biliary cirrhosis, other endocrine gland failure, vitiligo, vasculitis, post-MI, cardiotomy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, and other inflammatory, granulomatous, degenerative, and atrophic disorders and other disorders such as inflammatory skin diseases including psoriasis and sclerosis, responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis), respiratory distress syndrome (including adult respiratory distress syndrome, ARDS), meningitis, encephalitis, colitis, allergic conditions such as eczema and other conditions involving infiltration of T cells and chronic inflammatory responses, atherosclerosis, leukocyte adhesion deficiency, Reynaud's syndrome, and immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes typically found in tuberculosis, sarcoidosis, granulomatosis and diseases involving leukocyte diapedesis, central nervous system (CNS) inflammatory disorder, multiple organ injury syndrome, antigen-antibody complex mediated diseases, anti-glomerular basement membrane disease, Lambert-Eaton myasthenic syndrome, Beheet disease, giant cell arteritis, immune complex nephritis, IgA nephropathy, IgM polyneuropathies or autoimmune thrombocytopenia etc. (03581 In specific embodiments, the present invention encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with hypergammaglobulinemia (e.g., AIDS, autoimmune diseases, and some immunodeficiencies). In other specific embodiments, the present invention encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with hypogammaglobulinemia (e.g., an immunodeficiency). [03591 Immunodeficiencies ihat may be detected, diagnosed, prognosed, or monitored using the antibodies of the invention include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase 177 deficiency (ADA deficiency), X-linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-.linked infantile agammaglobulinemia, acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysganmaglobulinemia, hypogarnmaglobulinemia, transient hypogammaglobulinemia of infancy, unspecified hypogammaglcibulinemia, agammaglobulinemia, common variable immunodeficiency (CVID) (acquired), Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic alymphoplasia-aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lympho proliferative syndrome (XLP), Nezelof syndrome combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency. [0360] Elevated levels of soluble BLyS have been observed in the serum of patients with Systemic Lupus Erythematosus (SLE). In comparing the sera of 150 SLE patients with that of 38 control individuals, it was found that most of the SLE patients had more than 5ng/ml of serum BLyS, more than 30% of SLE patients had levels greater than lOng/mi, and approximately 10% of SLE patients had serum BLyS levels greater than 20ng/ml. In contrast, the majority of normal controls had BLyS levels less than 5ng/ml, and less than 10% had levels higher than lOng/mi. The elevated levels of BLyS protein in sera is present in the soluble form and has biologic activity as assayed by the ability to stimulate anti-IgM treated B cells in vitro. SLE patients with more than 15ng/ml serum BLyS were also found to have elevated levels of anti-dsDNA antibodies compared to both normal controls and SLE patients with less than 5ng/ml of serum BLyS.(unpublished data). [0361] In addition the serum of two subgroups of patients which were positive for anti-nuclear antibodies (ANA+) but did not meet the formal requirements of the American College of Rheumatology (ACR) for classification of SLE were analyzed for BLyS levels. 178 The first subgroup of sera was ANA+ sera that came from patients who did not present with the clinical impression of SLE. This group had only slightly elevated levels of BLyS (-9ng/ml BLyS). The second subgroup however, which was ANA+ sera from patients who presented with the clinical impression of SLE, had significantly increased BLyS levels (- 5ng/ml). These results suggest that an elevated level of BLyS precedes the formal fulfillment of the ACR criteria. The ACR criteria are described in Tan, E.M., et al, Arthritis and Rheumatism 25:1271 -- 1277 (1982). [0362] Thus in specific embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor Systemic Lupus Erythematosus or conditions associated therewith. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level.of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of SLE. [0363] In other specific embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor IgA nephropathy or conditions associated therewith. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of IgA nephropathy. [0364] In other specific embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor Sjdgren's Syndrome or conditions associated therewith. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby 179 an increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of Sj6gren's Syndrome. [03651 In other specific embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor HIV infection or conditions associated therewith (e.g. AIDS). The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample of an individual using one or more antibodies of the invention that imiunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase in the assayed level of BLyS compared to the standard lcvel of BLyS is indicative of HIV infection. (03661 In other specific embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor Myasthenia Gravis or conditions associated therewith. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of Myasthenia Gravis. [03671 In other specific embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor idiopathic thrombocytopenic purpura (ITP) or conditions associated therewith. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of idiopathic thrombocytopenic purpura (ITP). [03681 In other specific embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor hemolytic anemia or conditions associated therewith. The invention 180 provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of hemolytic anemia. [03691 . In other specific embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor thyroiditis or conditions associated therewith. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of thyroiditis. [0370] In other specific embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor Goodpasture's syndrome or conditions associated therewith. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of Goodpasture's syndrome. 103711 In other specific embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor multiple sclerosis or conditions associated therewith. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological ;ample of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an 181 increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of multiple sclerosis. [03721 In additional embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor Rheumatoid Arthritis. The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample (e.g., serum and synovial fluid) of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of Rheumatoid arthritis. 10373] In additional embodiments, antibodies of the invention which specifically bind to BLyS can be used for diagnostic purposes to detect, diagnose, prognose, or monitor an immune-based rheumatologic disease, (e.g., SLE, rheumatoid arthritis, CREST syndrome (a variant of scleroderma characterized by calcinosis, Raynaud's phenomenon, esophageal motility disorders, *clerodactyly, and telangiectasia.), Seronegative spondyloarthropathy (SpA), Polymyositis/dermatomyositis, Microscopic polyangiitis, Hepatitis C-associated arthritis, Takayasu's arteritis, and undifferentiated connective tissue disorder). The invention provides for the detection of aberrant expression of BLyS comprising: (a) assaying the expression of BLyS in a biological sample (e.g., serum and synovial fluid) of an individual using one or more antibodies of the invention that immunospecifically binds to BLyS; and (b) comparing the level of BLyS with a standard level of BLyS, e.g., in normal biological samples, whereby an increase in the assayed level of BLyS compared to the standard level of BLyS is indicative of monitor an immune-based rheumatologic disease. [0374] It has been observed, that serum BLyS levels inversely correlate with nephrotic range proteinuria (>3gm proteinuria in a 24 hour urine collection) using a sample of 71 SLE patients (p=O.O 19). Proteinuria was determined in 71 SLE patients within one month of phlebotomy for serum BLyS determination. Serum BLyS was classified as low, normal, or high based on the 5*' through 95th percentiles for normal controls. Nephrotic-range proteinuria was inversely correlated with serum Neutrokine alpha levels. Thus, in specific embodiments, serum levels of BLyS (determined using one 182 or more antibodies of the present invention) in individuals diagnosed with an immune based rheumatologic disease (e.g., SLE, rheumatoid arthritis, CREST syndrome (a variant of scleroderma characterized by calcinosis, Raynaud's phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia.), seronegative spondyloarthropathy (SpA), polymyositis/dermatomyositis, microscopic polyangiitis, hepatitis C-asociated arthritis, Takayasu's arteritis, and undifferentiated connective tissue disorder) may be used to determine, diagnose, prognose, or monitor the severity of certain aspects or symptoms of the disease, such as nephrotic-range proteinuria. [03751 In another specific embodiment, antibodies of the invention are used to diagnose, prognose, treat, or prevent conditions associated with CVID, including, but not limited to, conditions associated with acute and recurring infections (e.g., pneumonia, bronchitis, sinusitis, otitis media, sepsis, meningitis, septic arthritis, and osteomyelitis), chronic lung disease, autoimmunity, granulomatous disease, lymphoma, cancers (e.g., cancers of the breast, stomach, colon, mouth, prostate, lung, vagina, ovary, skin, and melanin forming cells (i.e. melanoma), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, and ulcerative proctitis), malabsorption, Hodgkin's disease, and Waldenstrom's macroglobulinemia. [03761 The invention provides a diagnostic assay for diagnosing or prognosing a disease or disorder, comprising: (a) assaying for the level of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically bind to BLyS; and (b) comparing the level of BLyS with a standard BLyS level, e.g., in a biological sample from a patient without the disease or disorder, whereby an increase or decrease in the assayed BLyS level compared to the standard level of BLyS is indicative of a particular disease or disorder. With respect to cancer, the presence of a relatively high amount of BLyS in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer. [03771 In specific embodiments, the presence of a relatively high amount of 183 membrane-bound BLyS in a biological sample is indicative of monocytic cell related leukemias or lymphomas, such as, for example acute myelogenous leukemia and/or the severity thereof. [03781 In other specific embodiments, the presence of a relatively high amount of BLyS receptor in a biological sample (as determined using antibodies of the invention that bind to soluble BLyS, but do not inhibit BLyS/BLyS receptor binding) is indicative of B cell related leukemias or lymphomas (e.g., chronic lymphocytic leukemia, multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease), and/or the severity thereof. [0379] In specific embodiments, the invention provides a diagnostic assay for diagnosing or prognosing Systemic Lupus Erythematosus, comprising: (a) assaying for the level of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically bind to BLyS; and (b) comparing the level of BLyS with a standard BLyS level, e.g., in a biological sample from a patient without Systemic Lupus Erythematosus, whereby an increase in the assayed BLyS level compared to the standard level of BLyS is indicative of Systemic Lupus Erythematosus. [0380] In specific embodiments, the invention provides a diagnostic assay for diagnosing or prognosing a Rheumatoid Arthritis, comprising: (a) assaying for the level of BLyS in a biological sample of an individual using one or more antibodies of the invention that immunospecifically bind to BLyS; and (b) comparing the level of BLyS with a standard BLyS level, e.g., in a biological sample from a patient without Rheumatoid Arthritis, whereby an increase or decrease in the assayed BLyS level compared to the standard level of BLyS is indicative of Rheumatoid Arthritis. [0381] The invention provides a diagnostic assay for diagnosing or prognosing a disease or disorder, comprising: (a) assaying for the level of BLyS receptor in cells or a tissue sample of an individual using one or more antibodies of the invention that immunospecifically binds only to soluble BLyS, but does not neutralize BLyS /BLyS receptor binding; and (b) comparing the level of BLyS receptor with a standard BLyS receptor level, e.g., in a tissue sample from a patient without the disease or disorder, whereby an increase or decrease in the assayed BLyS receptor level compared to the standard level of BLyS receptor is indicative of a particular disease or disorder. With respect to cancer, the presence of a relatively high amount of BLyS receptor in biopsied tissue from an individual may indicate a predisposition for the development of the disease, 184 or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer. [0382] Antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) can be used to assay protein levels in a biological sample using classical immunohistological methods as described herein or as known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell .Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immnunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, alkaline phosphatase, and horseradish peroxidase; radioisotopes, such as iodine (1211, 1231, 1251, 1311), carbon (1 4 C), sulfur ( 35 S), tritium ( 3 H), indium ( ".In, 1 2 1n , "3mIn, " 5 "'In), technetium (s 9 Tc,""'Tc), thallium ("Ti), gallium ("Ga, Ga), palladium ("Pd), molybdenum ("Mo), xenon ( 33 Xe), fluorine (!"F), 13Sm, 'mLu, ' 59 Gd, '*Pm, 1"La, ' 75 Yb, '6Ho, "Y, "Sc, '"Re, '8Re, "'Pr, 'Rh, and "Ru; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and hiotin. [0383] One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of BLyS or BLyS receptor in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled antibody of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically binds to BLyS; b) waiting for a time interval following the administering for permitting the labeled antibody to preferentially concentrate at sites in the subject where BLyS is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled antibody in the subject, such that detection of labeled antibody or fragment thereof above the background level and above or below the level observed in a person without the disease or disorder indicates that the subject has a particular disease or 185 disorder associated with aberrant expression of BLyS or BLyS receptor. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system. 103841 It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99 Tc. The labeled antibody will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982). [03851 Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days. [03861 In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disorder, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc. [03871 Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography. [0388] In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive 186 scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI). Immunophenotypine [0389] The antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be utilized for immunophenotyping of cell lines and biological samples by their BLyS expression or BLyS receptor expression. Various techniques can be utilized using antibodies, fragments, or variants of the invention to screen for cellular populations (i.e., immune cells, particularly monocytic cells or B-cells) expressing BLyS or BLyS receptor, and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (see, e.g., U.S. Patent 5,985,660; and Morrison et al., Cell, 96:737-49 (1999)). [0390] These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e., minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHiD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood. [03911 In one embodiment, antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) are used to identify cells of monocytic or B cell origin. Therapeutic Uses of Antibodies [0392] The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention and nucleic acids encoding antibodies (and 187 anti-idiotypic antibodies) of the invention as described herein. The antibodies of the invention can be used to treat, ameliorate or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of BLyS or BLyS receptor, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant BLyS expression and/or activity or aberrant BLyS receptor expression and/or activity includes, but is not-limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein. [03931 Antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that function as agonists or antagonists of BLyS, preferably of BLyS-induced signal transduction, can be administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant BLyS expression, lack of BLyS function, aberrant BLyS receptor expression, or lack of BLyS receptor function. For example, antibodies of the invention which disrupt the interaction between BLyS and its receptor may be administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant BLyS expression, excessive BLyS function, aberrant BLyS receptor expression, or excessive of BLyS receptor function. Antibodies of the invention which do not prevent BLyS from binding its receptor but inhibit or downregulate BLyS-induced signal transduction can be administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant BLyS expression, excessive BLyS function, aberrant BLyS receptor expression, or excessive BLyS receptor function. In particular, antibodies of the present invention which prevent BLyS-induced signal transduction by specifically recognizing the unbound BLyS, receptor-bound BLyS or both unbound and receptor-bound BLyS can be administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant BLyS expression, excessive BLyS function, aberrant BLyS receptor expression, or excessive BLyS receptor function. The ability of an antibody of the invention to inhibit or downregulate BLyS-induced signal transduction may be determined by techniques described herein or otherwise known in the art. For example, BLyS induced receptor activation and the activation of signaling molecules can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or a 188 signaling molecule by immunoprecipitation followed by western blot analysis (for example, as described herein). [03941 In a specific embodiment, an antibody of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that inhibits or downregulates BLyS activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, at least 50%, at least 45%, at least 40%, at least 45%, at least 35%, at least 30%, at least 25%, at least 20%, or at least 10% relative to BLyS activity in absence of the antibody is administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant BLyS expression, excessive BLyS function, aberrant BLyS receptor expression, or excessive BLyS receptor function. In another embodiment, a combination of antibodies, a combination of antibody fragments, a combination of antibody variants, or a combination of antibodies, antibody fragments, and/or variants that inhibit or downregulate BLyS activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 45%, at least 35%, at least 30%, at least 25%, at least 20%, or at least 10% relative to BLyS activity in absence of said antibodies, antibody fragments, and/or antibody variants are administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant BLyS expression, excessive BLyS function, aberrant BLyS receptor expression, or excessive BLyS receptor function. [0395]. Further, antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) which activate BLyS-induced signal transduction can be administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant BLyS expression, lack of BLyS function, aberrant BLyS receptor expression, or lack of BLyS receptor function. These antibodies may potentiate or activate either all or a subset of the biological activities of BLyS-mediated receptor activation, for example, by inducing multimerization of BLyS and/or multimerization of the receptor. The antibodies of the invention may be administered with or without being pre-complexed with BLyS. In a specific embodiment, an antibody of the present invention that increases BLyS activity by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 189 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% relative to BLyS activity in absence of the antibody is administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant BLyS expression, lack of BLyS function, aberrant BLyS receptor expression, or lack of BLyS receptor function. In another embodiment, a combination of antibodies, a combination of antibody fragments, a combination of antibody variants, or a combination of antibodies, antibody fragments and/or antibody variants that increase BLyS activity by at least 5%, at least 10/6, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% relative to BLyS activity in absence of the said antibodies or antibody fragments and/or antibody variants is administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant BLyS expression or lack of BLyS function or aberrant BLyS receptor expression or lack of BLyS receptor function. [03961 One or more antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to BLyS may be used locally or systemically in the body as a therapeutic. The antibodies of this invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may also be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies. 103971 The antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy, anti-tumor agents, anti-angiogenesis and anti-inflammatory agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments, or variants, (e.g., derivatives), or nucleic acids, are administered to a human patient for therapy or prophylaxis. 190 [03981 It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to BLyS, or polynucleotides encoding antibodies that immunospecifically bind to BLyS, for both immunoassays directed to and therapy of disorders related to BLyS polynucleotides or polypeptides, including fragments thereof. Such antibodies will preferably have an affinity for BLyS and/or BLyS fragments. Preferred binding affinities include those with a dissociation constant or KD less than or equal to 5 X 10 M, 10.2 M, 5 X 10-' M, 10- M, 5 X 10-4 M, 10-4 M, 5 X 105 M, or 10-' M. More preferably, antibodies of the invention bind BLyS polypeptides or fragments or variants thereof with a dissociation constant or KD less than or equal to 5 X 10~ M, 10- M, 5 X 10- M, 10- M, 5 X 10-8 M, or 108" M. Even more preferably, antibodies of the invention bind BLyS polypeptides or fragments or variants thereof with a dissociation constant or KD less than or equal to 5 X 10-9 M, 10~9 M, 5 X 1010 M, 10.10 M, 5 X 10~" M, 10-" M, 5 X 10-1 2 M, 10-1 M, 5 X -1 M, 10-1 M, 5 X 10-4 M, 10-4 M, 5 X 10-5 M, or 10-1 M. The invention encompasses antibodies that bind BLyS polypeptides with a dissociation constant or KD that is within any one of the ranges that are between each of the individual recited values. 10399] In a preferred embodiment, antibodies of the invention neutralize BLyS activity. In another preferred embodiment, antibodies of the invention inhibit B cell proliferation. [04001 In a preferred embodiment, antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) inhibit or reduce binding of the soluble form of BLyS to a BLyS receptor. In another preferred embodiment antibodies of the invention inhibit or reduce B cell proliferation induced by the soluble form of BLyS. In another preferred embodiment antibodies of the invention inhibit or reduce immunoglobulin production induced by the soluble form of BLyS. [04011 In a preferred embodiment, antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) inhibit or reduce binding of membrane-bound BLyS to a BLyS receptor. In another preferred embodiment, antibodies of the invention inhibit or reduce B cell proliferation induced by the membrane-bound form of BLyS. In another preferred 191 embodiment, antibodies of the invention inhibit or reduce immunoglobulin production induced by the membrane bound form of BLyS. [0402] In a preferred embodiment, antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) inhibit or reduce binding of both the soluble and membrane-bound forms of BLyS to a BLyS receptor. In another preferred embodiment, antibodies of the invention inhibit or reduce B cell proliferation induced by either or both forms of BLyS. In another preferred embodiment, antibodies of the invention inhibit or reduce immunoglobulin production induced by either or both forms of BLyS. [04031 In one embodiment, the invention provides a method of delivering antibody conjugates of the invention to targeted cells, such as, for example, monocytic cells expressing the membrane-bound form of BLyS, or B cells expressing a BLyS receptor. (0404] In one embodiment, the invention provides a method for the specific delivery of antibodies and antibody conjugates of the invention to cells by administering molecules of the invention that are associated with heterologous polypeptides or nucleic acids. In one. example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell. [0405] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering antibodies or antibody conjugates of the invention (e.g.; antibodies conjugated with radioisotopes, toxins, or cytotoxic prodrugs).In a specific embodiment, the invention provides a method for the specific destruction of cells of monocytic lineage (e.g., monocytic cell related leukemias or lymphomas, such as, for example acute myelogenous leukemia) by administering antibodies or antibody conjugates of the invention (e.g., antibodies conjugated with radioisotopes, toxins, or cytotoxic prodrugs) that immunospecifically bind the membrane-bound form of BLyS. In another specific embodiment, the invention provides a method for the specific destruction of cells of B cell lineage (e.g., B cell related leukcmias or lymphomas (e.g., chronic lymphocytic leukemia, multiple myeloma, non Hodgkin's lymphoma, and Hodgkin's disease) by administering antibodies or antibody 192 conjugates of the invention (e.g., antibodies conjugated with radioisotopes, toxins, or cytotoxic prodrugs) that bind soluble BLyS, but do not inhibit BLyS binding to a BLyS receptor on B cells. [0406] In another preferred embodiment antibodies of the invention (including antibody fragments and variants) promote or enhance B cell proliferation induced by the soluble form of BLyS. In another preferred embodiment, antibodies of the invention (including antibody fragments and variants) promote or enhance B cell proliferation induced by the membrane or soluble form of APRIL. In another preferred embodiment antibodies of the invention (including antibody fragments and variants) increase or enhance immunoglobulin production induced by the soluble form of BLyS. In another preferred embodiment antibodies of the invention (including antibody fragments and variants) increase or enhance immunoglobulin production induced by the membrane bound or soluble form of APRIL. Ir another preferred embodiment antibodies of the invention (including antibody fragments and variants) increase or enhance immunoglobulin production in response to T cell dependent immunogens. In another preferred embodiment antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance immunoglobulin production in response to T cell independent immunogens. [04071 In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate immune disorders. Immune disorders include, but are not limited to, autoimmune disorders (e.g., arthritis, graft rejection, Hashimoto's thyroiditis, insulin-dependent diabetes, lupus, idiopathic thrombocytopenic purpura, systemic lupus erythrematosus and multiple sclerosis), elective IgA deficiency, ataxia-telangiectasia, common variable immunodeficiency (CVID), X linked agammaglobulinemia, severe combined immunodeficiency (SCID), Wiskott Aldrich syndrome, idiopathic hype:r-eosinophilic syndrome, monocytic leukemoid reaction, monocytic leukocytosis, monocytic leukopenia, monocytopenia, monocytosis, and graft or transplant rejection. [0408] As discussed herein, antibodies and antibody compositions of the 193 invention, may be used to treat, prevent, ameliorate, diagnose or prognose various immune system-related disorders and/or conditions associated with these disorders, in mammals, preferably humans. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the . administration of antibody and antibody compositions of the invention that can inhibit an immune response, particularly the proliferation of B cells and/or the production of immunoglobulins, may be an effective therapy in treating and/or preventing autoimmune disorders. Thus, in preferred embodiments, antibodies and antibody compositions of the invention are used to treat, prevent, ameliorate, diagnose and/or prognose an autoimmune disorder, or condition(s) associated with such disorder. [04091 Autoimmune disorders and conditions associated with these disorders that may be treated, prevented, ameliorated, diagnosed and/or prognosed with the therapeutic and pharmaceutical compositions of the invention include, but are not limited to, autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmune neutropenia, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, gluten-sensitive enteropathy, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g., IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia, Polyendocrinopathies, Purpura (e.g., Henloch-Scoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Auto immune Pulmonary Inflammation, myocarditis, IgA glomerulonephritis, dense deposit disease, rheumatic heart disease, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease. [04101 Additional autoimmune disorders and conditions associated with these disorders that may be treated, prevented, ameliorated, diagnosed and/or prognosed with the therapeutic and pharmaceutical compositions of the invention include, but are not limited to, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis) (often characterized, e.g., by cell-mediated and humoral thyroid cytotoxicity), systemic lupus erhythematosus (often characterized, e.g., by circulating and locally generated immune complexes), discoid lupus, Goodpasture's syndrome (often characterized, e.g., by anti basement membrane antibodies), Pemphigus (often characterized, e.g., by epidermal acantholytic antibodies), Receptor autoimmunities such as, for example, (a) Graves' 194 Disease (often characterized, e.g., by TSH receptor antibodies), (b) Myasthenia Gravis (often characterized, e.g., by acetylcholine receptor antibodies), and (c) insulin resistance (often characterized, e.g., by insulin receptor antibodies), autoimmune hemolytic anemia (often characterized, e.g., by phagocytosis of antibody-sensitized RBCs), autoimmune thrombocytopenic purpura (often characterized, e.g., by phagocytosis of antibody sensitized platelets. [04111 Additional autoimmune disorders and conditions associated with these disorders that may be treated, prevented, ameliorated, diagnosed and/or prognosed with the therapeutic and pharmaceutical compositions of the invention include, but are not limited to, rheumatoid arthritis (often characterized, e.g., by immune complexes in joints), schleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis/dermatomyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes) such as primary glomerulonephritis and IgA nephropathy, bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes millitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies), chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitchondrial antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial antibodies), cardiotomy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM 195 antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), inflammatory myopathies, and many other inflammatory, granulomatous, degenerative, and atrophic disorders. [04121 In a preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, a member of the group: autoimmune hemolytic anemia, as primary glomerulonephritis, IgA glomerulonephritis, Goodpasture's :;yndrome, idiopathic thrombocytopenia, Multiple Sclerosis, Myasthenia Gravis, Pemphigus, polymyositis/dennatomyositis, relapsing polychondritis, rheumatoid arthritis, Sj6gren's syndrome, systemic lupus erythematosus, Uveitis, vasculitis,and primary biliary cirrhosis. [0413] In another preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, an immune based-rheumatologic disease, such as, for example, SLE, rheumatoid arthritis, CREST syndrome (a variant of scleroderma characterized by calcinosis, Raynaud's phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia.), Seronegative spondyloarthropathy (SpA), polymyositis/ dermatomyositis, microscopic polyangiitis, hepatitis C-associated arthritis, Takayasu's arteritis, and undifferentiated connective tissue disorder. [0414] In a specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, rheumatoid arthritis and/or medical conditions associated therewith. [0415] For example, an antibody, or antibodies, of the present invention are used to treat patients with clinical diagnosis of rheumatoid arthritis (RA). The patient treated preferably will not have a B cell malignancy. Moreover, the patient is optionally further treated with any one or more agents employed for treating RA such as salicylate; nonsteroidal anti-inflammatory drugs such as indomethacin, phenylbutazone, phenylacetic acid derivatives (e.g. ibuprofen and fenoprofen), naphthalene acetic acids (naproxen), pyrrolealkanoic acid (tometin), indoleacetic acids (sulindac), halogenated anthranilic acid (meclofenamate sodium), piroxicam, zomepirac and diflunisal; antimalarials such as 196 chloroquine; gold salts; penicillamine; or immunosuppressive agents such as methotrexate or corticosteroids in dosages known for such drugs or reduced dosages. Preferably however, the patient is only treated with an antibody, or antibodies, of the present invention. Antibodies of the present invention are administered to the RA patient according to a dosing schedule as described infra, which may be readily determined by one of ordinary skill in the art. The primary response is determined by the Paulus index (Paulus et al. Athritis Rheum. 33:477-484 (1990)), i.e. improvement in morning stiffness, number of painful and inflamed joints, erythrocyte sedimentation (ESR), and at least a 2-point improvement on a 5-point scale of disease severity assessed by patient and by physician. Administration of an antibody, or antibodies, of the present invention will alleviate one or more of the symptoms of RA in the patient treated as described above. 104161 In a specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, amelioate, diagnose or prognose, lupus andlor medical conditions associated therewith. Lupus-associated conditions that may be treated, prevented, ameliorated, prognosed and/or diagnosed with the antibodies and antibody compositions of the invention include, but are not limited to, hematologic disorders (e.g., hemolytic anemia, leukopenia, lymphopenia, and thrombocytopenia), immunologic disorders (e.g., anti-DNA antibodies, and anti-Sm antibodies), rashes, photosensitivity, oral ulcers, arthritis, fever, fatigue, weight loss, serositis (e.g., pleuritus (pleurisy)), renal disorders (e.g., nephritis), neurological disorders (e.g., seizures, peripheral neuropathy, CNS related disorders), gastroinstestinal disorders, Raynaud phenomenon, and pericarditis. In a preferred embodiment, therapeutic and pharmaceutical compositions of the invention are used to treat, prevent, ameliorate, diagnose, or prognose, renal disorders associated with systemic lupus erythematosus. In a most preferred embodiment, therapeutic and pharmaceutical compositions of the invention are used to treat, prevent, ameliorate, diagnose,. or prognose, nephritis associated with systemic lupus erythematosus. In another most preferred embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate lupus or glomerular nephritis. 197 [0417] In a further specific embodiment, antibodies of the invention are used to treat, inhibit, prognose, diagnose or prevent hemolytic anemia. For example, patients diagnosed with autoimmune hemolytic anemia (AIHA), e.g., cryoglobinemia or Coombs positive anemia, are treated with an antibody, or antibodies, of the present invention. AIHA is an acquired hemolytic anemia due to auto-antibodies that react with the patient's red blood cells. The patient treated preferably will not have a B cell malignancy. Further adjunct therapies (such as glucocorticoids, prednisone, azathioprine, cyclophosphamide, vinca-laden platelets or Danazol) may be combined with the antibody therapy, but preferably the patient is treated with an antibody, or antibodies, of the present invention as a single-agent throughout the course of therapy. Antibodies of the present invention are administered to the hemolytic anemia patient according to a dosing schedule as described infra, which may be readily determined by one of ordinary skill in the art. Overall response rate is determined based upon an improvement in blood counts, decreased requirement for transfusions, improved hemoglobin levels and/or a decrease in the evidence of hemolysis as determined by standard chemical parameters. Administration of an antibody, or antibodies of the present invention will improve any one or more of the symptoms of hemolytic anemia in the patient treated as described above. For example, the patient treated as described above will show an increase in hemoglobin and an improvement in chemical parameters of hemolysis or return to normal as measured by serum lactic dehydrogenase and/or bilirubin. [04181 In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, Sjogren's Syndrome and/or medical conditions associated therewith. [04191 . In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, HIV infection and/or medical condItions associated therewith (e.g. AIDS). 198 [04201 In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, Myasthenia gravis and/or medical conditions associated therewith. [04211 In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, IgA nephropathy and/or medical conditions associated therewith. 104221 In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, hemolytic anemia and/or medical conditions associated therewith. [04231 In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, thyroiditis and/or medical conditions associated therewith. 104241 In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, Goodpasture's Syndrome and/or medical conditions associated therewith. [0425] In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, multiple sclerosis and/or medical conditions associated therewith. 104261 In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, chronic lymphocytic leukemia (CLIL) and/or medical conditions associated therewith. [0427] In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, multiple myeloma and/or medical conditions associated therewith. [04281 In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, Non-Hodgkin's lymphoma and/or medical conditions associated therewith. [04291 In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, Hodgkin's disease and/or medical conditions associated therewith. [04301 In another specific embodiment, antibodies of the invention are used to treat, inhibit, prognose, diagnose or prevent adult immune thrombocytopenic purpura. 199 Adult immune thrombocytopenic purpura (ITP) is a relatively rare hematologic disorder that constitutes the most common of the immune-mediated cytopenias. The disease typically presents with severe thrombocytopenia that may be associated with acute hemorrhage in the presence of normal to increased megakaryocytes in the bone marrow. Most patients with ITP have an IgG antibody directed against target antigens on the outer surface of the platelet membrane, resulting in platelet sequestration in the spleen and accelerated reticuloendothelial destniction of platelets (Bussell, J.B. Hematol. Oncol. Clin. North Am. (4):179 (1990)). A number of therapeutic interventions have been shown to be effective in the treatment of ITP. Steroids are generally considered first-line therapy, after which most-patients are candidates for intravenous immunoglobulin (IVIG), splenectomy, or other medical therapies including vincristine or immunosuppressive/cytotoxic agents. Up to 80% of patients with ITP initially respond to a course of steroids, but far fewer have complete and lasting remissions. Splenectomy has been recommended as standard second-line therapy for steroid failures, and leads to prolonged remission in nearly 60% of cases yet may result in reduced immunity to infection. Splenectomy is a major surgical procedure that may be associated with substantial morbidity (15%) and mortality (2%). IVIG has also been used as second line medical therapy, although only a small proportion of adult patients with ITP achieve remission. Therapeutic options that would interfere with the production of autoantibodies by activated B cells without the associated morbidities that occur with corticosteroids and/or splenectomy would provide an. important treatment approach for a proportion of patients with ITP. Patients with clinical diagnosis of ITP are treated with an antibody, or antibodies of the present invention, optionally in combination with steroid therapy. The patient treated will not have a B cell malignancy. Antibodies of the present invention are administered to the RA patient according to a dosing schedule as described infra, which may be readily detennined by one of ordinary skill in the art. Overall patient response rate is determined based upon a platelet count determined on two consecutive occasions two weeks apart following 200 treatments as described above. See, George et al. "Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for The American Society of Hematology", Blood 88:3-40 (1996), expressly incorporated herein by reference. 104311 In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate an IgE-mediated allergic reaction or histamine-mediated allergic reaction. Examples of allergic reactions include, but are not limited to, asthma, rhinitis, eczema, chronic urticaria, and atopic dermatitis. In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent, or ameliorate anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility. In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate or modulate inflammation or an inflammatory disorder. Examples of chronic and acute inflammatory disorders that may be treated prevented or ameliorated with the therapeutic and pharmaceutical compositions of the invention include, but are not limited to, chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, Crohn's disease, inflammatory bowel disease, chronic and acute inflammatory pulmonary diseases, bacterial infection, psoriasis, septicemia, cerebral malaria, arthritis, gastroenteritis, and glomerular nephritis. [04321 In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate ischemia and arteriosclerosis. Examples of such disorders include, but are not limited to, reperfusion damage (e.g., in the heart and/or brain) and cardiac hypertrophy. [0433] Therapeutic or pharmaceutical compositions of the invention, may also be administered to modulate blood clotting and to treat or prevent blood clotting disorders, such as, for example, antibody-mediated thrombosis (i.e., antiphospholipid antibody syndrome (APS)). For example, therapeutic or pharmaceutical compositions of the invention, may inhibit the proliferation and differentiation of cells involved in producing anticardiolipin antibodies. These compositions of the invention can be used to treat, prevent, ameliorate, diagnose, and/or prognose thrombotic related events including, but 201 not limited to, stroke (and recurrent stroke), heart attack, deep vein thrombosis, pulmonary embolism, myocardial infarction, coronary artery disease (e.g., antibody -mediated coronary artery disease), thrombosis, graft reocclusion following cardiovascular surgery (e.g., coronary arterial bypass grafts, recurrent fetal loss, and recurrent cardiovascular thromboembolic events. 10434] Therapeutic or pharmaceutical compositions of the invention, may also be administered to treat, prevent, or ameliorate organ rejection or graft-versus-host disease (GVHD) and/or conditions associated therewith. Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of antibodies of the invention, that inhibit an immune response, may be an effective therapy in preventing organ rejection or GVHD. 104351 In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate a disease or disorder diseases associated with increased apoptosis including, but not limited to, AIDS, neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration), myelodysplastic syndromes (such as aplastic anemia), ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia. In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate bone marrow failure, for example, aplastic anemia and myelodysplastic syndrome. 104361 In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate growth, progression, and/or metastases of malignancies and proliferative disorders associated with increased cell survival, or the inhibition of apoptosis. Examples of such disorders, include, but are not limited to, leukemia (e.g., acute leukemia such as acute lymphocytic leukemia and acute myelocytic leukemia), neoplasms, tumors (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, 202 synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma), heavy chain disease, metastases, or any disease or disorder characterized by uncontrolled cell growth. 104371 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used to treat or prevent a disorder characterized by hpergammagloulinemia (e.g., AIDS, autoimmune diseases, and some immunodeficiencies). [04381 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used to treat or prevent a disorder characterized by deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, therapeutic or pharmaceutical compositions of the invention may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carnii. (0439] Therapeutic or pharmaceutical compositions of the invention of the invention thereof, may be used to diagnose, prognose, treat or prevent one or more of the following diseases or disorde:rs, or conditions associated therewith: primary immuodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, bone marrow transplant (e.g., recent bone marrow transplant in adults or children), chronic B 203 cell lymphocytic leukemia, HIV infection (e.g., adult or pediatric HIV infection), chronic inflammatory demyelinating polyneuropathy, and post-transfusion purpura. [04401 Additionally, therapeutic or pharmaceutical compositions of the invention may be used to diagnose, prognose, treat or prevent one or more of the following diseases, disorders, or conditions associated therewith, Guillain-Barre syndrome, anemia (e.g., anemia associated with parvovirus B 19, patients with stable multiple myeloma who are at high risk for infection (e.g., recurrent infection), autoimmune hemolytic anemia (e.g., warm-type autoimmune hemolytic anemia), thrombocytopenia (e.g., neonatal thrombocytopenia), and immune-mediated neutropenia), transplantation (e.g., cytomegalovirus (CMV)-negative recipients of CMV-positive organs), hypogammaglobulinemia (e.g., hypogammaglobulinemic neonates with risk factor for infection or morbidity), epilepsy (e.g., intractable epilepsy), systemic vasculitic syndromes, myasthenia gravis (e.g., decompensation in myasthenia gravis), dermatomyositis, and polymyositis. [04411 Additional preferred embodiments of the invention include, but are not limited to, the use of therapeutic or pharmaceutical compositions of the invention in the following applications: [0442] Administration to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response. In a specific nonexclusive embodiment, therapeutic or pharmaceutical compositions of the invention are administered to boost the immune system to produce increased quantities of IgG. In another specific nonexclusive embodiment, antibodies of the are administered to boost the immune system to produce increased quantities of IgA. In another specific nonexclusive embodiment antibodies of the invention are administered to boost the immune system to produce increased quantities of IgM. [0443] Administration to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by 204 means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. W098/24893, WO/9634096, WO/9633735, and WO/9110741). 10444] In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a vaccine adjuvant that enhances immune responsiveness to specific antigen. In a specific embodiment, the vaccine is an antibody described herein. In another specific embodiment, the vaccine adjuvant is a polynucleotide described herein (e.g., an antibody polynucleotide genetic vaccine adjuvant). As discussed herein, therapeutic or pharmaceutical compositions of the invention may be administered using techniques known in the art, including but not limited to, liposomal delivery, recombinant vector delivery, injection of naked DNA, and gene gun delivery. [0445] In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an adjuvant to enhance tumor-specific immune responses. [04461 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include, but are not limited to, virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected fTom the group consisting of: HIV/AIDS, Respiratory syncytial virus, Dengue, Rotavinis, Japanese B encephalitis, Influenza A and B, Parainfluenza, Measles, Cytomegalovirus, Rabies, Junin, Chikungunya, Rift Valley fever, Herpes simplex, and yellow fever. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to the HIV gp120 antigen. [0447] In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the 205 compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: Vibrio cholerae, Mycobacterium leprae, Salmonella typhi, Salmonella paratyphi, Neisseria meningitidis, Streptococcus pneumoniae, Group B streptococcus, Shigella spp., Enterotoxigenic Escherichia coli, Enterohemorrhagic E. coli, Borrelia burgdorferi, and Plasmodium (malaria). [04481 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an adjuvant to enhance anti-parasitic immune responses. Anti parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria). [0449] In a specific embodiment, compositions of the invention may be administered to patients as vaccine adjuvants. In a further specific embodiment, compositions of the invention may be administered as vaccine adjuvants to patients suffering from an immune-deficiency. In a further specific embodiment, compositions of the invention may be administered as vaccine adjuvants to patients suffering from HIV. [04501 In a specific embodiment, compositions of the invention may be used to increase or enhance antigen-specific antibody responses to standard and experimental vaccines. In a specific embodiment, compositions of the invention may be used to enhance seroconversion in patients treated with standard and experimental vaccines. In another specific embodiment, compositions of the invention may be used to increase the repertoire of antibodies recognizing unique epitopes in response to standard and experimental vaccination. [04511 In a preferred embodiment, antibodies of the invention (including antibody 206 fragments and variants, and anti-antibody antibodies) increase or enhance antigen-specific antibody responses to standard and experimental vaccines by regulating binding of the soluble form of BLyS to a BLyS receptor (e.g., BCMA and TACI). In another preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance antigen-specific antibody responses to standard and experimental vaccines by regulating binding of the soluble form of APRIL to an APRIL receptor (e.g., BCMA and TACI). [0452] In a preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance seroconversion in patients treated with standard and experimental vaccines by regulating binding of the soluble form of BLyS to BLyS receptor (e.g., BCMA and TACI). In another preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance seroconversion in patients treated with standard and experimental vaccines by regulating binding of the soluble form of APRIL to an APRIL receptor (e.g., BCMA and TACI). [04531 In a preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance the repertoire of antibodies recognizing unique epitopes in response to standard and experimental vaccination by regulating binding of the soluble form of BLyS to a BLyS receptor (e.g., BCMA and TACI). In another preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance the repertoire of antibodies recognizing unique epitopes in response to standard and experimental vaccination by regulating binding of the soluble form of APRIL to an APRIL receptor (e.g., BCMA and TACI). 104541 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a stimulator of B cell responsiveness to pathogens. 104551 In a specific embodiment, therapeutic or pharmaceutical compositions of 207 the invention are used as an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies. 104561 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to induce higher affinity antibodies. [04571 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to increase serum immunoglobulin concentrations. [04581 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to accelerate recovery of immunocompromised individuals. [04591 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to boost immunoresponsiveness among aged populations. 104601 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to Iransplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T--cell populations. In another specific embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations. 104611 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy. B cell immunodeficiencies that may be ameliorated or treated by administering the antibodies and/or compositions of the invention include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-linked infantile 208 agammaglobulinemia, acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient hypogammaglobulinenia of infancy, unspecified hypogammaglobulinemia, aganmaglobulinemia, common variable immunodeficiency (CVID) (acquired), Wiskott Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic alymphoplasia-aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof syndrome-combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency. [0462] In a specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate selective IgA deficiency. [0463] In another specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate ataxia-telangiectasia. [04641 In another specific embodiment antibodies and/or compositions of the invention are administered to treat or ameliorate common variable immunodeficiency. [04651 In another specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate X-linked agammaglobulinemia. [04661 In another specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate severe combined immunodeficiency (SCID). [04671 In another specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate Wiskott-Aldrich syndrome. [04681 In another specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate X-linked Ig deficiency with hyper IgM. [04691 As an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell 209 function that may be ameliorated or treated by administering antibodies and/or compositions of the invention include, but are not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL). (0470] In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to boost imnmunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering antibodies and/or compositions of the invention include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, recovery from surgery. [04711 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a regulator of antigen presentation by monocytes, dendritic cells, T cells and/or B-cells. In one embodiment, antibody polypeptides or polynucleotides enhance antigen presentation or antagonize antigen presentation in vitro or in vivo. Moreover, in related embodiments, this enhancement or antagonization of antigen presentation may be useful in anti-tumor treatment or to modulate the immune system. (04721 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a mediator of mucosal immune responses. The expression of BLyS on monocytes, the expression of BLyS receptor on B cells, and the responsiveness of B cells to BLyS suggests that it may be involved in exchange of signals between B cells and monocytes or their differentiated progeny. This activity is in many ways analogous to the CD40-CD154 signalling between B cells and T cells. Anti-BLyS antibodies and compositions of the invention may therefore be good regulators of T cell independent immune responses to environmental pathogens. In particular, the unconventional B cell populations (CDS+) that are associated with mucosal sites and responsible for much of the innate immunity in humans may respond to antibodies or compositions of the invention thereby enhancing or inhibiting individual's immune status. 10473] In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to direct an individual's immune system towards development of a humoral response (i.e. TH2) as opposed to a TH I cellular response. 210 104741 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly, their susceptibility profile would likely change. [04751 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a monocyte cell specific binding protein to which specific activators or inhibitors of cell growth may be attached. The result would be to focus the activity of such activators or inhibitors onto normal, diseased, or neoplastic B cell populations. 104761 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a B cell specific binding protein to which specific activators or inhibitors of cell growth may be attached. The result would be to focus the activity of such activators or inhibitors onto normal, diseased, or neoplastic B cell populations. [04771 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a means of detecting monocytic cells by virtue of its specificity. This application may require labeling the protein with biotin or other agents (e.g., as described herein) to afford a means of detection. [04781 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a means of detecting B-lineage cells by virtue of its specificity. This application may require labeling the protein with biotin or other agents (e.g., as described herein) to afford a means of detection. [04791 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable immunodeficiency. 104801 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as part of a monocyte selection device the function of which is to isolate monocytes from a heterogeneous mixture of cell types. Antibodies of the invention could be coupled to a solid support to which monocytes would then specifically bind. 211 Unbound cells would be washed out and the bound cells subsequently eluted. A non limiting use of this selection would be to allow purging of tumor cells from, for example, bone marrow or peripheral blood prior to transplant. [04811 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as part of a B cell selection device the function of which is to isolate B cells from a heterogeneous mixture of cell types. Antibodies of the invention (that do not inhibit BLyS/BLyS Receptor interaction) binding soluble BLyS could be coupled to a solid support to which B cells would then specifically bind. Unbound cells would be washed out and the bound cells subsequently eluted. A non-limiting use of this selection would be to allow purging of tumor cells from, for example, bone marrow or peripheral blood prior to transplant. 104821 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic: defect. [04831 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence such as observed among SCID patients. [04841 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an antigen for the generation of antibodies to inhibit or enhance BLyS mediated responses. [04851 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leishmania. [04861 In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as pretreatment of bone marrow samples prior to transplant. Such treatment would increase B cell representation and thus accelerate recovery. [0487] In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a means of regulating secreted cytokines that are elicited by BLyS and/or BLyS receptor. 212 [04881 Antibody polypeptides or polynucleotides of the invention may be used to modulate IgE concentrations in vitro or in vivo. [0489] Additionally, antibody polypeptides or polynucleotides of the invention may be used to treat, prevent, and/or diagnose IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema. [0490] In a specific embodiment, antibody polypeptides or polynucleotides of the invention, are administered to treat, prevent, diagnose, and/or ameliorate selective IgA deficiency. 10491] In another specific embodiment antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate ataxia telangiectasia. [04921 In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate common variable immunodeficiency. 104931 In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate X-linked agammaglobulinemia. 104941 In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate severe combined immunodeficiency (SCID). [04951 In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate Wiskott Aldrich syndrome. [04961 In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate X-linked Ig deficiency with hyper IgM. In a specific embodiment antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate X-linked Ig deficiency with hyper IgM. [0497] In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, and/or diagnose chronic myelogenous leukemia, acute myelogenous leukemia, leukemia, hystiocytic leukemia, monocytic leukemia (e.g., acute monocytic leukemia), leukemic reticulosis, Shilling Type monocytic 213 leukemia, and/or other leukemias derived from monocytes and/or monocytic cells and/or tissues. [04981 In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate monocytic leukemoid reaction, as seen, for example, with tuberculosis. [04991 In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate monocytic leukocytosis, monocytic leukopenia, monocytopenia, and/or monocytosis. [0500] In a specific embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, detect, and/or diagnose monocyte disorders and/or diseases, and/or conditions associated therewith. [05011 In a specific embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, detect, and/or diagnose primary B lymphocyte disorders and/or diseases, and/or conditions associated therewith. In one embodiment, such primary B lymphocyte disorders, diseases, and/or-conditions are characterized by a complete or partial loss of humoral immunity. Primary B lymphocyte disorders, diseases, and/or conditions associated therewith that are characterized by a complete or partial loss of humoral immunity and that may be prevented, treated, detected and/or diagnosed with compositions of the invention include, but are not limited to, X-Linked Agammaglobulinemia (XLA), severe combined immunodeficiency disease (SCID), and selective IgA deficiency. [0502] - In a preferred embodiment antibody polypeptides or polynucleotides of the invention are used to treat, prevent, and/or diagnose diseases or disorders affecting or conditions associated with any one or more of the various mucous membranes of the body. Such diseases or disorders include, but are not limited to, for example, mucositis, mucoclasis, mucocolitis, mucocutaneous leishmaniasis (such as, for example, American leishmaniasis, leishmaniasis americana, nasopharyngeal leishmaniasis, and New World leishmaniasis), mucocutaneous lymph node syndrome (for example, Kawasaki disease), mucoenteritis, mucoepidermoid carcinoma, mucoepidermoid tumor, mucoepithelial dysplasia, mucoid adenocarcinoma, mucoid degeneration, myxoid degeneration; myxomatous degeneration; myxomatosis, mucoid medial degeneration (for example, cystic medial necrosis), mucolipidosis (including, for example, mucolipidosis I, 214 mucolipidosis II, mucolipidosis III, and mucolipidosis IV), mucolysis disorders, mucomembranous enteritis, mucoenteritis, mucopolysaccharidosis (such as, for example, type I mucopolysaccharidosis (i.e., Hurler's syndrome), type IS mucopolysaccharidosis (i.e., Scheie's syndrome or type V nucopolysaccharidosis), type II mucopolysaccharidosis (i.e., Hunter's syndrome), type III mucopolysaccharidosis (i.e., Sanfidippo's syndrome), type IV mucopolysaccharidosis (i.e., Morquio's syndrome), type VI mucopolysaccharidosis (i.e.,. Maroteaux-Lamy syndrome), type VII mucopolysaccharidosis (i.e, mucopolysaccharidosis due to beta-glucuronidase deficiency), and mucosulfatidosis), mucopolysacchariduria, mucopurulent conjunctivitis, mucopus, mucormycosis (i.e., zygomycosis), mucosal disease (i.e., bovine virus diarrhea), mucous colitis (such as, for example, mucocolitis and myxomembranous colitis), and mucoviscidosis (such as, for example, cystic fibrosis, cystic fibrosis of the pancreas, Clarke-Hadfield syndrome, fibrocystic disease of the pancreas, mucoviscidosis, and viscidosis). In a highly preferred embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, and/or diagnose mucositis, especially as associated with chemotherapy. [05031 In a preferred embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, and/or diagnose diseases or disorders affecting or conditions associated with sinusitis. [0504] An additional condition, disease or symptom that can be treated, prevented, and/or diagnosed by antibody polypeptides or polynucleotides of the invention is osteomyelitis. [05051 An additional condition, disease or symptom that can be treated, prevented, and/or diagnosed by antibody polypeptides or polynucleotides of the invention is endocarditis. [0506] All of the above described applications as they may apply to veterinary medicine. [0507] Antibody polypeptides or polynucleotides of the invention may be used to treat, prevent, and/or diagnose diseases and disorders of the pulmonary system (e.g., bronchi such as, for example, sinopulmonary and bronchial infections and conditions associated with such diseases and disorders and other respiratory diseases and disorders. In specific embodiments, such diseases and disorders include, but are not limited to, 215 bronchial adenoma, bronchial asthma, pneumonia (such as, e.g., bronchial pneumonia, bronchopneumonia, and tuberculous bronchopneumonia), chronic obstructive pulmonary disease (COPD), bronchial polyps, bronchiectasia (such as, e.g., bronchiectasia sicca, cylindrical bronchiectasis, and saccular bronchiectasis), bronchiolar adenocarcinoma, bronchiolar carcinoma, bronchiolitis (such as, e.g., exudative bronchiolitis, bronchiolitis fibrosa obliterans, and proliferative bronchiolitis), bronchiolo-alveolar carcinoma, bronchitic asthma, bronchitis (such as, e.g., asthmatic bronchitis, Castellani's bronchitis, chronic bronchitis, croupous bronchitis, fibrinous bronchitis, hemorrhagic bronchitis, infectious avian bronchitis, obliterative bronchitis, plastic bronchitis, pseudomembranous bronchitis, putrid bronchitis, and verminous bronchitis), bronchocentric granulomatosis, bronchoedema, bronchoesophageal fistula, bronchogenic carcinoma, bronchogenic cyst, broncholithiasis, bronchomalacia, bronchomycosis (such as, e.g., bronchopulmonary aspergillosis), bronchopulmonary spirochetosis, hemorrhagic bronchitis, bronchorrhea, bronchospasm, bronchostaxis, bronchostenosis, Biot's respiration, bronchial respiration, Kussmaul respiration, Kussmaul-Kien respiration, respiratory acidosis, respiratory alkalosis, respiratory distress syndrome of the newborn, respiratory insufficiency, respiratory scleroma, respiratory syncytial virus, and the like. [05081 In a specific embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, and/or diagnose chronic obstructive pulmonary disease (COPD). [05091 In another embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, and/or diagnose fibroses and conditions associated with fibroses, including, but not limited to, cystic fibrosis (including such fibroses as cystic fibrosis of the pancreas, Clarke-Hadfield syndrome, fibrocystic disease of the pancreas, mucoviscidosis, and viscidosis), endomyocardial fibrosis, idiopathic retroperitoneal fibrosis, leptomeningeal fibrosis, mediastinal fibrosis, nodular subepidermal fibrosis, pericentral fibrosis, perimuscular fibrosis, pipestem fibrosis, replacement fibrosis, subadventitial fibrosis, and Symmers' clay pipestem fibrosis. [05101 In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate infectious diseases. Infectious diseases include diseases associated with yeast, fungal, viral and bacterial infections. Viruses causing viral infections which can be treated or prevented in 216 accordance with this invention include, but are not limited to, retroviruses (e.g., human T-cell lymphotrophic virus (HTLV) types I and ]I and human immunodeficiency virus (HIV)), herpes viruses (e.g., herpes simplex virus (HSV) types I and II, Epstein-Barr virus, HHV6-HHV8, and cytomegalovirus), arenavirues (e.g., lassa fever virus), paramyxoviruses (e.g., morbillivirus virus, human respiratory syncytial virus, mumps, and pneumovirus), adenoviruses, bunyaviruses (e.g., hantavirus), cornaviruses, filoviruses (e.g., Ebola virus), flaviviruses (e.g., hepatitis C virus (HCV), yellow fever virus, and Japanese encephalitis virus), hepadraviruses (e.g., hepatitis B viruses (HBV)), orthomyoviruses (e.g., influenza viruses A, B and C), papovaviruses (e.g., papillomavirues), picornaviruses (e.g., rhinoviruses, enteroviruses and hepatitis A viruses), - poxviruses, reoviruses (e.g., rotavimues), togaviruses (e.g., rubella virus), rhabdoviruses (e.g., rabies virus). Microbial pathogens causing bacterial infections include, but are not limited to, Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria gonorrhoea, Neisseria meningitidis, Corynebacterium diphtheriae , Clostridium botulinum, Clostridium perfringens, Clostridium tetani, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella ozaenae, Ktebsiella rhinoscleromotis, Staphylococcus aureus, Vibrio cholerae, Escherichia coli, Pseudomonas aeruginosa, Campylobacter (Vibrio) fetus, Campylobacterjejuni, Aeromonas hydrophila, Bacillus cereus, Edwardsiella tarda, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Shigella dysenteriae, Shigellaflexneri, Shigella sonnei, Salmonella typhimurium, Treponema pallidum, Treponema pertenue, Treponema carateneum, Borrelia vincentii, Borrelia burgdorferi, Leptospira icterohemorrhagiae, Mycobacterium tuberculosis, Toxoplasma gondii, Pneumocystis carinii, Francisella tularensis, Brucella abortus, Brucella suis, Brucella melitensis, Mycoplasma spp., Rickettsia prowazeki, Rickettsia tsutsugumushi, Chlamydia spp., and Helicobacter pylori. Gene Therapy [0511) In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives: thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of BLyS and/or its receptor, by way of gene therapy. Gene therapy refers to therapy performed by the 217 administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect. [05121 Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below. 105131 For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 1 1(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et aL. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990). 105141 In a preferred aspect, a composition of the invention comprises, or alternatively consists of, nucleic acids encoding an antibody, said nucleic acids being part of an expression vector that expresses the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acids have promoters, preferably heterologous promoters, operably linked to -the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et aL., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is an scFv; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments or variants thereof, of an antibody. [0515] Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient.. These two approaches are known, respectively, as in vivo or ex vivo gene therapy. 218 [05161 In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06 180; WO 92/22635; W092/203 16; W093/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Nati. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et aL, Nature 342:435-438 (1989)). [0517] In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention or fragments or variants thereof are used. For example, a retroviral vector can be used (see Miller et aL., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et aL, Biotherapy 6:29 1-302 (1994), which describes the use of a retroviral vector to deliver the mdr 1 gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et aL, J. Clin. Invest. 93:644-651(1994); 219 Klein et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110 114 (1993). [05181 Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses arc especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143- 155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication W094/12649; and Wang, et al., Gene Therapy 2:775 783 (1995). In a preferred embodiment, adenovirus vectors are used. [05191 Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. - 5,436,146). 105201 Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient. [05211 In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. 220 Enzymol. 217:599-618 (1993); Cohen et aL., Meth. Enzymol. 217:618-644 (1993); Clin. Pharma. Ther. 29:69-92m (1985)) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny. [05221 The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art. [0523] Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc. [05241 In a preferred embodiment, the cell used for gene therapy is autologous to the patient. [0525] In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody or fragment thereof are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 7 1:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)). [0526] In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such 221 that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Utility of a Composition 105271 The compounds of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays which can be used to determine whether administration of a specific antibody or composition of the present invention is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered an antibody or composition of the present invention, and the effect of such an antibody or composition of the present invention upon the tissue sample is observed. In various specific embodiments, in vitro assays can be carried out with representative cells of cell types involved in a patient's disorder, to determine if an antibody or composition of the present invention has a desired effect upon such cell types. Preferably, the antibodies or compositions of the invention are also tested in in vitro assays and animal model systems prior to administration to humans. 105281 Antibodies or compositions of the present invention for use in therapy can be tested for their toxicity in suitable animal model systems, including but not limited to rats, mice, chicken, cows, monkeys, and rabbits. For in vivo testing of an antibody or composition's toxicity any animal model system known in the art may be used. [05291 Efficacy in treating or preventing viral infection may be demonstrated by detecting the ability of an antibody or composition of the invention to inhibit the replication of the virus, to inhibit transmission or prevent the virus from establishing itself in its host, or to prevent, ameliorate or alleviate the symptoms of disease a progression. The treatment is considered therapeutic if there is, for example, a reduction in viral load, amelioration of one or more symptoms, or a decrease in mortality and/or morbidity following administration of an antibody or composition of the invention. [0530] Antibodies or compositions of the invention can be tested for the ability to induce the expression of cytokines such as IFN-y, by contacting cells, preferably human cells, with an antibody or composition of the invention or a control antibody or control composition and determining the ability of the antibody or composition of the invention to induce one or more cytokines. Techniques known to those of skill in the art can be used to 222 measure the level of expression of cytokines. For example, the level of expression of cytokines can be measured by analyzing the level of RNA of cytokines by, for example, RT-PCR and Northern blot analysis, and by analyzing the level of cytokines by, for example, immunoprecipitation followed by western blot analysis and ELISA. In a preferred embodiment, a compound of the invention is tested for its ability to induce the expression of IFN-y_ [0531] Antibodies or compositions of the invention can be tested for their ability to modulate the biological activity of immune cells by contacting immune cells, preferably human immune cells (e.g., T-cells, B-cells, and Natural Killer cells), with an antibody or composition of the invention or a control compound and determining the ability of the antibody or composition of the invention to modulate (i.e, increase or decrease) the biological activity of immune cells. The ability of an antibody or composition of the invention to modulate the biological activity of immune cells can be assessed by detecting the expression of antigens, detecting the proliferation of immune cells (i.e., B-cell proliferation), detecting the activation of signaling molecules, detecting the effector function of immune cells, or detecting the differentiation of immune cells. Techniques known to those of skill in the art can be used for measuring these activities. For example, cellular proliferation can be assayed by 3 H-thymidine incorporation assays and trypan blue cell counts. Antigen expression can be assayed, for example, by immunoassays. including, but not limited to, competitive and non-competitive assay systems using techniques such as western blots, immunobistochemistry radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement- fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays and FACS analysis. The activation of signaling molecules can be assayed, for example, by kinase assays and electrophoretic shift assays (EMSAs). In a preferred embodiment, the ability of an antibody or composition of the invention to induce B-cell proliferation is measured. In another preferred embodiment, the ability of an antibody or composition of the invention to modulate immunoglobulin expression is measured. 105321 Antibodies or compositions of the invention can be tested for their ability to reduce tumor formation in in vitro, ex vivo and in vivo assays. Antibodies or compositions 223 of the invention can also be tested for their ability to inhibit viral replication or reduce viral load in in vitro and in vivo assays. Antibodies or compositions of the invention can also be tested for their ability to reduce bacterial numbers in in vitro and in vivo assays known to those of skill in the art. Antibodies or compositions of the invention can also be tested for their ability to alleviate of one or more symptoms associated with cancer, an immune disorder (e.g., an inflammatory disease), a neurological disorder or an infectious disease. Antibodies or compositions of the invention can also be tested for their ability to decrease the time course of the infectious disease. Further, antibodies or compositions of the invention can be tested for their ability to increase the survival period of animals suffering from disease or disorder, including cancer, an immune disorder or an infectious disease. Techniques known to those of skill in the art can be used to analyze the function of the antibodies or compositions of the invention in vivo. Therapeutic/Prophylactic Compositions and Administration 105331 The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of antibody (or fragment or variant thereof) or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, an antibody or fragment or variant thereof is substantially purified (i.e., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to, animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably a human. 105341 Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below. [05351 Various delivery systems are known and can be used to administer antibody or fragment or variant thereof of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the antibody or antibody fragment, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include, but are not limited to, intradermal, 224 intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. [0536] In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, .said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb. 105371 In another embodiment, the composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et aL., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, ibid., pp. 3 17-327; see generally ibid.). [05381 In yet another embodiment, the composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:20 1 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); 225 Ranger and Peppas, J., Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et aL., Science 228:190 (1985); During et al., Ann. Neurol. 25:35 1 (1989); Howard et al., J.Neurosurg. 7 1:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). [05391 Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)). [05401 In a specific embodiment where the composition of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered in vivo to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad.-Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination. [05411 The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of an antibody or a fragment thereof, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, 226 sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable. pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the antibody or fragment thereof, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration. [0542] . In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocamne to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration. [0543] The compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived irom sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc. 227 (0544] The amount of the composition of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. [05451 For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a. patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of therapeutic or pharmaceutical compositions of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation. [0546] The antibodies and antibody compositions of the invention may be administered alone or in combination with other adjuvants. Adjuvants that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, antibody and antibody compositions of the invention are administered in combination with alum. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with QS-2 1. Further adjuvants that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, 228 rubella), polio, varicella, tetanus/diptheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis, and/or PNEUMOVAX-23'". Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately-but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second. [0547] In another specific embodiment, antibody and antibody compositions of the invention are used in combination with PNEUMOVAX-23'" to treat, prevent, and/or diagnose infection and/or any disease, disorder, and/or condition associated therewith. In one embodiment, antibody and antibody compositions of the invention are used in combination with PNEUMOVAX-23'" to treat, prevent, and/or diagnose any Gram positive bacterial infection and/or any disease, disorder, and/or condition associated therewith. In another embodiment, antibody and antibody compositions of the invention are used in combination with PNEUMOVAX-23'" to treat, prevent, and/or diagnose infection and/or any disease, disorder, and/or condition associated with one or more members of the genus Enterococcus and/or the genus Streptococcus. In another embodiment, antibody and antibody compositions of the invention are used in any combination with PNEUMOVAX-23'" to treat, prevent, and/or diagnose infection and/or any disease, disorder, and/or condition associated with one or more members of the Group B streptococci. In another embodiment, antibody and antibody compositions of the invention are used in combination with PNEUMOVAX-23'" to treat, prevent, and/or diagnose infection and/or any disease, disorder, and/or condition associated with Streptococcus pneumoniae. [0548] The antibody and antibody compositions of the invention may be administered alone or in combination with other therapeutic agents, including but not limited to, chemotherapeutic agents, antibiotics, antivirals, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents and cytokines. Combinations may be administered either concomitantly, e.g., as an admixture, separately 229 but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second. [05491 In one embodiment, the antibody and antibody compositions of the invention are administered in combination with other members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-.alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1 BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), TRAIL, AIM II (International Publication No. WO 97/34911), APRIL (J. Exp. Med. 188(6):1185-1190 (1998)), endokine-alpha (International Publication No. WO 98/07880), Neutrokine-alpha (Intematioanl Application Publication No. WO 98/18921), OPG, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TRS (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), 312C2 (International Publication No. WO .98/06842), and TR12, and soluble forms CD154, CD70, and CD153. [0550] In a preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with CD40 ligand (CD40L), a soluble form of CD40L (e.g., AVREND"'), biologically active fragments, variants, or derivatives of CD40L, anti-CD40L antibodies (e.g., agonistic or antagonistic antibodies), and/or anti CD40 antibodies (e.g., agonistic or antagonistic antibodies). 105511 In an additional embodiment, the antibody and antibody compositions of the invention are administered alone or in combination with an anti-angiogenic agent(s). Anti-angiogenic agents that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, Angiostatin (Entremed, 230 Rockville, MD), Troponin- 1 (Boston. Life Sciences, Boston, MA), anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel (Taxol), Suramin, Tissue Inhibitor of Metalloproteinase- 1, Tissue Inhibitor of Metalloproteinase-2, VEGI, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals. [05521 Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes. 105531 Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate:, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates. [0554] Representative examples of tungsten and molybdenum complexes also include oxo complexes; Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (Vl) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars. [0555] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include, but are not limited to, platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the 231 presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4 dehydroproline, Thiaproline, alphaalpha-dipyridyl, aminopropionitrile fumarate; 4 propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChlMP-3 (Pavloff et al., J. Bio. Chem. 267:17321 17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4- chloroanthronilic acid disodium or "CCA"; (Takeuchi et al., Agents Actions 36:312-316, 1992); and metalloproteinase inhibitors such as BB94. [05561 Additional anti-angiogenic factors that may also be utilized within the context of the present invention include Thalidomide, (Celgene, Warren, NJ); Angiostatic steroid; AGM-1470 (H. Brem and J. Folkman JPediatr. Surg. 28:445-51 (1993)); an integrin alpha v beta 3 antagonist (C. Storgard et al., JClin. Invest. 103:47-54 (1999)); carboxynaminolmidazole; Carboxyamidotriazole (CAI) (National Cancer Institute, Bethesda, MD); Conbretastatin A-4 (CA4P) (OXiGENE, Boston, MA); Squalamine (Magainin Pharmaceuticals, Plymouth Meeting, PA); TNP-470, (Tap Pharmaceuticals, Deerfield, IL); ZD-0101 AstraZeneca (London, UK); APRA (CT2584); Benefin, Byrostatin-1 (SC339555); CGP-41251 (PKC 412); CMIO; Dexrazoxane (1CRF187); DMXAA; Endostatin; Flavopridiol; Genestein; GTE; ImmTher; Iressa (ZD1839); Octreotide (Somatostatin); Panretin; Penacillamine; Photopoint; PI-88; Prinomastat (AG 3340) Purlytin; Suradista (FCE26644); Tamoxifen (Nolvadex); Tazarotene; Tetrathiomolybdate; Xeloda (Capecitabine); and 5-Fluorouracil. [05571 Anti-angiogenic agents that may be administered in combination with the compounds of the invention may work through a variety of mechanisms including, but not limited to, inhibiting proteolysis of the extracellular matrix, blocking the function of endothelial cell-extracellular matrix adhesion molecules, by antagonizing the function of angiogenesis inducers such as growth factors, and inhibiting integrin receptors expressed on proliferating endothelial cells. Examples of anti-angiogenic inhibitors that interfere 232 with extracellular matrix proteolysis and which may be administered in combination with the antibody and antibody compositions of the invention include, but are not limited to, AG-3340 (Agouron, La Jolla, CA), BAY-12-9566 (Bayer, West Haven, CT), BMS 275291 (Bristol Myers Squibb, Princeton, NJ), CGS-27032A (Novartis, East Hanover, NJ), Marimastat (British Biotech, Oxford, UK), and Metastat (Aetema, St-Foy, Quebec). Examples of anti-angiogenic inhibitors that act by blocking the function of endothelial cell-extracellular matrix adhesion molecules and which may be administered in combination with the antibody and antibody compositions of the invention include, but are not limited to, EMD-121974 (Merck KcgaA Darmstadt, Germany) and Vitaxin (lxsys, La Jolla, CA/Medimmune, Gaithersburg, MD). Examples of anti-angiogenic agents that act by directly antagonizing or inhibiting angiogenesis inducers and which may be administered in combination with the antibody and antibody compositions of the invention include, but are not limited to, Angiozyme (Ribozyme, Boulder, CO), Anti-VEGF antibody (Genentech, S. San Francisco, CA), PTK-787/ZK-225846 (Novartis, Basel, Switzerland), SU-101 (Sugen, S. San Francisco, CA), SU-5416 (Sugen/ Pharmacia Upjohn, Bridgewater, NJ), and SU-6668 (Sugen). Other anti-angiogenic agents act to indirectly inhibit angiogenesis. Examples of indirect inhibitors of angiogenesis which may be administered in combination with the antibody and antibody compositions of the invention include, but are not limited to, IM-862 (Cytran, Kirldand, WA), Interferon alpha, IL-12 (Roche, Nutley, NJ), and Pentosan polysulfate (Georgetown University, Washington, DC). 105581 In particular embodiments, the use of antibody and antibody compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of an autoimmune disease, such as for example, an autoimmune disease described herein. [05591 In a particular embodiment, the use of antibody and antibody compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of arthritis. In a more particular embodiment, the use of antibody and antibody compositions of the invention in combination with anti angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of rheumatoid arthritis. [05601 In another embodiment, antibody and antibody compositions of the 233 invention are administered in combination with an anticoagulant. Anticoagulants that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, heparn, warfarin, and aspirin. In a specific embodiment, antibody and antibody compositions of the invention are administered in combination with heparin and/or warfarin. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with warfarin. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with warfarin and aspirin. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with heparin. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with heparin and aspirin. 105611 In another embodiment, antibody and antibody compositions of the invention are administered in combination with an agent that suppresses the production of anticardiolipin antibodies. In specific embodiments, the polynucleotides of the invention are administered in combination with an agent that blocks and/or reduces the ability of anticardiolipin antibodies to bind phospholipid-binding plasma protein beta 2-glycoprotein I (b2GPI). [05621 In certain embodiments, antibody and antibody compositions of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the antibody and antibody compositions of the invention, include, but are not limited to, RETROVIR'" (zidovudine/AZT), VIDEX'" (didanosine/ddl), HIVID'" (zatcitabine/ddC), ZERIT' (stavudine/d4T), EPIVIR" (lamivudine/3TC), and COMBIVIR (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the antibody and antibody compositions of the invention, include, but are not limited to, VIRAMUNE'" (nevirapine), RESCRIPTOR'" (delavirdine), and SUSTIVA" (efavirenz). Protease inhibitors that may be administered in combination with the antibody and antibody compositions of the invention, include, but are not limited to, CRIXIVAN" (indinavir), NORVIR" (ritonavir), INVIRASE'" (saquinavir), and VIRACEPT'" (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non 234 nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with antibody and antibody compositions of the invention to treat, prevent, and/or diagnose AIDS and/or to treat, prevent, and/or diagnose HIV infection. 10563] In other embodiments, antibody and antibody compositions of the invention may be administered in combination with anti-opportunistic infection agents. Anti opportunistic agents that may be administered in combination with the antibody and antibody compositions of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE", DAPSONE'", PENTAMIDINE, ATOVAQUONE', ISONIAZID'", RIFAMPIN", PYRAZINAMIDE'", ETHAMBUTOL", RIFABUTIN", CLARITHROMYCIN", AZITHROMYCIN'", GANCICLOVIR', FOSCARNET"', CIDOFOVIR-, FLUCONAZOLE", ITRACONAZOLE'", KETOCONAZOLE", ACYCLOVIR, FAMCICOLVIR", PYRIMETHAMINE'", LEUCOVO:RIN", NEUPOGEN'" (filgrastim/G-CSF), and LEUK'NE" (sargramostim/GM-CSF). In a specific embodiment, antibody and antibody compositions of the invention are used in any combination with TRIMETHOPRIM SULFAMETHOXAZOLE"', DAPSONE", PENTAMIDINE'", and/or ATOVAQUONE"' to prophylactically treat, prevent, and/or diagnose an opportunistic Pneumocystis carinii pneumonia infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with ISONIAZID'", RIFAMPIN", PYRAZINAMIDE'", and/or ETHAMBUTOL" to prophylactically treat, prevent, and/or diagnose an opportunistic Mycobacterium avium complex infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with RIFABUTIN'", CLARITHROMYCIN T, and/or AZITHROMYCIN"' to prophylactically treat, prevent, and/or diagnose an opportunistic Mycobacterium tuberculosis infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with
GANCICLOVIR"'
T
, FOSCARNET"', and/or CIDOFOVIR ' to prophylactically treat, prevent, and/or diagnose an opportunistic cytomegalovirus infection. In another specific embodiment, antibody and antibody compositions of the invention arc used in any combination with FLUCONAZOLE"', ITRACONAZOLE", and/or KETOCONAZOLE'" to prophylactically treat, prevent, and/or diagnose an opportunistic 235 fungal infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with ACYCLOVIR'" and/or FAMCICOLVIR"' to prophylactically treat, prevent, and/or diagnose an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with PYRIMETHAMINE* and/or LEUCOVORIN'" to prophylactically treat, prevent, and/or diagnose an opportunistic Toxoplasma gondii infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with LEUCOVORIN"' and/or NEUPOGEN'" to prophylactically treat, prevent, and/or diagnose an opportunistic bacterial infection. [0564] In a further embodiment, the antibody and antibody compositions of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine. 105651 In a further embodiment, the antibody and antibody compositions of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, amoxicillin, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin. [05661 Conventional nonspecific immunosuppressive agents, that may be administered in combination with the antibody and antibody compositions of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs cyclophosphamide, cyclophosphamide IV, methylprednisolone, prednisolone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells. [05671 In specific embodiments, antibody and antibody compositions of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, ORTHOCLONE"' 236 (OKT3), SANDIMMUNE'"/NEORAL'"/SANGDYA" (cyclosporin), PROGRAF'" (tacrolimus), CELLCEPT'" (mycophenolate), Azathioprine, glucorticosteroids, and RAPAMUNE'" (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation. [05681 In a preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with steroid therapy. Steroids that may be administered in combination with the antibody and antibody compositions of the invention, include, but are not limited to, oral corticosteroids, prednisone, and methylprednisolone (e.g., IV methylprednisolone). In a specific embodiment, antibody and antibody compositions of the invention are administered in combination with prednisone. In a further specific embodiment, the antibody and antibody compositions of the invention are administered in combination with prednisone and an immunosuppressive agent. Immunosuppressive agents that may be administered with the antibody and antibody compositions of the invention and prednisone are those described herein, and include, but are not limited to, azathioprine, cylophosphamide, and cyclophosphamide IV. In a another specific embodiment, antibody and antibody compositions of the invention are administered in combination with methylprednisolone. In a further specific embodiment, the antibody and antibody compositions of the invention are administered in combination with metbylprednisolone and an immunosuppressive agent. Immunosuppressive agents that may be administered with the antibody and antibody compositions of the invention and methylprednisolone are those described herein, and include, but are not limited to, azathioprine, cylophosphamide, and cyclophosphamide IV. [05691 In a preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with an antimalarial. Antimalarials that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, hydroxychloroquine, chloroquine, and/or quinacrine. [05701 In a preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with an NSAID. [05711 In a nonexclusive embodiment, the antibody and antibody compositions of the invention are administered in combination with one, two, three, four, five, ten, or more of the following drugs: NRD-101 (Hoechst Marion Roussel), diclofenac 237 (Dimethaid), oxaprozin potassium (Monsanto), mecasermin (Chiron), T-614 (Toyama), pemetrexed disodium (Eli Lilly), atreleuton (Abbott), valdecoxib (Monsanto), eltenac (Byk Gulden), campath, AGM-1470 (Takeda), CDP-571 (Celltech Chiroscience), CM 101 (CarboMed), ML-3000 (Merckle), CB-2431 (KS Biomedix), CBF-BS2 (KS Biomedix), IL-IRa gene therapy (Valentis), JTE-522 (Japan Tobacco), paclitaxel (Angiotech), DW- I 66HC (Dong Wha), darbufelone mesylate (Warner-Lambert), soluble TNF receptor 1 (synergen; Amgen), IPR-6001 (Institute for Pharmaceutical Research), trocade (Hoffman-La Roche), EF-5 (Scotia Pharmaceuticals), BIIL-284 (Boehringer Ingelheim), BI1F-I 149 (Boehringer Ingelheim), LeukoVax (Inflammatics), MK-663 (Merck), ST-1482 (Sigma-Tau), and butixocort propionate (WamerLambert). [05721 In a preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with one, two, three, four, five or more of the following drugs: methotrexate, sulfasalazine, sodium aurothiomalate, auranofin, cyclosporine, penicillamine, azathioprine, an antimalarial drug (e.g., as described herein), cyclophosphamide, chlorambucil, gold, ENBREL'" (Etanercept), anti-TNF antibody, LP 394 (La Jolla Pharmaceutical Company, San Diego, California) and prednisolone. [0573] In a more preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with an antimalarial, methotrexate, anti TNF antibody, ENBREL'" and/or suflasalazine. In one embodiment, the antibody and antibody compositions of the invention are administered in combination with methotrexate. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with anti-TNF antibody. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with methotrexate and anti-TNF antibody. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with suflasalazine. In another specific embodiment, the antibody and antibody compositions of the invention are administered in combination with methotrexate, anti TNF antibody, and suflasalazine. In another embodiment, the antibody and antibody compositions of the invention are administered in combination ENBREL". In another embodiment, the antibody and antibody compositions of the invention are administered in combination with ENBREL'" and methotrexate. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with ENBREL"', 238 methotrexate and suflasalazine. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with ENBREL'", methotrexate and suflasalazine. In other embodiments, one or more antimalarials is combined with one of the above-recited combinations. In a specific embodiment, the antibody and antibody compositions of the invention are administered in combination with an antimalarial (e.g., bydroxychloroquine), ENBREL', methotrexate and suflasalazine. In another specfic embodiment, the antibody and antibody compositions of the invention are administered in combination with an antimalarial (e.g., hydroxychloroquine), sulfasalazine, anti-TNF antibody, and methotrexate. 105741 In an additional embodiment, antibody and antibody compositions of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the antibody and antibody compositions of the invention include, but not limited to, GAMMIAR', IVEEGAM", SANDOGLOBULIN", GAMMAGARD S/D'", and GAMIMUNE". In a specific embodiment, antibody and antibody compositions of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant). [0575] CD40 ligand (CD40L), a soluble form of CD40L (e.g., AVREND'"), biologically active fragments, variants, or derivatives of CD40L, anti-CD40L antibodies (e.g., agonistic or antagonistic antibodies), and/or anti-CD40 antibodies (e.g., agonistic or antagonistic antibodies). [05761 In an additional embodiment, the antibody and antibody compositions of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e acetamidocaproic acid, S-adenosylnethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap. 239 [05771 In another embodiment, compostions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNJ, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine. phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide). 105781 In a specific embodiment, antibody and antibody compositions of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, antibody and antibody compositions of the invention are administered in combination with Rituximab. In a further embodiment, antibody and antibody compositions of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP. 105791 In an additional embodiment, the antibody and antibody compositions of the invention are administered in combination with cytokines. Cytokines that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, GM-CSF, G-CSF, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, ILI3, IL15, anti-CD40, CD40L, IFN-alpha, IFN-beta, IFN-gamma, TNF-alpha, and TNF-beta. In preferred embodiments, antibody and antibody compositions of the invention are administered with BLyS (e.g., amino acids 134-285 of SEQ IF D NO:3228). In another embodiment, antibody and antibody compositions of the invention may be administered with any interleukin, including, but not limited to, IL-lalpha, IL-Ibeta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, 240 IL- 19, IL-20, IL-21, and IL-22. In preferred embodiments, the antibody and antibody compositions of the invention are administered in combination with 1L4 and IL10. 10580] In one embodiment, the antibody and antibody compositions of the invention are administered in combination with one or more chemokines. In specific embodiments, the antibody and antibody compositions of the invention are administered in combination with an c(CxC) chemokine selected from the group consisting of gamma interferon inducible protein-10 (ylP- 10), interleukin-8 (IL-8), platelet factor-4 (PF4), neutrophil activating protein (NAP-2), GRO-a, GRO-p, GRO-y, neutrophil-activating peptide (ENA-78), granulocyte chernoattractant protein-2 (GCP-2), and stromal cell derived factor-I (SDF-1, or pre-B cell stimulatory factor (PBSF)); and/or a @(CC) . chemokine selected from the group consisting of: RANTES (regulated on activation, normal T expressed and secreted), macrophage inflammatory protein-I alpha (MIP-ica), macrophage inflammatory protein-I beta (MIP- 1P), monocyte chemotactic protein-I (MCP-1), monocyte chemotactic protein-2 (MCP-2), monocyte chemotactic protein-3 (MCP-3), monocyte chemotactic protein-4 (MCP-4) macrophage inflammatory protein-I gamma (MIP-ly), macrophage inflammatory protein-3 alpha (MIP-3a), macrophage inflammatory protein-3 beta (MIP-3p), macrophage inflammatory protein-A (MIP-4/DC CK-I/PARC), eotaxin, Exodus, and 1-309; and/or the y(C) chemokine, lymphotactin.. [05811 In another embodiment, the antibody and antibody compositions of the invention are administered with chemokine beta-8, chemokine beta-1, and/or macrophage inflammatory protein-4. In a preferred embodiment, the antibody and antibody compositions of the invention are administered with chemokine beta-8. [05821 In an additional embodiment, the antibody and antibody compositions of the invention are administered in combination with an IL-4 antagonist. IL-4 antagonists that may be administered with the antibody and antibody compositions of the invention include, but are not limited to: soluble IL-4 receptor polypeptides, multimeric forms of soluble IL-4 receptor polypeptides; anti-IL-4 receptor antibodies that bind the IL-A receptor without transducing the biological signal elicited by IL-4, anti-IL4 antibodies that block binding of IL-4 to one or more IL-4 receptors, and muteins of IL-4 that bind IL-4 receptors but do not transduce the biological signal elicited by IL-4. Preferably, the antibodies employed according to ihis method are monoclonal antibodies (including antibody fragments, such as, for example, those described herein). 241 [05831 The invention also encompasses combining the polynucleotides and/or polypeptides of the invention (and/or agonists or antagonists thereof) with other proposed or conventional hematopoietic therapies. Thus, for example, the polynucleotides and/or polypeptides of the invention (and/or agonists or antagonists thereof) can be combined with compounds that singly exhibit erythropoietic stimulatory effects, such as erythropoietin, testosterone, progenitor cell stimulators, insulin-like growth factor, prostaglandins, serotonin, cyclic AMIP, prolactin, and triiodothyzonine. Also encompassed are combinations of the antibody and antibody compositions of the invention with compounds generally used to treat aplastic anemia, such as, for example, methenolene, stanozolol, and nandrolone; to treat iron-deficiency anemia, such as, for. example, iron preparations; to treat malignant anemia, such as, for example, vitamin B 12 and/or folic acid; and to treat hemolytic anemia, such as, for example, adrenocortical steroids, e.g., corticoids. See e.g., Resegotti et al., Panminerva Medica, 23:243-248 (1981); Kurtz, FEBS Letters, 14a:105-108 (1982); McGonigle et al., Kidney Int., 25:437 444 (1984); and Pavlovic-Kantera, Expt. Hematol., 8(supp. 8) 283-291 (1980), the contents of each of which are hereby incorporated by reference in their entireties. 105841 Compounds that enhance the effects of or synergize with erythropoietin are also useful as adjuvants herein, and include but are not limited to, adrenergic agonists, thyroid hormones, androgens, hepatic erythropoietic factors, erythrotropins, and erythrogenins, See for e.g., Dunn, ".Current Concepts in Erythropoiesis", John Wiley and Sons (Chichester, England, 1983); Kalmani, Kidney Int., 22:383-391 (1982); Shahidi, New Eng. J. Med., 289:72-80 (1973); Urabe et al., J. Exp. Med., 149:1314-1325 (1979); Billat et al., Expt. Hematol., 10:133-140 (1982); Naughton et al., Acta Haemat, 69:171 179 (1983); Cognote et al. in abstract 364, Proceedings 7th Intl. Cong. of Endocrinology (Quebec City, Quebec, July 1-7, 1984); and Rothman et al., 1982, J. Surg. Oncol., 20:105 108 (1982). Methods for stimulating hematopoiesis comprise administering a hematopoietically effective amount. (i.e., an amount which effects the formation of blood cells) of a pharmaceutical composition containing polynucleotides and/or poylpeptides of the invention (and/or agonists or antagonists thereof) to a patient. The polynucleotides and/or polypeptides of the invention and/or agonists or antagonists thereof is administered to the patient by any suitable technique, including but not limited to, parenteral, sublingual, topical, intrapulmonary and intranasal, and those techniques further discussed 242 herein. The pharmaceutical composition optionally contains one or more members of the group consisting of erythropoietin, testosterone, progenitor cell stimulators, insulin-like growth factor, prostaglandins, serotonin, cyclic AMP, prolactin, triiodothyzonine, methenolene, stanozolol, and nandrolone, iron preparations, vitamin B 1 2 , folic acid and/or adrenocortical steroids. 105851 In an additional embodiment, the antibody and antibody compositions of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, LEUKINE" (SARGRAMOSTIM"') and NEUPOGEN" (FILGRASTIM
M
). [05861 In an additional embodiment, the antibody and antibody compositions of the invention are administered in combination with fibroblast growth factors. Fibroblast growth factors that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, FGF-l, FGF-2, FGF-3, FGF-4, FGF-5, FGF 6, FGF-7, FGF-8, FGF-9, FGF-10, FGF- 11, FGF-12, FGF-13, FGF-14, and FGF-15. [05871 Additionally, the antibody and antibody compositions of the invention may be administered alone or in combination with other therapeutic regimens, including but not limited to, radiation therapy. Such combinatorial therapy may be administered sequentially and/or concomitantly. Kits [0588] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. [05891 The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In an alternative embodiment, a kit comprises an antibody fragment that immunospecifically binds to BLyS. In a specific embodiment, the kits of the present invention contain a substantially isolated BLyS polypeptide as a control. 243 Preferably, the kits of the present invention further comprise a control antibody which does not react with BLyS. In another specific embodiment, the kits of the.present invention contain a means for detecting the binding of an antibody to BLyS (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized BLyS. The BLyS provided in the kit may also be attached to a solid support. In a more specific embodiment the detecting means of the above-described kit includes a solid support to which BLyS is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to BLyS can be detected by binding of the said reporter-labeled antibody. [05901 In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with BLyS, and means for detecting the binding of BLyS to the antibody. In one embodiment, the antibody is attached to a' solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen. [05911 In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound BLyS obtained by the methods of the present invention. After BLyS binds to a specific antibody, the unbound serum components are removed by washing, reporter-labeled anti-hum an antibody is added, unbound anti-human antibody is removed by washing, and a reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-BLyS antibody on the solid support. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate. [0592] The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally 244 include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s). [0593] Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant BLyS, and a reporter-labeled anti-human antibody for detecting surface-bound anti-BLyS antibody. [05941 In specific embodiments, the present invention encompasses a single chain Fv (scFv) having an amino acid sequence of one of SEQ ID NOS: 1 to 2128. [05951 In specific embodiments, the present invention encompasses a single chain Fv (scFv) having an amino acid sequence of one of'SEQ ID NOS: I to 46, 321 to 329, 1563 to 1595,-and 1881 to 1908. [05961 In specific embodiments, the present invention encompasses a single chain Fv (scFv) having an amino acid sequence of one of SEQ ID NOS: 1563 to 1880. [05971 In specific embodiments, the present invention encompasses a single chain Fv (scFv) having an amino acid sequence of one of SEQ ID NOS: 1881 to 2128. [05981 In specific embodiments, the present invention encompasses a single chain Fv (scFv) having an amino acid sequence of one of SEQ ID NOS: 1 to 1562. (0599] In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS. (06001 In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 46, 321 to 329, 1563 to 1595, and 1881 to 1908. [06011 In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1881 to 2128, and in which said antibody or fragment thereof immunospecifically binds to the membrane-bound form of BLyS. 245 106021 In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1563 to 1880, and in which said antibody or fragment thereof immunospecifically binds to the soluble form of BLyS. [06031 In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ. ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS. [0604] In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 46, 321 to 329, 1563 to 1595, and 1881 to 1908. [0605] In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from anscFv having an amino acid sequence of one of SEQ ID NOS: 1881 to 2128, and in which said antibody or fragment thereof immunospecifically binds to the membrane-bound form of BLyS. 10606] In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1563 to 1880, and in which said antibody or fragment thereof immunospecifically binds to the soluble form of BLyS. [06071 In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. (0608] In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS and which also comprises a VI domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.and in which said VL and said VH domains are derived from the same scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. [06091 In specific embodiments, the present invention encompasses an antibody or 246 fragment thereof comprising an amino acid sequence of one of SEQ ID NOS: 2129 to 3227 wherein said antibody or fragment thereof immunospecifically binds BLyS. [0610] In specific embodiments, the antibody or fragment thereof of the invention is a whole immunoglobulin molecule. 106111 In specific embodiments, the antibody or fragment thereof of the invention is a Fab fragment. (06121 In specific embodiments, the antibody or fragment thereof of the invention is a Fv fragment. [0613] In specific embodiments, the present invention encompasses a chimeric protein comprising the antibody or fragment thereof of the invention covalently linked to a heterologous polypeptide. [06141 In specific embodiments, the present invention encompasses a composition comprising two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to BLyS, and each of which type of antibody or fragment thereof comprises a VH domain from a different scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. [06151 In specific embodiments, the present invention encompasses a composition comprising two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to BLyS, and each of which type of antibody or fragment thereof comprises a VL domain from a different scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128. [06161 - In specific embodiments, the present invention encompasses a composition comprising two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to BLyS, and each of which type of antibody or fragment thereof comprises a VL domain from a different scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128 and wherein each type of antibody or fragment thereof further comprises a VH domain from a different scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. [06171 In specific embodiments, the present invention encompasses a composition comprising two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to BLyS, and each of which type of antibody or fragment thereof comprises a VH CDR3 having an amino acid sequence of one of SEQ ID 247 NOS: 3129 to 3227. [06181 In specific embodiments, the present invention encompasses a panel of two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to BLyS, and each of which type of antibody or fragment thereof comprises a VH domain from a different scFv having an amino acid sequence of one of SEQ ID NO: I to 2128. 10619] In specific embodiments, the present invention encompasses a panel of two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to BLyS, and each of which type of antibody or fragment thereof comprises a VL domain from a different scFv having an amino acid sequence of one of SEQ ID NO: I to 2128. 10620] . In specific embodiments, the present invention encompasses a panel of two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to BLyS, and each of which type of antibody or fragment thereof comprises a VL domain from a different scFv having an amino acid sequence of one of SEQ ID NO: 1 to 2128 and wherein each type of antibody or fragment further comprises a VH domain from a different scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. [06211 In specific embodiments, the present invention encompasses a panel of two or more antibodies or fragments or variants thereof, each of which type immunospecifically binds to BLyS, and each of which type of antibody or fragment thereof comprises a VHCDR3 from a different scFv having an amino acid sequence of one of SEQ ID NOS: 2129 to 3227. [06221 In specific embodiments, the antibodies or fragments thereof of the antibody panel of the invention, are each in a well of a 96 well plate. 106231 In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS. 106241 In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment 248 thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 46, 321 to 329, 1563 to 1595, and 1881 to 1908, wherein said antibody or fragment thereof immunospecifically binds BLyS. 106251 In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1881 to 1908, wherein the antibody of fragment thereof immunospecifically binds the membrane-bound form of BLyS. [0626] In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1563 to 1569, wherein said antibody of fragment thereof immunospecifically binds the soluble form of BLyS. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed. 106271 In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host 249 cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed. [06281 In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 46, 321 to 329, 1563 to 1595, and 1881 to 1908, wherein said antibody or fragment thereof immunospecifically binds BLyS. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed. [06291 In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1881 to 2128, wherein the antibody of fragment thereof immunospecifically binds the membrane-bound form of BLyS. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed. 250 [0630] In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1563 to 1880, wherein said antibody of fragment thereof immunospecifically binds the soluble form of BLyS. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed. [06311 In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed. [06321 In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of 251 SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128 and in which said VL domain and said VH domain are derived from the same scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed. [06331 In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VHCDR3 from an scFv having an amino acid sequence of one of SEQ ID NOS: 2129 to 3227, wherein said antibody or fragment thereof .immunospecifically binds BLyS. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed. 106341 In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to BLyS, said antibody or fragment thereof comprising an amino acid sequence of a VH domain encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding a 252 VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. 106351 In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to BLyS, said antibody or fragment thereof comprising an amino acid sequence of a VL domain encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128. [0636] In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to BLyS, said antibody or fragment thereof comprising an amino acid. sequence of a VH domain encoded by a nucleotide sequence that hybridizes under highly stringent conditions to a nucleotide sequence encoding a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. [0637] In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to BLyS, said antibody or fragment thereof comprising an amino acid sequence of a VL domain encoded by a nucleotide sequence that hybridizes under highly stringent conditions to a nucleotide sequence encoding a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. [06381 In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to BLyS, said antibody or fragment thereof comprising an amino acid sequence of a CDR encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding a CDR from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. [06391 In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to BLyS, said antibody or fragment thereof comprising an amino acid sequence of a CDR encoded by a nucleotide sequence that hybridizes under highly stringent conditions to a nucleotide sequence encoding a CDR from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. [0640] In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to BLyS, said antibody or fragment 253 thereof comprising an amino acid sequence of a VH CDR3 encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding a VH CDR3 having an amino acid sequence of one of SEQ ID NOS: 2129 to 3227. [06411 In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to BLyS, said antibody or fragment thereof comprising an amino acid sequence of a VH CDR3 encoded by a nucleotide sequence that hybridizes under highly stringent conditions to a nucleotide sequence encoding a VH CDR3 having an amino acid sequence of one of SEQ ID NOS: 2129 to 3227. [06421 In specific embodiments, the present invention provides a method for detecting of aberrant expression of BLyS, comprising: [06431 assaying the level of BLyS expression in cells or a tissue sample of an individual using one or more antibodies or fragments or variants thereof that immunospecifically bind BLyS; and - [0644] comparing the level of BLyS assayed-in the cells or a tissue sample with a standard level of BLyS or a level of BLyS in cells or a tissue sample from an individual without aberrant BLyS expression, wherein an increase or decrease in the assayed level of BLyS or level in cells or a tissue sample from an individual without aberrant BLyS expression compared to the standard level of BLyS is indicative of aberrant expression. [06451 In specific embodiments, the present invention provides a method for diagnosing a disease or disorder associated with aberrant BLyS expression or activity, comprising: [06461 administering to a subject an effective amount of a labeled antibody or fragment thereof that immunospecifically binds to BLyS; [06471 waiting for a time interval following the administering for permitting the labeled antibody or fragment thereof to preferentially concentrate at sites in the subject where BLyS is expressed; [06481 determining background level; and [06491 detecting the labeled antibody or fragment thereof in the subject, such that detection of labeled antibody or fragment thereof above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of BLyS. 254 [06501 In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. 106511 In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above comprises a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128. 106521 In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above comprises a VH CDR3 having an amino acid sequence of one of SEQ ID NOS: 2129 to 3227. [0653] i specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above is conjugated to a diagnostic agent. 106541 In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above is conjugated to a diagnostic agent wherein the diagnostic agent is horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase. 10655] In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above is conjugated to a diagnostic agent wherein the diagnostic agent is fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin. [06561 In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above is conjugated to a diagnostic agent wherein the diagnostic agent is , 1311, mIn, 90 Y or "Tc. [06571 In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above is conjugated to a diagnostic agent wherein the diagnostic agent is luciferase, luciferin or aequorin. 106581 A pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS and a pharmaceutically acceptable carrier. 106591 A pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128, wherein said antibody or fragment thereof 255 immunospecifically binds BLyS and a pharmaceutically acceptable carrier. 106601 A pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128 and a pharmaceutically acceptable carrier. 106611 A pharmaceutical composition comprising at least one antibody or fragment thereof of comprising an amino acid sequence of one of SEQ ID NOS: 2129 to 3227 wherein said antibody or fragment thereof immunospecifically binds BLyS and a pharmaceutically acceptable carrier.. [06621 A method of treating, preventing or ameliorating a disease or disorder associated with aberrant BLyS expression or activity, comprising administering to an animal in need thereof the pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128 and a pharmaceutically acceptable carrier in an amount effective to treat, prevent or ameliorate the disease or disorder. This method may be used to treat an infectious disorder, cancer, and/or an autoimmune disease such as lupus or glomerular nephritis. 106631 A method of treating, preventing or ameliorating a disease or disorder associated with aberrant BLyS expression or activity, comprising administering to an animal in need thereof the pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS and a pharmaceutically acceptable carrier in an amount effective to treat, prevent or ameliorate the disease or disorder. This method may be used to treat an infectious disorder, cancer, and/or an autoimmune disease such as lupus or glomerular nephritis. (0664] A method of treating, preventing or ameliorating a disease or disorder associated with aberrant BLyS expression or activity, comprising administering to an 256 animal in need thereof the pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds BLyS and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: I to 2128 and a pharmaceutically acceptable carrier in an amount effective to treat, prevent or ameliorate the disease or disorder. This method may be used to treat an infectious disorder, cancer, and/or an autoimmune disease such as lupus or glomerular nephritis. [06651 A method of treating, preventing or ameliorating a disease or disorder associated with aberrant BLyS expression or activity, comprising administering to an animal in need thereof the pharmaceutical composition of comprising at least one antibody or fragment thereof of comprising an amino acid sequence of one of SEQ ID NOS: 2129 to 3227 wherein said antibody or fragment thereof immunospecifically binds BLyS and -a pharmaceutically acceptable carrier in an amount effective to treat, prevent or ameliorate the disease or disorder: This method may be used to treat an infectious disorder, cancer, and/or an autoimmune disease such as lupus or glomerular nephritis. 106661 This method may be used to treat an infectious disorder, cancer, and/or an autoimmune disease such as lupus or glomerular nephritis. EXAMPLES Abbreviations 0.2 M Tris-HCI, 0.5 mM EDTA, 0.5 M sucrose (TES) I -ethyl-3-[3-dimethylaminopropylcarbo diimide hydrochloride (EDC) 2TY supplemented with I OOg/ml ampicillin and 2% glucose (2TYAG) 2TY supplemented with IOOgg/ml ampicillin and 50jig/ml kanamycin (2TYAK) 3,3',5,5'-Tetramethyl Benzidine (TMB) 50% inhibitory concentration (1C 5 0 ) 6xPBS containing 18% Marvel blocking solution (6xMPBS) Absorbance (A) 257 Bovine serum albumin (BSA) Enzyme linked immunosorbent assay (ELISA) Foetal calf serum (FCS) Heavy chain variable (VH) Hepes buffered saline (HBS) Horseradish peroxidase (HRP) Immobilised Metal Affinity Chromatography (IMAC) Isopropyl B-D-thiogalactopyranoside (IPTG) Light chain variable(VL) Multiplicity of infection (MOI) N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] (1-lepes) Nanomolar (nM) N-Hydroxysuccinimide (NHS) PBS containing 3% Marvel (MPBS) Phosphate Buffered Saline (PBS) Phosphate Buffered Saline + 0.1% (v/v) Tween 20 (PBST) Picomolar (pM) Single chain fragment variable (scFv) Tumour Necrosis Factor-alpha (TNF-a) Tumour Necrosis Factor-beta (TNF-) TNF-related apoptosis inducing ligand (TRAIL) Definitions: [06671 In the following section "immobilized BLyS" refers to a soluble form of BLyS or biotinylated BLyS coated on a plastic assay plate (e.g., a 96 well plate), but does not refer to histidine tagged BLyS coated on a plastic assay plate.; "biotinylated BLyS" is a soluble form of BLyS except when used to coat an ELISA plate, in which case it would be "immobilized BLyS." Membrane bound forms of BLyS include, but are not limited to, U937 and P388 plasma membranes. 258 Example 1: Antibodies Immunospecifically Binding to Soluble And Membrane Bound BLyS [06681 A library of phage was screened in an assay to identify those phage displaying scFvs that immunospecifically bind to the soluble and membrane-bound forms of BLyS. Phage displaying scFvs that bound to immobilized BLyS were identified after panning on immobilized BLyS and assessment by ELISA for binding to immobilized BLyS. The BLyS that was immobilized on plates for these assays was purified from supernatants of Sf9 cells infected with a baculovirus expression construct as described in Moore et al., Science 285:260-263 which is hereby incorporated by reference in its entirety. Each of the identified scFvs were then sequenced. Certain sequences were isolated multiple times, thus a panel (panel 1) containing one member of each unique sequences was generated and further characterized for their ability to immunospecifically bind to the soluble and membrane-bound forms of BLyS. [0669] The derived amino acid sequences of these scFvs are shown in Table 1 above. The individual VH and VL segments of the scFvs were aligned to the known human germline sequences in V-BASE (Tomlinson et al, www.mrc-cpe.cam.ac.uk) and the closest germline identified. Example 2: Specificity of scFvs for BLyS and Membrane-Bound BLyS [06701 The specificity of each of the scFvs for both BLyS and membrane-bound BLyS was determined by phage ELISA. BLyS was immobilised onto plastic as a purified soluble form of the protein or as a membrane-bound form present on plasma membrane preparations from the human macrophage-like cell line, U937. Maintenance of U937 Cells [06711 U937 cells are a human monocyte-like, histiocytic lymphoma cell line known to express BLyS on their plasma membranes. They were maintained in RPMI 1640 supplemented with 4mM L-glutamine, 10% FCS, 10 U penicillin, 100 g/ml streptomycin (all reagents from Sigma). The cells were thawed from frozen stock and are either used for plasma membrane preparation, or split 1:5, after 2 days in culture when the cell density reaches 1 x 10 6 /ml. 259 Preparation of U937 Plasma Membranes (06721 To prepare plasma membranes, Ix10 9 U937 cells were harvested from their culture medium by centrifugation at 1000 rpm at 4*C for 5 minutes in a benchtop centrifuge. The cells were resuspended in 40 ml 12 mM Tris, pH 7.5, 250 mM sucrose and placed on ice. The cells are then lysed using a hand-held electric homogenizer (Labortechnik IKA Ultra-Turrax) for four, one minute, bursts. To check that cell lysis had occurred, 10 p1 cell lysate was added to 10 [1 Trypan blue and the cell lysate was examined under a microscope. After confirming lysis, the homogenate was centrifuged at 270 x g, for 10 minutes at 4*C to pellet the nuclear fraction and the supernatant was retained. The supernatant was centrifuged at 8000 x g, 10 mins, 4*C, to pellet the mitochondrial and lysosomal fractions and the supernatant was retained. The supernatant was then centrifuged at 100000 x g, 60 mins, 4"C to pellet the plasma membrane enriched fraction. The supernatant was discarded and the plasma membrane pellet was resuspended in I ml PBS and stored at -70*C. The protein concentration of the plasma membrane fraction was determined using a protein quantification kit (Biorad). Typical yields were between 5 and 10 mg of plasma membranes. Phaae ELISA (06731 To determine the specificity of each of the unique scFvs, a phage ELISA was performed for each scFv against human BLyS, U937 plasma membranes, TNFct (R&D Systems, Minneapolis, MN), BSA and uncoated well. Individual E. coli colonies containing a phagemid representing one of the unique scFvs from panel lwere inoculated into 96-well plates containing 100 jl 2TYAG medium per well. Plates were incubated at 37*C for 4 hours, shaking. M13KO7 helper phage was added to each well to a MOI of 10 and the plates were incubated for a further 1 hour at 37*C. The plates were centrifuged in a benchtop centrifuge at 2000 rpm for 10 minutes. The supernatant was removed and cell pellets were resuspended in 100 pl 2TYAK and incubated at 30*C overnight, shaking. The next day, plates were centrifuged at 2000 rpm for 10 min and the 100 jil phage containing supernatant from each well carefully transferred into a fresh 96-well plate. Twenty pl of 6xMPBS was added to each well, and incubated at room temperature for 1 hour to pre-block the phage prior to ELISA. 260 [001] Flexible 96-well plates (Falcon) were coated overnight at 4"C with human BLyS (1 pg/ml) in PBS, U937 plasma membranes (10 pg/ml) in PBS, TNFa (1 pg/ml) in PBS, BSA (1 pg/mli) in PBS, or PBS. After coating, the solutions were removed from the wells, and the plates were blocked for 1 hour at room temperature in MPBS. The plates were washed 3 times with PBS and then 50 pl of pre-blocked phage was added to each well. The plates were incubated at room temperature for 1 hour and then washed with 3 changes of PBST followed by 3 changes of PBS. To each well, 50 pl of an anti-gene VIII HRP conjugate (Pharmacia) at a 1 to 5000 dilution in MPBS was added and the plates incubated at room temperature for I hour. Each plate was washed three times with PBST followed by three times with PBS. Then 50 I1 of an HRP-labelled anti-mouse polymer (DAKO EnVision) diluted 1/50 in 3% MPBS was added and incubated for 1 hour at room temperature. Each plate was then washed three times with PBST followed by three times with PBS. Fifty pl of TMB substrate was then added to each well, and incubated at room temperature for 30 minutes or until colour development. The reaction was stopped by the addition of 25 pl of 0.5 M H 2
SO
4 . The signal generated was measured by reading the absorbance at 450nm (A 4 5) using a microtiter plate reader (Bio-Rad 3550). [0011 The results for 3 clones (1006E07, 1008D05 and I016F04) are shown in Figure 1. All 3 scFvs recognize immobilized BLyS and U937 plasma membranes but do not recognize TNFa, BSA or an uncoated well (PBS only). These results indicate that these scFvs specifically recognize immobilized BLyS and membrane-bound BLyS. Example 3: Inhibition in an In Vitro Receptor Binding Assay by Phage ScFvs [0676] All of the unique phage scFvs in panel 1 were assessed for their ability to inhibit soluble BLyS binding to its cognate receptor on IM9 cells. Biotinylation of BLyS 10677] One hundred pg of either human or mouse BLyS was dialysed overnight at 4 0 C against 50 mM sodium bicarbonate (sodium hydrogen carbonate) pH8.5 using a slide a-lyzer cassette (Pierce). The next day, NHS-biotin (Pierce) was dissolved in DMSO to 13.3 mg/mI. This was then added to the BLyS at a molar ratio of 20:1 biotin:BLyS, mixed 261 and incubated on ice for 2 hours. The biotinylated BLyS was then dialysed back into sterile PBS (Sigma) using a slide-a-lyzer cassette overnight at 4*C. The biological activity of the biotinylated BLyS was confirmed using the receptor binding inhibition assay (see below). Maintenance of IM9 cells 106781 IM9 cells are a human B lymphocyte cell line. They were maintained in RPMI-1640 supplemented with 4 mM L-glutamine, 10% FCS, 10 U penicillin, 100 g/ml streptomycin (all reagents from Sigma). The cells are thawed from frozen stock and can be used in assays after 5 days in culture when they reach a density of 4 - 8 x 105 /ml. Receptor binding inhibition assay 106791 Individual E. coli colonies containing a phagemid representing one of the unique scFvs from panel I were inoculated into 96-well plates containing 100 pl 2TYAG medium per well. Plates were incubated at 37* C for 4 hours, shaking. M13KO7 helper phage was added to each well to a MOI of 10 and the plates were incubated for a further I hour at 37*C. The plates were centrifuged in a benchtop centrifuge at 2000 rpm for 10 minutes. The supernatant was removed and ccl pellets were resuspended in 100 pl 2TYAK and incubated at 30*C overnight, shaking. The next day, plates were centrifuged at 2000 rpm for 10 min and the 100 pl phage-containing supernatant from each well carefully transferred into a fresh 96-well plate. Phage were diluted 1 in 2 in MPBS prior to use. [0011 Flat-bottomed 96-well plates (Costar) were coated with 100 RL per well of a 1:10 dilution of poly-L-lysine (Sigma) in PBS for 1 hour at room temperature. The plates were then washed twice with water, allowed to air-dry and placed at 4" C overnight. One hundred p1 of IM9 cells (at 10 6 /ml in RPMI- 1640 culture medium) were then added to each well. Plates were then centrifuged at 3200 rpm for 5 mins to pellet the cells. The media was carefully aspirated and 200 Il of MPBS added to each well. The plates were then allowed to block for 1 hour at room temperature. [06811 To a separate 96-well plate 10 pi of biotinylated BLyS (at 162.5 ng/ml) in MPBS was added to each well to give a final concentration of 25 ng/ml. Fifty-five t.1 of 262 each appropriate phage supernatant was added to each well and the final volume in each well was 65 pl. Plates were then incubated at room temperature for 30 minutes. (0682] The IM9 coated plates were washed twice in PBS, tapped dry and immediately 50 1 d of the phage/biotinylated-BLyS mix was added and incubated at room temperature for I hour. Plates were washed three times in PBST and three times in PBS, tapped dry and 50 pl of streptavidin-Delfia (Wallac) was added to each well at 1:1000 dilution in the Manufacturer's assay buffer. The plates were then incubated at room temperature for 1 hour and washed six times in Delfia wash solution (Wallac). After tapping the plates dry, 100 pA per well of Delfia enhancement solution (Wallac) was added. The plates were gently tapped to encourage micelle formation, incubated at room temperature for 10 minutes, and fluorescence read on a Wallac 1420 workstation at 6520 nM. (06831 Results for 3 phage scFvs (100 1C09, 101 8D07 and 1016H07) that inhibited the binding of biotinylated BLyS are shown in Figure 2. Maximal binding of biotinylated BLyS to its receptor (bio-BLyS only), the background signal in the absence of biotinylated BLyS (no bio-BLyS), and results with an irrelevant (i.e., does not recognize BLyS) phage antibody are also shown. All 3 phage scFvs inhibited biotinylated BLyS binding to its receptor on IM9 cells, identifying these scFvs as scFvs that bind the soluble form of BLyS. These scFvs also bind to U937 membranes, thus they also bind the membrane bound form of BLyS. [06841 Forty-eight of the scFvs from panel I that demonstrated the greatest inhibition as phage particles in this assay were chosen for further study. These 48 scFvs are listed in Table 3. Table 3. scFvs that Inhibit the Binding of Biotinylated-BLyS to its Receptor Antibody Antibody Antibody Antibody Antibody I008C02 1029D07 1008C03 1008C12 1028A06 1022E02 1061E07 1007H08 1061H01 1031C03 I018C02 I006D07 1008A I 1 I006D08 1031F02 263 1008B01 1017D10 1061D02 1026E03 1031F09 1016F04 1007B03 1008A09 1027A07 1031G 1I 1016E05 1018C10 1007F11 1016H07 1050A07 1018H08 I001C09 I037E07 1021B05 1050A12 I018H09 1018D07 I037E12 103lG10 I050BII 1029F11 1016F02 1031G08 1051C04 1022D01 1031C07 1003F12 1012A06 Example 4: Specificity of Anti-BLyS Antibodies [0685] The specificity of the 48 scFvs listed in Table 3 for human and murine BLyS was determined using phage ELISA. Phage ELISA [0011 To determine the specificity of the 48 scFvs, a phage ELISA was performed against human and mouse BLyS, and a panel of related and unrelated human antigens: Fas ligand, TRAIL, TNFc, TNF0, and PBS. The : Fas ligand, TRAIL, TNFc, and TNFp antigens were obtained from R&D Systems, Minneapolis, MN. Individual E. coli colonies containing phagemid were inoculated into 5 ml 2YTAG and incubated at 37*C for 4 hours, shaking. M13KO7 helper phage (Pharmacia) was added to each tube to a MOI of 10 and incubated for 30 minutes at 37*C for 1 hour, the first 30 minutes static and the final 30 minutes with gentle shaking. Cells were pelleted by centrifugation at 3,500 rpm for 10 minutes and the supernatant discarded. Cell pellets were resuspended in 5 ml 2TYAK and incubated at 30*( overnight with shaking. The next day, the cells were pelleted by centrifugation at 3,500 rpm for 10 minutes. The phage-containing supernatant (5 ml) was carefully transferred to a fresh tube, 1 ml of 6MPBS was added, and the tube was incubated at room temperature for 1 hour to pre-block the phage prior to ELISA. 106871 All antigens were coated at I ig/ml. ELISAs were performed essentially as described in Example 2. The only exception to this being the detection of phage antibody binding to mouse BLyS where the step involving incubation with the HRP 264 labelled anti-mouse polymer was omitted. Binding to mouse BLyS was detected with TMB as in Section Example 2. [0688] All 48 scFvs are specific for immobilized human BLyS and 43 out of the 48 scFvs cross-react with immobilized mouse BLyS but not with any other unrelated or related antigen tested. 1008C03, 1007F1 1, 1037E07, 1037E12, and 1016H07 did not bind murine BLyS. Results for two scFvs, 1022D01 and 103 1F02, are shown in Figure 3. Both these scFvs specifically recognize human and mouse BLyS but not any other unrelated or related antigen tested. Example 5: Specificity for the Membrane-Bound Form of BLyS [0689] The specificity of 48 scFvs for membrane-bound BLyS was determined by the phage ELISA described in Example 2. BLyS was immobilised onto plastic as a membrane-bound form present on plasma membranes preparations from the human macrophage-like cell line, U937. This cell line is known to express the membrane-bound form of human BLyS. (06901 To demonstrate that this binding is specific for membrane-bound BLyS, a competition ELISA was developed to determine if the ELISA signal for an individual antibody on U937's could be competed out by pre-incubation with either BLyS or TNFa. An anti-BLyS antibody that also recognizes membrane-bound BLyS would be expected to demonstrate a signal reduction with free BLyS but not free TNFa. Competition ELISA [06911 Individual E. coli colonies containing phagernid for each of the 48 scFvs listed in Table 3 were inoculated into 5 ml 2YTAG and incubated at 37"C for 4 hours, shaking. M13KO7 helper phage (Pharmacia) was added to each tube to a MOI of 10 and incubated for 30 minutes at 37* C for I hour, the first 30 minutes static and the final 30 minutes with gentle shaking. Cells were pelleted by centrifugation at 3,500 rpm for 10 minutes and the supernatant discarded. Cell pellets were resuspended in 5 ml 2TYAK and incubated at 30*C overnight with shaking. The next day, the cells were pelleted by 265 centrifugation at 3,500 rpm for 10 minutes. The phage-containing supernatants (5 ml) were carefully transferred to a fresh tube. [0692] For each of the 48 scFvs listed in Table 3, two aliquots of 20 1d 6xMPBS were pipetted into separate wells of a 96-well plate (Greiner). The first aliquot was supplemented with BLyS to a final concentration of 0.5 pg/ml. The second aliquot was supplemented with TNF-a to a final concentration of 0.5 pg/ml. Each experiment was performed in triplicate. One hundred [d of each phage supernatant was then added to each aliquot and mixed by pipetting up and down. The phage were incubated (± competing antigen) at room temperature for I hour. [0693] Flexible 96-well plates (Falcon) were coated overnight at 4*C with 50 PI of 10 pg/ml U937 plasma membranes. After coating, the plates were washed 3 times with PBS and blocked for 1 hour at room temperature with 200 pl MPBS. The plates were washed 3 times with PBS and 50 pl of phage (± competing antigen) was added to each appropriate well. The plates were incubated at room temperature for 1 hour and then washed with 3 changes of PBST followed by 3 changes of PBS. To each well, 50 p1 of a mouse anti-gene VIII-HRP conjugate (Pharmacia) at a 1:5000 dilution in MPBS was added and the plates incubated at room temperature for 1 hour. Each plate was washed three times with PBST followed by three times with PBS. Then 50 ll of an HRP-labellcd anti-mouse polymer (DAKO EnVision) diluted 1:50 in 3% MPBS was added and incubated for I hour at room temperature. Each plate was then washed three times with PBST followed by three times with PBS. Fifty pl of TMB substrate was then added to each well, and incubated at room temperature for 30 to 60 minutes or until color development. The reaction was stopped by the addition of 25 l of 0.5 M H 2
SO
4 . The signal generated was measured by reading the absorbance at 450nm (A 4 50 ) using a microtiter plate reader (Bio-Rad 3550). [06941 All 48 scFvs bind to U937 plasma membrane preparations. This signal could be competed out by pre-incubation of the phage antibody with BLyS but not by pre incubation with TNF-a. This indicates that the 48 scFvs specifically recognize membrane-bound BLyS as well as soluble BLyS. Typical results are exemplified by scFvs 1031F09, 1050A12 and 1051C04 and are shown in Figure 4. All 3 scFvs demonstrate binding to U937 plasma membranes. This binding was specifically competed 266 out with BLyS but did not compete with TNF-a, demonstrating specific recognition of membrane-boiind BLyS. Example 6: scFv Off-rate Determinations (06951 All off-rate determinations were performed on BlAcore 2000 machines, using the BlAcore 2000 Control Software and evaluated using the BlAevaluation 3.0 software. Preparation of a Low Density BLyS Surface [0696] A 500RU surface was prepared for kinetic studies with purified scFvs. A low density BLyS surface (500 RU BLyS coupled) was prepared in flow cell 2 by amine coupling to a CM5 chip. A new CMS chip was inserted into the BlAcore and a sensorgram initiated with HBS buffer at a flow rate of 5 1/min. The NHS and EDC coupling solutions (BlAcore) were mixed according to manufacturer's instructions and 30 pl injected over the CM5 surface. Fifty pi of BLyS at I pg/ml in 10 mM sodium acetate buffer, pH4, was then injected followed by 30 pL of ethanolamine-HCl solution (BlAcore). The flow rate was then adjusted to 20 pl/min and 10 pl of 4M guanidine hydrochloride in HBS injected over the surface. This strips the surface of non-covalently bound BLyS. Measurement of scFv off-rate kinetics on the low density surfaces (0697] The chip containing the low density BLyS surface was inserted in to the BlAcore. A dilution series of purified scFvs was prepared in HBS, typically 50 pg/ml doubling dilutions down to 1.5 ug/rml. The dilution series was then injected sequentially over the low density BLyS surface (and blank control) using the following program: MAIN FLOWCELL 1,2,3,4 APROG genab rldl abl APROG genab rld2 ab2 APROG genab rld3 ab3 APROG genab rld4 ab4 267 APROG genab rid5 ab5 APROG genab rld6 ab6 APPEND CONTINUE END DEFINE APROG genab PARAM %Abpos %AbId FLOW 20 KINJECT %Abpos 200 80 INJECT rlc6 10!guanidine hydrochloride regeneration step EXTRACLEAN END [06981 Bound scFvs were removed by injecting 10pl 4M GuHCl in HBS over the surface between scFv samples. (06991 The binding curves for individual scFvs were analyzed using the BIAevaluation software to determine antibody off-rates. Kinetic analysis for a typical scFv antibody, I003C02, is shown in Figure 5. 1003C02 has a Kff = 6 x 10 3 s~ . Example 7: Inhibition in an In Vitro Receptor Binding Assay by scFv Antibodies [0700] The 48 scFvs listed in Table 3 were purified and assessed for their ability to inhibit BLyS binding to its receptor on IM9 cells. Purification of scFv [0701] To determine the inhibitory potency of anti-BLyS scFv, scFv's were first prepared by IMAC. 2TYAG (5 ml) was inoculated with a single colony and grown overnight at 30*C, shaking. This overnight culture was then used to inoculate 500 ml of 2TY containing 100 pg/ml ampicillin and 0.1% Glucose, and grown at 300 C, shaking, until an A 600 of 1.0 was attained. IPTG was added to 1 mM and the culture was grown for a further 3.5 hours at 30*C. 268 10702] Cells were harvested by centrifugation at 5,000rpm, and resuspended in 10 ml of TES. A further 15 ml of a 1:5 dilution (in water) of TES was added, and the cell suspension incubated on a turning wheel at 4*C for 30 minutes. This causes osmotic shock and yields a periplasmic extract containing the scFv. Residual cells and debris were pelleted by centrifugation at 9,000 rpm for 20 minutes at 4'C. The supernatant was transferred to a new tube, and 50 pl of I M MgC 2 added. Two ml of a Ni-NTA agarose (Qiagen), pre-washed with buffer (50 mM sodium phosphate, pH 8, 300 mM NaCl) together with a protease inhibitor tablet (Boehringer Mannheim) were then added to the periplasmic extract. The preparation was incubated, rotating, overnight at 4*C. The Ni NTA was pelleted by centrifugation at 2,000 rpm for 5 minutes, and the supernatant was aspirated. The agarose beads were washed 3 times with 50 ml wash buffer, centrifuging to collect the agarose in between each wash. Ten ml of wash buffer was added after the final wash, and the slurry was loaded on to a polyprep column (BioRad). Two ml elution buffer (50 mM NaPi (sodium phosphate), pH 8, 300 mM NaCl, 250 mM imidazole) was added to the drained agarose, and the eluate was collected. IMAC purified scFv was buffer exchanged in to PBS by use of a Nap 5 column (Pharmacia) according to the manufacturer's instructions. The Am was read and the protein concentration determined using a molar extinction coefficient of 1 mg/mI protein = A, 1.4. Purified scFv was stored in 500 jl aliquots at -70*C. Receptor Binding Inhibition Assay 10011 Flat-bottomed 96-well plates (Costar) were coated with 100 [1 per well of a 1:10 dilution of poly-L-lysine (Sigma) in PBS for 1 hour at room temperature. The plates were then washed twice with water, allowed to air-dry and placed at 4 "C overnight. One hundred pl of IM9 cells (at 10 6 /ml in RPMI-1640) were then added to each well. Plates were then centrifuged at 3200 rpm for 5 mins to pellet the cells. The media was carefully aspirated and 200 pl of MPBS added to each well. The plates were then left to block for 1 hour at room temperature. 269 [07041 To a separate 96-well plate, titrate test scFvs in MPBS, in triplicate, over a concentration range from 10 jig/ml lown to 0.001 [g/ml were added. The final volume of test scFv in each well was 55 1 d. Competition with unlabelled BLyS was also included in every assay as a control. Unlabelled BLyS, in MPBS, was typically titrated in triplicate, over a concentration range from 1 ig/ml down to 0.001 Rg/ml. 10 td of biotinylated BLyS (at 162.5 ng/ml) in MPBS was added to each well to give a final concentration of 25 ng/ml. Plates were then incubated at room temperature for 30 minutes. [0705] The IM9 coated plates was washed twice in PBS, tapped dry and immediately 50 d of the scFv/biotinylated-BLyS mix was added and incubated at room temperature for 1 hour. Plates were washed three times in PBST and three times in PBS, tapped dry and 50 L per well added. of streptavidin-Delfia (Wallac) at 1:1000 dilution in the Manufacturer's assay buffer. The plates were then incubated at room temperature for 1 hour and washed six times in Delfia wash solution (Wallac). After tapping the plates dry, 100[l per well of Delfia enhancement solution (Wallac) was added. The plates were gently tapped to encourage micelle formation, incubated at room temperature for 10 minutes, and fluorescence read on a Wallac 1420 workstation at 6520 nM. [0706] Typical titration curves for two scFv antibodies, 1007F II and 1050A07, are shown in Figure 6. Unlabelled BLyS competed for binding to its receptor with an ICso value of 0.8 nM. The ICso values for 1007F I1 and I050A07 are 7.9 nM and 17.1 nM , respectively. The assay was performed in triplicate and standard error bars are shown. The 9 scFvs that demonstrated the greatest inhibition as scFv are listed in Table 4. This data also confirms that these9 scFvs recognize the soluble form of BLyS. Table 4: 9 ScFvs that demonstrated greatest potency in BLyS Receptor Binding Inhibition Assay ScFv Antibody 1017D10 1022D01 I008A1 1 1006D08 270 103 1F02 I050A12 1050B1I 1051C04 I003F12S Example 8: Antibodies recognizing a soluble form of BLyS [0707] A library of phage was screened in an assay to identify those phage displaying scFvs that immunospecifically bind to the soluble but not the membrane-bound forms of BLyS. [07081 A phage library was screened for the ability to bind to biotinylated BLyS. The phage were exposed to biotinylated BLyS, allowed an interval of time to bind the biotinylated BLyS. Phage binding bio-BLyS were then isolated by capture on streptavidin coated magnetic beads. 107091 The phage identified in the screen above (capture of Bio-BLyS from solution) were then screened by ELISA for their ability to bind immobilized BLyS. The scFv expressed by phage that bound immobilized BLyS were then cloned and sequenced. Again, several sequences were identified multiple times, thus a panel (panel 2) consisting of on example of each phage expressing a unique scFv was then characterized further. [0710] The derived amino acid sequences of these scFvs are shown in Table 1 above. The individual VH and VL segments of the scFvs were aligned to the known human germline sequences in V-BASE (Tomlinson et al, www.mrc-cpe.cam.ac.uk) and the closest germline identified. Example 9: Specificity For Soluble BLyS [0711] The scFvs were isolated from a library of phage based on their ability to bind a soluble form of BLyS. Briefly, phage were preincubated with biotinylated BLyS in solution. Phage that bound to this biotinylated BLyS were then isolated using streptavidin coated magnetic beads. [0712] The specificity of each of the unique scFvs for BLyS and for the membrane-bound form of BLyS, was determined by phage ELISA. BLyS was immobilised onto plastic as a purified soluble form of the protein or as a membrane-bound 271 form present on plasma membrane preparations from the human macrophage-like cell line, U937. Maintenance of U937 cells and plasma membrane preparations were performed as detailed in Example 2. Phage ELISA 107131 To determine the specificity of each of the scFvs, a phage ELISA was performed for each antibody against human BLyS, U937 plasma membranes, TNFa, BSA and an uncoated well. Antigen coating conditions were as described in Example 2, apart from human BLyS. BLyS was first biotinylated (as described in Example 3) and coated at 1 Lg/ml onto streptavidin coated plates (Reacti-Bind, Pierce) for 30 mins at room temperature. The plates were thcn washed, blocked and the phage ELISA performed as detailed in Example 2. 10011 The results for 3 clopes (1074B 12, 1075F12 and 1075A02) that bind the soluble but not the membrane-bound form of BLyS are shown in Figure 7. As a control, a phage antibody that recognizes TNFax, is also shown in Figure 7. There is a small non specific background signal on the U937 plasma membranes that is evident with both the anti-BLyS scFvs as well as the anti-TNFa control. All 3 anti-BLyS scFvs recognize BLyS but not U937 plasma membranes, TNFa, BSA or an uncoated well (PBS only). This indicates that the scFvs do not bind the membrane-bound form of BLyS. Further, The fact that these scFvs were isolated on the basis of their ability to bind soluble biotinylated BLyS indicates that they bind the soluble form of BLyS. Further confirmation of these scFvs' specificity for BLyS is provided in Example 10. Example 10: Inhibition in an in vitro receptor binding assay by phage scFvs [07151 All of the unique phage scFvs from panel 2 were assessed for their ability to inhibit BLyS binding to its cognate receptor on IM9 cells. The biotinylation of BLyS, maintenance of IM9 cells and receptor binding inhibition assay were performed as described in Example 3. (07161 Results for two phage scFvs, 10025B09 and 1026C04 are shown in Figure 8. Maximal binding of biotinylated BLyS to its receptor (bio-BLyS only), the background signal in the absence of biotinylated BLyS (no bio-BLyS), and results with an irrelevant (i.e. does not recognize BLyS) phage antibody are also shown. Both phage scFvs inhibited 2"2 biotinylated BLyS binding to its receptor on IM9 cells. 33 of the unique scFvs from panel 2 were identified for further study. These 33 scFvs demonstrated the greatest inhibition as phage particles in this assay and are listed in Table 5. Table 5: Identification of 33 phage scFvs to free BLyS that demonstrate the most significant inhibition of biotinylated-BLyS binding to its receptor Antibody Antibody Antibody Antibody 1026C04 1074B12 1073F04 10651D04 1003C06 lO75AO2 I078D08 1068C08 1025B09 1068B08 I078D02 1068F03 1027B12 1068B04 I(Y75GO1 1069B07 1025B06 1068C06 1071B03 1030A10 1075F12 I072B09 I002AO1R 1065D08 1078H08 1002A01 K 1065F08 1064C04 1026C04R 1067B10 1064C07 1026C04K 1067F05 P Example 11: Specificity of anti-BLyS scFvs [07171 The specificity of the 33 scFvs (listed in Table 5) for immobilized human and murine BLyS was determined using phage ELISA. Phage ELISA (0011 To determine the specificity of the 33 scFvs, a phage ELISA was performed as described in Example 4 against human and mouse BLyS, and a panel of related human antigens: TRAIL, LIGHT, TNFa, TNFp, and an uncoated well (PBS only). 107191 Typical results for two scFvs, 1067F05 and 1078D02 are shown in Figure 9. A control antibody that specifically recognizes TNFa is also shown. Both anti-BLyS scFvs specifically recognize immobilized human and mouse BLyS but not any other antigen tested. [07201 All 33 scFvs are specific for human BLyS. 14/33 cross-react with mouse BLyS but not with any other unrelated or related antigen tested. 273 Example 12: scFv Off-Rate Determinations 107211 Off-rate determinations, preparation of a low density BLyS surface and kinetic measurements were as detailed in Example 6. [07221 The binding curves for individual scFvs were analysed using the BlAevaluation software to determine antibody off-rates. Kinetic analysis for a typical scFv antibody, 1002A01, is shown in Figure 10. 1002A01 has a Kf = 9 x 10 ~4 s". Example 13: Inhibition in an in vitro receptor binding assay by scFv antibodies [07231 The 33 scFvs identified in Table 5 were prepared as purified scFvs and assessed for their ability to inhibit BLyS binding to its receptor on IM9 cells. The scFvs were purified and analysed in the receptor binding inhibition assay as described in Example 6.1.8. [0724] Typical titration curves for two scFvs, 10068C06 and 1074B12, are shown in Figure 11. Unlabelled BLyS competed for binding to its receptor with an inhibitory constant 50 (IC 50 ) value of 0.66 nM. The IC 50 values for 10068C06 and 1074B12 are 61 nM and 13 nM , respectively. The assay was performed in triplicate and standard error bars are shownt The 7 scFvs that demonstrated the greatest inhibition as scFv are listed in Table 6. Table 6: Identification of 7 scFvs to free BLyS that demonstrate the most significant inhibition of biotinylated-BLyS binding to its receptor as purified scFv's. Antibody 1002A0I-R 1002A01-K I026C04-R 1026C04-K 1068C06 1075F12 1067B10 Example 14: ScFvs Recognizing Membrane-bound BLyS 274 107251 A library of phage was screened in an assay to identify those phage displaying scFvs that immunospecifically bind to the membrane-bound but not the soluble form of BLyS. 10726] As a starting point, a library of phage expressing scFv antibodies were panned on immobilized HIS-tagged BLyS. Phage isolated by panning were then screened for the ability to bind to HIS-tagged BLyS. HIS-tagged BLyS was obtained by expressing amino acids 71-285 of SEQ ID NO:3228 using the pQE9 vector (Qiagen Inc., Valencia, CA) in E. coli and purifying the expressed protein. This phage clones identified by this screen were then sequenced. After sequencing, A panel (panel 3) of phage each expressing a unique scFv that bound HIS-tagged BLyS was generated and further characterized. [0727] The derived amino acid sequences of the unique scFvs from panel 3 are shown in Table 1 above. The individual Vi and VL segments of the scFvs were aligned to the known human germline sequences in V-BASE (Tomlinson et al, www.mrc cpe.cam.ac.uk) and the closest germline identified. Example 15: Recognition of Membrane-bound BLyS [0728] The specificity of each of the unique scFvs for both the membrane-bound form of BLyS as well as for the soluble form of BLyS, was determined by phage ELISA. [0729] BLyS was immobilised onto plastic either directly as a purified soluble form of the protein or biotinylated and coated on a streptavidin plate as in Example 9. Binding to HIS-tagged BLyS was used as a primary screen for scFv's that would bind the membrane-bound form of BLyS (see below). The membrane-bound form of BLyS was presented as plasma membranes preparations from the human macrophage-like cell line, U937 or the murine cell line P388. [07301 Mouse monoclonal antibodies have been raised against His-tagged BLyS according to standard procedures. Characterization of these mouse monoclonal antibodies revealed that they specifically recognized both His-tagged BLyS and the membrane-bound form of BLyS on U937 cells, but not soluble BLyS. Therefore, specific recognition of His-tagged BLyS was used as supporting evidence for the recognition of the membrane bound form of BLyS by phage and scFv antibodies. 275 Phage ELISA [0011 To determine the specificity of each of the scFvs, a phage ELISA was performed for each antibody against His-tagged human BLyS, U937 plasma membranes, TNFca, BSA and an uncoated well. Antigen coating conditions were as described in 2. apart from human BLyS. BLyS was first biotinylated (as described in Example 3) and coated at 1 ig/ml onto streptavidin coated plates (Reacti-Bind, Pierce) for 30 mins at room temperature. The plates were then washed, blocked and the phage ELISA performed as detailed in Example 2. [0732] The results for 3 clones, 1079C01, 108 ICIO and 1082A02, and a control phage antibody that recognizes TNFa, are shown in Figure 12. All 3 scFvs recognize U937 plasma membranes (U937) and His-tagged BLyS (HIS-BLyS) but not, biotinylated BLyS (bio-BLyS) or an uncoated well (PBS). This indicates that the scFvs recognize the membrane-bound form of BLyS. Example 16: Specificity for Membrane-bound BLyS [0733] The specificity of the scFvs for only the membrane-bound form of BLyS, and not for the soluble form, was confirmed using a competition ELISA. This assay assesses the ability of test phage scFvs to bind to the membrane-bound form of BLyS on U937 plasma membranes in the presence of different forms of competing BLyS. Competing BLyS was either the His-tagged form of BLyS or soluble BLyS. ScFvs specific for the membrane-bound B'LyS would be expected to be competed out by pre incubation with His-tagged BLyS but not by pre-incubation with soluble BLyS. 10734] Maintenance of U937 cells and plasma membrane preparations were performed as detailed in Example 2. Competition ELISA [0735] U937 plasma membranes (50s4 per well ) were coated at 10 g/ml in PBS onto Falcon 96-well plates overnight at 4*C. 10736] Individual E. coli colonies containing a phagemid representing one of the unique scFvs from the panel 3 were inoculated into 50 ml tubes (Falcon) containing 5 ml 2TYAG medium. Tubes were incubated at 37*C for 4 hours, shaking. M13K07 helper phage was added to each tube to an MOI of 10 and the tubes were incubated for a further 1 276 hour at 37*C. The tubes were centrifuged in a benchtop centrifuge at 3500 rpm for 10 minutes. The supernatant was removed and cell pellets were resuspended in 5 ml 2TYAK and incubated at 30*C overnight, shaking. The next day, tubes were centrifuged at 3500 rpm for 10 min and the phage-containing supernatant carefully transferred into a fresh tube. [07371 For each test phage antibody, 3 aliquots of 20pl 18% marvel/6xPBS were transferred into separate wells of a 96-well plate. The first aliquot was supplemented with His-tagged BLyS to a final concentration of 60 tg/ml. The second aliquot was supplemented with soluble BLyS to a final concentration of 60 [Lg/ml. The third aliquot was not supplemented with any competing antigen. One hundred [d of phage supernatant was then added to each aliquot and left to block at room temperature for I hour. [07381 The antigen-coated plates were washed once with PBS before the addition of 200 1i/well 3% marvel/PBS. These plates were left to block at 37*C for 1 hour and were then washed once with PBS. Duplicate samples of 50 pl pre-blocked phage (above) were added to the antigen-coated plates and left at room temperature for 1 hour. Plates were washed 3x with PBS/0.1%Tween 20, then 3x with PBS. Fifty pLl/well mouse anti M13 HRP (Pharmacia) at 1/5000 in 3% MarveVPBS was added and left for 1 hour at room temperature. Plates were washed 3 times with PBS/O.1%Tween 20, then 3 times with PBS. Fifty [L1/well HRP-labelled anti-mouse Envision polymer (DAKO) at 1/50 in 3% marvel/PBS was added and left for I hour at RT. Plates were washed 3 times with PBS/0.1% Tween 20, then 3 times with PBS. Next, 50l/well of TMB (Sigma) was added and plates left to develop for 30 to 60 minutes. When sufficient color has developed, 25[d/well 0.5M H 2
SO
4 was added to stop the reaction. The plates were read at 450nm on a microtiter plate reader (Bio-Rad 3550). 10011 The results for 3 closes, 1079B04, 1079F08 and 1080BO, and a control phage antibody that recognizes TN.Fa, are shown in Figure 13. All 3 scFvs recognize U937 plasma membranes (U937). This binding is competed out to background levels (i.e. comparable to the signal observed with the anti-TNFa. phage antibody) in the presence of His-tagged BLyS (HIS-BLyS) but not biotinylated BLyS (bio-BLyS). This confirms that the scFvs specifically recognize the membrane-bound form but not the soluble form of BLyS. 277 Example 17: High Throughput BI[Acore Screen to identify high affinity scFvs [0740] This is a 96-well screen where the test samples (scFvs) are derived from 1 ml periplasmic extracts of individual antibody expressing clones. Potentially higher affinity scFvs are then identified principally as those giving a large number of total RU's bound to a HIS-BLyS surface in BlAcore. This method of ranking does assume approximately equal yields of scFv from each clone. Since this is not always the case, some scFvs may also be identified that simply express high levels of scFv. These can be discriminated from those of higher affinity by further characterization of the scFvs (see Example 18). Preparation of ScFv from Imil E.coli Cultures [0741] Individual E.coli colonies containing a phagemid representing one of the unique scFvs from panel 3 were inoculated into 96-well plates containing 100 Pl 2TYAG medium per well. Eight wells on each plate were reserved for positive and negative control samples. The plate was grown overnight at 30'C with shaking at 120 rpm. [0742] Next day, Iml of 2TYAG + 345 mM sucrose was added to each well of an autoclaved 96 deep well plate (Beckman). Twenty tI of each overnight culture was resuspended and transferred to the appropriate well of the deep well plate. The plate was grown for approximately 3.5 hours at 30"C with shaking at 250 rpm (or until the OD6o = 0.6). Fifty p1 of IM IPTG was added to 5ml 2TY and lOI of this was added to each well. The plate was grown overnight at 30'C with shaking at 250rpm. [07431 Plates were kept at 4*C for the remainder of the procedure. The overnight plate (above) was centrifuged at 3500 rpm for 10 minutes at 4'C to pellet the cells. The supernatant was decanted and each pellet resuspended in 100[d TES (0.2M Tris HCl pH8.0, 0.5mM EDTA, 0.5M sucrose) and transferred to a fresh 96 well plate. This plate was incubated on ice for 30 minutes and then centrifuged for 10 minutes at 3500 rpm at 4'C to pellet the cell debris. During centrifugation, 15I of freshly made protease inhibitors cocktail (Roche, I tablet dissolved in 1.5 ml water) was added to each well of a fresh 96 well plate. Supernatants from the centrifuged plate were then transferred to the plate containing the protease inhibitors. The plate was centrifuged at 3500 rpm for 10 minutes at 4'C and the supernatant was transferred to a further 96-well plate. This step was repeated at least once more or until there was no sign of any cell debris following 278 centrifugation. Finally, the plate was covered in foil to prevent evaporation of samples during the BlAcore run. Generation of a high density HIS-BLyS surface [0744] All BIAcore analysis was performed on BlAcore 2000 machines, using the BlAcore 2000 control software and evaluated using the BlAevaluation 3.0 software. A high density His-tagged BLyS surface (>1000 RU HIS-BLyS coupled) was prepared in flow cell 2 by amine coupling to a CM5 chip. A new CM5 chip was inserted into the BlAcore and a sensorgram started over flow cell 2 with HBS buffer at a flow rate of 5ln/min. The NHS and EDC solution were mixed 1:1 before injecting 30[1I over the CM5 surface. Fifty [1 HIS-BLyS (at 10tg/ml in Sodium acetate buffer, pH4) was injected and allowed to couple to the surface. Thirty jil of ethanolamine-HCI solution was then injected to block free NHS esters. Prior to using the chip, I 0pl of 4M Guanidine hydrochloride in HBS was injected over the surface to strip the surface of non-covalently bound BLyS. A blank surface (no HIS-BLyS) was also prepared over flow cell I so that non-specific binding effects can be subtracted from the HIS-BLyS binding curves. 107451 Typically, a 5000 RU His-tagged BLyS surface was generated in this way and used for 96-well analysis of scFvs isolated from the periplasm of E.coli. BlAcore Analysis [0746] The 96-well plate containing periplasmic scFvs was secured inside the BlAcore. Two ml of 4M Guanidine hydrochloride in HBS was placed in a rack inside the BlAcore for regeneration of the HIS-BLyS surface between samples. The sensorgram was run over flow cells 1 and 2 at a flow rate of 20 1/minute. The following method was run: MAIN FLOWCELL 1,2,3,4 LOOP cycle STEP APROG inj %pos ENDLOOP 279 APPEND CONTINUE END DEFINE LOOP cycle LPARAM %pos rIal rib1 ric1 ridl riel rfl etc (all wells listed until rlhl2) END DEFINE APROG inj PARAM %pos FLOW 20 KINJECT %pos 35 30 !scfv injection QUICKINJECT r2f3 10 !regeneration EXTRACLEAN END [0011 When the run had fished, the sensorgram data for flow cell 1 was subtracted from the data for flow cell 2 for each sample using the BlAevaluation software. The clones were compared with one another principally by overall RU change as the scFv dissociates from the surface. In addition a few scFvs were identified as having potentially slower off-rates. An example of the dissociation section of a typical sensorgram for 8 scFvs is shown in Figure 14. An anti-TNFa antibody that does not recognize BLyS was included as a control. Of the 8 scFvs exemplified, 1079F06 was identified for further study due to the relatively high numbers of RU's bound to the surface. [07481 ScFvs were identified principally if they demonstrated a RU change of over 1200, a few were also identified as having potentially slower than typical off-rates. A total 280 of 28 clones were chosen on these criteria and are listed in Table 7. Table 7: Identification of 28 antibodies to membrane-bound BLyS that demonstrate the most significant RU changes by BlAcore Antibody Antibody 1079C01 I084C04 1082H08 I080E05 1079E02 I083B12 1029B05 1082G01 I079F06 I082G02 I079F08 I082C03 1079F11 I082A05 I079B12 I082D07 I080B01 1082B08 I080G09 I084A01 I099D03 I084B02 I080D03 T080A08 I080A03 I084C11 I083G03 I080G07 Example 18: scFv Affinity Determinations [0749] The affinity (KD) of the 28 scFvs was determined using the BlAcore. Low Density HIS-BLyS Surface for Kinetic Studies [0750] 500RU surfaces were used for kinetic studies of purified scFv binding to HIS-BLyS. The method to prepare these surfaces was identical to the method described in Example 17, only smaller volumes of IUS-BLyS were injected. Measurement of scFv Binding Kinetics 107511 The chip containing the low density HIS-BLyS surface was inserted into the BlAcore. A dilution series for each of the 28 purified scFvs (prepared as in Example 6) were diluted in HBS (typically starting with 50Wg/mI scFv and double diluting down to 1.5[ig/ml). The dilution series was then injected sequentially over the blank control (flow cell 1) and low density HI1S-BLyS surface (flow cell 2) using the following program: 281 MAIN FLOWCELL 1,2,3,4 APROG genab ridl ab1 APROG genab rld2 ab2 APROG genab rld3 ab3 APROG genab rld4 ab4 APROG genab rid5 ab5 APROG genab rld6 ab6 APPEND CONTINUE END DEFINE APROG genab PARAM %Abpos %AbId FLOW 20 KINJECT %Abpos 200 80 INJECT r2f3 10 EXTRACLEAN END [07521 Bound scFv were removed by injecting 10ld of 4M Guanidine hydrochloride in HBS (location r2f3 in the above program) over the surface between samples. Binding curves for individual scFv were analysed using the BlAevaluation software to determine antibody on- and off-rates. [0753] A typical example of the binding curves generated for the scFv antibody 1082C03 is shown in Figure 15. The off-rate for this clone was calculated as 2xl0- s 1 . The affinity of 1082C03 was calculated as 20 nM, assuming 100% activity of the scFv. The 5 scFvs with the highest affinities as scFvs are given in Table 8. Table 8: Identification of 5 antibodies to membrane-bound BLyS that have the highest affinities as scFvs 282 Antibody Affinity (KD) I079F11 5nM 1079E02 lOnM I082G02 6nM I082H08 lnM 1099D03 4nM Example 19: Recognition of mouse membrane-bound BLyS 107541 The ability of the 5 scFvs listed in Table 8 to also recognize murine membrane-bound BLyS was determined using a competition ELISA. This assay assesses the ability of test phage scFvs to bind to the membrane-bound form of BLyS on the murine cell line, P388, plasma membranes in the presence of different forms of competing human BLyS. Competing BLyS was either presented as the His-tagged form of BLyS, or soluble BLyS. ScFvs that recognize mouse membrane-bound BLyS would give an ELISA signal on the P388 plasma membranes that is competed out by pre-incubation with HIS tagged BLyS but not by pre-incubation with soluble BLyS. Maintenance of P388.D1 cells and preparation of plasma membranes 107551 P388.D1 cells are a mouse monocyte-macrophage like cell line. They were cultured in L-15 medium supplemented with 2mM L-glutamine, 10% CS, 1OU penicillin, 1OOg/mI streptomycin (all reagents from Sigma). Cells were split 1:4 every 3-4 days to maintain a cell density of 2-8 x 10' per ml. A fresh aliquot of cells was thawed from liquid nitrogen every 6 weeks. Plasma membrane fractions were prepared as described in Example 2. Competition ELISA 107561 P388 plasma membranes (50pl per well ) were coated at 10Ag/ml in PBS onto Falcon 96-well plates overnight at 4*C. The method is otherwise essentially as described Example 16. [07571 The results for 3 clones, 1079E02, 1082H08 and 1099D03 are shown in Figure 16. All 3 scFvs recognize P388 plasma membranes. This binding is competed out in the presence of HIS-tagged BLyS (IS-BLyS) but not in the presence of biotinylated BLyS (bio-BLyS). This confirms that these scFvs also recognize the membrane-bound 283 form but not the soluble form of mouse BLyS. Example 20: Conversion of seFvs to IgG1 format [07581 The VH domain and the VL domains of scFvs that we wished to convert into IgG molecules were cloned into vectors containing the nucleotide sequences of the appropriate heavy (human IgG1) or light chain (human kappa or human lambda) constant regions such that a complete heavy or light chain molecule could be expressed from these vectors when transfected into an appropriate host cell. Further, when cloned heavy and light chains are both expressed in one cell line (from either one or two vectors), they can assemble into a complete functional antibody molecule that is secreted into the cell culture medium. Methods for converting scFvs into conventional antibody molecules are well known within the art. Generation of NSO cell lines expressing anti-BLyS antibodies (IgG1) [07591 Plasmids containing the heavy and light chains were separately linearized using the Pvu 1 restriction enzyme. The linearized DNAs were purified by phenol chloroform extraction followed by ethanol precipitation and then resuspended in H 2 0. NSO cells (I0) from a growing culture were electroporated (0.25kV and 975pF) in PBS with 12.5 pg linearized heavy chain plasmid DNA and 37.5 pg linearized light chain DNA. The cells were washed in 20 ml non-selective medium (10% FCS in DMEM supplemented with 6mM glutamine, amino acids and penicillin/streptomycin) and then transferred in 12.5 ml medium into a T75cm 2 flask and incubated overnight at 37C, 5%
CO
2 /air. The day after transfection the cells were resuspended in selective medium containing 1mg/ml geneticin and dispensed into 5 x 96-well plates at 200 pl/well. After 18 days at 37C (5% C0 2 /air) the colony supernatants were screened by an ELISA that detects assembled human IgG in order to identify colonies expressing IgG. Approximately twenty positive colonies were expanded and adapted to growth in serum free, selective medium. Duplicate T25cm 2 flasks were set up. Cells from one flask were frozen down as a stock and cells in the second flask were grown to saturation. The productivity of the saturated cultures was assessed by ELISA. The highest producing cell lines were then selected for large-scale antibody production. [07601 The above procedure is exemplified for the 1006D08 anti-BLyS antibody 284 constructs. Following electroporation and selection of NSO cells, supernatants from ninety-three wells each containing a single colony were screened by ELISA to detect assembled IgG1, antibody. Twenty-seven of the supernatants were identified as containing IgG. The colonies from 24 of the positive wells were transferred to Iml selective medium in a 24-well plate and allowed to grow for 2 days. The Imi cultures of cells were then added to 4m1 selective medium containing reduced serum (0.5% FCS) in a T25cm2 flask. When the cultures reached confluency 1 ml cells were diluted in 4ml selective, serum-free medium in a T25cm 2 flask. At confluency this subculture regime was repeated again. Finally iml cells from the culture containing 0.1% FCS was diluted with 9 ml serum-free, selective medium and divided into 2 x T25cm 2 to form the saturated and stock cultures. The stock cultures were frozen down and stored in liquid nitrogen once the cultures were confluent. The saturation culture was grown until the viability of the culture was < 10%. Twenty-three out of the 24 colonies originally expanded were successfully adapted to growth in serum-free medium. The productivity of these scrum-free adapted cell lines ranged from 0.3 to 17 pg/ml by ELISA quantification of the saturated, 5ml serum-free cultures. The 1006D08-32 cell line produced 17 [Lg/ml. Large-scale IgG production [0011 . The highest-producing cell lines were revived from frozen stocks and then expanded to.400ml in selective, serum-free medium in 2 liter roller bottles. The cells were grown at 37'C and rolled at 4 rpm with the headspace being re-equilibrated with 5%
CO
2 /air every 2-3 days. Finally the culture was expanded to a 4 liter volume by the addition of serum-free medium without selection (400 ml per 2 liter roller bottle). The cultures were then grown to saturation. [0011 This procedure is exemplified by the production of 1006D08 antibody from the 1006D08-32 cell line. The frozen stock of I006D08-32 was revived into a T25 cm 2 containing 5 ml serum-free medium containing 1mg/ml geneticin and grown at 37'C in 5% CO2/air incubator. After two days growth the culture was diluted with 7.5 ml fresh medium and transferred to a T75cm 2 flask. After a further three days in the incubator the cells were transferred to 130 ml selective medium and transferred to a 2 liter roller bottle. After three days growth the cells were diluted with 500 ml selective medium and split into 2 x 2 liter roller bottles. After another 2 days 100 ml fresh selective medium was added to 285 each roller. Finally the next day the culture was expanded to a total volume of 4 liters with non-selective medium and divided into 10 x 2 liter roller bottles. After three days the medium was supplemented with 6mM glutamine. The cells were grown for 17 days from the final subculture into a 4 liter volume. The cells grew up to 3 x10 6 cells/ml before viability declined to < 0.2 x 106 cells/ml. At this low viability the culture supernatants were harvested. ELISA analysis indicated that the culture supernatant contained 33 pig/ml IgG. Hence, the 4 liter culture contained 132 mg IgG. IgG Purification [07631 The purification of the IgG from the fermentation broth is performed using a combination of conventional techniques commonly used for antibody production. Typically the culture harvest is clarified to remove cells and cellular debris prior to starting the purification scheme. This would normally be achieved' using either centrifugation or filtration of the harvest. Following clarification, the antibody would typically be captured and significantly purified using affinity chromatography on Protein A Sepharose. The antibody is bound to Protein A Sepharose at basic pH and, following washing of the matrix, is eluted by a reduction of the pH. Further purification of the antibody is then achieved by gel filtration. As well as removing components with different molecular weights from the antibody this step can also be used to buffer exchange into the desired final formulation buffer. Purification of 1006D08 IgGl 10011 .The harvest was clarified by sequential filtration through 0.5 iim and 0.22 [Lm filters. Clarified harvest was then applied to a column of recombinant Protein A Sepharose equilibrated at pH 8.0 and washed with the equilibration buffer. 1006D08 antibody was eluted from the Protein A Sepharose by application of a buffer at pH3.5. The collected antibody containing eluate was then neutralized to pH 7.4 by the addition of pH 8.0 buffer. The neutralized eluate was concentrated by ultrafiltration using a 30 KDa cut off membrane. Concentrated material was then purified by Sephacryl S300HR gel filtration using phosphate buffered saline as the mobile phase. The final monomeric IgG1 fraction from the gel filtration column was then concentrated to the desired formulation 286 concentration by ultrafiltration using a 30 KDa cut off membrane. The final product was filtered through a 0.22 pm filter. Example 21: Antibody neutralization of murine splenocyte proliferation as measured by 3HdT incorporation [07651 To determine if an antibody inhibited BLyS mediated B cell proliferation, a splenocyte proliferation assay was performed Briefly, murine splenocytes were isolated by flushing spleen with complete medium using a 2 5g needle and 10 ml of complete medium (RPMI 1640 with 10% FBS containing 100U/ml penicillin, 100 g/ml streptomycin, 4mM glutamine, 5xl0- 5 M s-mercaptoethanol). The cells were passed through a 100 micron nylon filter to remove cell clumps. The cell suspension was then ficolled at 400 x g for 25 minutes at room temperature (one 15 ml conical tube/spleen; 3 ml ficol, 10 ml cell suspension/spleen; Ficol 1083 from Sigma). The recovered cells were washed 3 times in complete medium and counted. Recovered cells were then diluted to a concentration of 3x10 6 /ml in complete medium containing a 3X concentration of SAC (3X = 1:33,333 dilution of stock) (Staph. aureus Cowan strain; Calbiochem). [0766] For each antibody, 50 microliters of antibody dilutions at 30[ig/ml, 3.0 g/ml, and 0.3pg/ml concentrations were aliquotted into individual wells of a 96 well plate in triplicate. Suitable positive controls, such as, for example monoclonal antibody 15C0, were also used. Medium containing no antibody (and human isotype controls (purchased commercially) when necessary) were used as negative controls. [07671 BLyS protein was diluted in complete medium to concentrations of 300ng/ml, 90ng/ml and 30ng/ml. 50 microliters of each of the BLyS dilutions were then added to the antibody dilution series in the plates. The plate containing the antibody and BLyS dilutions are then incubated for 30 minutes at 37*C, 5% CO 2 , after which 50 microliters of the splenocyte cell suspension containing SAC was added to all wells. The plates were then incubated for 72 hours (37*C, 5% CO 2 ). 10768] After 72 hours, each well was supplemented with 50sAl of complete medium containing 0.5 Ci of 3H-thymidine (6.7 Ci/mM; Amersham) and cells were incubated for an additional 20-24 hours at (37"C, 5% CO 2 ). Following incubation cells were harvested using a Tomtec Cell Harvester and filters counted in a TopCount 287 Scintillation counter (Packard). Example 22: Human B cell proliferation assay for in vitro screening of BLyS antagonist molecules [0769] The bioassay for assessing the effects of putative BLyS antagonists was performed in triplicate in 96 well format by mixing equal volumes of BLyS, responder cells, and putative antagonist each of which is prepared as a 3X stock reagent. [07701 B-lymphocytes were purified from human tonsil by MACS (anti-CD3 depletion), washed, and resuspended in complete medium (CM) (RPMI 1640 with 10% FBS containing IOOU/ml penicillin, 100Ig/ml streptomycin, 4mM glutamine, 5xlOE-5 M beta-mercaptoethanol) at a concentration of 3 x 10e6 cells/mL. Staphylococcus aureus, Cowan I (SAC, CalBiochem) was added to cells at 3X concentration (3X = 1:33,333 dilution of stock 107711 Meanwhile, eight serial dilutions (3-fold) of potential antagonist were prepared in CM such that the diluted antagonists are at 3X the final concentrations to be tested in the assay. Antibodies are routinely tested starting at a final concentration of lOug/mL and going down to about 1.5 ng/mL. [07721 Human rBLyS was prepared in CM to 3X concentration (3X = 300 ng/mL, 30 ng/mL, and 3 ng/mL) in CM. Potential inhibitors were routinely tested at several concentrations of BLyS to avoid fal-se negatives due to unexpectedly low affinity or antagonist concentration. [07731 Fifty microliters of diluted antagonist and SOuL of diluted BLyS were added to the putative antagonist dilution series. [07741 Cells were then incubated for 72 hours (37"C, 5% C0 2 ) in a fully humidified chamber. After 72 hrs., the cells were supplemented with 0.5 IiCi/well 3H thymidine (6.7 Ci/mmol) and incubated for an additional 24 hours. Plates were harvested using a Tomtec Cell Harvester and filters counted in a TopCount Scintillation counter (Packard). 288 Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. The invention includes all such variation and modifications. The invention also includes all of the steps, features, formulations and compounds referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features. Each document, journal article, abstract, laboratory manual, book reference, patent application or patent cited in this text is expressly incorporated herein in their entirety by reference, which means that it should be read and considered by the reader as part of this text. That the document, reference, patent application or patent cited in this text is not repeated in this text is merely for reasons of conciseness. None of the cited material or the information contained in that material should, however be understood to be common general knowledge. Additionally, the specifications and sequence listings of U.S. Provisional Application Nos. 60/212,210 filed June 16, 2000; 60/240,816 filed 17 October, 2000; 60/276,248 filed March 16, 2001; 60/277,379 filed March 21, 2001; and 60/293,499 filed May 25, 2001 are all hereby incorporated by reference in their entireties. Manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. The present invention is not to be limited in scope by any of the specific embodiments described herein. These embodiments are intended for the 289/1 purpose of exemplification only. Functionally equivalent products, formulations and methods are clearly within the scope of the invention as described herein. The invention described herein may include one or more range of values (eg size, concentration etc). A range of values will be understood to include all values within the range, including the values defining the range, and values adjacent to the range which lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range.Throughout the specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. Other definitions for selected terms used herein may be found within the detailed description of the invention and apply throughout. Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs. Each document, reference, patent application or patent cited in this text is expressly incorporated herein in their entirely by reference, which means that it should be read and considered by the reader as part of this text. That the document, reference, patent application, or patent cited in this text is not repeated in this text is merely for reasons of conciseness. Reference to cited material or information contained in the text should not be understood as a concession that the material or information was part of the common general knowledge or was known in Australia or any other country. 289/2 C'4' ~~-Z C, q q,,1 22 zz zzzzz 0. z F s, 9' '0 '0 '0'0'0 020 - u a ,n~ n n ~ C O O 0 5 0 0.5 0 a , m. 0 0 . 0 a , 0 5 0 0 5 ' 0 0 aa 0, a, 0 . r. 0C ,C, C , aC" cy"C a, a, C 0.0m0.0% 0, U 0.0(75Q50r, 00 a a 0, 0 0 05 asCC 0 0 " 0 0 0 - 0 0 - 0 - -m 0 - 8 0 80 C- C- c. , c;- :,C, CD C, C, C- C- CD C >CD .U . In W) 'n nn 'n In In In V)~~ ~ C4I 4.NN N nN N N N NN NN N wIn' )n n~ II I II I I 11 1 I II II IIInl II m 71 \ 'D\0\0 0 D 0 \ ' D ' \ 'D'0'0 10 0 0 1 I 1 'n '0 C- 000 0\ 'n Ln 'n 'n' r4 9 rl 0q - , N m" mn I In n n in n c n mn n n n 10 In n n n m m0 en n n In In In In In c, 4 NNC 5 qe 1 1 ~ 0 0 0 0 0 0 0 000; 000; 00000000000C- C C r NN C '0m0\a 0 a , C\C\ ,C\C , Y cCa a ,290 C \ ,O F, c'4Z C- C1 0 0 0 e n z z z 0 0 Z@@G2 9 z Z 76 oe 6~~~ ~ ~ ~ ozNN4 70 e2Z e V.z oe 2 e z @Z M E a. ..a. .a 0.a.a . .a.a a . a . .a a . .a. .a.a 0 .0.0 0 . .0 W . .0 0 . .0 .0e t~ ~e t~e ~e e n En n Rn R.e n~e ne ne te ne e n~' n' t~e ne ne ' a' CY a'a 'a a 'a ' 'a 'a a aa ga 'a 'a 'a 'a 'a 'a 'a 'a 'a 'a ~O . a' ~ ~ -w a'a 'a 'a 'a 'a a 'a 'a 'a 'a 'a'a 'a 'a 'a 'a ' 'a 'a 'a 'a 'a 'a'aa'o''a~aa > 0 0 0 0 000000000000 0 0 00000000 00 0 000 en n n n n n n n n n n u ne ne ne ne ne ne ne ne ne ne ne ne ne ne ne FU FR I en en ene ne ne ne ne ne ne ne ne ne ne ne ne ne ne ne ne ne n En ne ne ne ne ne ne ~e nele ne ne ne ne ne ne ne ne ne ne ne ne * S ' SI' S 5 55 5 55 stil Son 0a 'a a a a a a a a a Ca a a a 'a 'a ' a a a 'a a a ' a a a a a a oa a a (1 a 'a' a'a' a' m m N r C7 1 N r a, , a, a, N a, a, a, a, a, N l C, a, a, a, a, a, N m c C7 m m N N N N , N , Ny N , N , N 10% 01 1 41 0I 1555 SS5 SS 1 5 In In I 0% 1 0 0% D z % DID1 01 D 0\ 0I NNNNInNNNNN N NNV - n"en V In en I, A" m. a, a, a, a, aa'a 'a a00000 000 '00 00 00 m C 000a a, 0 0 a 0 0 0 a, C000000,00, C- el ci N N N en~e en en4 en4 MCI enn en4 rn MN Nn '4 Nn C4 Na C-a en 0a 'a ei 'a4 C4 Ca Cn C4 en e -NO NO smO %(N0 %U 00 00 00 00 s00 00 0w wwh(7wC aw( 0%"0000 M 00 00 ~ . t. ~ ~ etet~~ e e t t t e 0 0\ 0' \ ~ 0o \0 \ t0 D \0 W% 'n0 N C C N N NNNr m~ m 0 In N N en c.O N en en S.S0m N 0 ne 1 en men m' IV v0-T0-W0Iq0-00000v0000In 00n0-n 0w 0 0 0000 \00 \ 0 000000 00 C-;00 000000 000---------0000000000 00 291 Cl~ ~~~~~ me~ l~~ en~'en en- m~l o26"Z Z ZZZZZZZ~ZZZ~ZZZ Z~zqz; M. 9@222 ce CYC eC Y 2CY2-0 w w Os a . a . 0. a . Ow CL. A.00. a . A. a M.a a. a. a . Ow a' . aw . Ow Ow Ca . CL. Ow CL. 06 as 6 as as as , ' a a. as a a. a' I a. a (71 a' a, G\ a\ ON a, a\ a, G\ a, a'\ a, a\ a' a, a, Q\ a, a, 0\ a, cr' S, a% a' a' a', 8, a a, a', a, a, G\ a\ C\ a, 6' a, a, a, \0'a a ' 1,0110 ' 0 \0 \a' 'D m 'D 0 D a 0\ '0 '0 II. IL S I IL\ IL IS 115L 1 1 I 1 I SI II IS II '0 \Sm\0' L O 'D\ 0\ 0 0% 0000C)0 0 0 0 00000000000000000000C) C)0 C> 0000C)C D(DmC , ,RR 0 0OC 0 0 0 mf IT mn mn p 1-t An 'r q. An n vn In An I I Ir An n An qn An A IT vn wn I InInI 4 n A T In I T I In ;l Nl Cl -l C C4 C-4 C4 Cl Nl C4 Nl C-4 C4 C4 C4 C4 r4 Cl4 Cl1 Cl Nl C; N Cl4 N C4 Cl4 C4 Cl C4 C4 Nl Ml Nl Nl Nl Nl N N N CQM mmmm Mlmlmm mmmml w0 a, 00 op a' a. a% a' a\ a\ a' a\ q% a' a' a. a' q% q\ a' 00 w ' a' q% 05 (3% m 5 q% 0 0p a% q a a, a'a O a a 0 \c a, a's 'a 'a 'a 'a 'a 'a 'a 'a s 'a 'a 'a 'a 'a 'a 'a 'a ~a
---------------------------------------------------
'a t- 'a 'a0 C t- V- V l r- r- r- t-. t- r- t- t- t- r- C t- t l 'a Cl Cl t l t- t- Cl 'a C0 t l Cl t Cl t- t- t- Cl Cl Cl Cl lClC l C Cl Cl l C l Cl C C C Cl C C C l C C Cl C 4 C 4 Cl 4 N C 4 Cl Cl C 4 Nl ClC lClC lC lC 5 1 ,1 55 I. .I I .* I II IS . . .SI IS 5 I r 0-N0 wo m9e e % - 0 - - - - - - - - - - - - .0ll l l~~~~ Cl l l C?\ l l C7\N(7 a l al l~~ a, -l -l -l -l -lC ~~l l IS a,5 5S S SI I meNw OeCD Ce4qe\ r-weaemn Cle~l~~lnenneeneeneennenneeneene2 lnenne Cl 4 80E62 ---------------------------------- w----------------------- 0000-le 4 n'~l005 C e4I'a~00' Clen4 n ' C2092 ZZZZZzzZZzZZzZZZZZZZZz mom - QQMQO a =.. a.. a. a a.. a.. a.. ,0 e. . . . . . . . . .. a.a.a.a.a.a.a.a.a.a. . . . . . . . . . CL. A. P.a s sa 0. a' a' a'c 'a 'a'a 'a 'a'a 'a a 0. 1%. A. 0.0 a. 0' a ' C6 C a. 0. a' 91. CL. A '0. 'p0' ' 101 0 0 0 0 0 0In O'%0 'D0 0 10 0 0 ' '0o' o D' o' o' o% 0 1 0% 0 1 '0 '0'0'0 00.0 '0 1 0. 0 '0'. 000000' 0 '0 0 000 0 0 00.0 0 ' 0 '0.0 'L0%a.0 NNNNNNNNNNNNNNNNNNNNNNN N N N N N. N N N N N N N N N Nq N N N4 N 1 ~~~~~~~~~~~ ~ ~ ~ ~ ~ ~ C5 r .. .
14C.C 1 1.C C C C C C N NNr " C N N NN N N N~ - C4N N N NNN; NNq NNN C1 4NNC N CM M N N MN N M MN N N M NC M"MqMqN4C4M -4nMAnnr4M C N N N NN N N NM CM CM MN M-S P Mr 0 ' 0 5 0 *e 0 5 0 ., (a , In In Za' ' ' ' .' S''' ' '4 a' ' '4 :' 'n a'a' a' - .. C .N r-C -r- -C-r N~ ~ ~ ~ ~ ~~1 N0 N 1NNNNNNNNNNNNNNNN NNNN NN NN N N N N 1 C C C C C 1 r r 1 C M. M i, MI~ M ~r MI M M M S nMmMMMmM 4MMMMe) Mm m ne - - - - l000 0 Ne v % -- - - - - - - M 0 -- - - - - - - - - - -- , Ma, r- 0~00 mS0~ 0~ 10 wS0O oo00 000 - aNLLLL. a,. a,. a". U. U...4 293 C-4 C4 NN(( C, Ce 4 ,,'J C CIC4N(Nr zzozzz zZZZZ-ZZZZ'7ZZZZZZZZZZZ gfoyay aayycaeacvwfw "'U'v YC 9a WYa wwa a W cn M t -i 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 00 00 SnS S n nSnS n nSnS S n nS S n nSnS S nSnS S 4~S S nSnS S n nSnS n nS4P S~S Sn ~ ~ ~ ~ ~ ~ ~ ~ ~~~i Sn Sn 5n SnS n-S nS nS nS nS S nS nS nS nS / nS S nS nS nS nS nS zan aaa Sn On vn an SnS nS nS nSnS nS nS nSnS nS nS nSnS nS nS nSnS nS nS 50'' 0'55 'S 00' 00 '0' 0'0 'D ' '0 '0 'D ' 'D 0 'D 5 'D 0 D 0 z '0 '0 1 0 '0 0 '0 0' O Wl n n n Sn n mV nL n Sn Sn Sn Sn n 'A5 Sn Sn, Sn SAn Sn (N(NSn(( N (N (N ( N N N 4 (N (N( N N N N N N N N N N N N N N N 4 (N N (N (N N (N (N (N N (N N In W 1^n~n n~ Cn C' S' S -n V L 0~NN N z N 1 N(NN NNNN(((NNN(((NNN(((NN N NN (N (N NN (N NNNNN( (7s m 5 N 55 MI m~l M M sa 7 %MM0 ; %Ma ,MMmMcla ,o sMa n Sn TN n n n Sn Tn n C n n Sn n a, Tn a, 2n Tn 2n InS n a, In n a, TnS nS nS nSnS nS nS n 'S S nS t 'tS tS tS tS S tS tS tS tS tS tS t tS tS tS tS tS tS tS --------------------------. a, 0 0( N N N m N W) ID ( wN a, 0 00 00 C0N0I - - - - - - - - - - - - - - - - - - - - - - -e:(5N(4N(N(r:4 294 __p -~eN - :-- -- R p s m9 29 r 2 999222l2 ~29999 CL4U N 666650666666-2'O06000 4 44 4 44 4 44 44 44 44 44444 4 4444 44444 'C'C'COZZ od z zz zz z '00' CSO' C' C C' C 'Ca 'Ca aa f aC 'C 'Cf'C'CC'C ''C *~ 5,,55, 55S5S55 000~~~~~~~~~~i 0i 0MCA 000000000000000 0000 5, ,~5 S S* ,~5SS~S~~ ~ 5555 5 ,55S5, 5 5555 55M, 5 w 5 w 5 w S w 5, 5 55 55 5 55v 5, 55555( 5S555 55 5555 , 55VSV V S , V ,555 , 5555 5555 5 V S , V S 5 55,55 55,5,55 S S5, S 5 V ,5V > 5 en~ = >e ne ne ne ne ne ne ne ne ne n ne ne ne ne ne ne ne ne ne ne S'S 55 ,S SSS SSS IS SIS 555 5 5IS' S S> aC' C' C' C' CS C'C' C' C' C' C' C' 'C 'C 'C act aC aC 'yCy 'C , y 'C'C' C C C'C' OW Ow (I. CL. 0. (1. D. a. a. a. a. a. C3. 91. a. a. 0. CL. DN a. 06 CL. NS NSNS NS NSNS NSNS NS NS 555555 ~ ~ ~ ~ ~ ~ , l 7 055 0%5 a,5 a, a,' oSS5VSS5S aVSSV aSS a,5 m~S S S S S oNNSSS amacN Saa mo S , ,aa , ,aa a , ,cm0% a a 7 a, ~ ~ ~ CsSSS al SN SN, C7 laSNaa l 4,a,0 ,C SN S SN N SNSN S SN N S SN N SNSN S SN N S SN N SNSN S SN N S SN NDSNSN S SN N S S D N SNSN DS SN N S SSNS NSSNS NSSNSSNSSN N SN N SN S N SN N SN N SN N SN N N N SN N SN N SN N N N N N N N a 0 05550000555 0a5500 C)55550000 0 0 0 0 000 000 C, V -4 ! en q n en en Mn en Mn M n M M p en en en en ;I en en en M M en en en en en en en m en en m en en en en en en en en en Nl CA NN N N N N C4 r q N4 N N q N4 N CS N q Nq N Nq N N N N N N N Nq N N N N4 N Nq N Ns ON N, N, N, N, Nl Nl Nl N, N a, N7 N N a, N a, N N N , a, , N N , N N N , N N N N N , N , N , N % N N , NaN Fl'C F4' 550 'C5CC'C5'C'CC'C''C'CCsC'5C'CC'0 b a.,.'C 05a,0o 0 - ~ ~ ~ ~ ~ V -5 -S -, -55---55 -- --- 5 1 ~~~~~~~~~~~~~~~~~S SN CNS SN SNC 1 C C C C 1 C C C C C ' mIS~1 r-5 w5 SIS SS SSSSI S C4 en en en 4 eN C-4 en en en en4 en en en4 en4 en4 en4 ene ne nene ne nene ne4nene n e e eN e N e 44~~~~~ 444 44 44
.
444 44 .4 44 44 In a,4 4 4 4 4 m-E-2--E--2- - - - -- <- - - - - - - - - -- i ch00 0 000 00 0, 00, 00 00000 7, a 295 C44 ~N ( .. *2Noo o .. o d 6(i 50 (6 ( 6(6050--00*75 ~ZZ zzzzz Roma6W aw' 0 0 0n 0Y 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Y 0 0 0 , 0 Y 0Y 0 0 0Y 0 0 0 0 'a CD Ca 'a (D 'a CD ' D ' D 'a ' D ''a C, 'a 'D CD 'a (D CD Qa C) Qa C) CD Ca Ca Ca CD C) CD <D ' D I= 1= a 'a C) C> Ca C> In W)* 6 f INNN N nNN N N N N W% V nI nw W n - l n- n nInInIn W) N N N N N NN N "N N N N N N N~ N N N N N N N N N N N N N N N N " N N4 N, N N q q N4 N4 NN NN NN NN N N N N N NN NN N NN N N N N N N N N 4 N N C4 N N " N N N N N N4 N N N4 N N N N N N 0NN N N N N N N N N N N NP N N N N 0 N N N N N N4 N N, N, N, N, N, N N, N N, a, N, N, N, N N, N N N, N, N, N, N N N Ns N N m N, N a, N M a, a, N , N , N , a, N 7 NaN In66 16 In 2 6 66 6 66L In 66L 66 a,6 66 66 In66 ?ITI 64 NZ . 4 'a 'a Ma 'a M a 'a 'a 'a M Ma' Ma 'a Ma Ma Ma 'a 'a 'aM a' a' a0 ' a' a' ~a a a a a a a a a a a a a a ' ' ' ' ' ' ' ' ' ' ' ' ' 666 66 666 6666 66 1.'*''0 0' 0 0 ''00 0 ''''''~ ' 0 ''''0 ''0 0 0 '. N. ' t' t6''0 0~ ''0''0 N00a'0NC- -0 0 -'0 - 'f'N0 a0 - - -- -- -- - 7 -0N 0a'0 NC 7, 7V ) - A 00000000 Z700Z, .r T r' 'D \0b \0k r , , r t , t 00 0000 00 00 0 0 0 0 0 000 0 0 0 0 0 0 0 00I 296 00600046ddddOOOOO zzzzzo Z ZZZZZZ7Zzzzzzz~ZZZZZZz.. 2229 ne9 e22 2 9 2 992 2999ee2e9G222z9oZOzzzzzz aaaaa~a a' a'(ea a a'a a'aa'0 a'a a' a, a' a, a, m' C7, m a, a' a' a, a% a' a, a' 1 a' a' a' a' 1 a a, a, all a, a, a' a, a' u' a' 0' 1.' '0 'L '0 '0 'L '0 'L 'L '00L' ' 000000' '''o 'o 'o 'o '0 0 000 '0 10 10 10 0 0'D ( N(N N N N N N N N N N N N N N N N N N N N N N (N (N N (N N (N N (N N (N N (N N (N N (N (N Cl a0! 0a 0! 0 0 0 0a! 0 0 00 en !neene en0 o: C ,w- ( N(N(N" N (N V4 (N r-4 N 4 (N 4 (N N (N (N (N N (N " N N N (N (N N (N (N N (N (N (N w (N wN w MCA MN (N MN MN MN PN (N NN r4 (N NN (NI C4 (N NN N C r4 CIA c%' o\a, a' u, ca'a, a a a a a a \ m ca a\ m a, a, c, c' a, a, a' n' a' \05 10 1055 IS01 1105 In 10m III IS I S I S IS I en~~~~~~~~~~~~~ en en en en en en en en en -n ene-ne ne ne ne ne ne nene ne ne na '0 '0 WN 00 (N (N(N (N1 a% (N a, O\ CN CN (N C>( N( N( N( N( N(N( N( N ( N( N( N N (N N4 (N (N eN eN en en en en en en en en enemne ne e nene ne n ne ne en en en . Cq.~ ~ ~ ~ ~ ~ ~ .S **l 1 ~ 'l O 0 ~ ~ ~ ~ ., O O O O - - - - - - - - - - - - - - - - - - - (NNq ' NN' N( e a 0 0 (N \0 -4C4C\ 0\ COO O O~~~00 00 100 CD wD 297 C' N%0 N 0 ~ t Z0000-0 ZOZZZZOOZZZZZZZZZZZZ Zzzz 9 9
Z
2 z99922929z z Z z CYC Y YC c yc gac c vv fc £0WW W£W W£0, WWW C02w www www 2020 20 0 20 2 20 2 20 2000 20 0 20 0 20 0 20 000 0 '0 %''0 '0 %0 %0 0 '0 0 0 '0 %00 '0 '0% ' ' ' ' ' '0 0 '0 '0 '0 'D 0 0 '0 \D '0 '0 '0 '0 0 ' 0 0 '00'0 10' 10 0 0 0 \0 10 0 'D 'D 0 0'0 N N N N N NNNNNNNNNNNNN N" NN NN N" N1 N~ N N N N N N N N N N N N Nq N N N "t In NnNNnN, 1 ~~~ ~og to to to to to toC C C C stil it isi 5,ii lii * i*5, 5 iss I to~~ ~ 1-0 ot t t ot t 2 L2o n o n 2 2! M !o0 2 !02 !2 ~ 22 t 22 - 2 - 2 -0 - 2 -o -o - - - - - - L- t.% 0% L% L% L% L% E2 L%0 %0 %0 %0 %0 %0%0 %0 %0 %0 %0 %0%0 %0 %0 %0 %0 %0 ammm 0,0 %%0000 a,0 m%0 G,0 0 3, 00, a, mmmmmmama ,a %la , 0000000000000000000000000000000000000 0000000000000000000000 'I .r Iot ot ot oNt o t v to vo to N Ao Ao 'T Ao Ao Ao N to to to to to to tot ot ot 'C'0'C M .r n '00% '0' '0'0 t-- w , w C14 '0 t 0'MI0 0 w ,C M%0 %0 %0 %0 %0 %0 %0 %0 %0 %0 %0 %0 00 %0 %0 %0 %0 %0 %0 %0 %0 m-mmmmmmN N m~mnn mm nn enenN N NN N N <s si <ii - - -s-'is wwww www W == 22222 2 02222o~ 2 -12 2'N~ 2'N0 'N0 298 i00 - in N 0 C4 'n C4 An N0 - n ' -' N CO 0 zzzwz 22ZZZozzzD WL ~ :Ji J- -jJV]) N Ns N N7 N NY N N N m N N N N Nm nNN 0 C) C) C0 05 m0 C C 0 0 0 D 0 0 0 0 0 0 0 0 C 0 0 0 0> 0000000000 0, N 4 " N 4 N 4 . N . N . . . . N N N N N , N , N NNN 4N N N N N N N4 N4 Nq N N NN NN NN4N NN NN NN N N N N N NNNN N N N N N N N q r N N C4N4C III- -1 1 -il -I -~ l -1 11 -i - -i -l -I -1 1 -- r- - 00~~~ ~ 0000000000000000000000 N 0000000000000 00 00 00 in n i inin n i inin n n n n m n in m n m e0n C, mn en n n m mn mn mn mn in mn mn m in mn % 0% % 0m % 0s 0% as ON us 0 0% 0 % , 0, 0, m% 0 07% 0, Q% w% V, (7 0 0, 0, 0, 0%, 0% ON % 0 a, 0% as 0, m% al a, a, --- --- -- --- -- --- en m m m eneIne ne ne n ene ne e ne nene ne en en en en en en en en en en en en en en en en v en en N4 N N u W. N. N N , w Nl N. NZ S 0 0 N N 20 Fn N NNNNNNNN - - - - - - -n- - - - - - - - - - - - - - -- 0 0 0 1 1 1 enneenneenneenneenneenenneeenenneenneenneenneenn299nee N 0c 1 nnA. N ~ ' (N0-0~~000O 0'005((66,6~zoo66 0 zzzoz267oozo-zzzzzzozz0 0zzzz (N a aN (NCYN( N. N ( O6OO6), 0 . .. Z Z Z Z a~% O~ aN(N..( Zz z ZZa wZ Wf fC," , ( N (3 E n ( NS E S S W 3( N ( N ( N ( N ( N ( N ( N ( N ( N N ( N ( N ( N ( N ( N ( N ( N ( N ( 00 0 00 0 00 0 0 0000 0 00 0 ) 0 0 0 0 000 00 (N1 as mN (N mN mN a% m N m mN mN (N (N ON N( ( ( N C7 ON N 0% aN mN N m N m N (N , as (N Ch as (N N 00 0 000000000 0000 0 00 00 00 000 0 00 00 00 00 00 000 0CD0 00 00 00 00 00 000000 0 0 0 0 0 N0 0 am, a, Ig~ I ~ m rag . ., 11 .ti . a"W ) ""W I a~~ne ms Inai a mla ma mm In mm eng mm en a m m 000w 0000 =0=000 00000 00000 0 w000 000w00w0w00 w0w00000 00 =0 00 0000000000000000 000 N N4 NCA NNNN N N N N N N N N N N N N N N N N N N Nq N N Nq Nq N m ari a a l all(7 a, V'\ all a\ a,\ a mam ma C C 1 ,C mm aM , a 7,, aG\m w, a7,1 C a0\r m C O a , a , h a ,a m mr m aO CM 7, a0\m , a a my i c 7 mmm, m 0\ a , aU m a (7 a IT IT *0' v ml '0' 'r v v IT -I I ' l* W l -W ITI 't -- -W v -W -T - ' IT IV IT IT IT IT IT 'r IT 'IT I~ It It It m0 '''' 0 0 '0' '0' 0 ' 00 'a\ C> N' m0 .r ' \0 t- w0 ' 0 ' '0m 1w 4 3 4 44 n0'.ca n mn~ '00" 0( r- 0oo0'as (N(Nwnwaa00t-(M(N M00 0 300 C-4 060 U) ,5 U),5 U) 2Z zoiz)U zzzzzzzz 2@@9 g)U )U )U)U )U )U)U )U )U)U )U )U)U )U )U)U )U )U)U )U )U)U )U )U U) ) Ln (n U) W) U W) C W) V3 ) Ln Cn W) ) U) U) 14 ) V3 w) w) U) &n w) (n w) E) w) En En En w) En Ln &n (n cn U) U) ) ) ) U U U U)U)U)U)U) ) ) ) U U U U U)U)U)U) ) ) ) ) U U U U)U)U)U)UN )") )NU " U N enenenenenene e e e e e n n n n n nenenenenenene e e e e e n n n n n nenenenenene 11010 s s ss s ss ss 2 ss s s s ,g 0r0S011 \0 s r 'D 'D' D\iDi D' D' '3 '3 '3 '3 '3 '3 '3 '3 .3 '3 .3 .3 '3 '3 '. '3 '3 .3 .' . 3 .'3 '3 '3 \? '3 3 3' ' I3 '3 '3 \?3' '3' I?3' ' en n en en eneIne ne ne ne nn) enn I en e n ne en n n (N nen nen nen nen nen nen n INn((((( N (N -NNNNNN(((((( -N (N -N (N - - -((NNN(((N I? 0000000000000I00?00000000000 - N 0000000000000000000-00 ii 5i i i i m mimi mil i s i 000000000 00 0000 0000 0000 000000 00 000000 0000 0000 0000 00 0000co00 00 0000000 0 en en 4 en 4 en en en en en en en4 en en4 en4 en en en4 en1 en4 en en1 en en eneCne ne 4ne ne ne e ne ne ne (N (N( N( N( N( N N( N( N( ( N C- (4 (N (Nl N N (4 eq (N C CIA C1 -N "N (N C C4( ( N N ( V)- - - - - - - - - - - - - - - - - - - a., a., C4 a, 14 14 4 Fn C4 C4n7ne C4 n a., eNe T14 a, ezeF, 14 a, i en lz 0 '3 3 3' ' ' '33'' \ 3'' '333'' '3' '3'3'3'3'3'3'3'3'0'3 C C C n O L !0!C OL - - -- O !n 2 T -!- - - - - - - - - - - - - - - - - - - -- 00w w00w w m m w 3' 32 L' L' 3'- 3' 3'- L' t:3 '3 '3 '3 '3 '3 '3 '3 ' '3 '03 '3 '3 '3 '3 '3 '3 a, 00, 00 00 00 00 00, 00 00 00 a\ 00 00 00 C 3 Nm m a \a Na %C 00 00 00 00 0 00 a, C\ 0 0,00000 V. oo-e r oT ooo4 9Itleo-rv v oT oov -T oIT vITv T vA AA I vv T v v r o -1 0 1 1 C 1 C 1 ll O C C 1 1 C C 30 1 C C C 1 1 C C-4 C'4 C-4 N C4 N N N N N N4r-,C4 r r rq C-4 Cj C4c-4 . .. . oooo0000000000000000605600000000660000 N N2. N N N N N ON N ON N N N ON N, N Ns N N N ON N% ON Ns N% N N7 N ON N N N N N N a% Ns N% N% N , N N In ~ n n e ~n n e n ne e In In "I en Ien n *5 SS S S I T5 I? ITI T 1 5 I? I? I? I II??I?? NNNNN NNNNN NN NNN N N N N N N N N N NNN rN NNNNN4N N Sn~~~~~~~~~~ Sn Sn Sn Sn Sn Sn Sn Sn Sn -nS nS nS nS nS nS nS nS nS nS nS nS nS nS nS S W.0 w' w' a w w' O w a' w' w~ w~ w~ w~ w~ w~ w' w0 ws ws w' w' w' w' w' w5 w' w' w w w w w w w w w w w w SIpn q ppI m5 1 NNNNNNNNNNNNNNNNNNNNN N N N N N N N N N N4 N4 N N N N N N N ene ne n ne ne e ne e n en n n n n n n en en en2 n n n ! en n L en en en LO en en en en W ne a, a, a, C7, a, ma' a,a,' O\ aa' C7 a a, a' m50 m55550 0 O ' a a, 05 a, cs a, a, a, a'C 0\ 0\ a'\O a, CIO a',O a, *It -I 'r* I~ -It ' 't ' I-r - 0' v ' v 0 v 0 IT ' Ir* v0 Nr 'I IT' 4' It1 4' v4 It I' A* -I-t- t -. r 't w 0 v 'A A N N D N , N D N D N D N D ND N NNNNNN N N N N N N N N N N N N N N N N SW IS ISn W) 41 SW In In S S IS I 5 I n InS en , \aO Sn'C a' ~ e ~ ' N 0 ' ~ N n n C 0 ,a ,0Nea, 'C 00 a.~~~O0Oc 0000 C-- - - - NNN NN Naene en ne ene en ne '4 ' n nSnS S n nSnS S n nSnS S n nSnS S S n nSnS S n nSnS S n nSnS S3n0nSnS FZ~~~~zi~~~~'o 0, t-SN 0~ ~ ' '0 * .. 1 6 r - 1 - 4.C4q! 00600000000000000000600 00 00 0000.0000000000006 WI z z WIZ WIWI9% I IWI94 I I IWI0%9% % 4 9% I9/ W % I 9/ W % % 4 0 9% WI99 I % 4 0 0 % I %0%W WI WI 94 4 I W IW 4 I W I 9%9% W % W 9 I 0 4 I94 I9% 9% W 9 IW Iz% W 4 I 9% W I W / aff c% (%-D 9c 99%-cy y yf f f c -(D %9%9%99 9 9 %9% % 9 9 9 9 9%9%9%9%9% 9 9 9 9 9%9%re%9%99 9 9 9 9 w9 w9 99 w9 w9 99 99 9 99 9 99 9 99 99 9 9 9 '00''00'''0'00''000 0''00'''00 0 0% 0 0' ''00'00 0''0' ''00w' N4 N N1 N1 NA (N N ' 9 e i N N N N NN N NN N N N N N (14 99~~~~~~C 9999 S4 99 L9 9 9 9 9 9 9 9 9 9 9 9 9 o% 0 0 0 00 0 0 0 0 00 0 0 0 0 00 0 0 0 00 0 0 0 0 00 0 0 0 0 aa0,o ,a ^c ,g ,a Na rm a %c ,m a Co ,o la 0 000 00 a,0000000a%00 N C C N N N N N N q 1 qNC N N N N N N NNNNN NNN NN NN NNNr4 N N N NqNr WI W 94 WIWI I W WIWI 9% W WIWI I 9% W 94%WI I W WIWI I W WI I W WIWI I W 0%0% 0 0%0% % 0 WI0% I 0 0%~~~~~~~~ -% -% -% -% -% -% -% -% -% -% -% -% -% -% -% -% -% -%0 %0 %0 %0 %0 %0 %0 %0 %0 99% 99, m 99% 9% 9% a,% a,% 9% a, al m m m m C ,O la n N- n n T n n n n N- n n n n n N N !2 N2 NO N N2 N2 N! N N2 N! N NO N2 N2 N2 N!2NNNN - - - - - - - - - - - - - - - - - - - - - - - - -- 9 9 el2 1 l2 2 2 2 e 102 2 2 e1 99% 99% C7% (2% m9 m9 a,% a,% m9 m9 C% a,% 9% a,% M9 a,% a,% a,% (1 Q\% 9% a\% a,% ( M9 m9 a,% m9 m9 m9 0\% a,% 0\% a,% C\% a,% a,% ( m9 a,% m \
-----------------------
~~~~~~~~~~0 C0* a - 9*r-~9 0 ' * ' * '* * 9 *9* ~ 9 9 9* ~ ' *'* '* ~ 9 ? ~ 9 w - - r -------- ------- ----- 0l>>Q Q H CD9' W CCC CD% CD00N 9 CD('N0%0.~N9 I 0 0 0 O N9%WN0 0, C\ * C\a \a ,a 0% EO ,alO ,C C4% C, C, 7,IIWW '000, 0'0m0G\ 0m 0'0N N\ Q, N mm N3 N00 0 0 a 24 0% 0V 0% 2 % 0% WI 0% 2 4 9/ 9 / 0% 00 WI WI 2 94 94 WI I 2 4 12 94 a I WI 2 4 2 4 94 WI 2 4 94 WI WI % W W WI 303 o Mz~6~O .z~z~Z~z~z~zzZ4 C', 1L 0 L0L0U N~W~ I o 06 06 60-666 66 2O60zo-( Nz z z z z z z o z z zp z o Nz zz N MNNNNNNN-'NNNNNNNNNNNNN a'o '0 'o~a 'a'a ' 'a ~ 'a a .a a 'a'a 'a'a ' ~a ' 'a z a Z' 2' a' 2!R 20 a' a'a'a a ' 'a'a'a a ' 'a'a a a ' 'a'a a ' ' 'a'a a ' ' a 222a2afa'a'a' a 'a'a'a q'y','C'C, q'ccfg g c'0cyc,,'w ' CC'~~' 'CWc'C Cw y C aw 2 cw v0 wa w0 a0 \0 I0 '' I0 w~ IC w0 '0 a0 s os s s s s w 0s w > > 000000000000 SI I~S~ I SSI , I I~S, I I I~S~ I S,~ SI I~S~ I SSI I~S~SI IS, I SS4 ISSI -SS0 4.- SSI I SI~SISI SI S~ S, SI , , a l a,~ CI I O, mI mI SI , (7 S , 0~, I, a , I, I, I, SI, aI I I IS~ ~ , , , I , a, a, 0, C) Cn Cn Ine ne ne ne nene ne ne ne n n en m n C ,,e CD CD en en C D n D CD, S D CD CD, Sn D In In' ' C C' ' i In In V)' C C ' 0' O 'r, ' ' 'rIr 'r0 'r, 'C'0 In ' 'r. '0 In In -C -C -C -0 -C Innnnn Ine ne ne n r en InN n n nn In n n . n en In en en en en en en en en - - -ne ne N N N NN NN NN NN N N NNN N N N N N N N N N N 5555 5 5. SIS mIS 55 HISS IS SIS S ISS SS 5 IS 00~~~~~~~~~~~ 000000000000000 - 00-000000000000000 00000 00000 -N 00 0 0 0 0 0 0 00 0 0 0 0 0 0 N 00 00 00 00 000000 00 0 0 0 0 0 0 00 0 0 0 0 0 0 0 I N I1 C C C I I I IC r SI I I S~SS, I I I~ISSI I I S,~ .S, I I IS~SSI I 1 S,55S, I I IS~SSI I I SWSMS, I I a'~~~~~ a' a' a' W' a' W oo a'a ' a ' a ' a ' a ' a ' a 'a 'a'a ' a ' a ' a 'a ' a ' a ' enI en en en en en en en en n en n en en en N n en en en n en en II en -n ene ne e ne n ne nene n !2 22 en en en en en en en LOne e e n n n nOe n n n en en en n ? en n en e ne ne ne ne 0' 0 a'a' 0 0~0' a 0' a, (71 a, '0 a m 00 w a, C\ a, 'a 0\ m ' a, ' a, a, a, V\ a, 0\'G a\ 0 a a' 0\ a a, a\ 0 a 0 0 NItNN NN N N N N vN N vNNNw-It-INv n vNAANAANg'TN N5 IS NSI I5 NI NSS NIS I- - - - - - - - - - - - - - - - - - - - - - - - -0r 1 1 I 1 I I I I I I I I I I I I
-~------------------------
N~n~M In \00 r- oo dIn N 0 00 N n ' N ' N n
----------------------
304 -t~~~~~3 0 .T 'o0 ) N0 I IN ~ C-4 C4 -4 4 C cOca7:'Oaafa' cy a 'a'ya'. w' a a a '' a R,'''''''''''''''aaaa~ aa 'a 'a 'aaaaa 'aa~a 0000 0 0000 000 0 00 0 0000 000 00 000 a, N % N S N N N7 N N Ns N N% ON N N N% m N a, N m N 0% (7 N, N, N, N a, Nr N7 N, NC7NN N N 'Do t 'mot 'D ND 'o 'oot to t o 'o' o 'D t 'Dt 'D qN NN N NN N NN N C4N IN IN NI N N IN N N~ NNNN NININ NNNN o 0 0 0 0 0 0 0 0 w00,w0000 ww 0 0 w00w00w0w 00=00 0000000 00 000000 w00w0n0=w000ww00ww0000000 ww 00 IN IN INN INNNNNN N NNNNN CNN N NN4NC NNN N"NN 4N N N N "N a' a' a' a' a' a' a' a' a' a' a' a' C' a' a' a'a a ' 'a a , a .' .' .' .' .' .' m a M a ON as m' m' a m' m a, a7 1 s MM M ,Msn m Is m M, MI I , M, M, M, M, N, M, ~ M, MI M, M5, MM M 0\ a, a, a'm a a\ 0\ a' a, a'1 a' a, a% a, a, a, 0\ a, In a, a, all a' m a, a7' m' a m' a' a, a', m' a7 a\ a7' a m' a' m' ;----;------- ;--- --. 4--,t-- ----- ; : tor to, t to to a, to,o No Mo vo ao to wo mo Mo Mo In 'oNt ot ot ot oo r wo a, to No Mo Io I,, N, N, N FN N N M, n M N N N N M N N N N N N N \N N N N N N N N N - - - - - - - - - - - - - - - - - - - - - - - - -- o 0 0 a 0 0 0 0 0 \ I \ 1 M t-00 N 4 I '3 ~ ~ r W3' IN3333~''' 033'333' 'D'''' r333'' a,33'5' =3' E3' A33 ----- ---- ---- ---- ---- - ,' 1' 02 .- 0'z 0'o doooo5((,6506-05 gzzzzzzzz 01101101a1 C a' 0 a01 a as 0a0 a' aV a' ( ' a' a' a'C 0 a a ' a a' a'y ff f a'a' ffa' y w' w' w' w'a 'a 5a .a a' a' WW'W Ws . W'a 'a 'a'a 'a 'a a S wWWa a 'a 'a ' 'a 'a ' 'a 'a 'a'a 'a ' 0 ~ ~ ~ E 00 00. 0- 00000 000 0 0 0 0 00 0 0 IAIA / I A AIAI I I A AIAI I A A AIAI I A AIAI I I A A IAI I A A AIAI I A AIAI 10 w0 w0 w01 w1 cm0 m0 0 n . c 30 w01011010 0 '0 000000011111111 '0 010 W' 0 '0 '0 00 0 N, N, N N1 N N, N N N, NS Nh N N7 N N, N, N, N N, N, N, N N, N N m N Nr N, N N N N7 N7 Ny N, N N N N N N 00 00000,0 0 ,C ,C C ,C ,C ,0 000 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 0 000000 00000 00000 000000 C C IA VA IAIW AI)AI I AI I IIA IA In IA IA IA IA IA IA IA IA IA IA IA IA IA InAI AI AI AI AI ISIS.. .1 . ' .'D' o' 5155 'o5I 51 5 I 'o 'D 11 110D DIDC 1 11110 I 00 00 0000 0000 0000 0000 00 00 00000000 00 0000 0 0000 000000 00000 00 00 000000 00 0000 00 000000 00 C4 NNNN N N Ni N1 N N C- Nj C- N N4 N- N N N N N N C4 N N N N N N N N N rne e n en e l en en en en en en en en en en en en en en en n en en en en en en en en n en en n en en en enen nen n '01010101010101010101010100101010 1 111111111111 1011011001001001 - - - - - - - - - - - - - - - - - - - - - - - - -- C C 4 1~~a a' a' a'0000 0 02 ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~ N N oL On ! mnL onn2 2L 2L 0 en e I n am m n ) en00 IAmmm M m NenI 00 m0m m mm mm m m m mm em m0 2A IA IA IA 12 IA IA IA2 IA IA IA IA IA IA IA I IIA IA IA IA IA IA IA IA 2 IA 2 I IA IA IA I E IA IA IA I aaaa 000 a , 71a a a a , IO o , , ,aU0aa mm ma 01 ,m 0 071c0 r 0cy C ma 04t 00000-t- ItV't't ItIt't't't11" IA gg g v t*v v- vA ' TI 4I - - - - - - - - - - - - - - - - - - - - - - - - - - C C C 1 C C C C C 1 C 1 :;:;: : ; w w ; ; w : ;;;:;:; ; ;;; : ; : ; ; ; :;;;: : ; r -306rV-: ,C4 C, ,4 ' )" 4 'C4 14 C/J NC ' N~ -~Cd, 14C4 o C', .. . .. .. .. .. .. 6 01 C Cd 5 0 dCd C, i (, dCd C, dC, dCd C, dCd d,6 dCd C, dC, dCd C, dCd dCd C, d,(d C,(d C, dCd C, d (N z N NNNNN NNNN(NNNN NNNN NNNN 0. z z z z nz z z z z 0.z ~ zz 0.0 .0 .Oz.0 .0 S0 '0 .0 50 .0 .0 'C s0 .0 .0 .0 500 .0 SO 0.0.~~~~~~~ 0.0 .0 0 .0 .0.0 50 0 .0 5. .0 .5 0 a0 0f5. S 00'0.Os0.05 5 . 5 50 0 CY a, o, o, 0, 0, 0 a, a, W, 0 W, (Y ), a, 0 0 V 0, 0, C, 0,0 ,0 ,0 , 0 , 0 0 ,0 ,0 ,Sl0 , 0 0, , , , , , , , , 0 0 0 550 0 0 0 0,0,0,0,0,0,0,0,0, , , , , , , , , 0 0 0 0 0 0 0 0 ~5 5 5 ~5~5 55~ 5 5- 5 5 5 050505(5 5 5 5 55055555 5 5 5 55(5 05(5 5 5 5 5505(5(5(> 5 5 5 C C'C' ' C'C' ' C'C0~ C~C' C C'C' C C'0' ' C'CC'C0''CCC' C C' ' C>C' N ~ ~ ~ ~ LA NL N-I NNNNNNNNNNNNNN CL 91 NNNNNn 0, 0, 0, 0, 0, 0, 0, 0, md 0, 0, 0, (550, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, a, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0\ 0, 0, 0, a\.a, 0,.0N 0.0\ a0a,.a.o\.a,45N0a.a\05.a,050a\ c0m.0.07, m0,.6\0.0c7\., 60.\ 0\0\.6.0.0ON00.a,00.a\0a.ZX0. 0.0.0.0D.D0.D.CD.D.0.0.0.D000NC 0.C)0C0.0 00.Da.0D0.0.0m. CD0a.D.0 D0Q0D.0 D0.D.0.(D.C,.D.C.0.DC.0.D0. 'C ' D ' 'D 'C -W ' ' 'C 'C ' ' ' 'o \ 'C 'o ' 'o ' 'D 'D 'D 'D 'C 'C 'm 'C\ 'D ' 'o 'D '4S
--------------------------------
co 00 00 00 00 0 00 00 00 w w o 00 = w w w 0 w (www55 w 0 0 N 0 00 0. N NNNNNN N N Nq Nq N N N1 N1 N1 N1 N4 N N N N N1 N N4 N, C4 N N W)'C 0. V) W)00 N- 0, In 000 n0 0.InI0 n In 0 0 0 0- 4 C t LCi. CJLO .J. 41NN 0 000000 C C C , r 0 O S S N N NNn ! O! 2 2! a m n t ? 2 2!21 ? O O12 n222n 2 ? 0-2~ 00 00 0 0 0 0 0 00 0 0 0 0 0 0 0000002 21 2 1 aM-
--
\- - - - -- ,m-
--
a\am- - - - -- \-,- - - - -- ,aC\a,0\aCac\a 307 \ "ll 1 1\ a - ;p' a C ~~~; 4 - a In M: -T . : enInqene A ~C IC PN (oN r4 (N C - N QOOQOZ Z OO zZzZ ZZZZ aan99a9ts 9222929 98929999 99999 'a ' -- a*-'a'='-'as a-gg'a s sa assesassessessa oo'--3 --- aa a 'a 'a 000000000000000000000000000000000000000000 En e) cn en wn n e n en wo en e wn wn e V3 (en n n En V) 0 V3 W e V) w en en en e 'a ~ ~ 1 'a6 'a0 'a0 'a 'a %a ' a ' ' a ' a ' a ' a ' 'a 'a 'a 'a 'a 'a 'a 'a 'a a 'a 'a 'a 'a 'aD 'a 'a ' ' o' (N(N( (D (N (N CD (N (D (N CN (N aN ( > (N (N a > a, (N (N ( ( ) (N C (N (N (D (D C, <D N (N (N (N C, aN ( > QN aN D( Q~~~ ~ 0'. 0*1 0'. Is 1*0 *0 *O S0 0* 0* 00 0* 0 1 0 10 10 0 ' . ' 0* a' C * a' a' a' 0* C* Cs .* .* .* .' Nl C4 N1 Cq CN r4 N4 C1 N NNNN 4NNN N N N N N N N NN N N en~~~nenenenen ~ ~ ~ W ene ne ne n ne ne ne n en n en en , en ene ne ne ne e n en en en en e a a'0 a' a , C\ a' 1 a' 1 V\ c7' ca 'a 'a ' 'a 'a ' a, a, o, m' 0 , 0 , a7a a,' a, a a M' 0a0 a, c' C7, 0* . 4 4 4 4 4 . . .4 4. .4. . . .4. .4 4I . . . . . (N(N((N(N((N(NN(N(NN(N((N(N(~(N( CYNNNNNN(((((((NNNN,( 00 00 00 0r "0 00T 00 00 00 IT 00 00 00 00 00 00 00 000A 0 0 -- - - - - -It en en en en en en en In en~T T w - W 0 00 0 00000000000000M w00------------------------------- 308 P c nro a 640 22-2 29 92299222m 9 ~ 222229222222222222 CA l. CA A C CA C A CA (D C> C) C ACA C< CD CA C C C CD CO CA CA CD CD C> CD AC CA CA CA C C C OC C C C CA C1 C14 (N ( N N N N C4 (N (N N (N N (N N (N (N N N (N N (N (N (N (N .N .N .N . N (N C4 Cq N (N4 (N4 (N ( (N4 N (N4 ItC El E~ t~, it . ~ 0% 0% 0% 0% 0% 0% 0% 0% 0% C% 0% C% .% .% .% .% .% C% C% C% 0% C% 0% 0% 0 % 0 % 0 0 % 0 0 % 0 % % 0 N00 0''' C400''' N N"0q NN NC1 4 C4C %0%'4 ' '04 '0' ' C4 N0 N0 %C-4 11 '0 '04 'i N0 '0 p0 000000000000n0 In00W)0000000000000 (A ~ ~ ~ ~ ~ I a, (A zA mA (A IA, (A( A( A( A( A( A( A( A( A(A( A( A A( A( A( A( A( A -it~ v, IV% -T vt -- r IT v~ v v% (( It% I It -It A A vA (q A A A A A (A A 't (A (A A v (A (A (A v v v -TA m ( (N N 0 N N( (N N((wN((ON (N (N (Nt w m 0 00 wwww 00 00000000000 0000000000000000 000 00 0000 00000w0 00 00 00000000000000000000000000000000000000 0 0000000000 000000000000000000 ' ; ,' , , In (0 (D (N (N (A(A( ( A A(A( ( ( A A(A( ( A A A(A( ( A A(A( ( ( A A(A( ( A A A(A( 309
A(A(
eln - '3 :0 z~ NN Z ffZ lw Z Z 2N C Z o' - o CN 0 2Z Z 4Z . -3 U a~gz- "16 2 , S a inf~'~ wOO a2.w CYaWV 5 - (y~2 WZ S > W w n> ~y9UN LUEF>
----------------
Nt-- ---- 126 I55 SS5, 555 '555o'S zi355 tz.335 u j 0 03 05' (YOM 3''3'53' 0~~~~~ H 0N00N0000000000 0000000V 00 VS~ ~ ~ ~~~~~~~~~~. ck5 ,S RSV SV V SV SVSV SV S SV 0 F, ES 5S VSV SV dV SV S SV S3 V SV S V S . ~S VS) 2 SVS 55 S5 555 SSSS SSS SS S SIS 5 5 5 5S555 '353 ~ ~ ~ ~ ~ ~ ~ ~ 0 a, 0, a, t- a, a, a,' a, a, a, a, c3 o%5 a,3' m a, a, c3 a, m3 g3' 3'' 333 3' 3' 3'' N~~~~~~~~~~~~~~~~~~~~ N, N NNN7( NNN NNNNNNN 0 ( N N In , 1 0 10 10 D ' ' N N N N NmN N N N' N N N N N N N Nq N Nq N N N C, N N NCN N C4N c4 mN""NN NN NmN NN QS(N(N OS~~~~flVSO~ .' .~m .. .(0 5 O ' O .. .O ( .. .0( .. . . . . . C C C C C C . .Sm m S. - C S . . . . . . . S. S. C 1 .m(S N C4N N N N N N 62 NNNNN c C N N N N4 Nq Nq NNNN NNNN C4 NerNN mIN w ' w1010W N >N r- , It , N fNr- r cN0N '3S (N .( S0 '3C0 050'~ ~ .0 0 .500 .5 . . .0. . . . .0.0.0 . .0.' . . Poo- 0( 0r .0 -0OP O' \' 0 000t (N N N N N N N N NN0, N N , Lm m n (N00 0 (N (N NN C-N w(DmN D Oo0.'0'3.V~1----V12V 500 S.3Svn VS S lV V '0S.VS 0,0~V VSSSSSV VSr SV NNN N n n N N nN N NN N N N N N NA S.V'3N000' N m - V'(0O N " m S3(0 m~ cc 0V 0 m3S's( m nm. oa 00 00 O 00 0 w 0 0000000 310 _ 00 C 0 N 0 0 en N en OC-0 - 0 -nt "z -n n nznN- -- p6 n2,p-N z10 enz .N N N . Oc N 6o o 0 06 a9 9~ -9 0 s 2 S 2 S 99 2 CWY 2 9 cy 9 2 ~' 2 G" 99 w. 9 vi@ > LL. ' 0 aW. >s a.a a L. as Ll. W. '0.a as @ 00 oaaO0C 0000000000 ' 0'0 0'000'0000'000000 en n n n ~enenenen Sl n n e ~q n n t ent n enenen~ n e e e e en'teneneI I e e ~ c~i m~s2I '00''0~' Os '~ 00''0'00' 0 0 '000 0''00 '0W ' 0'''00'5'''' N N N N N N N NN NN NN NN NN N (NN NN NN NN N N N N N, el7 e aa a , cr ae, e ese ae ae a,5 0, Se a, (7, 0,a ,mcaIlla ,a , 0 , , 10 1a nn
-
'A' N rN N N N N N N .N N N NNN N N ""N N N N N CC4 N " N " T r, 0 N0 O00 00 0 .00 r0 Dn .,r 0,0 '~ 0 a ,T 00 r. ,wr 1 AY C'0'0'0'00C''0'00'0'00'!0-,! !.,!0' '! !,! ! '.0'0''! : 00 05 5' 0 .- - - - - - - - . .
. . . . . N N 'I NNNNN N N N N N N N N N N N N N 0 N N N MNNN
-----------------
w10 IDw w -- -- - - I~le 5g c' c ' 5 8 85N ' N N a ,'N 0 0 0 5 . ~ ' I ~ ' N N ' " -n -n - e !1 o--I .n e ene - - TL 2TL en enne w en 10"I 01 a 0I 0mN 0Nmen0-I I 0% (1a 00m1 *11 70 7" .~ . .~ .~ .e . . - - .r . . . . . . . . . . . . ..1 m " m m s~~~~ ~ ~ ~ ---- --- m - ----- V." I---, s- -- I----. F---. 120a 0~ m e 5 N0 e0 021 -'~n0 0 0 1 2E - 9 :9~ 0N(2 1 - n'0 oo0 co s q q c wCDm L 0 0 Cy, m w r .00 000000000V 0 t 00 0000000000000 00 311 '00 00N~'0 N 0"o C-4 0 00 N 0% N0 N( Z
-
0- Z -ArZ-6z~ 4 9ozZZ c ~9N C, 6
Z
6 6 .. no 20 2 ZZ 0 ZZ Lu jqzw9qcWZWES>Sn- ii, oaa ' cdw- 0'i >nu - ) c m - w w ~ w 2 > R%00%08%0 CY2 0% 0m q, C% a, w% m o% c, 0% ,0 l G0 8 mwa 3 %Cs a ,wc , c 0 ,Wa s 8C 00 0 00 0 0 00 0 0 0c 0n \0 00 \0 00 00 \00 0' 000 000 '0 '0 '0 \0 10 \0 '0'00\0 D 0 \0 \0 '0 10,0,0'0,0 'D 'D 'D '0'0 'D \0 'a0'D'0 '0 10'\ 000 10 10'0'10 \0 ' 0 0 (N (N (4 r4(N(( N N N (N N " (N (N (N N N N (N N N N " "N( N "( N C4N N 4 ( N N N N N N N C C4 C4 N ( In n1 mI 1- rm It p 5 11 m o 5 n5 1 mI nI AS gI 'rmn -- vA a, 55( (N (55 (NoNI(I( P N 0 ~ 5% ('n N ~ (9(S(%-(~~ b( m C) (N vS (N a5 (N wI nI (N CIS (S C I- (N ;; W (N (N4 (N4 (N (N M( N PqN(( Nj Nq (N N M(N N CM ( q ( q q (NM N N (Nq (N (N (N N (Nq (N (N(N (N (NN N (N N (N (N C4N (N (N t-'r-'0 % 0 N~ ON'tMWt N W% C>000 W C\ 0 A0%0%U 0'0-Nt- O M'A w 9~0 w 0 000 A 9 I A(N 'K N- C4 1' A 0 00 '0 'D t- M M t- N- '0 "ts~ 'D ' '0 M~ WA-I N'' N0 '0 N- MI N( LN N : Lz tz N- N- NR LN N: N: N- N N LN N- N '! NNNNNNNNNNN0
-------------------------
--------- ---------------- m I CI ,w ;r l 0 t o m m :( m CIm M ; - l r c r ~~~~~~~~~~~ 'A 14'A A AI I NAAA ''''~ A~*A ( NNNN C% 0 a, S, C 4 NM M Mmm O m " a vg9 , y M n 0 % 00 0 00 10 \0 0' 0t t - r -r r r - -r -8 312 0C NN 0 N 0 ~(40 0% 'C~. ".e S~ .. ~ ~ ~ P! z 6 w4o'Z-c -Z Z~ Z zZZ 'C74 2 02 2 6 N o~' 00' . 2 2 '- 2! .. 2 ZIL0 NZ. .. 00 OO % e~ 6 0 2> 00020O Z500a GOC Q..w ww aim~ -) aS 'C0'CC0 a C%0C'' E"CCC%'' R5 aCCnf 'C~~ C) 'C >C oC oC0C'' 2 C C C C' C' C ~ 'CCCCC' bOCCC Sn~~.- InS nS nS nSl5%S nS nS nS nSnS nS nS n- S nS nN S nS n nSnn S nS \0 I 00 0 0NNNO' 0 0 0 0 0 %0 N %0 \AD n r- ON O \A 0%n '00 '0 55 NNNC4 1 N N N N N4 N N N4 N N4 N N N Nr4N NN N CNCNN N N N N NNN NN N N N"N 1000 S N 0I r 0 0 S 0 0 Snwnm00 0 )00 0 Nr n n 0, C- (00' A -%0 055d% 0 C%%%00 4%0 S:40%0% 0 0
-
-N- N - --- --- --- -- 0 O r 0 r ND \0 r-0 w m 0% m% t, 0 00% 0 !i \NN 0 \ It m 00 00 m0%00%m 00 00 0 r- 8 R0N'C55 8 N 0 O'S
%
k 0 5 '0 8 00 0 S0 N N'CN8nIT'C'C'= v00w0Sn mC0S NN N NN N N, NN0 NN4N C1 C 4 a , N N4 N 4 Nl N, NN N N N NC C4 -------- \ 1 21 I ----------------- 10N10N10 mN 0 5 ~ ' ' ' N \0 0 10mN 10Ina, D 0 a k OORt 5 S n n5 % 'C 'C''CC''C~'CC''CC'C ''CC' 'CC''CC' V n''CC''C C C C n'CC'%0C' N N NNNNNNNN N N A N NN N N N N N N N N N NNN C ~ ~ ~ ~ ~ ~ ~ 5 0 N 0 N C0%55%0%55% C C C C .. C Sn ' 0 N - N 0-% CDN5 Sn -I N00aN1 n r a 0 % N N 0 0 N~ S 00 0000000100 0000000000000000000000000 0000000 a\ (1C 1 \(1a aO0 O 7%o, \a , ,aa ,c, ,c a, 0 0 0 ,\0%mOma\\ \C \t-C4 a A - - - - - - - - - - - - - - - - - - - pg 0 a m D - - - -,0 -- 313 10 "o 0%0'000 'A, z0 'A 6 % 0%0 0~00 7- 0 C 4 4 NN N 0% zJ oo0 0000 QCZ 0 >~ a- ZZ Z w. ZY ZOQ- z 2@ 7 G '4 0 a 9 Z > @9 , .. C' W C, 79z'cyz v z 0 0 t-o t-- Y- ,-' z ~ ~ ~ ~ ~~~- z<' 9~Z> i A. a. C" Q 0'0 y LJ Lx UJLL~ '~ ~ ZZ2Z '0 ~ ~ ~ ~ ~ ~ ~~ o wn en cm' ne 0e n ne nNN 0 0 0 0 0 Ln 00 0En a\ C\ a\ al m% 03% % a, C% a, a,0 % 0 0% a, 0% 0% 0% a, 0% a, 0% 0% a% 0% m % C7, m% 0 ON M 0% 0% a, 0%1 a, a, 0%\ a, C ~'o 0' D ' o n 0 ' ' o 0 0 \0'D \0 0 0 10 0 10 \0 \0 10 \0 '0 000 00 co Q DC D D %,a 0, 0 a, o% 0 a, 0> aC 0% 0, 0 0 a DC >0C DC DC >C >C )C 0 0% 000 00 0 0 00 0 " -T -T~ v "A 'T IT It A ' ' v 'r ,A' rA' A A' A' A nA 'A 'A 'n 'A A A 'A 'A ' \000 0'000'\ '00 '00'0 10I '0 0% 0 0 0000'00 \L \L 0 0 000 0 00 00 00 \0\0 \0 Nq C1 N N N N N N N N N N N N N N N4 N4 Nq N N N N N N N N N Nl N N N N N N N4 N N Nq N eq Ntl-CDNNr-w o 4 0\ln~clv o :; lowr-wr-wlw wren C4 NNN V4 N 4 C4N N N Nl N q N N N N N N N NN N N N N NN N4 r4 C4 N N N N N 4 N N NNN NNN N N N NN N NN n0 00 00 00 00 00 000000I N~~ ~ ~ -ev ) N o m N N N, N N- w N- N N7 m a r C NNNaNww Nw NNw \0~ ' ' m0 m% m 0m w o, r, a, 0 0 % G\Ne0 -n888 -I --- 0 N 00 00 00040 00n0 000N0 314 en 0 66 6~>6600 666 Z6 666N6 w0 000N666666 4 (56Z ZO Z 0Z ZZ ZZZZ Z0Z ZZZ ZZZZZ WZZZ ZZ Z ZZZ Z gzz Zo wWWZz _ t,,C~ Lcayl cef ay g WLZ Ls wwwwwaw www CA CACA C CACCA ~ ACA A C A C en a a'a 0 1 aa''C Rn P, V, P' asa 'a'a .0'a 'a'0 0 0. 0' 06 0 . 0.O . a. ow m. C6 a. a. a. 0 a' as as as as Oa'a'a' asas a' as as as a' Las as . as . asaCsa sa 'asa sa sa 'a.a x0 50 sO S ID D 0 r 1 10 10 10 0 0 1 1 1 'D 'D 'D D D ' ' 'D 'D 'n 'o %0 'o 'o 'o 'o s ' 'o 'C C ' C ' _n Sn 4 wn WnS S n n n WN C14 w) Sn n n 'A C14 W) W)S n4 S nS nS nSnS nS nS nS nS en n n n n n n n e e ~ enenenen e n en -en ene ne ne ne N ne N N C C its i i al a, (4aFE. S, Z mi 1,~i i ll is i, :i 0005 05 as 'o 'o x 'a a , aD a' \0 'D 'D \0 'D \0 0 'D0 '0 ' ' \' \0 ' \'0 C7 0' '0 10 0 0 1 a' \' a' en...................................................... .. . .. .. ...
-------------------------------------------------------------
00 e 'C'C C ' Sn'C C 'C0' C 0 'C'C C ' 'C C ' 'Ca' C ' 'CSn ' 'C'C C ' a''C C 'C'C C ' 'C'C C 0 en ~ 1 Nn Cn e1 Nn en en en en4 en4 en en4 en eni en4 en ene ne ne ne n e ne e ne e ne ne ne n
-------------------------------------------------------------
sC~~~~~sC'C~~~~~~~ -2CC'' -C -C 'C -C -C -CC' -CC''C-C''C-''' C-' 00m- - ' -- - - - - - - CNm -- - - - - - - - - - - - - -- D N M ' Sn ~ ~ ~ ~ ~ ~ ~ ~ ' SnS nS nS nS nSnS nS nS nS n SSl n S Sn S n enenenenen ~ ~ ~ ~ ~ ~~~~~L en nn nn en21 No !2e nnniiiN~e nNNNC C.e ne 44444444444444444E 4 ----- ---- ---- ---- ---- 0co 000 ' 0* 0 0* 0*0* 0 N V) 0 IC~ V)P0 , 00 Z z ~ z0 c0 0 00 .- O 9. ~ zr~Z 9C 4 Z Z 69 (5 6 49z Z o b ZzZ 0ww0.0 "'6LI Ww-W e > ~ ~ ~ ~ ~ ~ ~ ~ iwnd P =2 Yce w( L yr eC '-'I W0 - -c R R e IN IN' 0 ''' 00 ' ' '0 ' ' nuI nI n n I n I nI n > Q 0'O- w 0S0zzz Os O S0O0\'00 (D O0 ' ' ' 0 0 0 ' ' ' 0 0 ' ' ' 0 0 0 ' ' ' 0 ' ' 0 0 0 ' c;0 ~ 6~ F- 6626 >. In 2:1 In . n0~I n I n I n I n I I n I n I n I n I n I n I '00't ' =I n' :i =I :4 =i000''' '000 00000000 0 00 is 6,. ii *, 6 6 gu 'o ,s p. 1 6 , m 0 6I4 C4I 0I N I N IN IN IIN N e 00 N 00 00 00 00 '4 N .N N N N -~~~ ~ NN IN IN- INIMNI NI NI Cq N 000 " r4 N N N000 w00 w' w0 w00 w0 w00 0 000 w 'zw 0 -I m 10 '0 m~ m 6 m 6 m m60 m, m ml m m 160 m 1 0 00 0 IN ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ : IN IN. IN INItNI NI NI NI NI NI NI NI N NI NI NI NI NI NI NI -I NI - - - - - - - - - - - - - -- 2 v2 2 2 R 2 2 -- - - - - - - - - - IE 12 2
-------------
a, --- c, ---------- 0 ( iI00 w0' orN~~~n0N0' ~IS) ; IN o~~oM8 cO 0 I < II CQN IIN
------------------------
INn'INnON'0~N0N0ON O00 0- ~ ' INr4I 316 '3 00 ,oenZ Oz 0 0 ON W 3' 00 0 0 Z zzz0zz4 0gV N O N ' .-.r--zzzz '0ZZ GZ V Z z Zce NNZ (:z z~A' O00 0N0 .w q -" cy caa~ ff.O NNuc~g c N(:" f 9992990m 9 999 u 0o~ooCoCo0 0 0000 ~< < ~0 02-0 co00 pUp0 00 ?: 'A en ?; I N 0 en InN~'e n ~ Ne ne n ne ne 3Ne nN - ~ > ite e nene 00 ~ ~ ~ -~ ?0: 0 ?.3 000'3 000'3 03 000000'3 0'00'0' '003 00'03 a' ' s ' ' ' ' ' ' ' ' ' ' 3 3 a 03'3'05' 53.0 323 3:4'3'02' ' 52 3 03'it05' 53 'A ~ O '3 'A 'A' 33'A''' 3A A' 33'A' A' A A''''3'''' A n3' A3 A''I 3' 0 3' 3' 000 3' m 00 0' a l w' 00 w' 0 w' w' m5 m' a% M' 00 m' 0 0 0 3' m' 0 0 w' 0 w m 'n 'A '0 'A ' 'n ' ' In m 10 VA 'A 10 'A 10 A ' A~ A ~ ~ ' ' A~ .33..33..3..33..33.. '. t 'IT33.. v 3 v 3v .n '3 '3.33. '03.'33. -VI'Tv v NN N N C4 N N N N N N N N C4 N N N CN N Cq " N N N N C- CN N N Nq N N CN 4 N4 Nq Nl N N N~ N N InN- me) 0 00ea,0 0, w.~0 0, 0' 40 00 M O ' 0 a 0 e0N C-4 N NN NN NN NN N N N N NN NN NNNNNNN g C4 C4N N 4 N ", qC;; CMNNN4 4N N NM 4NM"N NNN 1 NNcqM4N N NN CNNNNq'N NNNe q eNN 000 twwr q >oN C-wr 0000 N w w00 G 00000.3 00 No 00 w 000000 N W00 No0'0~0300000 ' 00 NNNNNNNNNNNNNNNNN NNN NNNNNNNNN N NI N, ND N N N N N N en N N
-------------------------
'n NN N NN N NNNN NN N NN N NN NN NN NN NNNNN .C .. C C C C 10 N N N N N N4 N N C4 317 00 z C0 -40 CN w0f0 00 00 r' - WNN Nnw ~Z _~0'SO nn c C7, 0' z ceZZ Vom
M
6 9 Z~ Z L ~~ z z aZ6.
0 ONP.P- t N t"- 26 9 6 o z O - 00 y y 00' ' 9 0 o00Z w'- a- 0('2' 0 z-~ - U 0' z'-* z @' o '0~" ' ~ n t' 0 '''0'N0 ' '0 N .N N t~~~~N>~~ 0 ----- ---- ---- ---- --- 0\ N 0 0 0 \0 0 0\ 00 N 00 D 00 w 0 10 10 0 D \0 0 000 w 0 0 ' Sn n Sn Wn N) SnS nS nS nS nSnS nS n nSn n Sn Sn Sn Sn W) SnSn r~ 'n S n0 nS nS sO OSO'0 O O ' '0'0'0 0'0'00'0O'0'\0 '0''' ' 'D 'o 0 'o '0 %0 sO1O 00 0 ''''' N NN N N 4 Cq C4 N C Nq 4 C, 4 Nq C4 N N Nq N r4 N N N C14 N4 Nq N4 Nq r4NN \~~N0 NCnSn N2nn0 0Sn 0S '00 ' \"rr - W' \n00 0S'q(N'I fm n S0N NNN~ NNN NNN N~n~ NNN S.' NNNN N N N~n 55*~ ~~~ .5 . . .S .I S S , . S .' . .S .I .I . . . 0' 0 N ' N '0 'S-. - - - -0-N- - - - - - - - - N~~~NNNNNN~ ~~~~C W~N N NN ~ N N N ~ N 5 5 5 '5 5 SI SS SI 555 II 555 c c c cc C C '000'N N 0n' s 0 4 ~ OCN0 N r40 N'0N0S~ C 04 (n0'S N Sn N' n'' N. Nl Sn Snn0S 00'0'0' a, 0550 wo'00 050 0' 5, 000 0'' o 0 ' 0
S~
0 0 0 ~oo0\'0 r50 F!'0 00 0O !2'0 - - - - - - - - - - - - - - - - - - - - - - - - a, K ' r %0 m m o ~'0 0SnSn 0'0Sn ~ 0 N(NO 0'' 0''0 n 0 0 Sn0 -'00 0' ' N N S'0 n ~Sn n S SnSn 0 t
NNN
0 0 NNNNN NN000NNNN 00NI IO - - - - - - - - - - - - - - - - - - - - - - - w <0 n m m w' w0 100 0 1n0000'' C00 0 '0'0'0'00''0''00'0 n - - - - - - - - - - - - - - - In r4s 0 S . N0 0 n 0 ' N'0 n ' N C Sn1 C C C Snnnnn ~ ~ S C SnnC S~ Sn V Snn ~S Snn n~ C CSn C Cn. .. W 0\ 0 " M 'o M 0 " =Nw 00 m w 2 m
-----------
N0 N0 N N NrNN N N N Nq N N N N N N N N nS nSnS nS nS nS nS 318 00 oo ' o00 N CIA C1 - 0. C 0 0-'z C Mz Z -- Z 9 _ 2 0 -9 Nz 6 - Ci'Cl C waf w * 0 000.. 21 o , > s3 G >~ zoozozzzzoozozzdzwoz-m Z20>-. :2wZ9o9 E 02 00 02 00 Q2C, w a 0 0ww , c0 ww C0UJ 91 ~~~ ~s 2S0 2 ~~r ~N( 0 '~9 0 i0 0 0 00 "'n Nilze C z u 2 > 000'0'0'000'000000000. ~ ~ ~ U C40 000 a'S0'00~'0' - 00000000000 '0 '00''0m' a 0 0 ~ V .
Ii Vi'00 '0'0''0 <0 <0 <0 <0' <0. <' '0'0'H EI I000000' 0000'' 0000''''~'''''' \01 0 00 0 0 0 0'0 '0 0'0'0 %0 0 0 0 \0 0 10 10 0 00 00 0 00 000 0 0 0 0 NN N N N N CN N N N N N N N N Nq N N N N N N N N N N N Nq N N N N N N N N N N N N N en v31 en -1q A MA A A A A A 99C N NN NNq 0' 0' M0' 0 0;- 0 0' M 0.k s00 ;0'0'0' S c 0I 00.0 cc~ 00 N' 0 0n 0 00 '0'Vi0' -00' -00'' -N' -0 N N TN (N (N ' N '(
------------------------
NNNN N N N N - - N N N N e -N - N NN N -~ -N TL n I L- L - ------- : -- !.---------. !---- ---- L o o o o 0 0 0 O 00000 en Nn Nn eenn N neennene n en An An "n , n n An en In Af e n n 'D en vn en n n \. vn n en e 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 r 1 C I C
-------------------
0 V 0 N N \Vo ~~~~~19 0I 0r ' 1 7 11 Co 'o aa 00 00 00~ 00 V c4' 0 C,4 C4 90 (5 ZZ; "1 0990 0 Z EnR9-4-Z ... (999 c's C- - a 0 1 ' 2 .a.W - > >w w 0 0 0 0 ~ ~ 0 r2 Es 0s r-0 000 00 0 0 00' t' 0 ( S N > > C', aao w z 6666S6 666~~'a'a'wasw'a 0 V3 '0 '02 'ana''cfaaa''''''' af''''' sa a a' a' a' z'' 'aa' 'a 'a 'a 'a 'a >0aa'' OUQ'0 a' ' >a' 'a 'a a''a) 000 000 000 00 0 220 00 0 00 0>Pi VS 65 ( (565 6( (5 656( ( 65 65 ( 65 65 1 (565 ( (5 656( / 6( 6 ( 2, t ( 1 ( t t (5N N V ( ( ( 5 ' ( a0000e0' I .( wt > 0 V3 00 000Na a'a e o0 O ' P. n4~ nnenn~ en, 0- N N) DID 'a 'D 'D' O D ' S s It s I S Nc, 01 01 D1 N00 N0N N00N N 00 N N N 00 N C4 N 0000000 0N AN NN" NN N 4N N N 'N'aa NN NN' VS' Na N C NN ' a 'N 4 N NN C ~ ~ ~ ~ ~ . . . .. N Sa N 0 0- e asn' M00 0 e~ 'a 0 as a%~e ON M (7% ;-o61 C-4 mSV S' a' ' a O ~ ' N M O N N M Nq M M N0 00 0 0 00000 w0 0 0 0 M NNNNNNN NN2 *NN N 2N*2 NNNNNN ---- --- --- ---- --- -- 320 '0 N _ 00 00 'r .. ,.0 A -z 0CN z z Ci 2 CY 14 Z z 00 0z zz c ecIN 9 9 0 y.. Z . ZO Ce La z0lw 0 Iy0w Y 9o 2 0 9 >2 w 0 az > 0 -,,, Z ~ w q v- Y Y-ca W ~ ~ ~ ~ > ?, Z ,EWaC y2 > tw0z->a9 0', I" >' Os 05 '05 '0r5 '0' ' CsO ' 020O0 '0 usl0' 5 ' ' 0OO4 0 CV6*~ r5' p000''' 6.'00~ Q05 QOOp 00000CV030000000000N0N0000 .4 6U6 S6,V l~ f 4 4t6,6,6,666,V 4 4 S6,6,~ VV S6,V 4 4 46,6,6,V ~ V 4 4 S aC\U%6 6 % c 6 a% 666 6 6 c, as6 66 a% a, a,6 m a, m6 m6 m ,m66a6, l O 9 6 ,6 sO'CS '''0~ O~ WQr NS sI D\ CDCDC C D D DCDw0 C,0 )CD<D0C)0C><DC 0< C 0C C D > DC- ) C > )C)C)C 0C COI -*5555 -5665 - -T- - - r r r n I nI nV II r r nI ) In ~ ~ ~ ~ ~ ~ 56 66~ 6 6 5 65555N "I6N 5 - I" InW rIn" InVInIW)I )"II t-',t 'IIn r r II I I ? M I I ? , ,, ,?, ?, , 65 C-- 0' '? '?'? ' CC06VSC0? '4 \ 1 1 1 . t 0 1 . . . L L1 1 1 1.1.\ I 1 \ .0 Os 05 0o \. 05 '~. 00 'o . \ w III In5 0 N wr- 10 In -. 65 C-I 651 OCN 0r % N 0 \ -0NMM p0000000 S''''''' m00 S00'' ' It I"*'m -- t C- NNN 4 V S M1V S V S V ? SC C 1 1 ' C r 10NN N NN N N N N tNNNN0 N t NNNNNNNN I;, 0 'L w t-O N In 'N0 00~! LONN565665 LO66a,656 N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~ I N N- Nr M5665 565 M566 665 565~665~666 66 665665665665 566 65 L-CO S66 L- r- 65E6r60-L r L- .
0 0 0 QQ Q G 0. 4 -a 0 M M I n 2 2 222222!22222222 12 Iv 21 e : e1 a\ mM 10\0 - In \ w - 10 IN 0 010 :31 ) a -w C Nr -w m- N .cm 0'.C -ezg 000 Sno _ .. 6 2 o zc<D 02 es.o 2 CG CR -2 a EE Z NOC 00 ff zS, ff f CYC s cy zS o z W-. > - W g .' c4~.. ~ NS ~ 6O ~ 0 0 N'0~~00 9 V~w z'a 1. .'0 s " w0 eI n '0 D ID o0 o\ \0 10 \0 \0 0 \m '0 r 0\0 \0'0In SnD'D 'o0' '0'00'Oo 'D' '0'D' '.o '.D' '0.'O'Oo''''' \0 ' ' 0'0'0 ' 0 10 0 0 5545 Cq eq C4 C4 C4 C4 N, 1 5 SS1 C4C5 4C 4NC Nr qNC 4N 4C 4r 4N 4N5 N N N C7 N 0 N N N N ND N N N N N N N N Ch m N m mN4 4 m N N q m N C4C-4 N N 0q N N N SN N .- s'. N N N N eqN 0 0'N 55' 0' eq Nt 0 q SN N-0 C N NNN N N- N NNN NN ooD-w s0a, 00v0In \0 v -a 0 S w \St0 v t-r-Nl 0''N '0S05~ N 'l D 0 a\a 0 0n0 0 m 1 0 w m D D 0 r-m - a mNw' 0' m50 10 Sn n 0N 0 ' S~~ ~~~~0'.000'0'0'0~~'t00',.~' 0'' 00 0000 - - - - - - - - - - - - - - - - - - - - - - - CNO.' p 0 r C C C ?C C N N 1 oo ao r4 n ID - - - - - -- m n 0 - - - - - - -- 0 m n - - - - - - - - - -- 1 W a v - I I I n-n10 10 10 10 0 0 - - r t r t r Sn' In 10t~ %D~ ID~ Stnt nnSttS ---- M------------- Sn'0N000'0N~~32~n.
eno 00 I -14a v- ~ 00 Z - 6 - N en - - 0 c", -e z z 0en c'a . G o 00 00 C-49 Cq 0O .. J 0 Z N- 9- z - ~ dp-0' z V Zz o,0o -- zz(y 0- -> l - a 20OS0'Oy Cy Z N a'a '0 '0 '0 0 '0 '0 -0 '0 0 0000 00000000000N 000 00 0 00 00 00N =~~N N -=e NN NN c-NenN N N N 0 ~~~~ OzaOn'~N0' c> N N N N N N N En N C N N N o I Y (-- O > ti enN~~~~ ~~ :In WN~n~e en e eene FN nn eneN >N NN a <er V3N N 0N CN (D < 00 0'0' 'o ~ e 'o D'OD NN-VI kn0' a'~ ' en 'On In 'n N W)~~~~~~0 ' Ln W n t , )W )V 0 000 0 00 0 0 0 00 00 00000000000D'o a M 0 \0 0 \ 0 0 0 0 00 N ,4r c4cq'O4\D4SO4\D4%04\D4\D4 No%04NC- NNN q l C4N 1 C4C4C1 N" 323 C 4 - 0 C5 ZN 9' 0 :00N M -~00 -t Z i r 0"0-' r- Z 00 a~o Pr-0zz '-N -' *~9~zz Q N~ 9 5OZ29. 9 0 0 o V~V~0W~0' 9 z - zo a o 9 90W~N w 9 9 9 LuW 0 N N Z e . a w >- ,-, fy 3 10s ;@~ a- c CY LL.5 w 8, 00 00 00 000 00 'A~~~ >A UA 'A' A' A' A' A' A' A' A' A' A'A' A' A' A' A' A' A' A' A' >A >A >A >A' A' A' A' A' A' A' A' A' A' A' A' A' A' A' A' A' A' A p ' ,A ,A ,A ,A ~A ,A ,AA ,A ,A ,A ,A ,A ,' ,A p. s S m g55 5 SI iSS II 5> *5 SI I 51 15 15 , II 555 C C 1 11 "1 IS "1 .. .. 1 I a C,171-. 7,0 (1 mC) 7,a a C\G\a C\ ~-Q ~ 0 0, a-, a, 'AN' C\ a, m0aa.~ losisl 'o\ c\0' 0\ ' DC,'o \ -' \ D' NN N N IN N N N N N- N N N N I 1 1 1 .N eqN eqc NI 1 N 1eq N N 4C4NNNNC1 eN N %DNN ND N0 N No N N q a.Os00a.C C !- -! ' -, -! 5 2 m !!5 C 1 -C 00 00000000I I In 0 0 0 N 00 00 ' 00 0' 00 IN In000 0 0' 05 IN0 105 05. 0 \ C.50 a,0Q~ C7 cq C40 V'AN'A VN V C14 C14N NCN C1 N N C4 N C-4 N4N C1 NN N N N N N N 00F, - ! - 5 - a S' N N N N S' ' 01\ \D, "IS I, InAA A sn A Ir 10 8V,5\ 00 A, 0 0L00 N 00N N -0m%, r 0 a -I MI NM t- a'A'A -'A - r N m r-I II ' C VVr0\t a KV o.VV mVV V aN N n N, N N' N N N D V V V V V V V V V Vr vV V V V -IV V V V V V V VVnV VVII - I V V V VVr r ', I, n r C 0O 0 0 0 0 0 0 0 0000 000 C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00C C C - - - - - - - - - - - - - - - - - - - - - - - - - - 'l a, m m n ! m n t !! 142 - R n m n324 00 'a4 (' 1 Zr Na W'0 000~ 00D o 0 1.0 C5 tIn . -. 0 2 w eq ZZ..ZC-4~ 4 .. z Z.. 2 02 G 9n 0' r- in zec s s o 0~~~~~ ~ ~ ~ ~ 'nU, P .a - zN > S sc 0 0 O'a'qua a 0 0 YffN N' -- w wa all U 'm a En''''aaaa 'aaaaa0a '''aaaa0aa0aa0~'''a00~'0 >'a 'a 'aa2 ''a~'''a 'a 'a 'a a 'a 'a 'a 'a 'a 'a 'aaa.'0 ~ a aa'''aa ~s~aa''aaa' ' v a c'a> ('0 (71 C% ('0 m' m' (', Sfl ('0 ( ('1 - (1~ (0 a,0 " "' m' "' "' C', m' m' m' m' 0 C70 m' 0 ('0 0(0(0(0(0(4(0( ' !2 0 %0I %0 SI S D 5 1 5 1 IIo * 5 1 5 %C w ' 1a \a 10 'a 'a'\a' s a' ' a 'a \ ' a a ' a 'a 'a ' ' ' ' ' ' ' 'o Na Na 'a Ca 'a 'a 'aN a' a0 a 'r -- r T 0 ' 0 0 0 '0r' a 'at t m00C4 ;z n C' ~~~~~~ c''~0 '0 V 0 ~ g caaa a 'N N_ Nj Np aNNN N N m m In N N 'a ' N N4 N N 0' N Nq N N, 004 N, N, , i 554' C14 C14 I S IS4C- I 1 C C>C>- - -- W- - - - - - - - - - - - - - - - - ) o , j S (7 t o o i 0 - - - - S T ~ ~ I S ' S NISNSS.4 5555 c (' .0 .0 .0 .('0.. . C7 400 00 -T00 t t - - - - 'a 'a 'a 'a 'a 'a N N N N N N N N N_ N5 N0 N0 N N N N N N N N N N0 n I (0 M 00 00 00 00 0 00 0 000 00 00 0 00 0 000000 --- --- --- -- --- --- - C5mC325t C -C' ON0 0n 00 0 coele 1 000.o 000O~ 0' 0 N~ N. N 2 z 0 0'og "P-z oz z~ ~ ~ C2 z /I 7 0~ %~ 'w 00 ' %000 2%'00 w'' % 0 % ' a a- 0 % ' 2''00 0 '200 C2,11,2 2%~ 0 cy Es a 0a FY 0 c~~~y' ;- ,a >CC' MaoC S. 'C 'C .C 'C .C 0'00 0000%O OO 000 0), >000 %000000 ~~' A i A ' A ~~ , 'A'Oz'A'i'',0AAAAA'''' 0 ~ O 'A lA A' 'A 'A'A' Oz' Oz' 'A ''''' A A'a' enen ene ne n ne neenne ne e ne nene ne n ne ne e ne nene ne n ne ne S. 55 ' 5 ' 5 , 5 '5 5' '5 ' ' 5' 5 '0 i ' 5 ' ' ' N~ ~ ~ ~~~~~g N" Q N NNNNNNNNNNNNN Nen tfflH NN N NNmNN ~ N 0 j nN N ~enI00 '00 000 en eO'e eU nn N C4N >p N"lN en~~~I Nn en N% ne nenN n0e "D0 % 0 L 0L0L 0 '0 0 L '0'0 L I I L 0 10 1 0 1010,00 '0'0 0 '0 '0 N ' N N N N N '0 N 0 N N N N N N (-4 N N N N N N N C N N N4C 4NC N N N N N N N N N N t0A0'' t-CA0A'~ ''' ' CAA'0 A 'AC00' t C 0' CC00C 00C' C' c-At'' 'A--A''0 'A AA'N'AAAAR N - ; N M N CC44 NN4 NNl NN4 P4 C N "MNNNN 4 4 N N g N4C I l Q - N N, N N4 N C-NC4N 0 - n -0 e 0 en n - 0 0 0 to ~ne -e en 0-nn00 -- - '04 0-0-0-ena a. S. a 'C 0 0'0-N n -2 A -C N 00 0%1 0- N en 0'ACN00 '0-Ne - - -C N T0 T'0 N00-.N~en'0 0 re'C 0- r, 0 'D - - 0 - -N '-e . . . . . . . . . . .. ' A. . b 0 0O 0 0 00. . 7 . . . . . . . . . 0 0 000 2110 000 0 00 Vo o o o O O O 000 qNMM - C - NC C4 -C Cq A n w)%n W tn n n326 04 00 z 0 0 '0 - 0 \0F M 6t~ 'I'zF N rrJN C C U tZZ & , 'w z; 2 - 29 - L- ~ 2 2 2 2 N N n1) @ Z C, C) o~~~0 0 OG 6 0 o0 0(l 00%'0'022@WW2 0tO s wN0 w (N0",0 0% 00 s% <% -% .. 0% C) 00 0%0 %0 %0 %0 %0 '0%0 00000 00 %0 0 %0 %0 %0 %0 0% ~ ~ ~ ~ ~ c 0% :I- z% 0%0 %0 %0 %0 0 %0 %0 '0 % %0 %0 %0 %0%0 %0 %0 '00''0 00' z00''00'''00'' % 0O'M%' - a 0% 00 0 00 0 0 0 0 0 % %0 %0 %0 0 0 00 0 >0 MN Md MN C\ a\ (N\ (N (7N(N( N N (7, a, MN a, MN MN MN ( , (N 0\ (N (N 0, (N N a\ (N (N (N 0\ a, 0\ (N ( \ a, ko t %D\0 w v 0 \ %0 O % %0 o ' 'D'o ' 'o'D ' 0c o 0 '( k 0 0 V1 (N(N(aN(,(NDNCN(CDNC> CD C5 a\ 0,I 5 1 1 1 C, 0I CS 0 0 0 0 ) 0 > 0 \ M! . . . 'Do ,,0' \ 1, 1 0 0 0\0' \ \ D D%0' %D(NNg %0 4 Ir ' 0' 4 D' O 0' D' 0' D' o' N~~~~~~~~ ~ ~ ~ ~ ~ 000 N cq C qN NNNN q N.....N '0(N~ %( (N(N 0~M L- 'o0000~ M W)t~00 0 0%0%00%0000%0 . 00. . % . % . %%%% .%0 .%%0 .%0 00 . 0 ~.0b .% .% . .... M:; I.ll CD WI ISIS S lc: nI ,a \Ca a 0wwwMM\ 7 MMN0 M s~0CSf % -~~ 0 ( A c5 c0 Sn 0% c Sn SnS 00 %S n'~ ~ ' 0~ %0 %S nS ~ N cN0 N0 n0 n0 n' 0( (N ~ ~ ~ ~ ~ ~ ~ ~ ~ C (N '0 (N( 0( N( N( ( N( N( N( N 000 ( N( N N N 40 ' (00'(N '0 C4 (N (N (N(NN( C4'~000 0''' Nn n0''' '0'40I"NA4'0" l" C>~~ ~ ~ C, rq LS e.e 42r -0-0 o00 MM 1 0\ wMr-a 0% 00 o '0~'0S%0''0(000 ''0(00S5~S1 25%n~(0 12 \2 -- -3-7 CD10 00 z CO "q "4- ~jOl z@z'0 G z'y~-9 CMO Z ~ 9 .. ClllzC~ > 0C MN 00g0'0nll10l4 v)Z aa ' -- r~d d ~ -- 6 lY0 t 2 sa Sp mS>1 m a. w , > .W 00000 0'0 0''00 z'S00 'Q-~0 4500 0 0 'c 01~ ~ ~~ a 0000 M000C000C000 00000 M000000 ~~~~~Mq CM ONMM In 0 0 I ON'0C ON 8 Cl M0 OlN M M C,% M~ 'D00 'D '' 0 -1 1 0 10 ' 0r- 0 ' CM ''CC~ 0 'C 0 C 0 I ~ C '? .1 M 0 ?M c, CM CM CM CM CM CM C> CM D O' CM Q 000l0IC C QnCc>M22IIn C , C CM CM CM CCCCCC C M C C . CCCCC CC C M CM CM C C C 0 C' CMl0nmC 0 C,0CCMCa m ' m M'M~ In C N N N N N N 0''''0000''0 N 00C400 00' 01N 0010 N10 00 N00 0'4 N000' ----- ---- ----- ---- -- - 00 100 D n 0 01D 0
-
In In - - - W) In In IT000 CM CM CM CM CM CM' bI 10 ' '0 C' '01010 101 10 S 10101010101010 1010'0 '0101 00000000000000000000000000000000 a, M a, 7, 0,0,28
-
z ~0 0 c. 0 0' 0' c ,- r cN Q . O9, ~ 04-; zF No 6 ' z ~0 - .. .. z o Z' 0q 0' 0' Z' 0' ' ON, 0l 0 z' 0 0v 0 ' 02 0 '0W 0 0 o0' '''0' 'n~wz6Rzq2R 0 z 8NR 0'z2'f 'S W'. *''''' 0 2 Sn CG g vn .. 2 aonac Sn Sn 2a Sns 2n 0" Gn Sn Rn vn 2n P- Sn Sn vnS nS nS nS nS nS nS nS Sn ~> >2 2 SnS nS nSnS nS nS 0 nS nS' S nS nS n I i nS n nS nS nSnS nS n a-a' ~ o f 2 ~ z .fs G. s_', 9 cf, 9 Mf~, ,, w0'00'0' '0''00' §'0'0'0'0 cww~ Q'0'0ffw~ '0 '0~ ->o0000'''000'''~~'0'' 0000 N w Ne o w CL N- a (' NNNNNNNNNNNNNNNN n NN >0<~ swrA y< 0Sn-n>n nN0 '000'00'~~0'iNa '0Sn000S Sf f N ~ NNNNNN NNN>
----------------
0''> 0' 0'0 r40 0' 0 0 <~~0 Q '''00O 0'0X0 <'' ------- N 2---2 !--=------------ =n in = NN I n 0NI0 '~0 n S ) In In Nn '0 00- -9 - 0 - N- 0N N N N~ N N N N 0 N 0 ('9.0' '(l Snn 00 '0S'o '0t 0'' m n0 Nm S '0 0 0' N 9 Sn'm0N)00' N m0ON C0>snM 1Sn000 Wn 0 N ' S'N C4 N N0N N S4n q C N 00 p q M4MC N Nq cq CM N 1 CIN Nq -4MC C44CC4 ~qN "r ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 00 m 'wmm %< a T'TV"'10I Ar Sn~ ! SOSlS f OS nS OS OS nS O nS nS 0S O0 000''''''' '0O0'0000''''0000''' '0,''''''''0 '''' 0 ' 00 00 00 00 0
.
00 0 00 0 . 00 .000000 In-a-----------------l NO Nr, , Q m mCN 0 WN oo m NW e CqN 3290 00 O0' 0 01C7 s.0 *G* 0Z0 ' '.06-5 CY tZ ~ ~ ' "' 00 Gn Sn~~ Sn zn 00 ,. 00 w0~ ~ - C.0-, a, -. C4*) - C) C4 'D C4 en N6 MD WzZw S.
MW N 6 6W b. > -ZZ cy SE 9 w ~ ~ ~ -2 CO0>zs->49W OQ -0 0''' 00'''''0000. 0'00''0 C>,;> s > M, > > >'~ ''''000'''00000 '0 '0' 00'' ' 0' 0' N 0' 0' ' 0' 0' ' 0' 0' ' 0' 00'0' 0'''' 0 Ow oil0, 000 0 0 00 0 0 0 00 0 0 0 00 00 0 >nS n0S nS nS nS nS nS nS nS nS nS nS nS nS nS nS nS nS n~ S nS U.0 1<4 VSN \'0 0'0' 0 10 \0 0 a 0 1 '0' 0D 0 ~ ' 'D '0 0 '0 '0 0 0D 0 '0' D' o 'D '0 '0 0 '00 '0' ) \0 0 C) CCD (DC, C0 0 C>0 0 ' >C : C C 000 00 00 C5 00 00 0' c0'0'c00a,00 00 ~ ~ I 00 .NN' ' '0 - Sn In 'n 0''0T 0 - --- - ' ' W n n nW 'n .. 'n- .- .. 000. In '00 \0 'D~ Sn '0' \0 'D Sn N0 \0 '0~S '0 'D '0' ' 0 0\ 1 0 Nq N 4 NN N N Nq N N N N N N N 4 N 4 N q 4 N N N N Nqr qNr qr qc4c 4c 4c w~S0 ~ ~ ' ' '0 r. 2\ t- m , vMM 0 M M -; 000nn mn m ,SAnNNMm A. - . . 0' ' ' ' M0m0en'A'Q'NM00000000 I 0 ~O OO0 000 C 0000000000000.. .. . C r N r- \ n N 330 0 CD 0 z Z- - 0t t-- 0 0 U'zz z~ G@(5 z--o zz 0 000 0 t 0( V) 0oo
-
V)zzzaf. ,. zoZ! cyaZZZCYZ999 6 9~ oaQ W YYUa- e Y 9 w n s Nw ww z o@WVTh9 ~9 LU > > .Yf f 0 0 0 e ee Es 05 y S lI S a t ' @ t C5 AS~~ s A0 ~ ~ N Ns0 0 O a 00~ C 0 ~ 0 CY 0 c c 0 C '050~~~L 'C' ' C C' ISI S 15 mS 5 SII SI 15515 5 I I 11 00 00 00 00 0 00 00 00 0 8>00 00 00 0 \0 ' o 'o ' D ' ' \ 'D \0 'C 'D 'D 'a \C 00 C' C C ' ' C 4 C'4 r4 N C4 C4 N N N4 l C4 N N C4 N " V4 N N4 N N N4 N NA N N N' N C4 Nq C N N4 CN NN N4 N4 N NN ------ ------ ------ ----- n WSI r a' Fj I C-1 N04 IN N3 " "A q pC " - N 00 C4 N C4 C-4 " N N N N N NN N4 N 4 N N4 N IS . I . . . . 1 1 . . II IS 5 5 . 00 N N-- N - N N NC Nr N0 N N0 NaNN0 NNNNN' N N0 'c - - - - - - - - - - - - - - - - - - - - N N N 1 1 0~N NN N MNNN r-N \ tN C\tNN LO ~ ~ ~ ~ ~ ~ ~ e F. It -n In w C\ en t- w ,en n% r 0a m00 I 5 W ' ' m a, Nl mC N00 a, IA a\ - OICA31m(1 c 0 a C - - - - -- 0101 o o' ' o'o\ - - t- - - - - - - - - - - - - - 'C00' 2 NnI 2 52 2 2O2 2 2 2 2 2 2 2 s 2 2 2 12 2 2.2 2 2 2 2 ~ NN NN NN N enen~~ ~IAIAA~S331I ON m N( 04 10C1 0 6 d '5 gZg M ~' O ICIL 6 227," .. .. 6 -O > Z C'N 0Uw 00 w NwC @1 2 6 -. @
--
! ,, 2 2 2 2 z2 n V n 0 0 yN0N enR l ya Ae**e ao > a CY w Y WzQ 0I.. 4.w O- .~ C,~ a 0 > > U 30--y--- --- - -- j 010101mo -\0 ma1 CIO, 010101 101 S l~1 0% , c 7 ,m ,2 0'\ a\O1 Cc'% a, moo~o 00100 m 6% m m m0m010.m0m m 'A 'A I? 'A 'A \? \? I A A I A A' A ?A A I 'A 'A IA 'A 'A 'A IA IA IA IA \A \0 10I A 'A I A' IT 'A 'A n V en n en ene ne ne ne ne e ne ne ne n nen en en en 'n W) enn en e ne ne ne \0 \0 \0 101'0 1000'a 01D1\C)0\ 0 10 1 0 0 101010 %111 0 10 10110 0 1 10 In 101a0\0 ID0 %D1 101 N N4 CN Nq N N C1 N- N- Nq N- N CN N4 N N CN N N N4 N N4 N4 N N N4 N4 Nq N- N C N4 N N N4 N N4 C4 N4 N4 12N n \QNC-4 N 0 00 N N- en N) NN NN n -4 Cl N en . OenO~~O nN0 '0-00-N'- ON - N'0 - - -- -- 0N C"4~~ ~ en en en MNqN M ' en NI MN C4 Ne4C 010 8 00 00 00 0w In -1 M1 M1 w1 w1 -- 0t %C 0 01 01 01 a, \0 00 oo oo -r 0 m 01 a, 01 r 00 0 10 O 01 010 0 10011010101 '0d '00N en m 4 0 01010e' 0N N 'A N M01 M w0IA0 N N 00O 00N N NN N N N N S\ N &! N N! N N 00 n0001n !: -Ne \A1 N021 - 00 0- eE! n IA10 n 000 -N n 2 r-A0000111111 N- t N M N~ M N00w 000It000 0 0 Nw101v 0101l1 01 000000 0000 400000 in00000 00 00 0 00 00M 332 z F4 z0 -~ 0 o"n~ 2o. C) .- 2 0.aa LJ000 o 6@ az-- 00000 a Z fuzN ZL ZZ Z Z Z z7 y W7 z z czwa G 2 -6 e 00 z > > 00s U. ~~~~1~~c 't~S 0 ~ 't 00 4 N000.-) -0S 8 08 5 M O - St '05050 C4 Su ISu~ One ERE R I .0 wy o W 0-' 05'0- 05- 05 05 05=2W-->
---
ts asoo 0 S50 0500550550 gsOSOS > 002 RH RPM' no w ViIf tlViViV V V i l i lVi10V V V V V i i i iViViV V V S i i i i SISt S5* >V Ga,~ ~ ~ ~ ~ ~ ~~SS~'tSS 0,0 1a 1"1M" 1MMMw ,a ,o IMCIMM ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ n SnOMC Sn Sn SnI Sn, Sn0 %M2M a ca ,MM (,(,a nnnnnnnnnnnnnnnnnnnn nnnnn Snn (D C C>C. > C C5C> < <DC> > C C>0 C>0 0C) ) C 0 <D0 C>0 C 0 > 0a, , C,0 C OlC) ) C, 0 SN N N N NS N N N N NNNNNNNNNNNNNN 0 SIrS 0 ~ Sn Sn Sn SN SnR I r " r 1 ~ ~ ~ ~ ~ ~ ~ ~ 4NNN SNC C C C C C Sn In ; ; ; I 050 00' N S~S !1S S2ll E:; S2 S m mmamDr-' Nm1 n% r-0VmSD= C7 1 2 I! 2 n eI~ 12 n2 - 205 50 0 ----- ---- ---- ---- --- N00 SN' 5 N ~ C-4l 0 wNN C)SNSCDSNCDNNNN W- LO - !2 ?2LO !2 LO Lo 2 ?2 n T! LO115 !2I W-. LoT RR I R S292 2'S2' M-W-m M m w M 8 - 0 - - - - W nO=0 m 05S m elm e c) e mmm mmm m Smm n m- o m t -t t-t - ---- Prt -PP - r- -r- - -- -- t-- - -- t- C-r- -- Vis0SN 0050SS N nt 2'0SN00 50N n 3 8~~oooo ---- --- NN333 0 Ro eq 0z e 14 c, . -. 0 0 o''a a 0 -'O z 29 09 z Oczz ~ 2~ z 6 z 9~ CY z w ,2229F( wa6o~w w >> aff N ,,fac(' 00 0000 00 000 w0 ~ a 0 06 WS 0 0 0 0 0 0 0 ES I 2 55, pil HIf '0~ z H OC'5 0' 0'' '1 00'' 0' 0 0' 0' 0' 0'0' 0 ) 0' 0' ' 0' 0' 0'1 a a (N( Ne N( N( N( N( N( N( N( N( N N( N( N( N( N( N( N( N( N( N( sNN~N((( () C, u W C s(1G 1m ,0 \C\m ma,%m \C \C - paaaC , C,- a(1( 71 m( ,aC (N (N C (N 0\ (N (Nm (ND~ (N(N \ N(0 10 \0 10 \'0 10 10 10\ 0\ 01 0101 n 1 01 0 a,\ 01 01 0101 01 0 CN((N o(N((N((N( (N (N (N (N 0. o (N a C > D \ C)o o NCDoCD C.CC c'o W) ) 0 v n V. 0 r. W) kn' 00M M~ 00ON A' "N~' ( 0 (NM W W N 00 '00 NN 0'V 000 4 (N t0 '0 tN N0 mN (~0 0 N0 eqN C. 1 C4 4 C'4e C4 eq ie "N NN NN NN N1 (N (N N N C4 C4 N C(CN o , , 0 01 0 0 ' ( (7, 0(00 CD w,0N 0' (\ C7, C \0 w(N 0 0 ~02!L- a. n- naF..= 14 ,!aO o oo ~ t 3 - oc-r-w. ,t -w cc ,0 o c t *N\ rwow 7 oV v v' ' ' ' ' S05 105 '0'0(N(EN(N(N(N(N(N(N(N(N(N!2(N0!:005 ; :; : : \ (N~~~~~ ~~ (N (N (N (N (N (N (N .N .N (N (N(.N( N( N( N( N( N( N N( N( N( N( N( N N( 0 -00 0-00 0 -00 0- 000-0 00-0 00 v r % m m D mv 0 (1 Itm N cn -I t0 r 0 0 w , 334' (Ne4 z' : -1 -2z ( 2 E R_'a6 -- '6 2 -o---z woo-o0q en- n ~ 0> r 00z c C40 '0 %0 0 %000 a 0' 0% 0% ff% a' CYR W, ya' a'0 '0 .a %a '-2 '0 %0 '0 %O C00 00 00 a', 000z00000E0000000 Sifz a c SnS nS nS nS S nS nS5nS nS S nS nS nS nS C, Sn Sn EnS nS nS nS nS nS nS nS n nS n~ S nS nS nS nS nS n s Sn nSn n Sn~~~ Rn 5n !nS nS nS nS nS nS nS nS nS nSnS nS nS nS nS nS nS nS nS nS 'a' a' a' a a' a' a' ' a' a' a' 'a. Cy C N 'a '3 'a 'a' a' a' a' a' a' a' (N RN oN (N, WN (N( N( N( ( N( N( N(N( N( N( N N( N( N(N( N( N( N N( NO ~O~00~ow, >~'00'rS(~~aS Nn.SO0a Sn~nN~n Sn~nn ( Sn~~~ n~> (N rN N( ( ( (N (N wN (N Z, C) Z59I C)~I s ' C) ) 2W . . Sn c 00-S o(S% asa 000% 0r- c a, Sn, W00 M C(Na tha- Sn Ol C(N Ch0o, CIO Sn an- 0. a a% m a 7% s 000m s 00 Cs0% M0 % ON0N0 M O000000 a,0,0000000 am0,0C a (N (N 00000 000 0, 000am0000m0C In0 In 00' 'a r r- r- 'a C-. 'a kn t n W n (n k )' n nW ) W vN- S, S~ 'n tn -----------
-----------
0000000 a' 'o m0 Sn a' 0 l a' ~0 \ a .0- 000- ------------------------- ---- N M --tN C4 o0000000000000 0 a N. N''a0 0.0 a'i
N
% . %
''
.
0aa a N N C4
---------
Nr C4 4 ----------------- 4 c eq NCqqCM N 000 (N(N mN - N0 000000 0 0..00.00 .. 0000 . . \00000 - - - - - - - - - - - - - - - - - - - - - - - - 0000 0000 000 0000 00000 m w; M- 2 T !0 C2 - . O O -2 22m 2 2 0133!5C z a 00 !2- z 0 .. 00 Z '00 -- 8 0 00 -,2. 0-z Cfl6Z OZ00 .. 6--O z 6 2 o 0 0 z a" - zz2O e. Z O~L Z Z @ (cLLI R .W LI a - Y V)~F LLL.> Ess - 0 0 0-05 0 00 0~ 00000 0000 0) 00000 Cy 0a' '00 in t, n , i, t, i i I~ V a, at, i , m , a, i , m a, a, ( i ON 0% , a, 01 in i t t O C r - C-iIU t 0 U C7 , a , , , a , , , % ( , s , cy, a , Si, S, a%, 0, a% , 0iici C7, (Y' (7% Ci, a , i, Si, Sih il ON , CD~ Ci , 2 a, 2i , ci, , i '0 10 0 SO 130 0 0 0 0 0 0 0 w 05050 '0 0505D 0 '00 '0 '0 '500'0 0 00 '0 !0505D 0 0 3 10 0 C) ()'C C C D (' D C' C-I (D C C D CD CDI CDI CDI C-I C-I (N CD (D4 C-I (D CDI CDI ('4( C I C -I - (D I C '4 0 N C li C-I N cSI C> CDIS C > n " " vi n00n I CM~ CMi CM m C, e e-I (N Cl
.
IC C C o! Si ('41
CC
\.i-0 Si. '. '. ,, ,,,O Vi m m m a m m m v, ati~tti, i i m U0 , kn i'3tID a\ 0 ID 0 0 I 0 CiSCCiCii C-336-~,U'0-05~~i,0 C) mn V) 'n .N 0, @ s -. Z z Z T 0 OeZZ r0 005 Z; 00 Z WC ZZw .. ) - - O 2 zn
Z
0 uZ 9Y OZn en. eZn 5w -G P g -cyy0 - 6 -~ .--. P-N zo w z z z w C 0'00. 0 05 svv" 0 0000000000000~~~r N 00 0000 0EnN00N 0~0OO a, cSI t m mS m 8mtI StD mmM 55.M m aall ~0 '0 ~050t'0 . '0 .0 0 0 0 '00 \0 \D' \D'0 '0 '.0 ID 0 \D en 1e eo en en en en en en en eD en en enen 'D 0 0'0 o 'D \0 'D \N 'D \0 'D \0 N N N N N q C4 Nq N N N C4 N C4 N N4 N N Nq q Nq q C4 N N N N N NN r- CD "1 - i
.......--------------------
en Nq t0 N0 O k' ' n N en m 0 00wN 0 ON - \0 - ;; 0 00 00' 0'0 -. 05 50 050' C C C ' o I . I. 00.0.0.0 . ~~~~enen-~ ~ ~ ~~~~~~1 a, n0o0o''00nse ot n oNoote'O Ch N0 N\ N N0 NN(~ W'N N ~ n N \0 N~ nm Nm a,'M Csn0 't.
0 '00No 0 LO n -2 Zn 1, nNN 22 n00 ' VS N 0i~ ~ ~ N6 N7 en~ ~ ~ ~~~~~~~- eneLne ne ne ne ne ne n~ n~e n~~e ne ne ne nNe ne q 00000000 WNW0 ONN O a, A to - 000'"o N0 N t ' 0 ~ 0 e - C7 0 'e '00 s 0000......999 o0000000 000a, C, 0 c000 0N NN N 00N0 C 0c 00 0000 0 0000 0 00 0 000 337 0096= 6999 6$$$ $$ 00 In o~9~C 0eg z 220 el 868N Z:~~n~ 0 PZC'3I 0 InInI06~ =' 0 InN N Z~ e 0n en o 02..OO.OOZ--oOooO c oO OOO 4 0 N-l s |966096 o-05-O-- 6d a60 Z32z2 0 9 &3, 2'ZZ-Z.5 9 999 9989 ~z 9 0 9 0~~ Z 0 a a- ' z 7- ..
C9 . .-... . ... .0 ooo oOQ o e o 00g aa o Cuseessaes -. 0 ono a0C) 00 00f W ae c , y ) 0, 00 000 0 0000g000000 000 0A V0 0000 0 n 0 n W 0 n 0 00000000 0 0w E-n n o- 9o ooms - on'.ass 4,4,4,4,4, CIO ,4 ,I ,4 ,4 4 ,, c a m m 4, 0, a C, C, a, a, a, C,4 nI n nI nI I nI nI InI nI nI nI nI In W) In In Wn In In '0 n -- -n -n In In InI-nI nI nI n nI nI nI nI * 8 * IS8 889 S S 551 SItI et 111 S I 10 101013131310100 1 0 DID 13110110Do3 1 D3D13 o 'D' 'o'o o 338 ' 31031 10 N NNNNNN N N N N N N N N N N N " NN N " N N N N4 * Y a, S D 5 10 101 SI W I w1 1 5 C' I SI W5 W15 M W 'nM MM1 I m nN 1N0 31 0 0In 3 In 0 In 1 In3 300100In 00'3n003'01 '3'o w 00 CO00 W n 02 02 L !2n 2 12 2 ! !2Lo 22!2 0 0 !2 n0 00 0 n 00 C -T10 NC n m Im n , n0 mN m , 0 a, , 00 0 an~ r- 4 ,I a,0 In-IO 1 34 In0 NOCa 4,44,4 4,,,,4444 e N 10 In In N4 4,,, In ~n: n' It In nI In In 2 n In I III S l 155 S I II II 5 11 51 15 55 I 5 I 0~~~, 3 0 0 O ntn300In 1 -Wa 4 3n IDt- 01O m ~ a,1 00 N NNNNNNNNNN N N N N NN N N N N4 N4 N N N N N N N N CN N
---------------------
338 0 z z - z o a 0 N~~ Z zs >~'~~ N ( 0 q8 o Z 6O (Q C) 09 z Z C - z 7 . 7, .. a acy~o9OQ NQ9 CY 2 SnfJ Q wS w Q C, 0 2a- 0 0 00 cn U0 0 LL, -' 'C-2.00 0% U3 050*s 05%0% .. ~,sSsefsl5'lCn550'' "JC'' CC >CCC 0 '''5~' 'C'C ~ 'C ~ 'C' 'C' 'D' 'C 'a 'D \C 'D '0 'C 'C 'o 'C' C"C' 0 10 0 00 \0 00 0 o0 0D \0 00 0 0 0 0 0 0 0 l~ 0 0 0 0 00 0 000000 NCO N~ ' N No 'No '" N " N " N " N 'No " N N C . . N C-4 N NCA NNNNN ot n0 n0 00 00M ' S OOS q ~ N % 50 % S ' C>C % N 00 0% -C 0 -S OO - ~ 0 0 % n N S~ -N C % %S '~ -OS -n - - 00 - - ~ N' -0%- C- p lN " N N N N NN N N J ~ ~ N N N N N' 0%4 O O 0- N S ' S C-4C4NO 0N0 S nC4 r N C4 r 00 000 0% 0000000 0 \9 -r - I 0~ 050 't tn m % g % NO -I- m m - 0* 00en0m 0 55 m%0 6 0% g 'C 5 ID05 t- CC ' tN 0\ 'C m N a, -t v w 0m0\NN0 'NC 'I - - - - - - - - - - - - - - -- 2 2 2 -- - - -- - - - r. n n .19S n ~ Sn Sn -- - rnn 'o - 'Cn S 2 n0S n .n 0 -In n )n\n D 0 m 'C 5'Sc %000 0 -0 \''C 0 a% N NNN m N \000000 0 % 0 C m - m %D4 o k O '00000000 C' S 0 8 ~0 0 00000000000 0 000 D Nl N NN N N N N N N N N N N N N Nq N N N4 N- N N N N N N N N N N N N N1 N' N4 N N' N N4 N N- N N N N N N N N en en en -S mn en en en enemne ne ne ne ne ne ne 339 0 N0 00 P6 @6 6 '- 29za CY > z C 'A Z4zy 0 -w0w z -Z 629~ ZWZZ in.. ' 2'' o-'0 o''co''p ~ ~ 0' 0'' 0 0 0 0 0 0 a 0 0 as s 0 a a. c, C> s O Os O 0 0s c. Os5 CD C m In in 4- In "n "n imm m In In m nmmmm In In W) W) In mIn -n -n I In ' , In . . ~ .* In I IS 'n SI 6,I'e 100 0 s 0 \0 0 0 0 0 sO 00 0 0 \00 '0 '0 '0 '0 '0 '0 '0 '0 '0 0 \D 'D ' '0 '00'0 -0 5r5 IrS I I II Ir 1 r Sr 7, 7 r IS 7I , S rN 0 N ~ N '~ aOSOO0 . .0.. In0 N A "mm c C mN 't ,,t o0 \o0 000, 0w 0' a, a, s 00 In '0 0 'A 'A c n 'PI 'A 'A 'T'N ' 'AT C N N I, r ' Dr- t m~ I'D S- C, INr I'n 00 p5 ccmN NmInrt-o N m 0- 55-005-1 0 10~0 a, 00 00 -c In---tr00N m0 - m a\omIN INOS WO D0 DmC m0 0 0 0a 0mW - ;r v ~ S NN0 \0'0 '0fl0' a, '5 N 08'Cr 00 N L- N N1 C a~ 0 ~ - - - 2 N '0 N N 'A - -N - N N L -' N- N! E!i ',a 4N Nq" INC4NIINIIN4ININNNNIN N N IN N IN N NN NN NN N4 NN NN NNI in ing i n~o ni ni In m in m NA m m in m 2In ~m~m~ m 22 - - - - - - - - - - - - - - - - ~~'A'0N00a.0 ~ ~ ~ ~ ~Cm "I 'A N0'CN:A0 0 0 0O i ,A0 ~~s~~OsOOOOO0000 ---- ---.. NNN340N Editorial Note Case #2007202950 Due to amendments to the specification, pages 341-349 have been deleted. The following page is numbered 350.
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis) e indications made below relate to the deposited microorganism or other biological material referred to in the scription on page 20, paragraph 58. ENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet : of depositary institution: American Type Culture Collection ess of depositary institution (including postal code and country) 1 University Boulevard ( issas, Virginia 20110-2209 d States of America f deposit Accession Number 22 October 1996 97768 DDITIONAL INDICATIONS (leave blank ifnot applicable) This information is continued on an additional sheet ESIGNATED STATES FOR WBICH INDICATIONS ARE MADE (if the indications are notfor all designated States) 1pe pect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available :he publication of the mention of the grant of the European patent or until the date on which the application has been refused or rawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the ple (Rule 28(4) EPC). Continued on additional sheets SEPARATE FURNISHING OF INDICATIONS (leave blank ifnot applicable) indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession ber of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application [ This sheet was received by the International Bureau on: horized officer Authorized officer ed Forn PCTIRO/13 4 (January 2001) Pctrol34ep.sollist 350 ATCC Deposit No.: 97768 CANADA The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application. NORWAY The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) ofthe Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case. AUSTRALIA The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be'effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations). FINLAND The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. UNITED KINGDOM The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application. 351 ATCC Deposit No.: 97768 DENMARK The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case. SWEDEN The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case. NETHERLANDS The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 3 1F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier. 352 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis) ae indications made below relate to the deposited microorganism or other biological material referred to in the :scription on page 20, paragraph 59. )ENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet X [e of depositary institution: American Type Culture Collection press of depositary institution (including postal code and country) )1 University Boulevard assas, Virginia 20110-2209 ed States of America )f deposit Accession Number 10 December 199S 203518 DDITIONAL INDICATIONS (leave blank ifnot applicable) This information is continued on an additional sheet E IESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (ifthe indications are norfor all designated States) >pe ;pect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available the publication of the mention of the grant of the European patent or until the date on which the application has been refused or Irawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the le (Rule 28(4) EPC). Continued on additional sheets SEPARATE FURNISHING OF INDICATIONS (leave blank ifnot applicable) indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "A ccession ber ofDeposit") For receiving Office use only For International Bureau use only This sheet was received with the international application 0 This sheet was received by the International Bureau on: horized officer Authorized officer ed Form PCT/RO/134 (January 200 l) Pctro134ep.sollist 353 ATCC Deposit No.: 203518 CANADA The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application. NORWAY The applicant hereby requests that the application has been laid open to public inspection (by ( the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this.effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case. AUSTRALIA The applicant hereby gives notice that the furmishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled. addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations). FINLAND The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. UNITED KINGDOM The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application. 354 ATCC Deposit No.: 203518 DENMARK The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open. to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case. SWEDEN The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case. NETHERLANDS The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(l) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier. 355 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCI Rule l3bis) e indications made below relate to the deposited microorganism or other biological material referred to in the ;cription on page 145, Table 2. ENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet of depositary institution: American Type Culture Collection ess of depositary institution (including postal code and country) 1 University Boulevard issas, Virginia 20110-2209 A States of America f deposit Accession Number 27 March 2001 PTA-3238 [)DITIONAL INDICATIONS (leave blank ifnot applicable) This information is continued on an additional sheet ESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are notfor all designated States) pe >ect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available he publication of the mention of the grant of the European patent or until the date on which the application has been refused or rawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the le (Rule 28(4) EPC). Continued on additional sheets EPARATE FURNISHING OF INDICATIONS (leave blank fynot applicable) ndications listed below will be submitted to the international Bureau later (specify the general nature ofthe indications e.g., "Accession ber ofDeposit") For receiving Office use only For International Bureau use only 'his sheet was received with the international application 0 This sheet was received by the International Bureau on: orized officer Authorized officer ed Form PCT/RO/134 (January 2001) Petrol34ep.sollist 356 ATCC Deposit No.: PTA-3238 CANADA The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application. NORWAY The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case. AUSTRALIA The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations). FINLAND The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. UNITED KINGDOM The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application. 357 ATCC Deposit No.: PTA-3238 DENMARK The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case. SWEDEN The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case. NETHERLANDS The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 3 1F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier. 358 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis) be indications made below relate to the deposited microorganism or other biological material referred to in the scription on page 145, Table 2. )ENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet X Le of depositary institution: American Type Culture Collection ress of depositary institution (including postal code and country) )1 University Boulevard .assas, Virginia 20110-2209 ed States of America >f deposit Accession Number 27 March 2001 PTA-3239 ])DITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet i IESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (ifthe indications are notfor all designated Stares) >pe ;pect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available the publication of the mention of the grant of the European patent or until the date on which the application has been refused or Irawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the le (Rule 28(4) EPC). Continued on additional sheets SEPARATE FURNISHING OF INDICATIONS geave blank irnot applicable) indications listed below will be submitted to the international Bureau later (specify the general nature ofthe indications e.g., "Accession ber of.Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application E] This sheet was received by the International Bureau on: borized offcer Authorized officer ed Form PCTIRO/134 (January 2001) Pctrol34ep.sollist 359 ATCC Deposit No.: PTA-3239 CANADA The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to einStatement, or is withdrawn, the Commissioner of Patents only authorizes the -furishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application. NORWAY The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case. AUSTRALIA The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent. or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations). FINLAND The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. UNITED KINGDOM The applicant hereby requests that the finishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application. 350 ATCC Deposit No.: PTA-3239 DENMARK The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case. SWEDEN The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be-filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volune I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case. NETHERLANDS The applicant hereby requests.that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be fumished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier. 361 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis) indications made below relate to the deposited microorganism or other biological material referred to in the ;ription on page 145, Table 2. NTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet E of depositary institution: American Type Culture Collection ss of depositary institution (including postal code and country) University Boulevard ;sas, Virginia 20110-2209 I States of America deposit Accession Number 27 March 2001 PTA-3240 DITIONAL INDICATIONS (leave blank ifnot applicable) This information is continued on an additional sheet E SIGNATED STATES FOR WEICH INDICATION'S ARE MADE (ifthe indications are notfor all designated States) :ct of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available e publication of the mention of the grant of the European patent or until the date on which the application has been refused or awn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the e (Rule 28(4) EPC). Continued on additional sheets SEPARATE FURNISHING OF INDICATIONS (leave blank ifnot applicable) dications listed below will be submitted to the international Bureau later (specify the general nature ofthe indications e.g., "Accession er of Deposit") For receiving Office use only For International Bureau use only ais sheet was received with the international application This sheet was received by the International Bureau on: rized officer Authorized officer - Form PCT/Ro/134 (January 2001) Pctrol34ep.sollist 362 ATCC Deposit No.: PTA-3240 CANADA The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application. NORWAY The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case. AUSTRALIA The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations). FINLAND The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. UNITED KINGDOM The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application. 363 ATCC Deposit No.: PTA-3240 DENMARK The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case. SWEDEN The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Forn PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case. NETHERLANDS The applicant hereby requests that until the (late of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier. 364 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis) indications made below relate to the deposited microorganism or other biological material referred to in the optionn on page 145, Table 2. NTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet of depositary institution: American Type Culture Collection ss of depositary institution (including postal code and country) University Boulevard ;sas, Virginia 20110-2209 i States of America deposit Accession Number 27 March 2001 PTA-3241 DITIONAL INDICATIONS (leave blank ifnot applicable) This information is continued on an additional sheet ] SIGNATED STATES FOR WICH INDICATION S ARE MADE (Yfthe indications are noifor all designated States) -ct of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available ,e publication of the mention of the grant of the European patent or until the date on which the application has been refused or iwn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the e (Rule 28(4) EPC). Continued on additional sheets SEPARATE FURNISHING OF INDICATIONS (teave o ank tnot applicable) dications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession er of Deposit") For receiving Office use only For International Bureau use only bis sheet was received with the international application [ This sheet was received by the International Bureau on: prized officer Authorized officer dForn PCTIRO/134 (January 2001) Pctro134ep.sollist 365 §TCC Deposit No.: PTA-3241 ZANADA The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application. NORWAY The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case. AUSTRALIA The applicant hereby gives notice that the furmishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations). FINLAND The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. UNITED KINGDOM The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application. 366 ATCC Deposit No.: PTA-3241 DENMARK The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case. SWEDEN The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the; individual case. NETHERLANDS The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier. 367 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis) indications made below relate to the deposited microorganism or other biological material referred to in the ciption on page 145, Table 2. '4TFICATION OF DEPOSIT Further deposits are identified on an additional sheet III >f depositary institution: American Type Culture Collection s of depositary institution (including postal code and country) University Boulevard sas, Virginia 20110-2209 States of America leposit Accession Number 27 March 2001 PTA-3242 DITIONAL INDICATIONS (leave blank ifnot applicable) This information is continued on an additional sheet E 3IGNATED STATES FOR WBICH INDICATIONS ARE MADE (bthe indications are notfor all designated States) ct of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available publication of the mention of the grant of the European patent or until the date on which the application has been refused or iwn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the (Rule 28(4) EPC). Continued on additional sheets KARATE FURNISHING OF INDICATIONS (feave blank if not applicable) lications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "A ccession r ofDeposit") For receiving Office use only For Intemational Bureau use only is sheet was received with the international application O This sheet was received by the International Bureau on: rized officer Authorized officer Form PCT/RO/134 (January 2001) Pctrol34ep.sollist 368 ATCC Deposit No.: PTA-3242 CANADA The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material. referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inforn the International Bureau accordingly before completion of technical preparations for publication of the international application. NORWAY The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case. AUSTRALIA The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations). FINLAND The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. UNITED KINGDOM The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application. 369 ATCC Deposit No.: PTA-3242 DENMARK The applicant hereby requests that, until the: application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open. to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to-this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case. SWEDEN The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish. Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably 6n the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case. NETHERLANDS The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(l) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier. 3'70 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis) ie indications made below relate to the deposited microorganism or other biological material referred to in the scription on page 145, Table 2. iENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet [ e of depositary institution: American Type Culture Collection -ess of depositary institution (including postal code and country) 11 University Boulevard assas, Virginia 20110-2209 -d States of America if deposit Accession Number 27 March 2001 PTA-3243 DDITIONAL INDICATIONS (leave blank ifnot applicable) This information is continued on an additional sheet [ ESIGNATED STATES FOR WBICH INDICATIONS ARE MADE (fthe indications are notfor all designated states) 1pe pect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available he publication of the mention of the grant of the European patent or until the date on which the application has been refused or rawn oris deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the .e (Rule 28(4) EPC). Continued on additional sheets SEPARATE FURNISHING OF INDICATIONS (teove blank ffnot applicable) indications listed below will be submitted to the international Bureau later (specify the general nature ofthe indications e.g., "Accession ber of Deposit") For receiving Office use only For International Bureau use only his sheet was received with the international application [ This sheet was received by the International Bureau on: iorized officer Authorized officer ed Forrn PCT/RO/134 (January 2001) Pctro134ep.sollist 371 ATCC Deposit No.: PTA-3243 CANADA The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to anfindependent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application. NORWAY The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case. AUSTRALIA The applicant hereby gives notice that the furnishing of a. sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations). FINLAND The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. UNITED KINGDOM The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request. to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application. 372 ATCC Deposit No.: PTA-3243 DENMARK The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case. SWEDEN The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Fonn PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case. NETHERLANDS The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier. 373
Claims (42)
1. A method of treating a patient suffering from an autoimmune disease or condition comprising administering an isolated antibody which comprises a first amino acid sequence at least 85% identical to amino acid residues 1-123 of SEQ ID NO:327 or amino acid residues 1-123 of SEQ ID NO:2 and a second amino acid sequence at least 85% identical to amino acid residues 141-249 of SEQ ID NO:327 or amino acid residues 141-249 of SEQ ID NO:2, wherein said antibody immunospecifically binds a BLyS protein or a biologically active fragment thereof, and wherein said autoimmune disease or condition is selected from the group consisting of: (a) idiopathic thrombocytopietic purpura (ITP); (b) rheumatoid arthritis; (c) Waldenstrom's macroglobulinaemia; (d) multiple sclerosis; (e) diabetes; (f) transplant rejection; (g) systemic lupus erythematosus (SLE); (h) Sjogren's syndrome; and (i) vasculitis.
2. The method of claim 1, wherein said autoimmune disease or condition is (a).
3. The method of claim 1, wherein said autoimmune disease or condition is (b).
4. The method of claim 1, wherein said autoimmune disease or condition is (c).
5. The method of claim 1, wherein said autoimmune disease or condition is (d).
6. The method of claim 1, wherein said autoimmune disease or condition is (e).
7. The method of claim 1, wherein said autoimmune disease or condition is (f).
8. The method of claim 1, wherein said autoimmune disease or condition is (g).
9. The method of claim 1, wherein said autoimmune disease or condition is (h).
10. The method of claim 1, wherein said autoimmune disease or condition is (i).
11. The method of claim 1, wherein the amino acid differences between the first amino acid sequence and amino acid residues 1-123 of SEQ ID NO:327 are in one or more of the CDR regions located at amino acid residues 26-35, 50-66 and 99-112 of SEQ ID NO: 374 327 or wherein the amino acid differences between the first amino acid sequence and amino acid residues 1-123 of SEQ ID NO:2 are in one or more of the CDR regions located at amino acid residues 26-35, 50-66 and 99-112 of SEQ ID NO:2, and wherein the amino acid differences between the second amino acid sequence and amino acid residues 141 249 of SEQ ID NO:327 are in one or more of the CDR regions located at amino acid residues 163-173, 189-195 and 228-238 of SEQ ID NO:327 or wherein the amino acid differences between the second amino acid sequence and amino acid residues 141-249 of SEQ ID NO:2 are in one or more of the CDR regions located at amino acid residues 163 173, 189-195 and 228-238 of SEQ ID NO:2.
12. A method of treating a patient suffering from an autoimmune disease or condition comprising administering an isolated antibody which comprises a first amino acid sequence at least 95% identical to amino acid residues 1-123 of SEQ ID NO:327 or amino acid residues 1-123 of SEQ ID NO:2 and a second amino acid sequence at least 95% identical to amino acid residues 141-249 of SEQ ID NO:327 or amino acid residues 141-249 of SEQ ID NO:2, wherein said antibody immunospecifically binds a BLyS protein or a biologically active fragment thereof, and wherein said autoimmune disease or condition is selected from the group consisting of: (a) idiopathic thrombocytopietic purpura (ITP); (b) rheumatoid arthritis; (c) Waldenstrom's macroglobulinaemia; (d) multiple sclerosis; (e) diabetes; (f) transplant rejection; (g) systemic lupus erythematosus (SLE); (h) Sjogren's syndrome; and (i) vasculitis.
13. The method of claim 12, wherein said autoimmune disease or condition is (a).
14. The method of claim 12, wherein said autoimmune disease or condition is (b).
15. The method of claim 12, wherein said autoimmune disease or condition is (c).
16. The method of claim 12, wherein said autoimmune disease or condition is (d).
17. The method of claim 12, wherein said autoimmune disease or condition is (e).
18. The method of claim 12, wherein said autoimmune disease or condition is (f).
19. The method of claim 12, wherein said autoimmune disease or condition is (g). 375
20. The method of claim 12, wherein said autoimmune disease or condition is (h).
21. The method of claim 12, wherein said autoimmune disease or condition is (i).
22. The method of claim 12, wherein the amino acid differences between the first amino acid sequence and amino acid residues 1-123 of SEQ ID NO:327 are in one or more of the CDR regions located at amino acid residues 26-35, 50-66 and 99-112 of SEQ ID NO:327 or wherein the amino acid differences between the first amino acid sequence and amino acid residues 1-123 of SEQ ID NO:2 are in one or more of the CDR regions located at amino acid residues 26-35, 50-66 and 99-112 of SEQ ID NO:2, and wherein the amino acid differences between the second amino acid sequence and amino acid residues 141 249 of SEQ ID NO:327 are in one or more of the CDR regions located at amino acid residues 163-173, 189-195 and 228-238 of SEQ ID NO:327 or wherein the amino acid differences between the second amino acid sequence and amino acid residues 141-249 of SEQ ID NO:2 are in one or more of the CDR regions located at amino acid residues 163 173, 189-195 and 228-238 of SEQ ID NO:2.
23. A method of treating a patient suffering from an autoimmune disease or condition comprising administering an isolated antibody comprising amino acid residues 1 123 and 141-249 of SEQ ID NO:327 or amino acid residues 1-123 and 141-249 of SEQ ID NO:2, wherein said antibody immunospecifically binds a BLyS protein or a biologically active fragment thereof, and wherein said autoimmune disease or condition is selected from the group consisting of: (a) idiopathic thrombocytopietic purpura (ITP); (b) rheumatoid arthritis; (c) Waldenstrom's macroglobulinaemia; (d) multiple sclerosis; (e) diabetes; (f) transplant rejection; (g) systemic lupus erythematosus (SLE); (h) Sjogren's syndrome; and (i) vasculitis.
24. The method of claim 23, wherein said autoimmune disease or condition is (a).
25. The method of claim 23, wherein said autoimmune disease or condition is (b).
26. The method of claim 23, wherein said autoimmune disease or condition is (c).
27. The method of claim 23, wherein said autoimmune disease or condition is (d). 376
28. The method of claim 23, wherein said autoimmune disease or condition is (e).
29. The method of claim 23, wherein said autoimmune disease or condition is (f).
30. The method of claim 23, wherein said autoimmune disease or condition is (g).
31. The method of claim 23, wherein said autoimmune disease or condition is (h).
32. The method of claim 23, wherein said autoimmune disease or condition is (i).
33. A method of treating a patient suffering from an autoimmune disease or condition comprising administering an isolated antibody comprising amino acid residues 26 35, 50-66, 99-112, 163-173, 189-195, and 228-238 of SEQ ID NO: 327 or amino acid residues 26-35, 50-66, 99-112, 163-173, 189-195, and 228-238 of SEQ ID NO: 2, wherein said antibody immunospecifically binds a BLyS protein or a biologically active fragment thereof, and wherein said autoimmune disease or condition is selected from the group consisting of: (a) idiopathic thrombocytopietic purpura (ITP); (b) rheumatoid arthritis; (c) Waldenstrom's macroglobulinaemia; (d) multiple sclerosis; (e) diabetes; (f) transplant rejection; (g) systemic lupus erythematosus (SLE); (h) Sjogren's syndrome; and (i) vasculitis.
34. The method of claim 33, wherein said autoimmune disease or condition is (a).
35. The method of claim 33, wherein said autoimmune disease or condition is (b).
36. The method of claim 33, wherein said autoimmune disease or condition is (c).
37. The method of claim 33, wherein said autoimmune disease or condition is (d).
38. The method of claim 33, wherein said autoimmune disease or condition is (e).
39. The method of claim 33, wherein said autoimmune disease or condition is (f).
40. The method of claim 33, wherein said autoimmune disease or condition is (g).
41. The method of claim 33, wherein said autoimmune disease or condition is (h). 377
42. The method of claim 33, wherein said autoimmune disease or condition is (i). 378
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2007202950A AU2007202950B2 (en) | 2000-06-16 | 2007-06-21 | Antibodies that Immunospecifically Bind to Blys |
| AU2009200977A AU2009200977B2 (en) | 2000-06-16 | 2009-03-09 | Antibodies that Immunospecifically Bind to BLys |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/212,210 | 2000-06-16 | ||
| US60/240,816 | 2000-10-17 | ||
| US60/276,248 | 2001-03-16 | ||
| US60/277,379 | 2001-03-21 | ||
| US60/293,499 | 2001-05-25 | ||
| AU2001268427A AU2001268427B2 (en) | 2000-06-16 | 2001-06-15 | Antibodies that immunospecifically bind to blys |
| AU2007202950A AU2007202950B2 (en) | 2000-06-16 | 2007-06-21 | Antibodies that Immunospecifically Bind to Blys |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001268427A Division AU2001268427B2 (en) | 2000-06-16 | 2001-06-15 | Antibodies that immunospecifically bind to blys |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009200977A Division AU2009200977B2 (en) | 2000-06-16 | 2009-03-09 | Antibodies that Immunospecifically Bind to BLys |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2007202950A1 AU2007202950A1 (en) | 2007-08-02 |
| AU2007202950A9 AU2007202950A9 (en) | 2007-08-02 |
| AU2007202950B2 true AU2007202950B2 (en) | 2011-03-17 |
Family
ID=38346054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007202950A Expired AU2007202950B2 (en) | 2000-06-16 | 2007-06-21 | Antibodies that Immunospecifically Bind to Blys |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2007202950B2 (en) |
-
2007
- 2007-06-21 AU AU2007202950A patent/AU2007202950B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007202950A1 (en) | 2007-08-02 |
| AU2007202950A9 (en) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009200977B2 (en) | Antibodies that Immunospecifically Bind to BLys | |
| US7220840B2 (en) | Antibodies that immunospecifically bind to B lymphocyte stimulator protein | |
| US7879328B2 (en) | Antibodies that immunospecifically bind to B lymphocyte stimulator | |
| AU2001268427A1 (en) | Antibodies that immunospecifically bind to blys | |
| EP1456347A2 (en) | Antibodies that immunospecifically bind to blys | |
| US20030059862A1 (en) | Antibodies against tumor necrosis factor delta (APRIL) | |
| AU2007202950B2 (en) | Antibodies that Immunospecifically Bind to Blys | |
| DK2281843T3 (en) | Antibodies that immunospecifically bind to BLyS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |